1
00:00:05,400 --> 00:00:10,280
>>TODAY WE HAVE OUR FIRST

2
00:00:10,280 --> 00:00:12,720
PRESENTATION FROM DIVISION OF

3
00:00:12,720 --> 00:00:14,520
CANCER PREVENTION, AND THE

4
00:00:14,520 --> 00:00:15,840
VISION.

5
00:00:15,840 --> 00:00:18,400
THIS WILL BE PROVIDED I BE DR.

6
00:00:18,400 --> 00:00:20,480
CASTLE, DIRECTOR FOR THE

7
00:00:20,480 --> 00:00:21,680
DIVISION FOR CANCER PREVENTION.

8
00:00:21,680 --> 00:00:24,120
PHIL.

9
00:00:24,120 --> 00:00:32,320
>> 

10
00:00:32,320 --> 00:00:34,000
>> THANK YOU, EVERYONE.

11
00:00:34,000 --> 00:00:36,000
THANKS FOR THE OPPORTUNITY TO

12
00:00:36,000 --> 00:00:36,960
SPEAK.

13
00:00:36,960 --> 00:00:38,360
WHAT I WANTED TO DO TODAY IS

14
00:00:38,360 --> 00:00:41,360
TALK A BIT ABOUT WHERE DCP IS

15
00:00:41,360 --> 00:00:43,920
TODAY AND WHERE WE ARE GOING.

16
00:00:43,920 --> 00:00:45,760
AND I ALSO WANT TO EMPHASIZE

17
00:00:45,760 --> 00:00:48,200
THAT I'M SPEAKING ON BEHALF OF

18
00:00:48,200 --> 00:00:49,520
THE DIVISION AND EVERYTHING I'M

19
00:00:49,520 --> 00:00:52,160
PRESENTING IS REALLY A

20
00:00:52,160 --> 00:00:54,720
REFLECTION OF AMAZING STAFF THAT

21
00:00:54,720 --> 00:00:58,600
IS HARDWORKING AND DEDICATED TO

22
00:00:58,600 --> 00:01:02,320
PUBLIC SERVICE.

23
00:01:02,320 --> 00:01:04,160
NOT MOVING FORWARD.

24
00:01:04,160 --> 00:01:08,000
OKAY.

25
00:01:08,000 --> 00:01:12,160
SO JUST TO ORIENT YOU A LITTLE

26
00:01:12,160 --> 00:01:13,360
BIT THIS SLIDE HIGHLIGHTS THE

27
00:01:13,360 --> 00:01:14,480
FACT WE HAVE NOT MADE THE KIND

28
00:01:14,480 --> 00:01:16,920
OF PROGRESS WE WANT TO MAKE IN

29
00:01:16,920 --> 00:01:17,600
PREVENTING CANCER.

30
00:01:17,600 --> 00:01:20,560
THIS IS A COUPLE OF YEARS OLD

31
00:01:20,560 --> 00:01:24,720
BUT YOU ESSENTIALLY WERE AT FLAT

32
00:01:24,720 --> 00:01:25,960
LINE HERE.

33
00:01:25,960 --> 00:01:27,960
THANK GOODNESS WE ARE MAKING

34
00:01:27,960 --> 00:01:31,400
SOME PROGRESS IN REDUCING CANCER

35
00:01:31,400 --> 00:01:32,560
DEATH BUT THAT JUST MEANS ALSO

36
00:01:32,560 --> 00:01:37,000
WE HAVE MANY PEOPLE MOVING WITH

37
00:01:37,000 --> 00:01:40,240
CANCER WHO WE WOULD LIKE TO

38
00:01:40,240 --> 00:01:41,400
REDUCE THAT AND MAKE LIVES

39
00:01:41,400 --> 00:01:41,720
BETTER.

40
00:01:41,720 --> 00:01:44,160
KEEP IN MIND $200 BILLION ARE

41
00:01:44,160 --> 00:01:49,240
SPENT ON CANCER CARE EVERY YEAR.

42
00:01:49,240 --> 00:01:50,960
ABOUT 10% IS OUT OF POCKET

43
00:01:50,960 --> 00:01:56,120
EXPENSES.

44
00:01:56,120 --> 00:01:57,560
THIS IS THE NEW MISSION

45
00:01:57,560 --> 00:01:59,320
STATEMENT FOR DIVISION OF CANCER

46
00:01:59,320 --> 00:02:01,400
PREVENTION, NCI DIVISION CANCER

47
00:02:01,400 --> 00:02:04,040
PREVENTION LEADS AND SUPPORTS

48
00:02:04,040 --> 00:02:09,280
PROMOTES RIGOROUS INNOVATIVE

49
00:02:09,280 --> 00:02:10,400
TRAINING CANCER TO IMPROVE

50
00:02:10,400 --> 00:02:13,400
HEALTH OF ALL PEOPLE.

51
00:02:13,400 --> 00:02:16,600
THIS IS THE STAFF, THE

52
00:02:16,600 --> 00:02:17,320
LEADERSHIP DIVISION OF THE

53
00:02:17,320 --> 00:02:20,520
BRANCHES WITHIN THAT SO WE HAVE

54
00:02:20,520 --> 00:02:22,960
TEN BRANCHES, ONE PROTOCOL

55
00:02:22,960 --> 00:02:24,960
INFORMATION OFFICE AND CANCER

56
00:02:24,960 --> 00:02:29,560
PREVENTION FELLOWSHIP PROGRAM.

57
00:02:29,560 --> 00:02:33,080
SO REALLY THE DIVISION OF CANCER

58
00:02:33,080 --> 00:02:35,000
PREVENTION DOES DISCOVERY AND

59
00:02:35,000 --> 00:02:37,040
DEVELOPMENT OF CANCER PREVENTION

60
00:02:37,040 --> 00:02:38,520
STRATEGIES, WE WORK VERY CLOSELY

61
00:02:38,520 --> 00:02:40,080
WITH THE DIVISION OF CANCER

62
00:02:40,080 --> 00:02:43,960
BIOLOGY AS WELL AS DIVISION OF

63
00:02:43,960 --> 00:02:45,160
CANCER CONTROL AND POPULATION

64
00:02:45,160 --> 00:02:46,600
SCIENCES AND WE EMPHASIZE YOU

65
00:02:46,600 --> 00:02:49,160
WILL SEE THAT IN THE UPCOMING

66
00:02:49,160 --> 00:02:52,360
SLIDES, THREE AREAS OF RESEARCH,

67
00:02:52,360 --> 00:02:54,520
PREVENTIVE AGENTS AND YOU HEARD

68
00:02:54,520 --> 00:02:57,240
ABOUT THAT FROM SUZUKO

69
00:02:57,240 --> 00:02:58,440
YESTERDAY, WE WILL TALK ABOUT

70
00:02:58,440 --> 00:02:59,200
THAT TODAY.

71
00:02:59,200 --> 00:03:02,120
BIOMARKERS FOR SCREENING AND

72
00:03:02,120 --> 00:03:03,520
EARLY DETECTION, SYMPTOM SCIENCE

73
00:03:03,520 --> 00:03:09,480
PREVENTION AND MANAGEMENT.

74
00:03:09,480 --> 00:03:13,800
IN THE 19 MONTHS I HAVE BEEN AT

75
00:03:13,800 --> 00:03:15,760
DCP WE REALLY ENGAGE THE

76
00:03:15,760 --> 00:03:18,520
EXTRAMURAL AND STAKEHOLDERS AND

77
00:03:18,520 --> 00:03:19,360
DISCUSSIONS ABOUT WHERE WE

78
00:03:19,360 --> 00:03:22,440
SHOULD BE GOING, WE HAD A

79
00:03:22,440 --> 00:03:23,120
MULTI-CANCER EARLY DETECTION

80
00:03:23,120 --> 00:03:26,600
STUDY WORKSHOP CANCER SCREENING,

81
00:03:26,600 --> 00:03:29,120
TRANSLATIONAL ADVANCES AND KAREN

82
00:03:29,120 --> 00:03:30,920
PREVENTION AGENT DEVELOPMENT,

83
00:03:30,920 --> 00:03:33,200
CANDIDATES WORKSHOP AND FNIH

84
00:03:33,200 --> 00:03:37,000
CANCER PREVENTION WORKSHOP, FDA

85
00:03:37,000 --> 00:03:39,440
NCI CLOSING CANCER RISK

86
00:03:39,440 --> 00:03:42,640
REDUCTION WHICH LED TO A NEW FDA

87
00:03:42,640 --> 00:03:45,120
NCI WORKING GROUP AND CANCER

88
00:03:45,120 --> 00:03:46,000
PREVENTION, WE ARE IN THE

89
00:03:46,000 --> 00:03:49,400
PROCESS OF BRINGING ON KOL AND

90
00:03:49,400 --> 00:03:51,120
EXPERT THROUGH IPA MECHANISMS TO

91
00:03:51,120 --> 00:03:52,560
CONTINUE THE DISCUSSION ABOUT

92
00:03:52,560 --> 00:03:55,200
WHERE WE SHOULD BE GOING.

93
00:03:55,200 --> 00:03:58,000
OBVIOUSLY THIS DISCUSSION TODAY

94
00:03:58,000 --> 00:04:00,400
AND THEN WE ARE -- WE HAVE NEW

95
00:04:00,400 --> 00:04:01,400
ENGAGEMENTS WITH INDUSTRY

96
00:04:01,400 --> 00:04:02,480
PARTNERS WHICH VERY EXCITING AS

97
00:04:02,480 --> 00:04:03,760
WELL.

98
00:04:03,760 --> 00:04:06,080
SO THIS IS WHERE WE ARE AT.

99
00:04:06,080 --> 00:04:10,000
AND I REMIND YOU THAT MANY

100
00:04:10,000 --> 00:04:15,560
THINGS HERE AVOIDING VACCINATION

101
00:04:15,560 --> 00:04:17,360
TREATMENT AND SCREENING ARE

102
00:04:17,360 --> 00:04:19,600
TOOLS -- NOT AVOIDING THOSE,

103
00:04:19,600 --> 00:04:20,640
THEY ARE THE SAME TOOLS

104
00:04:20,640 --> 00:04:24,160
HIGHLIGHTED BY THE COVID

105
00:04:24,160 --> 00:04:25,560
PANDEMIC.

106
00:04:25,560 --> 00:04:28,040
AVOIDING TOBACCO AND TOBACCO

107
00:04:28,040 --> 00:04:31,480
CESSATION FOR SECONDARY AND

108
00:04:31,480 --> 00:04:32,480
VACCINATION TREATMENT OF H

109
00:04:32,480 --> 00:04:34,080
PYLORI AND SCREENING DIAGNOSIS

110
00:04:34,080 --> 00:04:41,040
AND REMOVAL OF ADENOMA TISSUE.

111
00:04:41,040 --> 00:04:41,840
THE INTERCEPTION OF CANCER TO

112
00:04:41,840 --> 00:04:43,320
DATE HAS BEEN STARTING TO EXPAND

113
00:04:43,320 --> 00:04:44,400
BUT STILL NOT WHERE WE NEED IT

114
00:04:44,400 --> 00:04:47,080
TO BE.

115
00:04:47,080 --> 00:04:50,000
TAMOXIFEN AND DERIVATIVES FOR

116
00:04:50,000 --> 00:04:54,600
BREAST CANCER COLORECTAL CANCER

117
00:04:54,600 --> 00:04:56,200
N SAID, IMMUNE MODULATORS LIKE

118
00:04:56,200 --> 00:04:58,080
STAT 3 INHIBITORS, DRUG THAT

119
00:04:58,080 --> 00:05:00,880
TARGET ONCOGENIC DRIVERS AND

120
00:05:00,880 --> 00:05:03,000
REACTIVATION OF TUMOR SUPPRESSER

121
00:05:03,000 --> 00:05:11,880
GENES.

122
00:05:11,880 --> 00:05:14,000
I WOULD LIKE TO FRAME THE WORK

123
00:05:14,000 --> 00:05:14,880
WITH A TEAGUE LINE ACROSS

124
00:05:14,880 --> 00:05:16,160
TRANSLATION RESEARCH CONTINUUM.

125
00:05:16,160 --> 00:05:17,880
YOU HEARD ABOUT PREVENT

126
00:05:17,880 --> 00:05:21,000
YESTERDAY, AND SUSUKO MENTIONED

127
00:05:21,000 --> 00:05:24,200
OUR EIGHT NEW AGENT TARGET

128
00:05:24,200 --> 00:05:26,720
DISCOVERY PROGRAM.

129
00:05:26,720 --> 00:05:29,280
THEN THESE VIEWED INTO CPT NET

130
00:05:29,280 --> 00:05:30,240
EARLY PHASE CLINICAL TRIALS AND

131
00:05:30,240 --> 00:05:38,640
THE NCOR LED BY CONFIDENTLY LED

132
00:05:38,640 --> 00:05:39,720
BY MCCAUSE SKILL STEVENS.

133
00:05:39,720 --> 00:05:42,840
WE HAVE COMPLIMENTARY ACTIVITIES

134
00:05:42,840 --> 00:05:45,280
WHICH IS FOCUSED ON HPV

135
00:05:45,280 --> 00:05:48,160
PREVENTION STRATEGIES AND PEOPLE

136
00:05:48,160 --> 00:05:51,000
LIVING WITH HIV, THE CANCER

137
00:05:51,000 --> 00:05:51,800
PREVENTION AND CONTROL CLINICAL

138
00:05:51,800 --> 00:05:54,200
TRIALS PAR AND WE ARE JUST

139
00:05:54,200 --> 00:05:56,600
STARTING A PLANNING FEEDSIBILITY

140
00:05:56,600 --> 00:05:59,800
GRANT MECHANISM R 33 U 33

141
00:05:59,800 --> 00:06:01,800
BECAUSE PREVENTION TRIALS ARE SO

142
00:06:01,800 --> 00:06:04,480
DIFFICULT WE FELT THAT THIS IS

143
00:06:04,480 --> 00:06:08,000
LED BY BRANDY TO -- IT WOULD BE

144
00:06:08,000 --> 00:06:09,920
BENEFICIAL TO HAVE SOME PILOT

145
00:06:09,920 --> 00:06:11,760
DATA BEFORE LAUNCHING INTO LARGE

146
00:06:11,760 --> 00:06:15,240
CLINICAL TRIALS.

147
00:06:15,240 --> 00:06:17,680
SO YOU HEARD ABOUT THIS

148
00:06:17,680 --> 00:06:19,360
YESTERDAY ABOUT PREVENT PROGRAM,

149
00:06:19,360 --> 00:06:21,560
I WANT TO HIGHLIGHT AGAIN IT IS

150
00:06:21,560 --> 00:06:24,000
A MULTI-STEP PROCESS TO GO FROM

151
00:06:24,000 --> 00:06:27,200
DISCOVERY INTO VALIDATION AND

152
00:06:27,200 --> 00:06:28,800
EFFICACY WITH LOTS OF GO, NO

153
00:06:28,800 --> 00:06:32,000
GOs AND REVIEWS ALL ALONG THIS

154
00:06:32,000 --> 00:06:32,400
PIPELINE.

155
00:06:32,400 --> 00:06:35,080
SO I WANT TO CONGRATULATE DR.

156
00:06:35,080 --> 00:06:36,760
SAY AND DR. SHOEMAKER FOR THEIR

157
00:06:36,760 --> 00:06:38,840
AMAZING LEADERSHIP OVER THE LAST

158
00:06:38,840 --> 00:06:42,360
TEN YEARS IN THE COMING FIVE

159
00:06:42,360 --> 00:06:45,480
YEARS SINCE WE APPROVED THIS

160
00:06:45,480 --> 00:06:46,600
PROGRAM THANKFULLY, A

161
00:06:46,600 --> 00:06:48,440
FOUNDATIONAL PROGRAM FOR THE

162
00:06:48,440 --> 00:06:48,800
DIVISION.

163
00:06:48,800 --> 00:06:52,240
THEN WE HAVE THE CPCT NET LED BY

164
00:06:52,240 --> 00:06:56,240
DR. ZABO REALLY PHASE ZERO PHASE

165
00:06:56,240 --> 00:06:57,680
1, PHASE 2 TRIALS YOU CAN SEE

166
00:06:57,680 --> 00:07:00,000
THE ADMINISTRATIVE OFFICES AND

167
00:07:00,000 --> 00:07:02,600
THE DMACC, ACROSS THE UNITED

168
00:07:02,600 --> 00:07:06,600
STATES SO FAIRLY REPRESENTATIVE

169
00:07:06,600 --> 00:07:08,320
OF THE UNITED STATES WITH THE

170
00:07:08,320 --> 00:07:10,680
IDEA THAT THIS WOULD THEN FEED

171
00:07:10,680 --> 00:07:13,040
INTO NCOR FOR PROMISING AGENTS

172
00:07:13,040 --> 00:07:16,640
THAT CAME OUT OF CPCTNET.

173
00:07:16,640 --> 00:07:22,120
SOME EXAMPLES OF PROTOCOLS AND

174
00:07:22,120 --> 00:07:28,400
CPCTNET WITH SENOPRIL, HERE FOR

175
00:07:28,400 --> 00:07:28,920
NON-ALCOHOLIC FATTY LIVER

176
00:07:28,920 --> 00:07:32,400
DISEASE, SOME WORK ON MONOVALENT

177
00:07:32,400 --> 00:07:37,080
PROPHYLACTIC HPV VACCINATION,

178
00:07:37,080 --> 00:07:39,800
PROSTATE CANCER PATIENTS, SOME

179
00:07:39,800 --> 00:07:43,240
WORK ON METAPHORMAN AND SO

180
00:07:43,240 --> 00:07:43,440
FORTH.

181
00:07:43,440 --> 00:07:45,440
THIS IS JUST A TIP OF THE

182
00:07:45,440 --> 00:07:47,240
ICEBERG, THERE IS ANOTHER DOZEN

183
00:07:47,240 --> 00:07:48,360
PROTOCOLS LINED UP TO BE

184
00:07:48,360 --> 00:07:52,560
LAUNCHED IN CPCTNET IN THE

185
00:07:52,560 --> 00:07:56,280
FOLLOWING YEAR OR SO.

186
00:07:56,280 --> 00:07:57,400
ANOTHER IMPORTANT COMPONENT OF

187
00:07:57,400 --> 00:08:01,200
THE DIVISION IS SCREENING AND

188
00:08:01,200 --> 00:08:02,880
EARLY DETECTION.  MORE AND MORE

189
00:08:02,880 --> 00:08:04,880
THINKING RISK INFORMED SCREEN

190
00:08:04,880 --> 00:08:07,000
HIGHER THE RISK MORE SCREEN

191
00:08:07,000 --> 00:08:09,400
DIFFERENTIAL MANAGEMENT AND ALSO

192
00:08:09,400 --> 00:08:11,080
POTENTIAL FOR INTERVENTION WITH

193
00:08:11,080 --> 00:08:14,200
TARGETED PREVENTIVE AGENTS.

194
00:08:14,200 --> 00:08:16,320
TODAY WE ARE SOMEWHAT LIMITED TO

195
00:08:16,320 --> 00:08:20,040
BREAST CERVIX COLORECTAL LUNG

196
00:08:20,040 --> 00:08:21,600
HCV FOR LIVER AND PROSTATE IN

197
00:08:21,600 --> 00:08:22,600
SELECT POPULATIONS.

198
00:08:22,600 --> 00:08:24,240
OBVIOUSLY THAT IS NOT ENOUGH AND

199
00:08:24,240 --> 00:08:25,680
THERE'S MUCH MORE WORK TO BE

200
00:08:25,680 --> 00:08:27,920
DONE FOR SCREENING TO REALLY

201
00:08:27,920 --> 00:08:31,720
START TO IMPACT INCIDENCE RATES

202
00:08:31,720 --> 00:08:35,400
OF CANCER AND CANCER MORTALITY.

203
00:08:35,400 --> 00:08:37,760
SO THIS IS IT HAS ACRONYMS AND I

204
00:08:37,760 --> 00:08:39,240
APOLOGIZE KNOW SHY WAY TO LAY

205
00:08:39,240 --> 00:08:39,640
THIS OUT.

206
00:08:39,640 --> 00:08:42,080
I WILL TRY TO EXPLAIN SOME OF

207
00:08:42,080 --> 00:08:44,560
THEM, EDRM IS ESSENTIAL TO

208
00:08:44,560 --> 00:08:48,800
BIOMARKER DISCOVERY AND EARLY

209
00:08:48,800 --> 00:08:50,200
DETECTION PROGRAMS THEN THERE

210
00:08:50,200 --> 00:08:52,040
ARE COMPLIMENTARY PROGRAMS

211
00:08:52,040 --> 00:08:54,160
DEDICATED ONE TO PANCREATIC

212
00:08:54,160 --> 00:08:59,560
CANCER LIVER CANCER, BIAS

213
00:08:59,560 --> 00:09:02,000
CONSORTIM, IMAGING PROGRAM, OUR

214
00:09:02,000 --> 00:09:04,400
NEW PROGRAM DIFFERENTIATE

215
00:09:04,400 --> 00:09:09,240
BETWEEN AGGRESSIVE AND INDOLENT

216
00:09:09,240 --> 00:09:11,240
DISEASE, I MENTIONED BEFORE

217
00:09:11,240 --> 00:09:14,360
WHICH DOVE TAILS INTO A

218
00:09:14,360 --> 00:09:15,280
PRAGMATIC RULE TRIAL FOR SCREEN

219
00:09:15,280 --> 00:09:16,840
FOR ANYONE LIVING WITH HIV.

220
00:09:16,840 --> 00:09:18,400
LAST MILES OUR EFFORT TO GET

221
00:09:18,400 --> 00:09:23,800
WORK WITH THE FDA TO GET

222
00:09:23,800 --> 00:09:25,080
SELF-COLLECTION HPV TESTING

223
00:09:25,080 --> 00:09:28,800
APPROVED FOR CERVICAL CANCER

224
00:09:28,800 --> 00:09:30,840
SCREEN INCOME THE UNITED STATES.

225
00:09:30,840 --> 00:09:32,320
-- SCREENING IN THE UNITED

226
00:09:32,320 --> 00:09:34,920
STATES.

227
00:09:34,920 --> 00:09:37,040
THIS IS THE ERN, AS YOU KNOW

228
00:09:37,040 --> 00:09:41,400
FROM COUPLE OF SESSIONS AGO NOW

229
00:09:41,400 --> 00:09:48,120
IT IS 20, 21EST YEAR A COMPLEX

230
00:09:48,120 --> 00:09:53,560
PROGRAM THAT TOUCHES THE WORLD.

231
00:09:53,560 --> 00:09:54,600
EDRM COLLABORATE IN CHINA,

232
00:09:54,600 --> 00:09:58,600
JAPAN, INDIA, FRANCE.

233
00:09:58,600 --> 00:09:59,560
COLLABORATORS, 350 ASSOCIATE

234
00:09:59,560 --> 00:10:02,360
MEMBERS FOCUSED ON PROSTATE

235
00:10:02,360 --> 00:10:03,960
NEUROLOGIC DISEASE BREAST AND

236
00:10:03,960 --> 00:10:06,440
OTHER GYNECOLOGIC LUNG UPPER AIR

237
00:10:06,440 --> 00:10:16,080
DIGESTIVE COLON AND UP PER GI.

238
00:10:16,080 --> 00:10:17,960
THIS IS THE NCOR, HIGHLIGHT

239
00:10:17,960 --> 00:10:19,160
REDIRECT EXAMINATION MINORITY

240
00:10:19,160 --> 00:10:24,400
CENTERS.

241
00:10:24,400 --> 00:10:27,200
AND TREMENDOUS LEADERSHIP JOB TO

242
00:10:27,200 --> 00:10:29,880
KEEP THIS PROGRAM GOING AND

243
00:10:29,880 --> 00:10:30,400
GROWING.

244
00:10:30,400 --> 00:10:34,880
NOW OVER A THOUSAND CLINICAL

245
00:10:34,880 --> 00:10:37,760
SITES THROUGH 46 CENTERS AND

246
00:10:37,760 --> 00:10:38,920
AFFILIATES AND THOUSANDS OF

247
00:10:38,920 --> 00:10:41,800
INVESTIGATORS.  A NATIONAL

248
00:10:41,800 --> 00:10:44,160
INTERNATIONAL PROGRAM ON CANCER

249
00:10:44,160 --> 00:10:47,600
PREVENTION CONTROL AND ONCOLOGY.

250
00:10:47,600 --> 00:10:50,280
JUST TO UPDATE YOU ON TEAMNESS

251
00:10:50,280 --> 00:10:53,040
SINCE THIS WAS MY FIRST

252
00:10:53,040 --> 00:10:54,880
INTRODUCTION BSA 18 MONTHS OR

253
00:10:54,880 --> 00:10:57,440
SO, THE PRIMARY END POINTS

254
00:10:57,440 --> 00:10:58,800
REMAIN ADVANCE CANCER BUT

255
00:10:58,800 --> 00:11:04,400
THERE'S SOME MODIFICATIONS,

256
00:11:04,400 --> 00:11:06,800
ADVANCED CANCER FIXED TIME

257
00:11:06,800 --> 00:11:10,000
PERIOD FOUR AND A HALF YEARS

258
00:11:10,000 --> 00:11:10,680
REVITALIZATION.

259
00:11:10,680 --> 00:11:12,120
ADVANCE CANCER ANY TIME UP TO

260
00:11:12,120 --> 00:11:16,280
SEVEN YEARS FROM RANDOMIZATION.

261
00:11:16,280 --> 00:11:19,240
WE LOWERED THE POWER FROM 85% TO

262
00:11:19,240 --> 00:11:22,960
90% TO REDUCE SAMPLE SIZE BY

263
00:11:22,960 --> 00:11:26,240
36,000 BUT THE DERIVATION OF

264
00:11:26,240 --> 00:11:29,400
SAMPLE SIZE CONTINUES TO ASSUME

265
00:11:29,400 --> 00:11:31,320
20% RELATIVE REDUCTION IN H

266
00:11:31,320 --> 00:11:32,760
ADVANCE CANCER FOUR AND A HALF

267
00:11:32,760 --> 00:11:34,640
YEARS FOLLOWING RANDOMIZATION.

268
00:11:34,640 --> 00:11:40,800
THE READ OUT EXPECTED BY MID

269
00:11:40,800 --> 00:11:41,200
2027.

270
00:11:41,200 --> 00:11:45,280
HERE IS UPDATED ACCRUE THANK YOU

271
00:11:45,280 --> 00:11:47,600
TO WARTA'S TEAM FOR PROVIDING

272
00:11:47,600 --> 00:11:47,800
THAT.

273
00:11:47,800 --> 00:11:49,360
YOU CAN SEE THE DIP FOLLOWING

274
00:11:49,360 --> 00:11:53,920
ONSET OF PANDEMIC BUT THEIR

275
00:11:53,920 --> 00:11:56,000
CREDIT THEY ARE CONSISTENTLY

276
00:11:56,000 --> 00:12:00,360
ABOVE 2000 ENROLLMENTS MONTHLY

277
00:12:00,360 --> 00:12:05,200
AND AS OF 12, 1, 2021 AT 60,000,

278
00:12:05,200 --> 00:12:07,000
HALF THE ENROLLMENT.

279
00:12:07,000 --> 00:12:11,520
HERE ARE SOME OF THE OTHER

280
00:12:11,520 --> 00:12:15,320
ACTIVITIES IN THE NCOR.

281
00:12:15,320 --> 00:12:18,880
3-D MAMMOGRAPHY.

282
00:12:18,880 --> 00:12:22,800
PORTE JUST LAUNCHED TO LOOK AT

283
00:12:22,800 --> 00:12:27,400
WHETHER FIVE VERSUS TEN YEAR

284
00:12:27,400 --> 00:12:28,240
COLONOSCOPY FOR LOW GRADE

285
00:12:28,240 --> 00:12:29,000
POLYPS.

286
00:12:29,000 --> 00:12:30,920
T A IMMUNE CHECK POINT

287
00:12:30,920 --> 00:12:32,480
OPTIMIZING FUNCTIONAL OUTCOMES

288
00:12:32,480 --> 00:12:35,920
OVER CANCER SURVIVORS AFTER

289
00:12:35,920 --> 00:12:39,600
CHEMOTHERAPY WE HAVE CYST

290
00:12:39,600 --> 00:12:42,120
SURVEILLANCE PROJECT, LOOKING AT

291
00:12:42,120 --> 00:12:44,240
SURGICAL REMOVAL OF OVARIES

292
00:12:44,240 --> 00:12:47,240
VERSUS OVARIES AND FA LOANIAN

293
00:12:47,240 --> 00:12:50,480
TUBES REDUCING RISK OF OVARIAN

294
00:12:50,480 --> 00:12:56,200
CANCER IN BRACA 1 PATIENTS.

295
00:12:56,200 --> 00:12:57,560
THERE HAS BEEN TALK AND INTEREST

296
00:12:57,560 --> 00:13:00,200
IN LIQUID BIOPSY CALLING NOW

297
00:13:00,200 --> 00:13:01,960
MULTI-CANCER EARLY DETECTION

298
00:13:01,960 --> 00:13:05,800
PREVENTION SPACE, AND SO ABOUT

299
00:13:05,800 --> 00:13:09,560
12 MONTHS AGO UNDER NED'S

300
00:13:09,560 --> 00:13:10,880
ADVISEMENT AND LEADERSHIP WE

301
00:13:10,880 --> 00:13:14,360
HAVE STOOD UP A TRANSNCI, BEYOND

302
00:13:14,360 --> 00:13:18,000
NCI WE HAVE FOLKS FROM CMS FDA

303
00:13:18,000 --> 00:13:20,960
SITTING IN ON MEETINGS.

304
00:13:20,960 --> 00:13:23,400
LOOKING AT EVERYTHING FROM BASIC

305
00:13:23,400 --> 00:13:25,000
SCIENCE WHY THESE MARKERS

306
00:13:25,000 --> 00:13:26,760
GETTING BLOOD AND WHAT IS BASIS

307
00:13:26,760 --> 00:13:30,520
OF HETEROGENEITY IN THOSE BLOOD

308
00:13:30,520 --> 00:13:32,560
BORN MARKERS, HOW TO USE COHORT

309
00:13:32,560 --> 00:13:34,240
STUDIES TO STUDY NATURAL HISTORY

310
00:13:34,240 --> 00:13:37,000
OF THESE BIOMARKERS.

311
00:13:37,000 --> 00:13:38,480
TO AND I WILL TALK ABOUT THIS IN

312
00:13:38,480 --> 00:13:41,400
A SECOND, THE NEED FOR RANDOMIZE

313
00:13:41,400 --> 00:13:43,000
CLINICAL TRIALS TO REALLY

314
00:13:43,000 --> 00:13:45,200
UNDERSTAND THE BENEFITS AND

315
00:13:45,200 --> 00:13:46,840
HARMS OF THESE INTERVENTIONS,

316
00:13:46,840 --> 00:13:50,440
THESE ASSAYS, THESE TECHNOLOGIES

317
00:13:50,440 --> 00:13:52,880
TECHNOLOGIES.

318
00:13:52,880 --> 00:13:54,680
WE HAD N SAID STUDY DESIGN

319
00:13:54,680 --> 00:13:56,920
WORKSHOP, INCREDIBLY COMPLICATED

320
00:13:56,920 --> 00:13:58,760
TO LOOK AT MULTI-CANCER EARLY

321
00:13:58,760 --> 00:14:02,080
DETECTION, LED BY LORI MINASIAN

322
00:14:02,080 --> 00:14:02,800
MY DEPUTY DIRECTOR.

323
00:14:02,800 --> 00:14:05,920
THE OUTCOMES FROM THE WORKSHOP

324
00:14:05,920 --> 00:14:08,920
REALLY WHAT WE KNOW IS THE MCED

325
00:14:08,920 --> 00:14:11,160
ASSAYS HAVE LIMITED SENSITIVITY

326
00:14:11,160 --> 00:14:15,000
OR AT BEST MODEST SENSITIVITY

327
00:14:15,000 --> 00:14:16,360
FOR EARLY STAGE GREATER FOR

328
00:14:16,360 --> 00:14:18,120
ADVANCE STAGE, SPECIFICITY

329
00:14:18,120 --> 00:14:20,000
REMAINS -- APPEARS TO BE HIGH

330
00:14:20,000 --> 00:14:21,400
BUT WE DON'T KNOW WHAT THE

331
00:14:21,400 --> 00:14:23,400
BENEFITS ARE OF THESE TESTS.

332
00:14:23,400 --> 00:14:24,560
THEY BIND CANCER BUT WE DON'T

333
00:14:24,560 --> 00:14:27,000
KNOW IF THERE IS END STAGE SHIFT

334
00:14:27,000 --> 00:14:28,880
OR MORTALITY BENEFIT AND WE

335
00:14:28,880 --> 00:14:30,440
CERTAINLY DON'T KNOW WHAT THE

336
00:14:30,440 --> 00:14:31,160
HARMS ARE.

337
00:14:31,160 --> 00:14:32,760
THERE ARE SOME NOVEL

338
00:14:32,760 --> 00:14:34,520
IMPLEMENTATION CHALLENGES, HOW

339
00:14:34,520 --> 00:14:37,400
QUICKLY AND RELIABLY WE CAN FARM

340
00:14:37,400 --> 00:14:39,520
CANCER STATUS IN SIGHT AFTER

341
00:14:39,520 --> 00:14:40,200
POSITIVE TEST.

342
00:14:40,200 --> 00:14:42,960
HOW BEST TO SCREEN MULTI-CANCER

343
00:14:42,960 --> 00:14:44,560
WITH DIFFERENT LATENCY PERIODS.

344
00:14:44,560 --> 00:14:46,280
ARE ALL TESTS THE SAME FOR ALL

345
00:14:46,280 --> 00:14:50,240
THE POPULATION GIVEN THEY TARGET

346
00:14:50,240 --> 00:14:52,600
DIFFERENT BIOMARKERS AND HOW

347
00:14:52,600 --> 00:14:54,560
WELL ARE THOSE BIOMARKERS

348
00:14:54,560 --> 00:14:55,360
REPRESENTED ACROSS THE

349
00:14:55,360 --> 00:14:55,800
POPULATION.

350
00:14:55,800 --> 00:14:57,080
WE DON'T KNOW ANY OF THOSE

351
00:14:57,080 --> 00:15:00,000
THINGS.

352
00:15:00,000 --> 00:15:02,320
THERE IS UNIFORM AGREEMENT, THIS

353
00:15:02,320 --> 00:15:06,080
WAS A MEETING OF 60 EXPERTS THAT

354
00:15:06,080 --> 00:15:08,520
THE NCI MEETS TO SUPPORT A TRIAL

355
00:15:08,520 --> 00:15:10,000
TO EVALUATE THESE TECHNOLOGIES.

356
00:15:10,000 --> 00:15:11,840
THERE ARE A LOT OF UNKNOWNS,

357
00:15:11,840 --> 00:15:13,400
THIS IS JUST THE TIP OF THE

358
00:15:13,400 --> 00:15:16,960
ICEBERG AND WE HAVE PAGES OF

359
00:15:16,960 --> 00:15:18,640
VARIABILITY AND DIAGNOSTIC WORK

360
00:15:18,640 --> 00:15:20,600
UP, DIFFERENT ASSAY TO PROVIDE

361
00:15:20,600 --> 00:15:23,680
TISSUE OF ORIGIN, NOT ALL OF

362
00:15:23,680 --> 00:15:25,880
THEM, EVEN IF YOU HAVE A TISSUE

363
00:15:25,880 --> 00:15:27,320
LOCATER WE DON'T KNOW -- WE

364
00:15:27,320 --> 00:15:28,800
HAVEN'T WORKED THROUGH WHAT IS

365
00:15:28,800 --> 00:15:30,200
THE DIAGNOSTIC RESOLUTION AND

366
00:15:30,200 --> 00:15:32,600
WHAT YOU DO IF YOU DON'T FIND

367
00:15:32,600 --> 00:15:34,400
CANCER WHERE YOU ARE SUPPOSED TO

368
00:15:34,400 --> 00:15:35,200
FIND IT.

369
00:15:35,200 --> 00:15:37,480
SO WE NEED TO ASSESS WHAT THE

370
00:15:37,480 --> 00:15:40,200
PROCESS WOULD BE AND WHEN TO

371
00:15:40,200 --> 00:15:45,200
STOP THE WORK UP.

372
00:15:45,200 --> 00:15:47,320
ADDITIONAL THEMES, ENSURING

373
00:15:47,320 --> 00:15:50,440
ENROLLMENT OF VARIOUS POPULATION

374
00:15:50,440 --> 00:15:52,480
POPULATIONS AND THIS IS A POINT

375
00:15:52,480 --> 00:15:53,800
DR. SHARPLESS HAS EMPHASIZED

376
00:15:53,800 --> 00:15:55,800
FROM THE BEGINNING WE NEED TO

377
00:15:55,800 --> 00:15:56,720
MAKE SURE THE REPRESENTATIVE

378
00:15:56,720 --> 00:16:01,080
POPULATIONS INCLUDING

379
00:16:01,080 --> 00:16:02,160
UNDERSERVED, HAS TO BE DIVERSE,

380
00:16:02,160 --> 00:16:04,200
WE HAVE TO REACH VULNERABLE

381
00:16:04,200 --> 00:16:05,400
POPULATIONS THAT GET GREATEST

382
00:16:05,400 --> 00:16:11,400
BENEFIT AS WE  AS WE ALL REALIZE
HOW TO

383
00:16:11,400 --> 00:16:12,480
INCORPORATE HIGH RISK

384
00:16:12,480 --> 00:16:12,800
POPULATIONS.

385
00:16:12,800 --> 00:16:14,000
WE NEED COMMUNICATION STRATEGY

386
00:16:14,000 --> 00:16:17,760
FOR THE TRIAL AND IN GENERAL

387
00:16:17,760 --> 00:16:19,200
ABOUT THIS BECAUSE AS YOU KNOW A

388
00:16:19,200 --> 00:16:21,400
LOT IS GOING DIRECT TO CONSUMER,

389
00:16:21,400 --> 00:16:22,640
BEING OFFERED WITHOUT FDA

390
00:16:22,640 --> 00:16:27,120
APPROVAL.

391
00:16:27,120 --> 00:16:29,560
WE NEED TO ASSURE ADEQUATE

392
00:16:29,560 --> 00:16:30,680
FOLLOW-UP TO MAKE SURE PEOPLE

393
00:16:30,680 --> 00:16:32,920
GET WHAT THEY NEED FOR CARE.

394
00:16:32,920 --> 00:16:34,240
OBVIOUSLY THE FIRST TWO WHAT I

395
00:16:34,240 --> 00:16:37,480
CALL MY HOLY GRAIL YOU SEE TWO

396
00:16:37,480 --> 00:16:40,800
PIPELINES I PRESENTED COME

397
00:16:40,800 --> 00:16:44,480
TOGETHER.

398
00:16:44,480 --> 00:16:46,720
WHERE A BIOMARKER CAN BE USED TO

399
00:16:46,720 --> 00:16:48,320
IDENTIFY SOMEBODY AT RISK AND

400
00:16:48,320 --> 00:16:53,360
THEN WE HAVE REMOVAL A WHOLE

401
00:16:53,360 --> 00:16:54,200
TISSUE, GOING FORWARD.

402
00:16:54,200 --> 00:16:56,600
SO I HOPE IN MY TIME AT DCP WE

403
00:16:56,600 --> 00:16:58,200
WILL SEE A TRIAL THAT BRINGS

404
00:16:58,200 --> 00:17:01,200
THOSE TWO ELEMENTS TOGETHER.

405
00:17:01,200 --> 00:17:04,080
THEN FINALLY SYMPTOM SCIENCE

406
00:17:04,080 --> 00:17:05,080
SITS IN DCP.

407
00:17:05,080 --> 00:17:07,960
I THINK THIS HAS A TREMENDOUS

408
00:17:07,960 --> 00:17:10,200
GROWTH POTENTIAL, REALLY WE NEED

409
00:17:10,200 --> 00:17:13,720
-- WE MOW VERY WELL THAT BETTER

410
00:17:13,720 --> 00:17:15,600
SYMPTOM SCIENCE BETTER SYMPTOM

411
00:17:15,600 --> 00:17:16,720
MANAGEMENT CAN ONLY BENEFIT

412
00:17:16,720 --> 00:17:18,040
CANCER PATIENTS AND THEIR

413
00:17:18,040 --> 00:17:20,000
ABILITY TO GET ADDITIONAL

414
00:17:20,000 --> 00:17:22,040
THERAPIES.

415
00:17:22,040 --> 00:17:26,000
SO HERE IS OUR PIPELINE HERE, WE

416
00:17:26,000 --> 00:17:28,880
HAVE A VARIETY OF RFAs AND

417
00:17:28,880 --> 00:17:32,160
PFAR AND RFAs TO SUPPORT EARLY

418
00:17:32,160 --> 00:17:33,120
DISCOVERY AND TRANSLATION TO

419
00:17:33,120 --> 00:17:36,120
HUMANS AND NCORP AT THE CENTER

420
00:17:36,120 --> 00:17:39,280
OF SYMPTOM SCIENCE ACTIVITIES.

421
00:17:39,280 --> 00:17:42,080
WE HAVE MOON SHOT TOLERABILITY

422
00:17:42,080 --> 00:17:46,120
CONSORTIUM FOCUSED ON HELPING US

423
00:17:46,120 --> 00:17:49,600
TO FIND END POINTS.

424
00:17:49,600 --> 00:17:52,200
SO SYMPTOM MANAGEMENT TOXICITY

425
00:17:52,200 --> 00:17:53,360
MITIGATION, UNDERSTANDING

426
00:17:53,360 --> 00:17:54,800
MECHANISMS OF ACTION FOR CHRONIC

427
00:17:54,800 --> 00:17:59,360
ADVERSE EFFECTS.

428
00:17:59,360 --> 00:18:01,400
CHARACTERIZE CLINICAL SYNDROMES

429
00:18:01,400 --> 00:18:02,920
FOR TOXICITY AND SYMPTOMS,

430
00:18:02,920 --> 00:18:04,160
CAPTURE HOW THE PATIENT

431
00:18:04,160 --> 00:18:06,920
FUNCTIONS AND FEELS, THROUGH

432
00:18:06,920 --> 00:18:07,760
PATIENT REPORTED OUTCOMES.

433
00:18:07,760 --> 00:18:10,960
THERE IS A HEAVY RELIANCE ON

434
00:18:10,960 --> 00:18:12,960
CLINICAL READ OUTS, CLINICIAN

435
00:18:12,960 --> 00:18:17,280
REPORTS OF THIS AND WE SEE THE

436
00:18:17,280 --> 00:18:18,400
DATA THE CORRELATIONS ARE NOT

437
00:18:18,400 --> 00:18:19,800
THAT GREAT AND WE NEED TO FIGURE

438
00:18:19,800 --> 00:18:24,600
OUT HOW TO COLLECT THE PATIENT

439
00:18:24,600 --> 00:18:25,440
EXPERIENCE AND BASE OUR

440
00:18:25,440 --> 00:18:27,400
MANAGEMENT ON THAT AS MUCH AS

441
00:18:27,400 --> 00:18:30,760
CLINICAL READ OUTS.

442
00:18:30,760 --> 00:18:33,800
THESE ARE THE TRANSNCI RESEARCH

443
00:18:33,800 --> 00:18:35,000
OPPORTUNITIES, PROVOCATIVE

444
00:18:35,000 --> 00:18:36,000
QUESTION WHAT ARE MOLECULAR

445
00:18:36,000 --> 00:18:37,600
CELLULAR MECHANISMS THAT

446
00:18:37,600 --> 00:18:38,600
UNDERLIE DEVELOPMENT OF CANCER

447
00:18:38,600 --> 00:18:43,400
THERAPY INDUCED SERIOUS SEVERE

448
00:18:43,400 --> 00:18:45,000
ADVERSE SEQUELAE, CLINICAL

449
00:18:45,000 --> 00:18:46,000
CHARACTERIZATION OF CANCER,

450
00:18:46,000 --> 00:18:49,520
THERAPY INDUCED SEQUELAE AND

451
00:18:49,520 --> 00:18:51,600
MECHANISM BASED INTERVENTION

452
00:18:51,600 --> 00:18:52,920
STRATEGIES AND ANALYZING

453
00:18:52,920 --> 00:18:53,680
INTERPRETING CLINICAL AND

454
00:18:53,680 --> 00:18:55,400
PATIENT ADVERSE EVENT DATA TO

455
00:18:55,400 --> 00:18:57,320
BETTER UNDERSTAND TOLERABILITY.

456
00:18:57,320 --> 00:19:01,400
WHAT THIS IS LEADING TO IS

457
00:19:01,400 --> 00:19:02,840
PRECISION SYMPTOM MANAGEMENT.

458
00:19:02,840 --> 00:19:04,320
AND PREVENTION.

459
00:19:04,320 --> 00:19:07,440
BUT THE IDEA WE ARE APPLYING THE

460
00:19:07,440 --> 00:19:11,960
SAME IDEAS THE SAME TECHNOLOGIES

461
00:19:11,960 --> 00:19:13,960
FOR HOW WE TREAT PATIENTS AND

462
00:19:13,960 --> 00:19:15,520
PREVENT THEM AND NEED TO DO SAME

463
00:19:15,520 --> 00:19:20,040
FOR SYMPTOM MANAGEMENT, THAT IS

464
00:19:20,040 --> 00:19:21,080
POSSIBLE.

465
00:19:21,080 --> 00:19:27,640
I WANT TO HIGHLIGHT SEVERAL

466
00:19:27,640 --> 00:19:30,600
ALEXIS BAK ONS AND SEVERAL

467
00:19:30,600 --> 00:19:34,120
MEMBERS FROM THE DIVISIONS HAD A

468
00:19:34,120 --> 00:19:35,920
WORKSHOP THIS YEAR AND THE

469
00:19:35,920 --> 00:19:36,800
MONOGRAPH IS PUBLISHED LAST

470
00:19:36,800 --> 00:19:37,200
WEEK.

471
00:19:37,200 --> 00:19:40,280
IT IS A CUTTING EDGE LOOK AT

472
00:19:40,280 --> 00:19:41,200
CANNABIS USE IN CANCER CONTROL

473
00:19:41,200 --> 00:19:42,920
CARE.

474
00:19:42,920 --> 00:19:46,560
SO SOME OF PROPOSED DCP

475
00:19:46,560 --> 00:19:47,880
PRIORITIES, AND MY FINAL

476
00:19:47,880 --> 00:19:49,000
COMMENTS BIOLOGICAL POPULATION

477
00:19:49,000 --> 00:19:51,320
RISK INFORMED INTERVENTIONS

478
00:19:51,320 --> 00:19:53,800
OBVIOUSLY BIOLOGY TELLS US ABOUT

479
00:19:53,800 --> 00:19:58,120
HOW TO TARGET AND PREEVENTUAL

480
00:19:58,120 --> 00:19:59,640
POPULATION WHICH TELLS US WHO

481
00:19:59,640 --> 00:20:01,920
NEEDS IT.

482
00:20:01,920 --> 00:20:02,920
OBESITY CONTINUES TO PLAGUE US

483
00:20:02,920 --> 00:20:05,400
IN THE SENSE THAT 20% CANCER ARE

484
00:20:05,400 --> 00:20:08,400
ATTRIBUTABLE TO CANCER BUT WE

485
00:20:08,400 --> 00:20:11,040
DON'T KNOW UNDERSTAND HOW

486
00:20:11,040 --> 00:20:12,800
OBESITY CONTRIBUTES TO

487
00:20:12,800 --> 00:20:13,320
CARCINOGENESIS.

488
00:20:13,320 --> 00:20:15,240
IF WE DID WE COULD MITIGATE

489
00:20:15,240 --> 00:20:16,360
EFFECTS AND I DON'T THINK WE

490
00:20:16,360 --> 00:20:17,800
SHOULD WAIT FOR BEHAVIORAL

491
00:20:17,800 --> 00:20:19,600
INTERVENTIONS TO SOLVE THIS

492
00:20:19,600 --> 00:20:21,480
PROBLEM BECAUSE WE SHOULD INVEST

493
00:20:21,480 --> 00:20:22,960
IN THAT BUT THE FACT IS WE HAVE

494
00:20:22,960 --> 00:20:25,600
COHORT OF PEOPLE WHO HAVE BEEN

495
00:20:25,600 --> 00:20:28,360
OBESE AND HAVE BEEN EXPOSED TO

496
00:20:28,360 --> 00:20:29,760
THESE CARCINOGENS.

497
00:20:29,760 --> 00:20:32,760
AS I EMPHASIZE WE NEED TO DONOR

498
00:20:32,760 --> 00:20:34,320
SYMPTOM SCIENCE PRECISION

499
00:20:34,320 --> 00:20:35,960
SYMPTOM PREVENTION MANAGEMENT.

500
00:20:35,960 --> 00:20:37,920
HOW DO WE USE BIOLOGY GENETICS

501
00:20:37,920 --> 00:20:39,760
AND EPIDEMIOLOGY TO UNDERSTAND

502
00:20:39,760 --> 00:20:42,440
ETIOLOGY SYMPTOMS.

503
00:20:42,440 --> 00:20:44,600
EXPLAIN ADVERSE RESPONSES TO

504
00:20:44,600 --> 00:20:45,600
TREATMENT AND REMOVE SYMPTOM

505
00:20:45,600 --> 00:20:46,840
MANAGEMENT FROM TRIAL AND ERROR

506
00:20:46,840 --> 00:20:49,400
TO PRECISION MEDICINE.

507
00:20:49,400 --> 00:20:51,000
HEALTH DISPARITIES I WORKED 20

508
00:20:51,000 --> 00:20:52,640
YEARS IN HEALTH DISPARITIES,

509
00:20:52,640 --> 00:20:56,080
NEAR AND DEAR TO MY HEART, MUCH

510
00:20:56,080 --> 00:20:57,920
OF MY INTEREST IN THIS IS REALLY

511
00:20:57,920 --> 00:21:00,600
HOW WE DO INNOVATIVE OR HOW DO

512
00:21:00,600 --> 00:21:03,960
WE INN INVESTIGATE IN TECHNOLOGY

513
00:21:03,960 --> 00:21:04,880
-- INNOVATE IN TECHNOLOGY

514
00:21:04,880 --> 00:21:06,000
SELF-SELECTION POINT OF CARE

515
00:21:06,000 --> 00:21:07,480
TESTING TO BRING STANDARD CARE

516
00:21:07,480 --> 00:21:08,800
OR BETTER FOR UNDERSERVED

517
00:21:08,800 --> 00:21:09,920
POPULATIONS PARTICULARLY HIGH

518
00:21:09,920 --> 00:21:10,600
RISK OF CANCER.

519
00:21:10,600 --> 00:21:12,600
WE TALK ABOUT GENETIC

520
00:21:12,600 --> 00:21:13,400
PRE-DISPOSITION FOR CANCER AS

521
00:21:13,400 --> 00:21:15,880
HIGHER RISK, THIS IS ALSO HIGH

522
00:21:15,880 --> 00:21:17,280
RISK GROUP AND WE NEED TO GET

523
00:21:17,280 --> 00:21:18,240
AFTER IT.

524
00:21:18,240 --> 00:21:22,000
WE ARE INUNDATED WITH NEW

525
00:21:22,000 --> 00:21:22,840
TECHNOLOGIES, ARTIFICIAL

526
00:21:22,840 --> 00:21:24,280
INTELLIGENCE, IF THIS IS LIKE --

527
00:21:24,280 --> 00:21:25,600
ARTIFICIAL INTELLIGENCE LIKE THE

528
00:21:25,600 --> 00:21:27,600
MICROBIOME TEN YEARS AGO,

529
00:21:27,600 --> 00:21:29,560
EVERYONE THAT COMES IN WITH

530
00:21:29,560 --> 00:21:31,400
ARTIFICIAL INTELLIGENCE ANGLE,

531
00:21:31,400 --> 00:21:33,480
WE NEED TO BE ABLE TO

532
00:21:33,480 --> 00:21:34,640
DISTINGUISH BETWEEN WHAT IS GOOD

533
00:21:34,640 --> 00:21:35,320
AND WHAT IS NOT.

534
00:21:35,320 --> 00:21:37,360
SO WE ARE GOING TO -- WE ARE

535
00:21:37,360 --> 00:21:38,600
GOING TO MAKE AN INVESTMENT BOTH

536
00:21:38,600 --> 00:21:40,800
IN STAFFING AND OUR KNOWLEDGE TO

537
00:21:40,800 --> 00:21:41,280
GET AFTER THIS.

538
00:21:41,280 --> 00:21:44,240
I HAVE TALKED MULTI-CANCER EARLY

539
00:21:44,240 --> 00:21:44,800
DETECTION.

540
00:21:44,800 --> 00:21:48,080
AND IMMUNOLOGY AND PREVENTIVE

541
00:21:48,080 --> 00:21:49,200
VACCINATION HAS BEEN TALKED

542
00:21:49,200 --> 00:21:51,200
ABOUT, WHAT CONSTITUTES AN

543
00:21:51,200 --> 00:21:52,800
EFFECTIVE IMMUNE RESPONSE TO

544
00:21:52,800 --> 00:21:54,920
CARCINOGEN INSULT.

545
00:21:54,920 --> 00:21:57,600
AND INVESTMENT IN NEOANTIGEN

546
00:21:57,600 --> 00:22:02,880
IDENTIFICATION AND VALIDATION.

547
00:22:02,880 --> 00:22:04,720
MY FINAL COMMENT IS O TO SAY WE

548
00:22:04,720 --> 00:22:07,680
NEED TO REDEFINE PRECISION

549
00:22:07,680 --> 00:22:09,000
CANCER PREVENTION TO PROMOTE

550
00:22:09,000 --> 00:22:09,760
HEALTH EQUITY.

551
00:22:09,760 --> 00:22:11,560
MAXIMIZE THE BENEFITS AND HARMS

552
00:22:11,560 --> 00:22:14,440
FOR THE ENTIRE POPULATION NOT

553
00:22:14,440 --> 00:22:15,720
FOR SELECT POPULATION,

554
00:22:15,720 --> 00:22:17,280
UNDERSTANDING ALL CAUSES OF

555
00:22:17,280 --> 00:22:19,280
DIFFERENCES, NOT JUST BIOLOGICAL

556
00:22:19,280 --> 00:22:21,240
INFORMS HOW WE CAN BE MORE

557
00:22:21,240 --> 00:22:21,840
PRECISE.

558
00:22:21,840 --> 00:22:25,080
SO WHO, AGAIN POPULATION RISK,

559
00:22:25,080 --> 00:22:28,720
WHAT USING BIOLOGIC RISK TO

560
00:22:28,720 --> 00:22:30,160
TARGET WE CAN ADD INTO THIS

561
00:22:30,160 --> 00:22:32,440
EQUATION INCREASING ACCESS TO

562
00:22:32,440 --> 00:22:35,120
ALTERNATIVE HEALTHCARE DELIVERY

563
00:22:35,120 --> 00:22:37,200
STRATEGIES, AND HOW WE CAN USE

564
00:22:37,200 --> 00:22:40,560
DIFFERENT DELIVERIES LIKE

565
00:22:40,560 --> 00:22:43,000
TOPICAL TAMOXIFEN DERIVATIVES TO

566
00:22:43,000 --> 00:22:45,320
INCREASE BIOAVAILABILITY AT THE

567
00:22:45,320 --> 00:22:48,080
TARGET SITE AND LIMIT SYSTEMIC

568
00:22:48,080 --> 00:22:52,200
EXPOSURE AND REDUCE TOXICITY AND

569
00:22:52,200 --> 00:22:54,560
HARMS SO I WANT TO FINISH, I

570
00:22:54,560 --> 00:22:57,360
THINK I STOLE THIS SLIDE FROM

571
00:22:57,360 --> 00:22:58,400
DOUG LOWY.

572
00:22:58,400 --> 00:23:01,320
JUST A DISCLOSURE THERE, I WANT

573
00:23:01,320 --> 00:23:04,320
TO REALLY THANK THE STAFF AT DCP

574
00:23:04,320 --> 00:23:06,960
WHO DO AMAZING JOB EVERY DAY AND

575
00:23:06,960 --> 00:23:09,200
WELCOMED ME WITH OPEN ARMS, IT

576
00:23:09,200 --> 00:23:11,960
HAS BEEN A THRILL TO WORK WITHIN

577
00:23:11,960 --> 00:23:15,840
THE LAST 19 MONTHS, I WANT TO

578
00:23:15,840 --> 00:23:21,120
ACKNOWLEDGE DEN BRA WHEN WHO

579
00:23:21,120 --> 00:23:23,160
MADE IT A CRAZY TIME TO COME TO

580
00:23:23,160 --> 00:23:23,600
NCI.

581
00:23:23,600 --> 00:23:26,080
NCI LEADERSHIP NED SHARPLESS

582
00:23:26,080 --> 00:23:28,960
UNDER LEADERSHIP AND MENTORSHIP.

583
00:23:28,960 --> 00:23:32,400
I HAVE KNOWN DOUG 20 YEARS AND

584
00:23:32,400 --> 00:23:35,480
ME PROVIDES SAGE ADVICE.

585
00:23:35,480 --> 00:23:37,160
BOB DAN STEVEN TOMMY SHE WOULD

586
00:23:37,160 --> 00:23:40,960
ALL HELPED GETTING THESE GREAT

587
00:23:40,960 --> 00:23:42,280
REVISED HEALTH, A SHOULDER TO

588
00:23:42,280 --> 00:23:44,520
CRY ON WHEN NOT GOING QUITE THE

589
00:23:44,520 --> 00:23:45,000
WAY I WANT.

590
00:23:45,000 --> 00:23:47,360
SO I CAN'T THANK THEM ENOUGH FOR

591
00:23:47,360 --> 00:23:49,400
ALL THE THEY DO AND THE SUPPORT

592
00:23:49,400 --> 00:23:50,640
THEY HAVE GIVEN THEM AND WITH

593
00:23:50,640 --> 00:23:51,800
THAT I WILL TAKE ANY QUESTIONS.

594
00:23:51,800 --> 00:23:54,240
THANK YOU SO MUCH.

595
00:23:54,240 --> 00:23:58,200
>> THANK YOU SO MUCH, PHIL.

596
00:23:58,200 --> 00:24:01,680
THANK YOU FOR STAYING ON TIME

597
00:24:01,680 --> 00:24:04,680
AND BEING DIRECT AND SUCCINCT

598
00:24:04,680 --> 00:24:09,000
BUT FANTASTIC AND FASCINATING

599
00:24:09,000 --> 00:24:09,400
PRESENTATION.

600
00:24:09,400 --> 00:24:11,960
I'LL ASK THE FIRST QUESTION

601
00:24:11,960 --> 00:24:14,400
MICHELLE'S HAND AS WELL, A

602
00:24:14,400 --> 00:24:18,640
NUMBER OF HANDS SO WHERE DOES

603
00:24:18,640 --> 00:24:20,920
FOR INSTANCE RISK OR RISK

604
00:24:20,920 --> 00:24:22,600
ASSESSMENT FALL WITHIN THIS AND

605
00:24:22,600 --> 00:24:24,600
HOW IS IT BEING INTEGRATED?

606
00:24:24,600 --> 00:24:27,280
I KNOW WE HAVE THE INTRAMURAL

607
00:24:27,280 --> 00:24:28,320
PROGRAM UNDER STEVE.

608
00:24:28,320 --> 00:24:30,320
WE ALSO HAVE BOB'S PROGRAM, I

609
00:24:30,320 --> 00:24:32,880
KNOW A LOT OF THAT WORK

610
00:24:32,880 --> 00:24:34,000
PERMEATES IN THOSE SPACES BUT

611
00:24:34,000 --> 00:24:35,640
HOW ARE YOU INTEGRATING THE

612
00:24:35,640 --> 00:24:37,240
WHOLE CONCEPT OF RISK.

613
00:24:37,240 --> 00:24:38,800
RISK ASSESSMENT FROM THE

614
00:24:38,800 --> 00:24:41,040
STANDPOINT OF GENETIC RISK OR

615
00:24:41,040 --> 00:24:42,480
POLYGENIC RISK SCORES, YOU

616
00:24:42,480 --> 00:24:44,600
MENTION YOU TOUCHED ON IT, HOW

617
00:24:44,600 --> 00:24:47,280
DOES THAT INTEGRATE INTO THE

618
00:24:47,280 --> 00:24:50,400
VISION IN THE FUTURE FOR

619
00:24:50,400 --> 00:24:50,800
PREVENTION?

620
00:24:50,800 --> 00:24:53,000
>> GREAT QUESTION, JOHN.

621
00:24:53,000 --> 00:24:56,960
I APOLOGIZE, I GAVE YOU A

622
00:24:56,960 --> 00:25:00,440
100,000 SO I MEAN CAN'T COVER A

623
00:25:00,440 --> 00:25:02,200
PROGRAM IN 20 MINUTES.

624
00:25:02,200 --> 00:25:06,680
CERTAINLY WE ARE TALKING ABOUT

625
00:25:06,680 --> 00:25:08,760
AND JUST JOIN SOD WE HAVEN'T HAD

626
00:25:08,760 --> 00:25:10,840
A DEEP CONVERSATION ABOUT HOW TO

627
00:25:10,840 --> 00:25:11,760
USE IT.

628
00:25:11,760 --> 00:25:13,720
THE DATA IS STARTING TO COME OUT

629
00:25:13,720 --> 00:25:15,600
WHERE WE CAN USE POLYGENIC RISK

630
00:25:15,600 --> 00:25:17,200
SCORE PARTICULARLY IN THE

631
00:25:17,200 --> 00:25:19,320
SCREENING CONTEXT WITH PROSTATE

632
00:25:19,320 --> 00:25:22,160
AND BREAST CANCER.

633
00:25:22,160 --> 00:25:23,200
ACTUALLY STEVEN AND I HAVE BEEN

634
00:25:23,200 --> 00:25:25,520
TALKING ABOUT WHETHER WE CAN

635
00:25:25,520 --> 00:25:28,400
STAND UP A PROS SATE CANCER

636
00:25:28,400 --> 00:25:31,200
SCREENING TRIAL WITH LOTS OF

637
00:25:31,200 --> 00:25:33,640
ISSUES HOW TO DO THAT.

638
00:25:33,640 --> 00:25:36,520
KEEP IN MIND PEOPLE FOCUS ON

639
00:25:36,520 --> 00:25:39,760
POLYGENIC RISK SCORE JUST FOR

640
00:25:39,760 --> 00:25:40,120
SCREENING.

641
00:25:40,120 --> 00:25:42,080
YOU CAN THINK POLYGENIC RISK

642
00:25:42,080 --> 00:25:45,000
SCORE ACROSS THE ENTIRE CARE

643
00:25:45,000 --> 00:25:45,400
CONTINUUM.

644
00:25:45,400 --> 00:25:48,200
IN FACT I WOULD LIKE TO USE MY

645
00:25:48,200 --> 00:25:49,600
EXPERIENCE AND 15 YEARS AGO I

646
00:25:49,600 --> 00:25:52,520
PROPOSED MANAGEMENT BASED ON

647
00:25:52,520 --> 00:25:54,880
RISK IN THE CERVIX WORLD AND NOW

648
00:25:54,880 --> 00:25:56,320
THAT HAS BECOME THE FOUNDATION

649
00:25:56,320 --> 00:25:58,240
FOR HOW DECISIONS HAVE BEEN --

650
00:25:58,240 --> 00:26:01,440
ARE BEING MADE.

651
00:26:01,440 --> 00:26:02,920
SO I WANT TO BRING THAT

652
00:26:02,920 --> 00:26:05,000
EXPERIENCE TO THIS WORKING WITH

653
00:26:05,000 --> 00:26:06,000
THE OTHER DOCTORS TO IMPLEMENT

654
00:26:06,000 --> 00:26:07,960
THAT.

655
00:26:07,960 --> 00:26:10,200
I THINK THE OTHER ISSUE, SURE

656
00:26:10,200 --> 00:26:11,840
MANY OF YOU APPRECIATE,

657
00:26:11,840 --> 00:26:14,600
EVERYBODY HAS THEIR RISK

658
00:26:14,600 --> 00:26:15,760
CALCULATOR.

659
00:26:15,760 --> 00:26:19,240
MOST OF THEM A LOT OF ACADEMIC

660
00:26:19,240 --> 00:26:20,600
INSTITUTIONS DO.

661
00:26:20,600 --> 00:26:22,280
THEY HAVEN'T BEEN VALIDATED OR

662
00:26:22,280 --> 00:26:23,400
THEY HAVE BEEN VALIDATED WITHIN

663
00:26:23,400 --> 00:26:26,320
THEIR POPULATION, NOT

664
00:26:26,320 --> 00:26:28,640
NECESSARILY OUR -- SO WE HAVE TO

665
00:26:28,640 --> 00:26:30,040
GET OUR HEADS AROUND THAT.

666
00:26:30,040 --> 00:26:31,480
THE FINAL THING, WE ARE WORKING

667
00:26:31,480 --> 00:26:35,680
WITH DCCPS, PAUL HOTT, THE OTHER

668
00:26:35,680 --> 00:26:37,000
CHALLENGE IS HOW TO COMMUNICATE

669
00:26:37,000 --> 00:26:38,920
ABOUT THIS.

670
00:26:38,920 --> 00:26:40,000
BECAUSE AT INDIVIDUAL LEVEL,

671
00:26:40,000 --> 00:26:43,040
PAUL TAUGHT ME THIS, IT WAS AN

672
00:26:43,040 --> 00:26:46,600
EYE OPENING THING, THAT PEOPLE

673
00:26:46,600 --> 00:26:48,800
DON'T EXPERIENCE 10% RISK THEY

674
00:26:48,800 --> 00:26:51,120
EITHER GET CANCER OR DON'T.

675
00:26:51,120 --> 00:26:54,200
THAT'S THE REALITY SO I THINK WE

676
00:26:54,200 --> 00:26:55,880
SAW THIS PLAY OUT WITH THE

677
00:26:55,880 --> 00:26:57,000
PANDEMIC, THE PEOPLE DON'T

678
00:26:57,000 --> 00:26:58,600
REALLY FUNDAMENTALLY UNDERSTAND

679
00:26:58,600 --> 00:27:00,400
RISK AND HOW IT RELATES TO THEM.

680
00:27:00,400 --> 00:27:02,480
SO WE HAVE TO DO A BETTER JOB OF

681
00:27:02,480 --> 00:27:06,200
COMMUNICATING ABOUT THAT.

682
00:27:06,200 --> 00:27:07,400
PARTICULARLY RECRUITING FOR

683
00:27:07,400 --> 00:27:08,200
TRIALS.

684
00:27:08,200 --> 00:27:09,360
PEOPLE DON'T UNDERSTAND THEY

685
00:27:09,360 --> 00:27:10,400
WON'T GO HEY I WANT TO BE ON

686
00:27:10,400 --> 00:27:17,120
THAT TRIAL.

687
00:27:17,120 --> 00:27:19,200
WE ARE AT THE BEGINNING OF USING

688
00:27:19,200 --> 00:27:20,480
RISK NOT IN THE MIDDLE.

689
00:27:20,480 --> 00:27:24,600
>> GREAT.

690
00:27:24,600 --> 00:27:28,480
THINKING HOW IT INTEGRATE ACROSS

691
00:27:28,480 --> 00:27:29,000
VARIOUS PROGRAMS.

692
00:27:29,000 --> 00:27:30,440
THAT IS IN PLACE, COMMUNICATING

693
00:27:30,440 --> 00:27:33,640
TALKING TRYING TO FIGURE OUT HOW

694
00:27:33,640 --> 00:27:35,520
TO BEST IMPLEMENT ONCE VALIDATED

695
00:27:35,520 --> 00:27:36,920
AND READY FOR PRIME TIME.

696
00:27:36,920 --> 00:27:38,800
SO THERE ARE NUMBER OF HANDS, I

697
00:27:38,800 --> 00:27:41,480
THINK I SAW THE ORDER, WE WILL

698
00:27:41,480 --> 00:27:44,000
START WITH MICHELLE, GO TO ANDY

699
00:27:44,000 --> 00:27:46,720
AND ANDREA AND THEN KAREN.

700
00:27:46,720 --> 00:27:49,560
>> THANK YOU, DR. CASTLE FOR

701
00:27:49,560 --> 00:27:50,440
THAT TERRIFIC TALK.

702
00:27:50,440 --> 00:27:53,560
I'M DELIGHTED THAT NCI FOCUSING

703
00:27:53,560 --> 00:27:54,800
ON MULTI-CANCER EARLY DETECTION

704
00:27:54,800 --> 00:28:00,800
TESTS AND MY QUESTIONS TO YOU,

705
00:28:00,800 --> 00:28:04,000
HOW ARE YOU THINKING ABOUT THE

706
00:28:04,000 --> 00:28:06,160
TEST -- ARE YOU THINKING

707
00:28:06,160 --> 00:28:07,720
INCLUSIVELY OF TEST BEYOND DNA

708
00:28:07,720 --> 00:28:09,600
AND RNA, THINKING PROTEIN,

709
00:28:09,600 --> 00:28:12,720
LIQUID BIOPSIES, BREATH AND

710
00:28:12,720 --> 00:28:14,280
OTHER URINE OTHER TYPES OF

711
00:28:14,280 --> 00:28:15,240
TESTS?

712
00:28:15,240 --> 00:28:18,200
AND HOW DO YOU ENVISION

713
00:28:18,200 --> 00:28:20,480
STRUCTURING CLINICAL TRIALS TO

714
00:28:20,480 --> 00:28:22,360
ENSURE WE HAVE SUFFICIENT

715
00:28:22,360 --> 00:28:23,160
REPRESENTATION OF

716
00:28:23,160 --> 00:28:24,480
UNDER-REPRESENTED POPULATIONS?

717
00:28:24,480 --> 00:28:26,000
BECAUSE I THINK THIS IS THE

718
00:28:26,000 --> 00:28:29,400
BIGGEST CONCERN WE ALL HAVE

719
00:28:29,400 --> 00:28:29,920
REGARDING THESE.

720
00:28:29,920 --> 00:28:32,120
>> LET ME ADDRESS THE LAST ONE

721
00:28:32,120 --> 00:28:33,600
FIRST, HOLD MY FEET TO THE FIRE

722
00:28:33,600 --> 00:28:37,280
ON THE FIRST ONE.

723
00:28:37,280 --> 00:28:39,200
WHEN NED AND I FIRST STARTED

724
00:28:39,200 --> 00:28:40,920
ABOUT THIS, THIS WAS THE FIRST

725
00:28:40,920 --> 00:28:43,800
THING WE GOT TALKING ABOUT, WE

726
00:28:43,800 --> 00:28:46,160
DON'T WANT TO SEE FANCY NEW

727
00:28:46,160 --> 00:28:47,600
TECHNOLOGY EXACERBATING

728
00:28:47,600 --> 00:28:49,080
DISPARITIES WHICH WE HAVE ALL

729
00:28:49,080 --> 00:28:50,920
SEEN OVER AND OVER AND OVER.

730
00:28:50,920 --> 00:28:52,000
>> EXACTLY.

731
00:28:52,000 --> 00:28:54,000
>> SO CERTAINLY IN THE CLINICAL

732
00:28:54,000 --> 00:28:55,680
TRIAL SETTING, ONE OF THE

733
00:28:55,680 --> 00:28:58,000
STRENGTHS OF THE NCOR IF WE WERE

734
00:28:58,000 --> 00:29:00,560
TO DO NCOR BUT THERE COULD BE

735
00:29:00,560 --> 00:29:03,240
OTHER STRATEGIES, AS YOU SAW 20%

736
00:29:03,240 --> 00:29:10,400
NCOR RECRUITMENT ROUTINENESS IS

737
00:29:10,400 --> 00:29:11,200
MINORITIES 28% I DON'T REMEMBER

738
00:29:11,200 --> 00:29:14,720
THE EXACT NUMBER BUT POINT IS WE

739
00:29:14,720 --> 00:29:16,280
HAVE INFRASTRUCTURE TO DO A

740
00:29:16,280 --> 00:29:18,720
TRIAL THAT IS TRULY REPRESENTED

741
00:29:18,720 --> 00:29:20,800
MY CONCERN IF I CAN BE HONEST

742
00:29:20,800 --> 00:29:22,720
BIOMARKERS THAT GO INTO THOSE

743
00:29:22,720 --> 00:29:25,480
TESTS INFORMED BY PREVIOUS

744
00:29:25,480 --> 00:29:26,480
COLLECTION WHERE THERE MIGHT

745
00:29:26,480 --> 00:29:28,680
HAVE BEEN SYSTEMATIC BIAS ABOUT

746
00:29:28,680 --> 00:29:32,280
HOW BIOMARKERS WERE DISCOVERED

747
00:29:32,280 --> 00:29:36,600
CAN'T FIX THAT BUT GOOD TO KNOW

748
00:29:36,600 --> 00:29:37,920
WHETHER THIS WILL WORK WITH

749
00:29:37,920 --> 00:29:39,600
EVERYBODY AND SUBSET, AND HOW TO

750
00:29:39,600 --> 00:29:40,400
IMPROVE THAT.

751
00:29:40,400 --> 00:29:43,560
COMING BACK TO THE FIRST POINT

752
00:29:43,560 --> 00:29:45,800
WE HAVE THE LIQUID BIOPSY

753
00:29:45,800 --> 00:29:47,280
CONSORTIUM WITHIN DCP AND A LOT

754
00:29:47,280 --> 00:29:48,880
OF WHAT YOU WERE TALKING ABOUT

755
00:29:48,880 --> 00:29:50,960
IN TERMS OF DIFFERENT SPECIMENS,

756
00:29:50,960 --> 00:29:53,040
DIFFERENT BIOMARKERS, ET CETERA,

757
00:29:53,040 --> 00:29:55,000
SO SOME BASIC SCIENCE, AROUND

758
00:29:55,000 --> 00:29:56,800
HOW DO WE GET TO SMALLER VOLUME,

759
00:29:56,800 --> 00:30:00,440
CAN WE USE URINE, USE BREATH,

760
00:30:00,440 --> 00:30:02,560
ALL THOSE THINGS.

761
00:30:02,560 --> 00:30:04,000
IN TERMS OF THE CLINICAL TRIAL

762
00:30:04,000 --> 00:30:06,400
I'M AGNOSTIC, I DON'T CARE WHAT

763
00:30:06,400 --> 00:30:07,120
THEY ARE DETECTING.

764
00:30:07,120 --> 00:30:10,200
I CARE ABOUT DO THEY HAVE

765
00:30:10,200 --> 00:30:13,400
SUFFICIENT DATA THAT WARRANTS

766
00:30:13,400 --> 00:30:13,960
INCLUSION IN THE TRIAL?

767
00:30:13,960 --> 00:30:15,440
THEN WE WILL PUT THEM THROUGH

768
00:30:15,440 --> 00:30:16,040
THE PACES.

769
00:30:16,040 --> 00:30:17,400
THERE'S NO OTHER PLACE WHERE WE

770
00:30:17,400 --> 00:30:22,280
CAN REALLY GET HONEST BROKER

771
00:30:22,280 --> 00:30:25,360
READ OUT WHETHER THESE THINGS

772
00:30:25,360 --> 00:30:27,400
WORK SO WHAT WE ARE HOPING TO DO

773
00:30:27,400 --> 00:30:32,400
IS HAVE A PLATFORM TRIAL

774
00:30:32,400 --> 00:30:34,200
RANDOMIZE CONTROL TRIAL, IN

775
00:30:34,200 --> 00:30:36,960
WHICH AS TECHNOLOGIES EMERGE WE

776
00:30:36,960 --> 00:30:39,040
THEN PUT THEM INTO A SEPARATE

777
00:30:39,040 --> 00:30:40,240
ARM OF THE TRIAL COMPARED TO

778
00:30:40,240 --> 00:30:44,880
STANDARD OF CARE.

779
00:30:44,880 --> 00:30:45,800
IF WE CAN IMPLEMENT THAT,

780
00:30:45,800 --> 00:30:47,040
STANDARD OF CARE IS MOVING

781
00:30:47,040 --> 00:30:48,480
PARTICULARLY IF THESE GET OUT

782
00:30:48,480 --> 00:30:50,560
HAND THERE'S CONTAMINATION, THE

783
00:30:50,560 --> 00:30:54,520
OTHER ISSUE IS WE DON'T WANT

784
00:30:54,520 --> 00:30:57,200
PEOPLE TO NOT GET STANDARD OF

785
00:30:57,200 --> 00:30:59,080
CARE, WHILE WE EVALUATE THEY

786
00:30:59,080 --> 00:31:00,000
BENEFIT THE POPULATION.

787
00:31:00,000 --> 00:31:01,240
THERE'S SO MANY ISSUES.

788
00:31:01,240 --> 00:31:06,160
LET ME SAILORRY IS GOING TO COME

789
00:31:06,160 --> 00:31:08,400
AT THE NEXT -- I THINK NEXT

790
00:31:08,400 --> 00:31:10,600
SESSION OR ONE AFTER THAT, NOT

791
00:31:10,600 --> 00:31:13,360
QUITE SURE, REALLY TALK ABOUT

792
00:31:13,360 --> 00:31:16,120
THE DISCUSSION I STARTED HERE.

793
00:31:16,120 --> 00:31:18,360
MUCH FULLER DEPTH PLUS WE WILL

794
00:31:18,360 --> 00:31:19,760
HAVE ANOTHER MEETING

795
00:31:19,760 --> 00:31:21,400
STAKEHOLDERS ON THIS.

796
00:31:21,400 --> 00:31:23,400
SO THIS -- I WANT TO GIVE YOU A

797
00:31:23,400 --> 00:31:25,120
LITTLE HINT, A LITTLE PRIMER

798
00:31:25,120 --> 00:31:26,800
MORE TO COME ABOUT THIS

799
00:31:26,800 --> 00:31:28,760
DISCUSSION WHERE WE ARE GOING

800
00:31:28,760 --> 00:31:29,800
WITH IT.

801
00:31:29,800 --> 00:31:34,240
DID I ADDRESS YOUR QUESTIONS?

802
00:31:34,240 --> 00:31:35,040
>> YES.

803
00:31:35,040 --> 00:31:39,680
THANKS.

804
00:31:39,680 --> 00:31:42,920
>> YOU STRUCK A NERVE, A LOT OF

805
00:31:42,920 --> 00:31:43,760
COOL DISCUSSION.

806
00:31:43,760 --> 00:31:45,320
WE ARE GOING TO GO IN THIS ORDER

807
00:31:45,320 --> 00:31:48,960
WE WILL GO AGAIN TO ANDY,

808
00:31:48,960 --> 00:31:51,400
ANDREA, KAREN AND THEN DEBORAH

809
00:31:51,400 --> 00:31:53,640
AND THEN TO ANNA BARKER IF WE

810
00:31:53,640 --> 00:31:55,240
CAN GET THERE WITHIN THE NEXT

811
00:31:55,240 --> 00:31:57,320
EIGHT MINUTES OR SO.

812
00:31:57,320 --> 00:31:59,400
>> THANKS VERY MUCH FOR SHARING

813
00:31:59,400 --> 00:32:02,400
THAT REALLY EXCITING VISION,

814
00:32:02,400 --> 00:32:03,160
PHIL.

815
00:32:03,160 --> 00:32:05,360
AS WE KNOW WITH PREVENTION ONE

816
00:32:05,360 --> 00:32:07,040
MAJOR BARRIER IS COST OF DOING

817
00:32:07,040 --> 00:32:08,400
CLINICAL TRIALS BECAUSE OF THE

818
00:32:08,400 --> 00:32:11,400
NEED FOR LARGE POPULATIONS.

819
00:32:11,400 --> 00:32:12,960
WHAT ARE THE THOUGHTS ABOUT

820
00:32:12,960 --> 00:32:14,840
USING SOME OF THE STUDIES OR

821
00:32:14,840 --> 00:32:17,920
TRIALS THAT ALREADY UNDERWAY

822
00:32:17,920 --> 00:32:20,200
LIKE FOR DAY OR TEENNESS TO

823
00:32:20,200 --> 00:32:21,080
EMBED OTHER CLINICAL TRIALS

824
00:32:21,080 --> 00:32:23,800
WITHIN THEM LIKE CLINICAL TRIALS

825
00:32:23,800 --> 00:32:26,000
EARLY DETECTION MARKERS, ET

826
00:32:26,000 --> 00:32:26,920
CETERA, IS THAT SOMETHING

827
00:32:26,920 --> 00:32:28,280
ACTIVELY PURSUED OR IS THAT

828
00:32:28,280 --> 00:32:28,640
ALREADY PLANNED?

829
00:32:28,640 --> 00:32:29,560
THE

830
00:32:29,560 --> 00:32:31,720
>> MOST OF THE TRIALS HAVE A

831
00:32:31,720 --> 00:32:33,360
BIOMARKER COMPONENT, TEAMNESS

832
00:32:33,360 --> 00:32:35,800
DOES, ALL THAT BUT HERE IS THE

833
00:32:35,800 --> 00:32:37,200
PROBLEM PARTICULARLY FOR

834
00:32:37,200 --> 00:32:39,000
SCREENING AND EARLY -- THIS IS

835
00:32:39,000 --> 00:32:41,320
JUST MY OPINION.

836
00:32:41,320 --> 00:32:43,200
SO DON'T PUNISH THE REST OF THE

837
00:32:43,200 --> 00:32:45,480
VISION FOR MY VIEW.

838
00:32:45,480 --> 00:32:47,600
ONE IS OBSERVATIONAL.

839
00:32:47,600 --> 00:32:49,200
BECAUSE YOU CAN INTERVENE ON

840
00:32:49,200 --> 00:32:50,880
THAT, OTHERWISE YOU WILL AFFECT

841
00:32:50,880 --> 00:32:52,200
THE MAIN TRIAL.

842
00:32:52,200 --> 00:32:55,080
SO IT IS COUNTER FACTUAL YOU ARE

843
00:32:55,080 --> 00:32:56,880
OBSERVING YOU DON'T KNOW WHETHER

844
00:32:56,880 --> 00:32:58,280
IF YOU ACTED ON THAT IT WILL

845
00:32:58,280 --> 00:32:59,400
BENEFIT THE POPULATION.

846
00:32:59,400 --> 00:33:00,560
SINCE MOST OF THE THINGS YOU

847
00:33:00,560 --> 00:33:05,200
WOULD DO IS NOT GOING TO BE 100%

848
00:33:05,200 --> 00:33:06,440
EFFICACIOUS YOU DON'T KNOW

849
00:33:06,440 --> 00:33:08,120
WHETHER THE ONES THAT YOU

850
00:33:08,120 --> 00:33:10,040
EFFECTED WERE ONES THAT WERE

851
00:33:10,040 --> 00:33:12,400
GOING TO BE ADVANCE CANCER.

852
00:33:12,400 --> 00:33:15,320
WE HAVE STRUGGLED WITH THIS WITH

853
00:33:15,320 --> 00:33:16,920
SCREENING TRIALS, WE HAVE HAD A

854
00:33:16,920 --> 00:33:20,640
NUMBER OF WORKSHOPS ATTENDING A

855
00:33:20,640 --> 00:33:23,400
CRK ONE IN A WEEK TO DISCUSS ARE

856
00:33:23,400 --> 00:33:24,640
THOSE SURROGATE END POINTS

857
00:33:24,640 --> 00:33:28,760
BECAUSE WAITING FOR MORTALITY IS

858
00:33:28,760 --> 00:33:29,360
EXPENSIVE.

859
00:33:29,360 --> 00:33:32,200
AND SO WHERE ARE WE IN SCIENCE

860
00:33:32,200 --> 00:33:34,520
OF END POINTS IS REALLY BEEN

861
00:33:34,520 --> 00:33:36,400
TOPIC SINCE I HAVE COME.

862
00:33:36,400 --> 00:33:38,080
SO IT IS HARD TO EMBED INTO

863
00:33:38,080 --> 00:33:40,640
THOSE STUDIES BECAUSE YOU CAN'T

864
00:33:40,640 --> 00:33:43,200
EFFECT OUTCOME OF THAT STUDY.

865
00:33:43,200 --> 00:33:44,840
WE CAN OBVIOUSLY COLLECT A LOT

866
00:33:44,840 --> 00:33:49,600
OF BIOSPECIMENS, FOR AIS DOING A

867
00:33:49,600 --> 00:33:52,600
TEAMNESS PANCREATIC CYST AND

868
00:33:52,600 --> 00:33:55,160
OTHER TRIALS THAT WILL INFORM

869
00:33:55,160 --> 00:33:58,480
RESEARCH FOR SURE WE HOPE PEOPLE

870
00:33:58,480 --> 00:34:00,080
COME AND USE THAT RESOURCE.

871
00:34:00,080 --> 00:34:01,840
BUT YOU ARE ONLY GOING TO GET SO

872
00:34:01,840 --> 00:34:04,520
FAR AND ULTIMATELY HAVE TO SHOW

873
00:34:04,520 --> 00:34:05,520
THAT IT BENEFIT IT IS POPULATION

874
00:34:05,520 --> 00:34:06,400
DIRECTLY.

875
00:34:06,400 --> 00:34:10,040
IN MY OPINION, YOU MAY DISAGREE.

876
00:34:10,040 --> 00:34:12,360
>> THANKS, PHIL.

877
00:34:12,360 --> 00:34:13,880
ANDREA.

878
00:34:13,880 --> 00:34:14,600
>> THANK YOU VERY MUCH.

879
00:34:14,600 --> 00:34:16,000
I HAVE A QUESTION ABOUT THE

880
00:34:16,000 --> 00:34:20,360
LIQUID BIOPSIES AND I APPRECIATE

881
00:34:20,360 --> 00:34:22,400
THE WORK DONE TO SHOW IT IS

882
00:34:22,400 --> 00:34:22,800
EFFICACIOUS.

883
00:34:22,800 --> 00:34:23,800
I HAVE CONFIDENCE THEY ARE GOING

884
00:34:23,800 --> 00:34:25,880
TO END UP BEING SOMETHING WE USE

885
00:34:25,880 --> 00:34:26,960
WITH TEAM IN THE FUTURE.

886
00:34:26,960 --> 00:34:30,000
WHAT I HOPE IS AS WE ARE

887
00:34:30,000 --> 00:34:31,680
DEVELOPING THEM AND LOOKING AT

888
00:34:31,680 --> 00:34:32,320
THESE CLINICAL TRIALS THAT WE

889
00:34:32,320 --> 00:34:35,040
CAN MAKE SURE THAT THE EASE OF

890
00:34:35,040 --> 00:34:36,560
PROCESSING THE SPECIMENS IS

891
00:34:36,560 --> 00:34:37,480
TAKEN INTO ACCOUNT.

892
00:34:37,480 --> 00:34:39,400
I KNOW SOME OF THESE SPECIMENS

893
00:34:39,400 --> 00:34:40,880
CAN BE FROZEN OR REFRIGERATED,

894
00:34:40,880 --> 00:34:42,760
IF YOU THINK ABOUT SOME SMALL

895
00:34:42,760 --> 00:34:44,040
COMMUNITIES WHERE YOU MIGHT HAVE

896
00:34:44,040 --> 00:34:48,280
MOBILE CLINICS OR RURAL AREAS,

897
00:34:48,280 --> 00:34:51,000
THE EASE OF PROCESSING SPECIMENS

898
00:34:51,000 --> 00:34:53,120
IS SORT OF TAKEN INTO

899
00:34:53,120 --> 00:34:54,800
CONSIDERATION AS WE GET MORE

900
00:34:54,800 --> 00:34:56,840
DOWN THE LINE HOW TO USE THESE

901
00:34:56,840 --> 00:34:58,680
LIQUID BIOPSIES.

902
00:34:58,680 --> 00:35:00,600
>> THAT IS A GREAT POINT.

903
00:35:00,600 --> 00:35:05,280
A LOT OF STUFF HAPPENS AT YOUR

904
00:35:05,280 --> 00:35:06,160
ACADEMIC INSTITUTIONS AND IT

905
00:35:06,160 --> 00:35:08,920
DOESN'T NECESSARILY MEAN IT CAN

906
00:35:08,920 --> 00:35:10,720
BE IMPLEMENTED MORE BROADLY.

907
00:35:10,720 --> 00:35:14,160
SO THAT IS ONE OF OUR GREAT

908
00:35:14,160 --> 00:35:16,360
CONCERNS HOW DO THESE FANCY

909
00:35:16,360 --> 00:35:17,400
TECHNOLOGIES REACH THE PEOPLE

910
00:35:17,400 --> 00:35:18,320
WHO NEED IT THE MOST.

911
00:35:18,320 --> 00:35:24,200
YOU HIGHLIGHTED VERY IMPORTANT

912
00:35:24,200 --> 00:35:24,560
POINT.

913
00:35:24,560 --> 00:35:25,800
IF WE CAN'T IMPLEMENT FOR

914
00:35:25,800 --> 00:35:27,400
EVERYBODY SHOULD WE BE

915
00:35:27,400 --> 00:35:29,440
IMPLEMENTING IT FOR ANYBODY.

916
00:35:29,440 --> 00:35:32,800
>> THAT IS A GREAT POINT, PHIL.

917
00:35:32,800 --> 00:35:34,680
THE DEVELOPMENT AND DESIGN OF

918
00:35:34,680 --> 00:35:38,360
THESE ASSAYS AND FIELD RESEARCH,

919
00:35:38,360 --> 00:35:43,200
RIGHT, WHERE ANDREA WAS SAYING,

920
00:35:43,200 --> 00:35:45,560
COMMUNITIES, ARE -- FALL OUTSIDE

921
00:35:45,560 --> 00:35:47,000
OF THESE ENVIRONMENTS THAT CAN

922
00:35:47,000 --> 00:35:49,240
QUICKLY PROCESS SAMPLES AND SPIN

923
00:35:49,240 --> 00:35:50,520
DOWN PLASMA.

924
00:35:50,520 --> 00:35:51,680
MENT AND THE LIKE.

925
00:35:51,680 --> 00:35:54,720
SO THAT IS A GREAT POINT.

926
00:35:54,720 --> 00:35:56,200
>> LET ME JUST SAY SOME OF THOSE

927
00:35:56,200 --> 00:35:57,880
IMPLEMENTATION ISSUES IS REALLY

928
00:35:57,880 --> 00:36:00,560
SWEET SPOT OF DCCPS SO WE LOOK

929
00:36:00,560 --> 00:36:03,800
FORWARD TO TEAMING WITH THEM

930
00:36:03,800 --> 00:36:05,880
AROUND THOSE IMPLEMENTATION

931
00:36:05,880 --> 00:36:06,280
SCIENCE QUESTIONS.

932
00:36:06,280 --> 00:36:08,800
>> LET'S JUMP TO KAREN.

933
00:36:08,800 --> 00:36:11,280
THEN DEBRA AND ANNA.

934
00:36:11,280 --> 00:36:12,840
AND THEN DAVE TOO IF WE HAVE

935
00:36:12,840 --> 00:36:13,040
TIME.

936
00:36:13,040 --> 00:36:13,760
KIM.

937
00:36:13,760 --> 00:36:16,120
>> DR. CASTLE, THANK YOU FOR A

938
00:36:16,120 --> 00:36:16,920
WONDERFUL PRESENTATION.

939
00:36:16,920 --> 00:36:18,920
I WILL SWITCH GEARS FROM

940
00:36:18,920 --> 00:36:22,400
PREVENTION TO SUPPORTIVE CARE.

941
00:36:22,400 --> 00:36:24,440
I HAVE A COUPLE OF QUESTIONS I

942
00:36:24,440 --> 00:36:25,920
WOULD LOVE TO KNOW YOUR THOUGHTS

943
00:36:25,920 --> 00:36:27,920
AND VISIONS ARE HOW YOU MIGHT

944
00:36:27,920 --> 00:36:30,280
USE THE CLINICAL TRIALS PLANNING

945
00:36:30,280 --> 00:36:33,280
GRANTS IN ORDER TO PREPARE FOR

946
00:36:33,280 --> 00:36:35,000
THESE LARGE CLINICAL TRIALS THAT

947
00:36:35,000 --> 00:36:36,160
WE LAUNCH AND SUPPORTIVE CARE

948
00:36:36,160 --> 00:36:40,120
AND CORE MECHANISM.

949
00:36:40,120 --> 00:36:43,840
TWO OTHER RELATED PIECES.

950
00:36:43,840 --> 00:36:45,480
WHAT IS YOUR VISION OR THOUGHTS

951
00:36:45,480 --> 00:36:48,640
HOW YOU THINK ABOUT RESOURCING

952
00:36:48,640 --> 00:36:52,400
THIS COMMUNITY NCORPS THAT ARE

953
00:36:52,400 --> 00:36:54,600
FUNDED TO ENROLL PATIENTS ON

954
00:36:54,600 --> 00:36:57,800
TRIALS AROUND TWO PARTICULAR

955
00:36:57,800 --> 00:36:58,200
THINGS.

956
00:36:58,200 --> 00:36:59,840
ONE IS HOW YOU LOOK AT FUNDING

957
00:36:59,840 --> 00:37:02,640
AND SUPPORTING THEM TO ENROLL

958
00:37:02,640 --> 00:37:04,600
MORE UNDER-REPRESENTED

959
00:37:04,600 --> 00:37:07,520
MINORITIES ON TO THOSE CLINICAL

960
00:37:07,520 --> 00:37:10,640
TRIALS AT THAT COMMUNITY LEVEL.

961
00:37:10,640 --> 00:37:12,560
THE RESEARCH BASE VERSUS DONE A

962
00:37:12,560 --> 00:37:14,320
GOOD JOB STARTING TO ROLL OUT

963
00:37:14,320 --> 00:37:15,880
STUDY DESIGNS TO DO THIS WORK

964
00:37:15,880 --> 00:37:17,720
BUT THERE IS A HUGE GAP AND HOLE

965
00:37:17,720 --> 00:37:20,120
AT THE NCORP COMMUNITY SITES FOR

966
00:37:20,120 --> 00:37:22,640
THEM TO BE ABLE TO RESOURCE TO

967
00:37:22,640 --> 00:37:23,600
DO THOSE.

968
00:37:23,600 --> 00:37:24,800
SECOND AREA I WOULD BE

969
00:37:24,800 --> 00:37:27,400
INTERESTED TO KNOW ABOUT

970
00:37:27,400 --> 00:37:29,040
RESOURCING IS A LOT OF

971
00:37:29,040 --> 00:37:31,600
SUPPORTIVE CARE IS NOT

972
00:37:31,600 --> 00:37:33,400
PHARMACEUTICAL, THE AGENTS THAT

973
00:37:33,400 --> 00:37:35,200
DO THE MOST RECOMMENDED IN THE

974
00:37:35,200 --> 00:37:37,120
GUIDELINES THAT WE NEED TO SEE

975
00:37:37,120 --> 00:37:39,840
MORE OF THESE LARGE PHASE 3

976
00:37:39,840 --> 00:37:40,880
DEFINITIVE CLINICAL TRIALS ON

977
00:37:40,880 --> 00:37:42,920
ARE LIFESTYLE INTERVENTIONS THAT

978
00:37:42,920 --> 00:37:45,040
INVOLVE EXERCISE NUTRITION,

979
00:37:45,040 --> 00:37:48,560
OTHER TYPES OF LIFESTYLE

980
00:37:48,560 --> 00:37:50,000
BEHAVIORS AND HOW HAVE YOU

981
00:37:50,000 --> 00:37:51,560
THOUGHT ABOUT A EATER USING

982
00:37:51,560 --> 00:37:53,480
SUPPLEMENTS TO EXPEDITE THAT

983
00:37:53,480 --> 00:37:56,200
THROUGH NCORP OR OTHER THINGS OR

984
00:37:56,200 --> 00:37:59,280
RESOURCING THE NCORPS AGAIN AT

985
00:37:59,280 --> 00:38:01,000
THE LEVEL WITH RESOURCES THROUGH

986
00:38:01,000 --> 00:38:04,160
GRANTS THEY NEED TO DO THOSE?

987
00:38:04,160 --> 00:38:05,560
>> WOW.

988
00:38:05,560 --> 00:38:05,960
OKAY.

989
00:38:05,960 --> 00:38:06,880
ALL GOOD QUESTIONS.

990
00:38:06,880 --> 00:38:08,600
I DON'T KNOW THAT I HAVE GOOD

991
00:38:08,600 --> 00:38:10,800
ANSWERS, I MAY HAVE TO COME BACK

992
00:38:10,800 --> 00:38:13,560
TO AND RESPOND MORE DEPTH.

993
00:38:13,560 --> 00:38:16,920
I AGREE OUR ABILITY TO REACH OUT

994
00:38:16,920 --> 00:38:19,160
INTO THE -- REALLY MAKING THESE

995
00:38:19,160 --> 00:38:22,320
THINGS REPRESENTATIVE IS A

996
00:38:22,320 --> 00:38:24,000
CHALLENGE.

997
00:38:24,000 --> 00:38:26,200
WHEN WE -- WHEN I TALK TO FOLKS

998
00:38:26,200 --> 00:38:27,880
WHO WORK IN MAINE AND SAY IT

999
00:38:27,880 --> 00:38:31,120
TAKES FOUR HOURS TO COME TO THE

1000
00:38:31,120 --> 00:38:31,600
MAINE CLINIC.

1001
00:38:31,600 --> 00:38:33,600
WE ARE NOT REACHING THOSE

1002
00:38:33,600 --> 00:38:35,720
PEOPLE, BE HONEST ABOUT THAT.

1003
00:38:35,720 --> 00:38:37,720
SO I DON'T KNOW WHAT THE EASY

1004
00:38:37,720 --> 00:38:40,520
ANSWER FOR THAT IS.

1005
00:38:40,520 --> 00:38:42,840
AND SOME OF THIS HAS TO DO WITH

1006
00:38:42,840 --> 00:38:45,440
ISSUES LIKE PERSISTENT POVERTY

1007
00:38:45,440 --> 00:38:48,120
WHICH IS SOMETHING DCCPS IS

1008
00:38:48,120 --> 00:38:51,480
WORKING ON, THESE ARE AREAS

1009
00:38:51,480 --> 00:38:53,320
WHERE YOU HAVE MORALITY THAT

1010
00:38:53,320 --> 00:38:55,400
GETS IN THE WAY OF

1011
00:38:55,400 --> 00:38:56,320
REPRESENTATION.

1012
00:38:56,320 --> 00:38:58,800
SO I DON'T HAVE A GOOD SIMPLE

1013
00:38:58,800 --> 00:39:00,400
ANSWER FOR ANY TO BE HONEST.

1014
00:39:00,400 --> 00:39:02,200
I WON'T TRY TO PRETEND THAT I

1015
00:39:02,200 --> 00:39:03,240
DO.

1016
00:39:03,240 --> 00:39:05,040
I THINK WE HAVE ALL STRUGGLED

1017
00:39:05,040 --> 00:39:07,040
WITH THEM.

1018
00:39:07,040 --> 00:39:08,760
RESOURCES ARE ALWAYS -- WE ARE

1019
00:39:08,760 --> 00:39:11,520
ALWAYS STRUGGLING TO HAVE

1020
00:39:11,520 --> 00:39:12,280
ENOUGH.

1021
00:39:12,280 --> 00:39:13,120
YOUR POINT IS TAKEN.

1022
00:39:13,120 --> 00:39:14,320
WE HAVE TO DO BETTER.

1023
00:39:14,320 --> 00:39:16,880
I JUST DON'T KNOW HOW TO BE

1024
00:39:16,880 --> 00:39:18,080
HONEST WITH YOU.

1025
00:39:18,080 --> 00:39:20,880
>> BILL, BY THE WAY, I APOLOGIZE

1026
00:39:20,880 --> 00:39:23,000
FOR BEING A LITTLE LATE, I

1027
00:39:23,000 --> 00:39:25,960
WOULDN'T MISS FOR THE WORLD

1028
00:39:25,960 --> 00:39:28,600
EXCEPT CONGRESS ASKED ME TO

1029
00:39:28,600 --> 00:39:29,280
SPEAK TO THEM.

1030
00:39:29,280 --> 00:39:30,800
NOW I'M HERE.

1031
00:39:30,800 --> 00:39:32,360
THERE WAS A REALLY GOOD QUESTION

1032
00:39:32,360 --> 00:39:34,400
ABOUT UNDER-REPRESENTED MINORITY

1033
00:39:34,400 --> 00:39:36,280
ACCRUAL AND NCORP REALLY

1034
00:39:36,280 --> 00:39:37,520
IMPORTANT TOPIC AND WE SHOULD

1035
00:39:37,520 --> 00:39:39,840
HAVE A PRESENTATION ON THAT IN A

1036
00:39:39,840 --> 00:39:40,440
FUTURE DAY.

1037
00:39:40,440 --> 00:39:42,240
NCI STORY IS GOOD THERE IN SOME

1038
00:39:42,240 --> 00:39:45,200
WAYS BUT IT IS COMPLICATED AND

1039
00:39:45,200 --> 00:39:47,680
RATHER THAN TRYING TO ANSWER

1040
00:39:47,680 --> 00:39:48,800
THAT IN BREVITY TODAY SAVE FOR

1041
00:39:48,800 --> 00:39:51,320
FUTURE DISCUSSION BECAUSE IT IS

1042
00:39:51,320 --> 00:39:51,920
INTERESTING.

1043
00:39:51,920 --> 00:39:54,200
>> I THINK WHARTA WOULD BE

1044
00:39:54,200 --> 00:39:55,040
BETTER SUITED TO.

1045
00:39:55,040 --> 00:39:57,720
>> TOTALLY AGREE FOR THINGS

1046
00:39:57,720 --> 00:40:01,760
RELATED TO NCORP, QUESTIONS AND

1047
00:40:01,760 --> 00:40:04,080
COMMENTS.

1048
00:40:04,080 --> 00:40:06,520
WE ARE AT 10:40 AND SHOULD BE

1049
00:40:06,520 --> 00:40:12,600
JUMPING TO OUR NEXT PRESENTATION

1050
00:40:12,600 --> 00:40:13,760
I KNOW THERE WERE A COUPLE OF

1051
00:40:13,760 --> 00:40:16,000
HANDS, DEBRA PUT HER QUESTION IN

1052
00:40:16,000 --> 00:40:18,160
THE CHAT SO IT WOULD BE GREAT IF

1053
00:40:18,160 --> 00:40:21,880
YOU COULD PERUSE CHAT, LOT OF

1054
00:40:21,880 --> 00:40:22,600
GREAT COMMENTS THERE.

1055
00:40:22,600 --> 00:40:24,000
I KNOW YOU WANT TO SEE THE NEXT

1056
00:40:24,000 --> 00:40:24,880
PRESENTATION BUT IF YOU CAN

1057
00:40:24,880 --> 00:40:29,800
ADDRESS THOSE IT WOULD BE GREAT.

1058
00:40:29,800 --> 00:40:31,400
>> THANK YOU SO MUCH AND THANKS

1059
00:40:31,400 --> 00:40:32,400
FOR THE OPPORTUNITY AGAIN.

1060
00:40:32,400 --> 00:40:37,360
>> THANK YOU FOR THAT REALLY

1061
00:40:37,360 --> 00:40:40,720
TREMENDOUS PRESENTATION.

1062
00:40:40,720 --> 00:40:43,040
NEXT PRESENTATION IS ACHIEVING

1063
00:40:43,040 --> 00:40:44,920
HEALTH EQUITY THROUGH PREVENTION

1064
00:40:44,920 --> 00:40:46,520
AND IMPLEMENTATION SCIENCE OF

1065
00:40:46,520 --> 00:40:47,400
PATIENT NAVIGATION AND

1066
00:40:47,400 --> 00:40:49,400
UNDERSERVED POPULATIONS THAT

1067
00:40:49,400 --> 00:40:51,520
WILL BE PRESENTED PROVIDED TO US

1068
00:40:51,520 --> 00:40:54,120
BY DR. MELISSA SIMON, VICE CHAIR

1069
00:40:54,120 --> 00:40:59,320
OF RESEARCH DEPARTMENT OF

1070
00:40:59,320 --> 00:41:01,720
OBSTETRICS GYNECOLOGY, THE

1071
00:41:01,720 --> 00:41:03,400
PROFESSOR CLINICAL GYNECOLOGY

1072
00:41:03,400 --> 00:41:05,640
PROFESSOR OBSTETRICS GYNECOLOGY

1073
00:41:05,640 --> 00:41:07,000
AND MEDICAL PREVENTION AND

1074
00:41:07,000 --> 00:41:08,320
MEDICAL SOCIAL SCIENCES AND

1075
00:41:08,320 --> 00:41:10,080
FOUNDING DIRECTOR FOR THE CENTER

1076
00:41:10,080 --> 00:41:13,800
OF HEALTH EQUITY TRANSFORMATION

1077
00:41:13,800 --> 00:41:15,760
FOUNDING DIRECTOR CHICAGO HEALTH

1078
00:41:15,760 --> 00:41:18,400
EQUITY COLLABORATIVE AT

1079
00:41:18,400 --> 00:41:19,400
NORTHWESTERN UNIVERSITY FINEBURG

1080
00:41:19,400 --> 00:41:21,600
SCHOOL OF MEDICINE AND THE

1081
00:41:21,600 --> 00:41:23,080
ROBERT LOUIS COMPREHENSIVE

1082
00:41:23,080 --> 00:41:24,760
CANCER CENTER.

1083
00:41:24,760 --> 00:41:25,200
MELISSA.

1084
00:41:25,200 --> 00:41:27,200
>> THANK YOU FOR HAVING ME,

1085
00:41:27,200 --> 00:41:28,360
APPRECIATE IT.

1086
00:41:28,360 --> 00:41:30,680
ACTUALLY I HEARD THE LAST

1087
00:41:30,680 --> 00:41:32,440
QUESTION AND SOME OF MY WORK AND

1088
00:41:32,440 --> 00:41:34,240
WHAT I WILL PRESENT DOVE TAILS

1089
00:41:34,240 --> 00:41:36,080
WITH THAT INQUIRY.

1090
00:41:36,080 --> 00:41:38,920
NEXT SLIDE PLEASE.

1091
00:41:38,920 --> 00:41:40,400
I HAVE NOTHING TO DISCLOSE.

1092
00:41:40,400 --> 00:41:44,080
NEXT SLIDE.

1093
00:41:44,080 --> 00:41:46,000
ARCHITECTURE AND DESIGN REALLY

1094
00:41:46,000 --> 00:41:48,200
MATTER AND SUPPLIES WHETHER YOU

1095
00:41:48,200 --> 00:41:49,240
TALK DIVERSITY AND CLINICAL

1096
00:41:49,240 --> 00:41:52,040
TRIALS ARE TYPE OF RESEARCH ANY

1097
00:41:52,040 --> 00:41:54,440
TYPE OF RESEARCH THAT STRUCTURE

1098
00:41:54,440 --> 00:41:57,320
AND WHOLE RESEARCH PROCESS IS

1099
00:41:57,320 --> 00:41:59,160
REALLY CRITICAL TO EXAMINE WHEN

1100
00:41:59,160 --> 00:42:01,200
YOU ARE TRYING TO HAVE

1101
00:42:01,200 --> 00:42:03,440
ANTI-RACISM APPROACHES AND EMBED

1102
00:42:03,440 --> 00:42:06,640
HEALTH EQUITY IN EVERY STEP OF

1103
00:42:06,640 --> 00:42:08,800
THAT PROCESS IN ORDER TO GET TO

1104
00:42:08,800 --> 00:42:11,240
BETTER PATIENT CARE AND OUTCOMES

1105
00:42:11,240 --> 00:42:13,040
ESPECIALLY THAT MEET THE

1106
00:42:13,040 --> 00:42:14,600
EVOLVING DEMOGRAPHY AND

1107
00:42:14,600 --> 00:42:15,400
DEMOGRAPHIC NEEDS OF UNITED

1108
00:42:15,400 --> 00:42:20,760
STATES OF AMERICA.

1109
00:42:20,760 --> 00:42:25,480
AS YOU ALL KNOW THE BASIC

1110
00:42:25,480 --> 00:42:27,720
FORMULA FOR RESEARCH IS REALLY

1111
00:42:27,720 --> 00:42:30,200
HAVING SOLID GOOD DATA TO GO

1112
00:42:30,200 --> 00:42:31,960
INTO A TRIAL, WELL DESIGNED

1113
00:42:31,960 --> 00:42:33,360
TRIAL IN ORDER TO HAVE REALLY

1114
00:42:33,360 --> 00:42:35,120
GOOD RESULTS BUT IF YOU DON'T

1115
00:42:35,120 --> 00:42:36,040
HAVE REPRESENTATION IN THE

1116
00:42:36,040 --> 00:42:38,280
TRIALS AND IN THE STUDIES AND

1117
00:42:38,280 --> 00:42:39,440
RESEARCH THEN WHAT ARE THE

1118
00:42:39,440 --> 00:42:40,800
RESULTS GOING TO BE APPLICABLE

1119
00:42:40,800 --> 00:42:42,680
TO, WHO ARE THEY REALLY GOING TO

1120
00:42:42,680 --> 00:42:43,400
APPLY TO.

1121
00:42:43,400 --> 00:42:45,400
WE SEE THAT PLAY OUT TIME AND

1122
00:42:45,400 --> 00:42:47,680
TIME AGAIN WITH HEALTH

1123
00:42:47,680 --> 00:42:49,600
DISPARITIES IN PRETTY MUCH EVERY

1124
00:42:49,600 --> 00:42:51,400
SINGLE CANCER IN AMERICA -- IN

1125
00:42:51,400 --> 00:42:52,040
THE UNITED STATES OF AMERICA.

1126
00:42:52,040 --> 00:42:53,960
SO YOU HAVE TO ASK THE RIGHT

1127
00:42:53,960 --> 00:42:54,840
QUESTIONS INVOLVE THE RIGHT

1128
00:42:54,840 --> 00:42:56,240
PEOPLE AT TABLE EVERY STEP OF

1129
00:42:56,240 --> 00:42:57,920
THE PROCESS AND PATIENT

1130
00:42:57,920 --> 00:42:59,240
NAVIGATION AND THAT

1131
00:42:59,240 --> 00:43:00,080
IMPLEMENTATION SCIENCE APPROACH

1132
00:43:00,080 --> 00:43:01,880
IS REALLY CRITICAL TO INVOLVING

1133
00:43:01,880 --> 00:43:04,240
ALL TYPES OF STAKEHOLDERS AT

1134
00:43:04,240 --> 00:43:06,240
EVERY STAGE IN THAT RESEARCH

1135
00:43:06,240 --> 00:43:07,840
PROCESS.

1136
00:43:07,840 --> 00:43:10,000
BECAUSE THEY HELP THE COMMUNITY

1137
00:43:10,000 --> 00:43:11,560
AND ALL THE DIFFERENT

1138
00:43:11,560 --> 00:43:13,360
STAKEHOLDERS HELP ASK THE RIGHT

1139
00:43:13,360 --> 00:43:14,600
QUESTIONS BECAUSE IF YOU DON'T

1140
00:43:14,600 --> 00:43:15,640
IS ASK THE RIGHT QUESTIONS AND

1141
00:43:15,640 --> 00:43:17,640
INVOLVE THE RIGHT PEOPLE, THEN

1142
00:43:17,640 --> 00:43:21,960
THE OUTPUT WILL NOT BE RELEVANT.

1143
00:43:21,960 --> 00:43:23,160
SO YOU HAVE TO LOOK UNDER HOOD

1144
00:43:23,160 --> 00:43:24,680
OF THE CAR AND SCRUTINIZE THE

1145
00:43:24,680 --> 00:43:26,640
RELATED PROCESSES NEXT SLIDE

1146
00:43:26,640 --> 00:43:31,000
PLEASE.

1147
00:43:31,000 --> 00:43:32,040
REALLY IMPORTANT TO UNDERSTAND

1148
00:43:32,040 --> 00:43:34,680
ABOUT THE WORK AND PATIENT

1149
00:43:34,680 --> 00:43:36,560
NAVIGATION AND IMPLEMENTATION

1150
00:43:36,560 --> 00:43:38,720
SCIENCE ACROSS DIVERSE

1151
00:43:38,720 --> 00:43:40,840
POPULATIONS FOR IMPROVED

1152
00:43:40,840 --> 00:43:41,120
OUTCOMES.

1153
00:43:41,120 --> 00:43:42,400
YOU HAVE TO UNDERSTAND

1154
00:43:42,400 --> 00:43:45,560
DEFINITION SO IN EQUALITY

1155
00:43:45,560 --> 00:43:47,320
MEANING SOME STRUCTURE, IN THIS

1156
00:43:47,320 --> 00:43:49,000
CASE IT IS A TREE STRUCTURE ARE

1157
00:43:49,000 --> 00:43:50,200
NOT ORGANIC NECESSARILY, THEY

1158
00:43:50,200 --> 00:43:53,080
ARE HUMAN MADE AND HUMAN POSE

1159
00:43:53,080 --> 00:43:56,280
BUT POLICY OF PROGRAM AT THIS, A

1160
00:43:56,280 --> 00:43:58,360
PROTOCOL DESIGN EXCLUSION OR

1161
00:43:58,360 --> 00:44:02,000
INCLUSION OR EXCLUSION CRITERIA

1162
00:44:02,000 --> 00:44:04,680
OR SOMETHING THAT IS BENT AND

1163
00:44:04,680 --> 00:44:05,480
NOT RIGHT.

1164
00:44:05,480 --> 00:44:07,200
BENT AND ACTIVELY FAVORING ONE

1165
00:44:07,200 --> 00:44:11,160
PATIENT OR POPULATION AND ACTIVE

1166
00:44:11,160 --> 00:44:12,400
DISADVANTAGE IN THE OTHER.

1167
00:44:12,400 --> 00:44:14,640
UPPER RIGHT HAND CORNER WHEN YOU

1168
00:44:14,640 --> 00:44:16,400
TALK IT IS EQUAL, EQUAL CHANCE

1169
00:44:16,400 --> 00:44:18,200
OF PARTICIPATING IN A TRIAL AND

1170
00:44:18,200 --> 00:44:21,160
DESIGN THIS PATIENT NAVIGATION

1171
00:44:21,160 --> 00:44:23,280
INTERVENTION EQUALLY YOU STILL

1172
00:44:23,280 --> 00:44:25,280
IF YOU ARE FUNDAMENTAL

1173
00:44:25,280 --> 00:44:26,800
UNDERLYING STRUCTURE IS BENT OR

1174
00:44:26,800 --> 00:44:29,920
YOUR PROCESS OR PROTOCOL IS BENT

1175
00:44:29,920 --> 00:44:31,720
IN SOME WAY YOU ARE NOT GOING TO

1176
00:44:31,720 --> 00:44:33,000
GET EVERYBODY TO REACH THE SAME

1177
00:44:33,000 --> 00:44:34,040
OUTCOME OR THE APPLE ON THE

1178
00:44:34,040 --> 00:44:34,560
TREE.

1179
00:44:34,560 --> 00:44:38,200
THE LOWER LEFT HAND CORNER

1180
00:44:38,200 --> 00:44:40,880
EQUITY, USE HEALTH EQUITY AS

1181
00:44:40,880 --> 00:44:42,240
WORD AND INVOLVE -- ACKNOWLEDGES

1182
00:44:42,240 --> 00:44:43,680
THAT YOU NEED DIFFERENT LISTS

1183
00:44:43,680 --> 00:44:46,520
AND DIFFERENT SUPPORTS TO GET

1184
00:44:46,520 --> 00:44:47,160
DIVERSE PARTICIPATION AND TRIALS

1185
00:44:47,160 --> 00:44:49,400
AND RETENTION AND ACCRUAL EWE

1186
00:44:49,400 --> 00:44:51,400
NEED TO HELP PEOPLE OVERCOME

1187
00:44:51,400 --> 00:44:53,720
BARRIERS WHICH IS WHAT

1188
00:44:53,720 --> 00:44:55,760
NAVIGATORS DO TO HEALTHCARE.

1189
00:44:55,760 --> 00:44:59,960
TO GET TO GOOD CANCER OUTCOMES.

1190
00:44:59,960 --> 00:45:01,960
IN THE JUSTICE FRAMEWORK IS

1191
00:45:01,960 --> 00:45:03,520
WHERE THE IMPLEMENTATION SCIENCE

1192
00:45:03,520 --> 00:45:06,200
REALLY LIES AND WHERE HEALTH

1193
00:45:06,200 --> 00:45:09,480
EQUITY RESEARCH NCI IS STARTING

1194
00:45:09,480 --> 00:45:10,640
TO INVEST IN THIS.

1195
00:45:10,640 --> 00:45:12,400
THAT IS ABOUT ASKING THE RIGHT

1196
00:45:12,400 --> 00:45:13,800
QUESTION, HAVING THE RIGHT

1197
00:45:13,800 --> 00:45:16,400
PEOPLE AT THE TABLE THAT ASK THE

1198
00:45:16,400 --> 00:45:17,720
QUESTIONS AS WHY THE DARN TREE

1199
00:45:17,720 --> 00:45:19,200
IS BENT IN THE FIRST PLACE, HOW

1200
00:45:19,200 --> 00:45:21,200
DO YOU UNBEND THE TREE AND MAKE

1201
00:45:21,200 --> 00:45:24,520
SURE THAT THAT LIFT AND THAT

1202
00:45:24,520 --> 00:45:26,600
OPPORTUNITY AND RESEARCH PROJECT

1203
00:45:26,600 --> 00:45:28,880
AND OUTCOMES ACTUALLY ALLOW

1204
00:45:28,880 --> 00:45:30,240
EVERYBODY TO HAVE OPPORTUNITY TO

1205
00:45:30,240 --> 00:45:36,400
ACHIEVE THAT OUTCOME.

1206
00:45:36,400 --> 00:45:37,360
SOME DETERMINANTS OF HEALTH ARE

1207
00:45:37,360 --> 00:45:39,400
BIG PART OF THIS AND THAT IS

1208
00:45:39,400 --> 00:45:41,360
NAVIGATION ADDRESSES AND MANY

1209
00:45:41,360 --> 00:45:42,400
DIFFERENT WAYS.

1210
00:45:42,400 --> 00:45:44,080
BUT IT IS ALSO IMPORTANT TO

1211
00:45:44,080 --> 00:45:46,080
ACKNOWLEDGE SOCIAL DETERMINANTS

1212
00:45:46,080 --> 00:45:47,880
OF HEALTH AND SOCIAL ECONOMIC

1213
00:45:47,880 --> 00:45:49,200
FACTORS THAT ARE DRIVEN BY

1214
00:45:49,200 --> 00:45:51,080
SYSTEMIC RACISM AND DRIVEN BY

1215
00:45:51,080 --> 00:45:53,000
THOSE TREES THAT ARE BENT AND

1216
00:45:53,000 --> 00:45:55,360
STRUCTURE THAT ARE BENT THAT

1217
00:45:55,360 --> 00:45:57,160
MAKE THOSE SOCIAL ECONOMIC

1218
00:45:57,160 --> 00:45:59,920
FACTORS WORSE AND IMPACT

1219
00:45:59,920 --> 00:46:00,800
POTENTIAL PARTICIPANT FROM BEING

1220
00:46:00,800 --> 00:46:02,720
ON A TRIAL BUT ALSO ACHIEVING

1221
00:46:02,720 --> 00:46:04,840
THE RIGHT CANCER CARE DELIVERY

1222
00:46:04,840 --> 00:46:07,400
OR THE SCREENING TEST OR

1223
00:46:07,400 --> 00:46:09,720
DIAGNOSTIC RESOLUTION OF

1224
00:46:09,720 --> 00:46:11,600
ABNORMAL TEST AND OR ENTRY INTO

1225
00:46:11,600 --> 00:46:13,800
REAM IN A TIMELY WAY AND

1226
00:46:13,800 --> 00:46:16,240
COMPLETION OF TREATMENT.

1227
00:46:16,240 --> 00:46:17,400
NEXT SLIDE.

1228
00:46:17,400 --> 00:46:20,240
THE ENTIRE RESEARCH PIPELINE HAS

1229
00:46:20,240 --> 00:46:22,000
OPPORTUNITIES WHERE STRUCTURAL

1230
00:46:22,000 --> 00:46:23,160
INEQUITIES OR STRUCTURAL RACISM

1231
00:46:23,160 --> 00:46:24,800
AND BIAS, THAT STARTS WITH

1232
00:46:24,800 --> 00:46:27,840
FUNDER AND DESIGN FUNDING

1233
00:46:27,840 --> 00:46:30,960
OPPORTUNITY SO ACKNOWLEDGE IT'S

1234
00:46:30,960 --> 00:46:31,800
BONDFUL NCI HAS BEEN --

1235
00:46:31,800 --> 00:46:33,280
WONDERFUL NCI IS ADVANCING THE

1236
00:46:33,280 --> 00:46:35,320
WAYS IT EMBRACES DEI FOR EXAMPLE

1237
00:46:35,320 --> 00:46:38,320
AS A NEW COMPONENT IN THE CCSG,

1238
00:46:38,320 --> 00:46:39,680
CANCER CENTER SUPPORT GRANT,

1239
00:46:39,680 --> 00:46:41,360
THAT IS CRITICAL TO HELP BEGIN

1240
00:46:41,360 --> 00:46:44,200
TO MOVE THE DIVERSE WORK FORCE

1241
00:46:44,200 --> 00:46:46,560
FORWARD IN ALL AREAS OF THE

1242
00:46:46,560 --> 00:46:48,200
CANCER CENTER AND WITH RESPECT

1243
00:46:48,200 --> 00:46:50,960
TO RFA AND EVERYTHING ELSE SO

1244
00:46:50,960 --> 00:46:52,080
DESIGN OF THE WHO HOW THE

1245
00:46:52,080 --> 00:46:53,400
SCIENTISTS ARE MENTORED WHO GETS

1246
00:46:53,400 --> 00:46:56,040
TO BE A SCIENTIST, WHO -- ALL

1247
00:46:56,040 --> 00:46:57,480
DESIGN OR STUDY PROTOCOL,

1248
00:46:57,480 --> 00:47:00,600
RESEARCH FINDINGS DISSEMINATION

1249
00:47:00,600 --> 00:47:01,600
AND IMPACT ALL HAVE

1250
00:47:01,600 --> 00:47:04,080
OPPORTUNITIES WHERE THERE'S BIAS

1251
00:47:04,080 --> 00:47:07,120
COULD BE UNBENT AND RETHOUGHT,

1252
00:47:07,120 --> 00:47:08,800
AGAIN UNDER THE HOOD OF THE CAR.

1253
00:47:08,800 --> 00:47:12,400
NEXT SLIDE PLEASE.

1254
00:47:12,400 --> 00:47:14,480
SO ANOTHER PART OF THIS PROCESS

1255
00:47:14,480 --> 00:47:15,960
IN CANCER CARE DELIVERY WITH

1256
00:47:15,960 --> 00:47:17,400
RESPECT TO PATIENT NAVIGATION I

1257
00:47:17,400 --> 00:47:18,960
WILL GET TO IN A MINUTE IT IS

1258
00:47:18,960 --> 00:47:20,880
IMPORTANT TO UNDERSTAND THAT

1259
00:47:20,880 --> 00:47:22,120
EVEN RECOMMENDATION THAT

1260
00:47:22,120 --> 00:47:23,320
CLINICIANS, CLINICAL ONCOLOGISTS

1261
00:47:23,320 --> 00:47:25,120
ARE TRYING -- PRIMARY CARE

1262
00:47:25,120 --> 00:47:28,040
DOCTORS ARE TRYING TO IMPLEMENT

1263
00:47:28,040 --> 00:47:29,920
ARE NOT NECESSARILY DEVELOPED

1264
00:47:29,920 --> 00:47:32,600
WITH THE RIGHT DATA.

1265
00:47:32,600 --> 00:47:34,240
AGAIN, UNDERSTANDING THAT

1266
00:47:34,240 --> 00:47:35,480
RECOMMENDATIONS AND THE PROCESS

1267
00:47:35,480 --> 00:47:38,360
OF GUIDELINES FOR CLINICAL

1268
00:47:38,360 --> 00:47:40,000
ONCOLOGY CARE PRIMARY CARE ARE

1269
00:47:40,000 --> 00:47:41,600
REALLY AND SCREENING ARE

1270
00:47:41,600 --> 00:47:42,000
CRITICAL.

1271
00:47:42,000 --> 00:47:43,120
SO I HAVE BEEN A MEMBER OF THE

1272
00:47:43,120 --> 00:47:44,960
UNITED STATES PREVENTIVE

1273
00:47:44,960 --> 00:47:45,800
SERVICES FASTOR TASK FORCE TO

1274
00:47:45,800 --> 00:47:47,600
HELP TRY TO THINK ABOUT HOW WE

1275
00:47:47,600 --> 00:47:48,800
DO THAT BETTER, CREATE

1276
00:47:48,800 --> 00:47:51,600
RECOMMENDATIONS THAT ARE MORE

1277
00:47:51,600 --> 00:47:52,720
GENERALIZABLE TO THE ACTUAL

1278
00:47:52,720 --> 00:47:53,800
EVOLVING DEMOGRAPHY OF OUR

1279
00:47:53,800 --> 00:47:54,200
POPULATION.

1280
00:47:54,200 --> 00:47:57,000
NEXT SLIDE.

1281
00:47:57,000 --> 00:47:58,720
ONE EXAM IS COLORECTAL CANCER

1282
00:47:58,720 --> 00:48:01,640
AND REDUCE AGE TO 45.

1283
00:48:01,640 --> 00:48:04,000
THE OTHER EXAMPLE IS LUNG CANCER

1284
00:48:04,000 --> 00:48:07,120
SCREENING WHERE WE REDUCE THE

1285
00:48:07,120 --> 00:48:07,840
PACK YEAR HISTORY.

1286
00:48:07,840 --> 00:48:09,400
THOSE ARE CRITICAL BECAUSE THAT

1287
00:48:09,400 --> 00:48:13,280
HELPS AVAIL A SCREENING

1288
00:48:13,280 --> 00:48:14,600
OPPORTUNITY FOR MORE BLACK

1289
00:48:14,600 --> 00:48:15,920
PEOPLE IN OUR COUNTRY.

1290
00:48:15,920 --> 00:48:18,000
NEXT SLIDE, THEY ARE THE BRUNT

1291
00:48:18,000 --> 00:48:20,520
OF THE CANCER DISPARITIES.

1292
00:48:20,520 --> 00:48:22,200
IMPLEMENTATION SCIENCE IS

1293
00:48:22,200 --> 00:48:24,200
BRIDGING THE SCIENCE PRACTICE

1294
00:48:24,200 --> 00:48:26,400
GAP AND TRYING TO GET MORE

1295
00:48:26,400 --> 00:48:29,200
TRANSLATION HAPPENING AT T-4

1296
00:48:29,200 --> 00:48:30,040
ACROSS EVERY SINGLE COMMUNITY

1297
00:48:30,040 --> 00:48:34,480
HEALTH CENTER AND PRACTICE SITE

1298
00:48:34,480 --> 00:48:36,280
ACROSS UNITED STATES.

1299
00:48:36,280 --> 00:48:37,640
SO THE CONSOLIDATED FRAMEWORK

1300
00:48:37,640 --> 00:48:39,000
FOR IMPLEMENTATION RESEARCH IS

1301
00:48:39,000 --> 00:48:42,240
ONE OF MANY IMPLEMENTATION FRAME

1302
00:48:42,240 --> 00:48:43,680
WORKS AND REALLY TALKS ABOUT HOW

1303
00:48:43,680 --> 00:48:49,600
YOU ARE LOOKING AT THAT PROCESS

1304
00:48:49,600 --> 00:48:51,800
OF IMPLEMENTING EVIDENCE BASED

1305
00:48:51,800 --> 00:48:54,160
INTERVENTION FROM A TRIAL IN TO

1306
00:48:54,160 --> 00:48:54,560
PRACTICE.

1307
00:48:54,560 --> 00:48:56,960
IT IS ULTRATIVE AND THERE IS

1308
00:48:56,960 --> 00:48:58,600
INTERNAL AND EXTERNAL

1309
00:48:58,600 --> 00:48:59,840
ENVIRONMENT AND HOW THEY

1310
00:48:59,840 --> 00:49:00,240
INTERACT.

1311
00:49:00,240 --> 00:49:02,720
NEXT SLIDE PLEASE.

1312
00:49:02,720 --> 00:49:06,480
WHAT IS IMPORTANT ABOUT HOW

1313
00:49:06,480 --> 00:49:08,160
PATIENT NAVIGATION WORK WORKS

1314
00:49:08,160 --> 00:49:09,480
WITH RESPECT TO HYBRID DESIGN

1315
00:49:09,480 --> 00:49:11,640
MEANING LOOKING AT THE PROCESS

1316
00:49:11,640 --> 00:49:13,840
OR THE IMPLEMENTATION, WHILE YOU

1317
00:49:13,840 --> 00:49:17,440
ARE ATTEMPTING INTERVENTION

1318
00:49:17,440 --> 00:49:18,800
ITSELF OR THE PROGRAM, WHATEVER,

1319
00:49:18,800 --> 00:49:20,600
THE APPROACH TO SCREENING FOR

1320
00:49:20,600 --> 00:49:22,600
CERVICAL CANCER FOR EXAMPLE

1321
00:49:22,600 --> 00:49:24,240
ITSELF, THERE IS OPPORTUNITY FOR

1322
00:49:24,240 --> 00:49:26,160
AS I HAVE SAID BEFORE,

1323
00:49:26,160 --> 00:49:29,320
STRUCTURAL ISSUES, BIAS AND

1324
00:49:29,320 --> 00:49:30,040
EVERY PART OF THIS.

1325
00:49:30,040 --> 00:49:32,800
PART PLAYS IN THE OUTER ROUND

1326
00:49:32,800 --> 00:49:33,800
WHERE I ALREADY SHOWED YOU THE

1327
00:49:33,800 --> 00:49:36,080
FRAME W OF SOCIETY AND SOCIO

1328
00:49:36,080 --> 00:49:38,080
POLITICAL STRUCTURE AND

1329
00:49:38,080 --> 00:49:39,360
ORGANIZATIONAL CULTURE WITHIN

1330
00:49:39,360 --> 00:49:41,680
PARTICULAR COMMUNITY HEALTH

1331
00:49:41,680 --> 00:49:44,560
CENTER OR PARTICULAR HEALTHCARE

1332
00:49:44,560 --> 00:49:46,640
DELIVERY TEAM EXPECTATIONS,

1333
00:49:46,640 --> 00:49:48,360
NORMS, INDIVIDUALS INVOLVED THE

1334
00:49:48,360 --> 00:49:51,520
PATIENT EXPERIENCE OF

1335
00:49:51,520 --> 00:49:52,840
DISCRIMINATION OF DISTRUST AND

1336
00:49:52,840 --> 00:49:55,160
EVEN IN THE PROCESS ITSELF SO

1337
00:49:55,160 --> 00:49:58,120
REALLY THAT IS WHERE OUR WORK

1338
00:49:58,120 --> 00:50:00,360
HAS REALLY TAKEN OFF AND WHERE

1339
00:50:00,360 --> 00:50:03,360
WE NEED TO DIVE IN AND EXAMINE

1340
00:50:03,360 --> 00:50:05,400
MORE.

1341
00:50:05,400 --> 00:50:08,600
NEXT SLIDE EXAMPLE IN SHOG

1342
00:50:08,600 --> 00:50:11,520
SHYING, NEXT SLIDE.

1343
00:50:11,520 --> 00:50:13,600
IN CHICAGO FOR BREAST CANCER

1344
00:50:13,600 --> 00:50:14,960
DISPARITIES, WE HAVE DONE A LOT

1345
00:50:14,960 --> 00:50:18,320
OF PATIENT NAVIGATION WORK SINCE

1346
00:50:18,320 --> 00:50:21,000
2006 AND PATIENT NAVIGATION

1347
00:50:21,000 --> 00:50:22,000
ESPECIALLY BREAST CANCER THROUGH

1348
00:50:22,000 --> 00:50:23,600
THE CERVICAL CANCER THROUGH THE

1349
00:50:23,600 --> 00:50:25,680
GRACIOUS FUNDING OF NCI

1350
00:50:25,680 --> 00:50:26,880
CONTINUOUSLY WITH A VARIETY OF

1351
00:50:26,880 --> 00:50:27,920
COMMUNITY AREAS.

1352
00:50:27,920 --> 00:50:31,560
AND IN CHICAGO BREAST CANCER

1353
00:50:31,560 --> 00:50:35,560
MORTALITY RATES BLACK, WHITE,

1354
00:50:35,560 --> 00:50:37,200
DIFFERENT, 62% BY 2007 IN THE

1355
00:50:37,200 --> 00:50:39,200
EARLY '80s ON THE LEFT SIDE OF

1356
00:50:39,200 --> 00:50:42,080
THAT GRAPH IT WAS APPROXIMATELY

1357
00:50:42,080 --> 00:50:42,800
THE SAME.

1358
00:50:42,800 --> 00:50:45,680
THAT IS EGREGIOUS AND IT WAS

1359
00:50:45,680 --> 00:50:47,600
VERY DIFFERENT THAT 62%

1360
00:50:47,600 --> 00:50:50,440
MORTALITY GAP FOR BLACK WOMEN IN

1361
00:50:50,440 --> 00:50:51,320
CHICAGO VERSUS WHITE WOMEN IN

1362
00:50:51,320 --> 00:50:52,400
BREAST CANCER IS VERY DIFFERENT

1363
00:50:52,400 --> 00:50:53,520
THAN THE 27% THAT WAS IN NEW

1364
00:50:53,520 --> 00:50:55,800
YORK CITY AT THE SAME TIME OR

1365
00:50:55,800 --> 00:50:58,000
THE 40% IN THE UNITED STATES.

1366
00:50:58,000 --> 00:51:03,360
NEXT SLIDE.

1367
00:51:03,360 --> 00:51:05,000
TAKING THE SOCIAL ECOLOGICAL

1368
00:51:05,000 --> 00:51:06,120
MODEL PATIENT NAVIGATION IN

1369
00:51:06,120 --> 00:51:08,160
VARIETY OF FORMS AND NOT JUST IN

1370
00:51:08,160 --> 00:51:10,600
THE IN PERSON FORM, REALLY

1371
00:51:10,600 --> 00:51:12,080
LOOKING AT INTERPERSONAL

1372
00:51:12,080 --> 00:51:13,560
BARRIERS, THE MOST INNER CIRCLE

1373
00:51:13,560 --> 00:51:16,200
AND REALLY TRYING TO THINK ABOUT

1374
00:51:16,200 --> 00:51:20,160
WHAT ARE PROCESSES ACROSS EACH

1375
00:51:20,160 --> 00:51:22,040
CLINIC AND EVERY OPPORTUNITY

1376
00:51:22,040 --> 00:51:24,840
THAT A WOMAN, A WOMAN OF COLOR

1377
00:51:24,840 --> 00:51:27,200
SPECIFICALLY BLACK WOMEN IN

1378
00:51:27,200 --> 00:51:28,760
CHICAGO HAD WITH THEIR

1379
00:51:28,760 --> 00:51:30,600
MAMMOGRAPHY CENTER, AND WITH

1380
00:51:30,600 --> 00:51:33,200
CLINICS AND WE DID AN

1381
00:51:33,200 --> 00:51:35,520
ENVIRONMENTAL SCAN WITH SYSTEMS

1382
00:51:35,520 --> 00:51:36,880
ENGINEERS FROM BUSINESS SCHOOL

1383
00:51:36,880 --> 00:51:41,480
AT NORTHWESTERN TO REALLY FIGURE

1384
00:51:41,480 --> 00:51:43,200
OUT WE FOLLOWED WOMEN FROM 27

1385
00:51:43,200 --> 00:51:44,360
CLINICS TO FIGURE FROM THE TIME

1386
00:51:44,360 --> 00:51:47,600
THEY GOT TO CLINIC EVERY PROCESS

1387
00:51:47,600 --> 00:51:48,800
THAT -- AND EVERY SINGLE

1388
00:51:48,800 --> 00:51:50,280
INTERACTION WAS DOCUMENTED OF

1389
00:51:50,280 --> 00:51:51,280
THIS PATIENT FROM THE TIME THEY

1390
00:51:51,280 --> 00:51:53,200
GOT INTO THE TIME THEY LEFT

1391
00:51:53,200 --> 00:51:54,920
WITHIN THE MAMMOGRAPHY REFERRAL.

1392
00:51:54,920 --> 00:51:56,680
THAT WAS REALLY DIGGING INTO THE

1393
00:51:56,680 --> 00:51:59,680
PROCESS AND LOOKING AT

1394
00:51:59,680 --> 00:52:01,960
STRUCTURE, WHAT WAS GOING ON AND

1395
00:52:01,960 --> 00:52:02,400
WHAT WAS HINGERING.

1396
00:52:02,400 --> 00:52:04,960
AND THEN WE ALSO LOOK AT

1397
00:52:04,960 --> 00:52:07,800
MAMMOGRAPHY SUITES AND REALIZE

1398
00:52:07,800 --> 00:52:09,000
WOMEN WEREN'T GETTING RESULTS OF

1399
00:52:09,000 --> 00:52:10,200
MAMMOGRAMS THEY THOUGHT THEY

1400
00:52:10,200 --> 00:52:14,200
WERE NORMAL.

1401
00:52:14,200 --> 00:52:15,400
SO THESE NEEDED TO BE CORRECTED

1402
00:52:15,400 --> 00:52:16,800
THROUGH PATIENT NAVIGATION.

1403
00:52:16,800 --> 00:52:19,320
ANOTHER PATIENT NAVIGATION MORE

1404
00:52:19,320 --> 00:52:20,640
SYSTEMS LEVEL NEEDED TO HAPPEN

1405
00:52:20,640 --> 00:52:23,240
TOO, THE MIDDLE CIRCLES WHICH

1406
00:52:23,240 --> 00:52:32,680
WERE IN QUALITY IMPROVEMENT WE

1407
00:52:32,680 --> 00:52:34,800
NEEDED TO TEACH AND COACH THEM

1408
00:52:34,800 --> 00:52:36,480
AND HELP EVIDENCE BASED

1409
00:52:36,480 --> 00:52:40,080
INTERVENTIONS TO FIX FACETS THAT

1410
00:52:40,080 --> 00:52:46,240
WERE NOT WORKING WELL FOR WOMEN.

1411
00:52:46,240 --> 00:52:48,240
SO THE CORE PRINCIPLES OF

1412
00:52:48,240 --> 00:52:49,480
NAVIGATION PATIENT CENTERED

1413
00:52:49,480 --> 00:52:50,920
COMMUNITY CENTERED EVIDENCE

1414
00:52:50,920 --> 00:52:56,240
BASED IS REALLY TO IMPLEMENTING

1415
00:52:56,240 --> 00:52:57,800
DIFFERENT TYPES OF PATIENT

1416
00:52:57,800 --> 00:52:58,960
NAVIGATION.

1417
00:52:58,960 --> 00:53:05,120
THAT WHAT WAS REALLY CRITICAL IS

1418
00:53:05,120 --> 00:53:06,840
BEING ABLE TO STUDY NAVIGATION

1419
00:53:06,840 --> 00:53:09,040
AS PHYSICAL NAVIGATORS OR

1420
00:53:09,040 --> 00:53:10,200
CHECKLIST AND HOW THOSE WORKED

1421
00:53:10,200 --> 00:53:13,080
WITH RESPECT TO OUTCOMES BUT HOW

1422
00:53:13,080 --> 00:53:15,080
THAT PHYSICAL PROCESS OF HAVING

1423
00:53:15,080 --> 00:53:16,760
A PATIENT NAVIGATOR WITH A

1424
00:53:16,760 --> 00:53:21,200
CLINICAL CARE TEAM AND HAVING

1425
00:53:21,200 --> 00:53:22,240
CHECKLIST WITH CLINICAL CARE

1426
00:53:22,240 --> 00:53:23,680
TEAM IMPROVED PATIENT OUTCOMES

1427
00:53:23,680 --> 00:53:25,120
SO STUDYING THE METHOD AND THE

1428
00:53:25,120 --> 00:53:27,960
APPROACH AND THE PROCESSES

1429
00:53:27,960 --> 00:53:30,200
ITERATIVELY WHILE THE ACTUAL

1430
00:53:30,200 --> 00:53:31,200
INTERVENTION ITSELF AND

1431
00:53:31,200 --> 00:53:32,160
INTERACTION WITH EACH DIFFERENT

1432
00:53:32,160 --> 00:53:33,160
TYPE OF PATIENT WAS REALLY

1433
00:53:33,160 --> 00:53:41,720
CRITICAL.

1434
00:53:41,720 --> 00:53:44,600
THIS WAS EXAMPLE CHECKLIST WITH

1435
00:53:44,600 --> 00:53:45,720
BREAST CANCER, THIS IS A

1436
00:53:45,720 --> 00:53:47,640
SEQUENCE CARE SO LOOKS LIKE A

1437
00:53:47,640 --> 00:53:49,200
GANT CHART AND HELPING TO EMBED

1438
00:53:49,200 --> 00:53:52,760
EQUITY BECAUSE THE PATIENT AND

1439
00:53:52,760 --> 00:53:57,040
THE CAREGIVER GOT HARD FORM AND

1440
00:53:57,040 --> 00:53:59,360
PATIENT TEAM AND NAVIGATOR SO

1441
00:53:59,360 --> 00:54:00,360
EVERYBODY WAS ON THE SAME PAGE

1442
00:54:00,360 --> 00:54:01,680
WITH RESPECT TO WHAT WAS NEEDED

1443
00:54:01,680 --> 00:54:04,240
TO BE DONE AND APPROXIMATELY

1444
00:54:04,240 --> 00:54:08,360
WHAT TIME AND CARE TRAJECTORY,

1445
00:54:08,360 --> 00:54:16,400
AND THEN ON THE BACK WE ARE TYPE

1446
00:54:16,400 --> 00:54:17,800
OF CONTACT NUMBERS SO TYPE OF

1447
00:54:17,800 --> 00:54:19,000
NAVIGATION WITHOUT IN PERSON AND

1448
00:54:19,000 --> 00:54:21,600
HELPING GUIDE THE WHOLE TEAM ME

1449
00:54:21,600 --> 00:54:23,160
BEYOND THE SAME PAGE WITH SAME

1450
00:54:23,160 --> 00:54:25,360
QUALITY CARE CONSISTENTLY ACROSS

1451
00:54:25,360 --> 00:54:26,800
EACH PATIENT REGARD OF THE COLOR

1452
00:54:26,800 --> 00:54:28,680
OF THE SKIN WHERE THEY ARE FROM,

1453
00:54:28,680 --> 00:54:34,920
OR PAYER STATUS.

1454
00:54:34,920 --> 00:54:37,800
NAVIGATION PROCESS, ONE OF OUR

1455
00:54:37,800 --> 00:54:39,440
STUDIES, IT WAS ABLE THE BRING

1456
00:54:39,440 --> 00:54:41,600
RELATIONSHIPSING TO, BUILD

1457
00:54:41,600 --> 00:54:42,520
RELATIONSHIPS AND BRING

1458
00:54:42,520 --> 00:54:44,280
ORGANIZATIONS TOGETHER WHICH IS

1459
00:54:44,280 --> 00:54:48,480
CRITICAL FOR SUBURBAN AREAS IN

1460
00:54:48,480 --> 00:54:50,920
COOK COUNTY AND SURROUNDING

1461
00:54:50,920 --> 00:54:52,600
BECAUSE NOT ALL PLACES HAVE

1462
00:54:52,600 --> 00:54:55,720
PUBLIC HEALTH SAFETY NETS.

1463
00:54:55,720 --> 00:54:57,000
WHEN THE YOU DON'T HAVE PUBLIC

1464
00:54:57,000 --> 00:54:59,560
HEALTH SAFETY NET URBAN

1465
00:54:59,560 --> 00:55:01,000
METROPOLIS PATIENT NAVIGATORS

1466
00:55:01,000 --> 00:55:02,560
AND NAVIGATION PROCESS ABLE

1467
00:55:02,560 --> 00:55:04,160
BRING RELATIONSHIPS DIFFERENT

1468
00:55:04,160 --> 00:55:05,640
COMMUNITY ORGANIZATIONS TOGETHER

1469
00:55:05,640 --> 00:55:06,760
THAT WOULD HAVE BEEN WORKING

1470
00:55:06,760 --> 00:55:12,160
TOGETHER TO WRAP AROUND IT WASES

1471
00:55:12,160 --> 00:55:13,680
NEED AND DETERMINE ECONOMICS

1472
00:55:13,680 --> 00:55:14,720
DETERMINANTS OF HEALTH FOR EACH

1473
00:55:14,720 --> 00:55:19,920
PATIENT.

1474
00:55:19,920 --> 00:55:23,960
ITERATIVE PROCESS, COLLABORATIVE

1475
00:55:23,960 --> 00:55:25,760
COLLABORATIVE, WE WERE ABLE TO

1476
00:55:25,760 --> 00:55:28,600
CLOSE GAP TO 36% IN 2017 AND

1477
00:55:28,600 --> 00:55:32,640
CLOSE A LITTLE MORE.

1478
00:55:32,640 --> 00:55:33,520
DURING COVID I CAN'T TELL YOU

1479
00:55:33,520 --> 00:55:35,280
WHAT HAPPEN BUT SOON TO SEE BUT

1480
00:55:35,280 --> 00:55:36,520
THERE IS STILL WORK TO DO.

1481
00:55:36,520 --> 00:55:41,240
IT IS NOT GOOD ENOUGH.

1482
00:55:41,240 --> 00:55:43,680
GOOD BUT NOT GOOD ENOUGH.

1483
00:55:43,680 --> 00:55:45,720
THIS IS PART OF IT, THANKS THE

1484
00:55:45,720 --> 00:55:48,400
NATIONAL CANCER INSTITUTE FOR

1485
00:55:48,400 --> 00:55:49,840
FUNDING US UNIVERSITY OF

1486
00:55:49,840 --> 00:55:52,160
ILLINOIS CHICAGO, UNIVERSITY OF

1487
00:55:52,160 --> 00:55:55,400
ILLINOIS NORTHWESTERN NOW IN #TH

1488
00:55:55,400 --> 00:55:58,000
YEAR OF U 54 MECHANISM, IT IS

1489
00:55:58,000 --> 00:55:58,720
EXTRAORDINARY WITH RESPECT TO

1490
00:55:58,720 --> 00:56:01,240
THE AMOUNT OF RESEARCH,

1491
00:56:01,240 --> 00:56:05,400
COMMUNITY COLLABORATION ACROSS

1492
00:56:05,400 --> 00:56:07,000
CITY, DIVERSE WORK FORCE

1493
00:56:07,000 --> 00:56:07,960
DEVELOPMENT WHICH IS CRITICAL TO

1494
00:56:07,960 --> 00:56:11,040
THIS WORK.

1495
00:56:11,040 --> 00:56:13,600
HERE IS OUR COMMUNITY

1496
00:56:13,600 --> 00:56:14,000
FOOTPRINTS.

1497
00:56:14,000 --> 00:56:19,200
WE HAVE THE SHOW TIME ACTRESS

1498
00:56:19,200 --> 00:56:21,480
VISIT US THIS YEAR WITH OUR

1499
00:56:21,480 --> 00:56:26,360
COMMUNITY FORUMS.

1500
00:56:26,360 --> 00:56:29,040
ANOTHER IMPORTANT INITIATIVE THE

1501
00:56:29,040 --> 00:56:31,600
PATIENT NAVIGATORS ARE CONNECTED

1502
00:56:31,600 --> 00:56:33,360
WITH IS OUR LIBRARY

1503
00:56:33,360 --> 00:56:34,680
PARTNERSHIPS, WE PARTNER WITH

1504
00:56:34,680 --> 00:56:36,400
CHICAGO PUBLIC LIBRARIES, WE

1505
00:56:36,400 --> 00:56:38,280
HAVE A HEALTH FOR ALL PLATFORM

1506
00:56:38,280 --> 00:56:41,400
FUNDED BY NATIONAL LIBRARY OF

1507
00:56:41,400 --> 00:56:43,000
MEDICINE, SEVERAL GRANTS,

1508
00:56:43,000 --> 00:56:44,400
DISPELLING MYTHS ABOUT CLINICAL

1509
00:56:44,400 --> 00:56:47,480
TRIAL PARTICIPATION TO HELP

1510
00:56:47,480 --> 00:56:49,400
SUPPORT TO MEET NEEDS IN TRUSTED

1511
00:56:49,400 --> 00:56:50,120
SPACES.

1512
00:56:50,120 --> 00:56:51,920
LIBRARIES AND LIBRARIANS ARE

1513
00:56:51,920 --> 00:56:53,600
TRUSTED SPACES AND PROFESSIONALS

1514
00:56:53,600 --> 00:56:56,080
IN OUR COUNTRY.

1515
00:56:56,080 --> 00:56:57,640
SO YOU HAVE TO GO WHERE THERE IS

1516
00:56:57,640 --> 00:56:59,040
TRUST AND GIVE THAT INFORMATION

1517
00:56:59,040 --> 00:57:03,920
IN PLACES THAT ARE TRUSTED.

1518
00:57:03,920 --> 00:57:06,160
THEN COMMUNITY SCIENTIST, SOME

1519
00:57:06,160 --> 00:57:08,600
CALL THEM CITIZEN SCIENTIST, I

1520
00:57:08,600 --> 00:57:11,600
DON'T LIKE THE WORD CITIZEN MY

1521
00:57:11,600 --> 00:57:14,040
PEOPLE LET CITIZEN IS NOT OUR

1522
00:57:14,040 --> 00:57:15,400
PREFERRED WORD SO COMMUNITY

1523
00:57:15,400 --> 00:57:18,960
SCIENTIST IS WHAT WE BUILT, WE

1524
00:57:18,960 --> 00:57:20,440
HAVE STRONG SET OF COMMUNITY

1525
00:57:20,440 --> 00:57:22,680
SCIENTISTS THAT WORK WITH OUR

1526
00:57:22,680 --> 00:57:25,000
BENCH SCIENCE TEAMS SO OUR T 0 T

1527
00:57:25,000 --> 00:57:26,960
1 AND TO INFLUENCE SCIENCE AND

1528
00:57:26,960 --> 00:57:28,960
THAT HELPS BECAUSE THEY ARE LIKE

1529
00:57:28,960 --> 00:57:32,880
NAVIGATORS OF THE SORT AND HELP

1530
00:57:32,880 --> 00:57:35,160
NAVIGATE RESEARCHERS TO HAVING

1531
00:57:35,160 --> 00:57:36,600
BETTER RESEARCH AND ROBUST

1532
00:57:36,600 --> 00:57:37,000
PROTOCOLS.

1533
00:57:37,000 --> 00:57:38,880
THIS IS ALL CONNECTED.

1534
00:57:38,880 --> 00:57:40,120
PATIENT NAVIGATION AN OUTCOMES

1535
00:57:40,120 --> 00:57:42,200
AND THE TYPES OF NAVIGATION WE

1536
00:57:42,200 --> 00:57:47,160
DO IS ALL CONNECTED.

1537
00:57:47,160 --> 00:57:48,240
ANOTHER OPPORTUNITY WE ARE

1538
00:57:48,240 --> 00:57:51,800
WORKING ON RIGHT NOW WITH

1539
00:57:51,800 --> 00:57:53,560
MULTIPLE BIG TEN SITES ACROSS

1540
00:57:53,560 --> 00:57:54,800
THE COUNTRY AND IMPLEMENTATION

1541
00:57:54,800 --> 00:57:56,520
SCIENCE AND EVIDENCE BASED

1542
00:57:56,520 --> 00:57:58,840
INTERVENTIONS WITH NAVIGATION IS

1543
00:57:58,840 --> 00:58:00,880
PART OF IT IS WITH CERVICAL

1544
00:58:00,880 --> 00:58:01,680
CANCER MEETING THE NEEDS IN

1545
00:58:01,680 --> 00:58:04,880
ORDER TO ADDRESS THE STAGNANT

1546
00:58:04,880 --> 00:58:06,200
CERVICAL CANCER RATES IN THIS

1547
00:58:06,200 --> 00:58:07,800
COUNTRY WITH DECADES, WE HAVE TO

1548
00:58:07,800 --> 00:58:10,400
ADDRESS ALL THREE PILLARS OF THE

1549
00:58:10,400 --> 00:58:12,480
WORLD HEALTH ORGANIZATION

1550
00:58:12,480 --> 00:58:13,800
CERVICAL CANCER ELIMINATION

1551
00:58:13,800 --> 00:58:15,320
STRATEGY, THAT IS WHAT WE ARE

1552
00:58:15,320 --> 00:58:19,960
EMBARKING ON NOW.

1553
00:58:19,960 --> 00:58:21,920
>> IF YOU CAN BEGIN TO WRAP UP.

1554
00:58:21,920 --> 00:58:25,280
>> LAST SLIDE.

1555
00:58:25,280 --> 00:58:27,000
FINALLY, IN ORDER TO DO PATIENT

1556
00:58:27,000 --> 00:58:27,920
NAVIGATION WORK AN

1557
00:58:27,920 --> 00:58:28,760
IMPLEMENTATION SCIENCE YOU NEED

1558
00:58:28,760 --> 00:58:30,320
A PIPELINE, DIVERSE SET OF

1559
00:58:30,320 --> 00:58:31,360
SCIENTISTS AND I WANT TO THANK

1560
00:58:31,360 --> 00:58:33,400
THE NIH FOR THEIR NIH UNITE

1561
00:58:33,400 --> 00:58:36,400
INITIATIVE FOR THE FIRST GRANT

1562
00:58:36,400 --> 00:58:39,280
INITIATIVE.

1563
00:58:39,280 --> 00:58:42,520
THINGS CHANGING CCS DATA AND DEI

1564
00:58:42,520 --> 00:58:44,720
COMPONENT TO OPTIMIZE TRAINING

1565
00:58:44,720 --> 00:58:45,840
MENTORSHIP CAREER DEVELOPMENT

1566
00:58:45,840 --> 00:58:47,640
PATHWAYS FOR DIVERSE

1567
00:58:47,640 --> 00:58:49,120
INVESTIGATORS LIKE MYSELF.

1568
00:58:49,120 --> 00:58:49,600
THANK YOU.

1569
00:58:49,600 --> 00:58:50,840
NEXT SLIDE IS CONTACT

1570
00:58:50,840 --> 00:58:51,160
INFORMATION.

1571
00:58:51,160 --> 00:58:55,000
>> THANKS, MELISSA.

1572
00:58:55,000 --> 00:58:55,520
FANTASTIC.

1573
00:58:55,520 --> 00:59:02,720
IF WE CAN GO OUT TO VIEW

1574
00:59:02,720 --> 00:59:05,640
PARTICIPANTS WE PROBABLY ONLY

1575
00:59:05,640 --> 00:59:07,160
HAVE TIME FOR ONE OR TWO

1576
00:59:07,160 --> 00:59:10,440
QUESTIONS, THAT WAS AN EXCELLENT

1577
00:59:10,440 --> 00:59:13,560
PRESENTATION WHY DON'T WE START

1578
00:59:13,560 --> 00:59:15,200
WITH KAREN AND UNLESS THERE IS

1579
00:59:15,200 --> 00:59:17,960
ONE -- LOOKS LIKE TYLER.

1580
00:59:17,960 --> 00:59:21,000
WE ARE ONLY GOING TO TAKE TWO

1581
00:59:21,000 --> 00:59:22,000
QUESTIONS WE WANT TO STAY ON

1582
00:59:22,000 --> 00:59:26,640
TIME.

1583
00:59:26,640 --> 00:59:28,800
>> I DIDN'T HAVE A QUESTION I

1584
00:59:28,800 --> 00:59:29,760
DIDN'T LOWER MY HAND.

1585
00:59:29,760 --> 00:59:32,120
>> I DON'T SEE ANY HANDS BUT I

1586
00:59:32,120 --> 00:59:36,320
HAVE A QUESTION.

1587
00:59:36,320 --> 00:59:39,640
WHEN I LOOK AT THE NOVEMBER

1588
00:59:39,640 --> 00:59:43,160
NAVIGATOR APPROACH, IT IS

1589
00:59:43,160 --> 00:59:46,240
FINANCIAL IT SAID CALL YOUR CASE

1590
00:59:46,240 --> 00:59:49,400
WORKERS SO SEEMS LIKE THAT

1591
00:59:49,400 --> 00:59:51,800
FINANCE PERSONAL PIECE CAN ALSO

1592
00:59:51,800 --> 00:59:55,200
BE REALLY IMPORTANT AND WHAT ARE

1593
00:59:55,200 --> 00:59:56,800
THOUGHTS EXPANDING THERE?

1594
00:59:56,800 --> 00:59:58,840
>> THAT IS ONE VERSION OF THE

1595
00:59:58,840 --> 00:59:59,200
FORM.

1596
00:59:59,200 --> 01:00:03,520
THERE IS A LOT.

1597
01:00:03,520 --> 01:00:05,240
THAT IS COOL GLAD YOU DID

1598
01:00:05,240 --> 01:00:07,200
BECAUSEOR BECAUSE FINANCIAL TO

1599
01:00:07,200 --> 01:00:09,200
BE TESSIE IS A BIG ISSUE, LOT OF

1600
01:00:09,200 --> 01:00:10,240
OUT OF POCKET COSTS WITH

1601
01:00:10,240 --> 01:00:12,000
PARTICIPATING IN RESEARCH IN

1602
01:00:12,000 --> 01:00:13,240
GENERAL LET ALONE CLINICAL

1603
01:00:13,240 --> 01:00:16,280
TRIALS SPECIFICALLY.

1604
01:00:16,280 --> 01:00:17,640
PATIENT NAVIGATION A BIG PART OF

1605
01:00:17,640 --> 01:00:20,840
WHAT OUR NAVIGATOR TEAMS DO, IS

1606
01:00:20,840 --> 01:00:22,360
ADDRESS FINANCIAL ISSUES AND TRY

1607
01:00:22,360 --> 01:00:23,400
TO CONNECT PEOPLE TO DIFFERENT

1608
01:00:23,400 --> 01:00:28,760
RESOURCES THAT ARE AVAILABLE.

1609
01:00:28,760 --> 01:00:31,440
CRITICAL WORK THAT TAKES TIME

1610
01:00:31,440 --> 01:00:32,680
BUT UNDERSTANDING HOW

1611
01:00:32,680 --> 01:00:33,240
IMPLEMENTED IN DIFFERENT

1612
01:00:33,240 --> 01:00:34,360
CLINICAL CARE SETTINGS IS

1613
01:00:34,360 --> 01:00:36,200
CRUCIAL AND THAT IS WHY THESE

1614
01:00:36,200 --> 01:00:41,000
TYPES OF HYBRID STUDIES OF

1615
01:00:41,000 --> 01:00:44,240
NAVIGATION WITH STUDYING THE END

1616
01:00:44,240 --> 01:00:46,840
POINTS GET MORE ANTI-RACIST AND

1617
01:00:46,840 --> 01:00:49,880
HIGHER EQUITY WHILE ADDRESSING

1618
01:00:49,880 --> 01:00:51,400
THE INTERVENTION ITSELF, IT

1619
01:00:51,400 --> 01:00:54,600
COSTS MONEY, IT IS MORE THAN A

1620
01:00:54,600 --> 01:00:55,840
USUAL RO1 BUDGET.

1621
01:00:55,840 --> 01:00:57,000
THAT IS THE CHALLENGE BECAUSE

1622
01:00:57,000 --> 01:00:58,800
YOU HAVE TO BE IN SO MANY SITES

1623
01:00:58,800 --> 01:01:02,200
TO LOOK AT AND EXAMINE THE

1624
01:01:02,200 --> 01:01:03,720
VARIABILITY ACROSS SITES WHILE

1625
01:01:03,720 --> 01:01:08,040
EXAMINING THE VARIABILITY OF THE

1626
01:01:08,040 --> 01:01:09,200
INTERVENTIONS WITHIN POPULATIONS

1627
01:01:09,200 --> 01:01:10,440
AT EACH SITE.

1628
01:01:10,440 --> 01:01:13,000
THESE TYPES OF STUDIES REQUIRE

1629
01:01:13,000 --> 01:01:15,080
LOTS OF SITES AND HUSBAND MORE

1630
01:01:15,080 --> 01:01:17,120
THAN REGULAR RO1 TYPE BUDGET.

1631
01:01:17,120 --> 01:01:17,960
>> THANKS.

1632
01:01:17,960 --> 01:01:18,440
MELISSA.

1633
01:01:18,440 --> 01:01:22,480
I THINK WE ONLY HAVE TIME FOR

1634
01:01:22,480 --> 01:01:24,520
WOMB MORE QUESTION OR LEE WE

1635
01:01:24,520 --> 01:01:30,200
WILL LOSE TIME DURING THE BREAK.

1636
01:01:30,200 --> 01:01:32,600
>> I APOLOGIZE FOR INTERRUPTING

1637
01:01:32,600 --> 01:01:32,960
YOU.

1638
01:01:32,960 --> 01:01:36,400
OUR SPEAKER IS HAVING ISSUES

1639
01:01:36,400 --> 01:01:38,480
JOINING.

1640
01:01:38,480 --> 01:01:40,440
SO

1641
01:01:40,440 --> 01:01:47,400
>> GREAT.

1642
01:01:47,400 --> 01:01:52,200
I WILL START WITH TRAY THEN

1643
01:01:52,200 --> 01:01:52,920
ASHE.

1644
01:01:52,920 --> 01:01:56,800
>> IN THAT CASE I WILL RERAISE

1645
01:01:56,800 --> 01:01:58,320
MY HAND.

1646
01:01:58,320 --> 01:02:00,520
I THOUGHT YOUR SLIDE

1647
01:02:00,520 --> 01:02:02,000
QUANTITATING OUTCOME DISPARITY

1648
01:02:02,000 --> 01:02:03,040
BETWEEN BLACK AND WHITE WOMEN

1649
01:02:03,040 --> 01:02:05,200
WAS ABSOLUTELY STUNNING AND

1650
01:02:05,200 --> 01:02:06,160
ESPECIALLY SEE IT

1651
01:02:06,160 --> 01:02:06,800
QUANTITATIVELY.

1652
01:02:06,800 --> 01:02:09,360
I GUESS THE QUESTION IS, BASIC

1653
01:02:09,360 --> 01:02:13,800
ONE FOR HOW DO YOU THINK ABOUT

1654
01:02:13,800 --> 01:02:17,200
DECON SOLVING COMPLEX WEB OF

1655
01:02:17,200 --> 01:02:20,480
FACTORS BETWEEN RACE BETWEEN

1656
01:02:20,480 --> 01:02:23,000
CHICAGO GEOGRAPHY SOCIOECONOMIC

1657
01:02:23,000 --> 01:02:25,200
STATUS, ALL THESE THINGS CLEARLY

1658
01:02:25,200 --> 01:02:28,080
INVOLVE BUT HOW DOES WHEN WE USE

1659
01:02:28,080 --> 01:02:29,760
HOW DO YOU THINK ABOUT THAT,

1660
01:02:29,760 --> 01:02:31,880
DOES IT MATTER OR DO YOU NEED TO

1661
01:02:31,880 --> 01:02:33,520
AND HOW DO YOU DO IT?

1662
01:02:33,520 --> 01:02:35,080
>> I DON'T THINK IT MATTERS IN

1663
01:02:35,080 --> 01:02:37,400
MANY WAYS BUT WHAT YOU IMMEDIATE

1664
01:02:37,400 --> 01:02:38,680
TO KNOW IS BE INFORM.

1665
01:02:38,680 --> 01:02:39,680
OR YOU HAVE TO UNDERSTAND THE

1666
01:02:39,680 --> 01:02:41,360
DEEP HISTORY OF RACISM AND RED

1667
01:02:41,360 --> 01:02:43,880
LINING AND JIM CROW LAWS IN THE

1668
01:02:43,880 --> 01:02:45,560
AREAS THAT WE ARE WORKING IN

1669
01:02:45,560 --> 01:02:47,240
CHICAGO SOUTH AND WEST SIDES FOR

1670
01:02:47,240 --> 01:02:47,640
SURE.

1671
01:02:47,640 --> 01:02:50,080
THE HEALTH DISPARITIES

1672
01:02:50,080 --> 01:02:52,000
ESPECIALLY IN CANCER MAP OUT TO

1673
01:02:52,000 --> 01:02:54,120
THAT RED LINING HISTORY AND ALL

1674
01:02:54,120 --> 01:02:57,760
OF THAT YEARS OF DISINVESTMENT

1675
01:02:57,760 --> 01:02:59,960
FROM OUR CITY, IT MAPS OUT IN

1676
01:02:59,960 --> 01:03:02,120
EVERY SINGLE HEALTH INDICATOR SO

1677
01:03:02,120 --> 01:03:04,720
UNDERSTANDING THAT HISTORY AND

1678
01:03:04,720 --> 01:03:06,400
BEING MORE PROACTIVE BECAUSE WE

1679
01:03:06,400 --> 01:03:07,880
DONE NEED DETAIL DISPARITY WE

1680
01:03:07,880 --> 01:03:11,880
NEED TO DO SOMETHING ABOUT IT.

1681
01:03:11,880 --> 01:03:13,800
SO SO MOBILIZING IS REALLY

1682
01:03:13,800 --> 01:03:15,600
IMPORTANT, WE NEED TO MOBILIZE

1683
01:03:15,600 --> 01:03:16,560
MANY ORGANIZATIONS NOT JUST

1684
01:03:16,560 --> 01:03:17,560
COMMUNITY ORGANIZATIONS BUT

1685
01:03:17,560 --> 01:03:20,240
MOBILIZE MEDIA BECAUSE MEDIA

1686
01:03:20,240 --> 01:03:23,920
HELPED PUSH THE OLDER MEN, MAYOR

1687
01:03:23,920 --> 01:03:25,360
AND GOVERNOR SAY MAKE THE DATA

1688
01:03:25,360 --> 01:03:27,440
GO AWAY, YOU CAN'T WHISK IT AWAY

1689
01:03:27,440 --> 01:03:29,240
YOU NEED TO MAKE BETTER POLICIES

1690
01:03:29,240 --> 01:03:31,240
AND UNBEND THOSE TREES TO DO A

1691
01:03:31,240 --> 01:03:33,480
BETTER JOB OF CARE DELIVERY SO

1692
01:03:33,480 --> 01:03:35,440
THE PATIENT NAVIGATION BECAME

1693
01:03:35,440 --> 01:03:36,600
MOVER SYSTEM, SYSTEMATIC

1694
01:03:36,600 --> 01:03:38,200
APPROACH AND HAVING ON THE

1695
01:03:38,200 --> 01:03:40,960
GROUND ONE ON ONE RA TRADITIONAL

1696
01:03:40,960 --> 01:03:43,720
DR. HAROLD FRIEDMAN NAVIGATORS

1697
01:03:43,720 --> 01:03:46,120
BUT BUILT MORE TO HOW DO YOU

1698
01:03:46,120 --> 01:03:47,600
FULFILL THAT BECAUSE IT IS

1699
01:03:47,600 --> 01:03:49,480
EXPENSIVE, NAVIGATORS --

1700
01:03:49,480 --> 01:03:51,040
INDIVIDUAL NAVIGATORS ARE FUNDED

1701
01:03:51,040 --> 01:03:55,640
BY PHILANTHROPIC MEANS OR ALSO

1702
01:03:55,640 --> 01:03:57,400
GRANTS.

1703
01:03:57,400 --> 01:03:59,000
WHEN THAT FUNDING GOES AWAY HOW

1704
01:03:59,000 --> 01:04:00,400
DO YOU CONTINUE THAT WORK WHEN

1705
01:04:00,400 --> 01:04:03,560
EVIDENCE BASED INTERVENTION.

1706
01:04:03,560 --> 01:04:04,600
TRILLIONS THEY ARE NOT PART OF

1707
01:04:04,600 --> 01:04:06,520
THE WORK FORCE SO THOSE ARE THE

1708
01:04:06,520 --> 01:04:07,840
CHALLENGES THERE IN PARENT

1709
01:04:07,840 --> 01:04:09,640
NAVIGATION WORK SO HOW DO YOU

1710
01:04:09,640 --> 01:04:11,120
SCALE IT AND THAT IS WHY WE DID

1711
01:04:11,120 --> 01:04:14,160
THE CHECKLIST APPROACH TO TRY TO

1712
01:04:14,160 --> 01:04:15,960
-- AND WE ARE STUDYING THAT NOW

1713
01:04:15,960 --> 01:04:17,840
WITH MERCK FUNDS AN NCI FUNDS TO

1714
01:04:17,840 --> 01:04:20,040
TRY TO FIGURE HOW CAN WE SUSTAIN

1715
01:04:20,040 --> 01:04:21,760
NAVIGATION AND DO IT IN MANY

1716
01:04:21,760 --> 01:04:26,360
DIFFERENT WAYS.

1717
01:04:26,360 --> 01:04:28,040
>> I APOLOGIZE TO EVERYONE, WE

1718
01:04:28,040 --> 01:04:30,200
ARE FIVE MINUTES BEHIND.

1719
01:04:30,200 --> 01:04:32,840
>> U EMAIL.

1720
01:04:32,840 --> 01:04:35,000
>> WE WOULD LIKE NOVEMBER THINGS

1721
01:04:35,000 --> 01:04:35,800
ALONG IF POSSIBLE BECAUSE WE

1722
01:04:35,800 --> 01:04:38,040
HAVE A BREAK WE NEED TO TAKE.

1723
01:04:38,040 --> 01:04:40,000
WE WANT TO MAKE SURE WE HAVE

1724
01:04:40,000 --> 01:04:40,600
TIME.

1725
01:04:40,600 --> 01:04:42,320
SO BUT PLEASE, PLEASE, PLEASE

1726
01:04:42,320 --> 01:04:45,040
TYPE THE QUESTIONS IN THE CHAT.

1727
01:04:45,040 --> 01:04:47,720
AND MELISSA YOU CAN PERUSE THE

1728
01:04:47,720 --> 01:04:49,200
CHAT AS PHIL DID AND ADDRESS

1729
01:04:49,200 --> 01:04:51,080
SOME OF THE QUESTIONS AND

1730
01:04:51,080 --> 01:04:52,760
COMMENTS THAT SOME OF THE

1731
01:04:52,760 --> 01:04:54,120
COMMITTEE MEMBERS MIGHT HAVE.

1732
01:04:54,120 --> 01:04:55,360
AGAIN, I APOLOGIZE BUT WE ARE

1733
01:04:55,360 --> 01:04:57,280
RUNNING A LITTLE BIT BEHIND AND

1734
01:04:57,280 --> 01:04:58,280
WE WANT TO STAY ON TIME.

1735
01:04:58,280 --> 01:04:58,720
THANK YOU.

1736
01:04:58,720 --> 01:04:59,960
>> THANK YOU.

1737
01:04:59,960 --> 01:05:02,720
>> OUR FINAL PRESENTATION IS

1738
01:05:02,720 --> 01:05:04,640
ENTITLED IMPLEMENTING PROGRAM

1739
01:05:04,640 --> 01:05:07,760
BASED INTERVENTIONS TO IMPROVE

1740
01:05:07,760 --> 01:05:09,560
POPULATION LEVEL LUNG CANCER

1741
01:05:09,560 --> 01:05:10,200
OUTCOMES.

1742
01:05:10,200 --> 01:05:12,440
THE MID SOUTH MIRACLE.

1743
01:05:12,440 --> 01:05:15,760
THIS PRESENTATION WILL BE GIVEN

1744
01:05:15,760 --> 01:05:20,360
BY DR. RAYMOND OSAROGIAGBON,

1745
01:05:20,360 --> 01:05:22,160
PHYSICIAN BMG BAPTIST CANCER

1746
01:05:22,160 --> 01:05:24,600
CENTER AND CHIEF SCIENTIST FOR

1747
01:05:24,600 --> 01:05:26,880
THE BAPTIST MEMORIAL HEALTHCARE

1748
01:05:26,880 --> 01:05:27,280
SYSTEM.

1749
01:05:27,280 --> 01:05:29,160
HE IS ALSO DIRECTOR OF

1750
01:05:29,160 --> 01:05:30,720
MULTI-DISCIPLINARY THORACIC

1751
01:05:30,720 --> 01:05:33,040
ONCOLOGY PROGRAM AND THORACIC

1752
01:05:33,040 --> 01:05:35,560
ONCOLOGY RESEARCH OR OTHER GROUP

1753
01:05:35,560 --> 01:05:37,080
AND MEMBER OF THE LONGEVITY

1754
01:05:37,080 --> 01:05:38,000
HEALTH EQUITY COUNCIL.

1755
01:05:38,000 --> 01:05:40,160
RAYMOND.

1756
01:05:40,160 --> 01:05:42,640
>> THANK YOU VERY MUCH, JOHN.

1757
01:05:42,640 --> 01:05:44,840
GOOD AFTERNOON OR IS IT GOOD

1758
01:05:44,840 --> 01:05:45,440
MORNING, EVERYONE.

1759
01:05:45,440 --> 01:05:48,360
THANK YOU FOR INVITATION TO BE

1760
01:05:48,360 --> 01:05:48,960
HERE TODAY.

1761
01:05:48,960 --> 01:05:52,000
I'M GOING TO TALK TO YOU ABOUT

1762
01:05:52,000 --> 01:05:53,480
OUR MID SOUTH MIRACLE.

1763
01:05:53,480 --> 01:05:58,600
DO I HAVE CONTROL OF THESE

1764
01:05:58,600 --> 01:06:07,840
SLIDES?

1765
01:06:07,840 --> 01:06:08,320
>> YES.

1766
01:06:08,320 --> 01:06:19,800
>> I WILL JUST SAY NEXT SLIDE.

1767
01:06:19,800 --> 01:06:21,800
>> SO MY OBJECTIVES TODAY WILL

1768
01:06:21,800 --> 01:06:24,200
BE TO CONTEXTUALIZE MY

1769
01:06:24,200 --> 01:06:26,760
HEALTHCARE SYSTEM WITHIN THE

1770
01:06:26,760 --> 01:06:28,760
EPIDEMIOLOGY GEOGRAPHIC

1771
01:06:28,760 --> 01:06:29,720
EPIDEMIOLOGY OF LUNG CANCER IN

1772
01:06:29,720 --> 01:06:32,600
THE UNITED STATES.

1773
01:06:32,600 --> 01:06:36,600
AND TAKING POPULATION BENEFIT

1774
01:06:36,600 --> 01:06:38,800
PERSPECTIVE, TALK ABOUT

1775
01:06:38,800 --> 01:06:41,440
POPULATION IMPACT AND HOW WE

1776
01:06:41,440 --> 01:06:44,800
INTEND TO DEPLOY PROGRAMS, SEVEN

1777
01:06:44,800 --> 01:06:46,480
SPECIFIC PROGRAMS TO ATTACK

1778
01:06:46,480 --> 01:06:48,720
BURDEN THAT IS LUNG CANCER IN

1779
01:06:48,720 --> 01:06:51,880
THE MID SOUTH WHAT WE CALL OUR

1780
01:06:51,880 --> 01:06:52,680
MID SOUTH NERVE HUB.

1781
01:06:52,680 --> 01:06:54,040
MAYBE AT THE END I WILL TALK

1782
01:06:54,040 --> 01:06:55,760
ABOUT HOW WE PROPOSE TO MEASURE

1783
01:06:55,760 --> 01:06:58,600
THE IMPACT OF THESE EFFORTS.

1784
01:06:58,600 --> 01:07:01,280
NEXT SLIDE.

1785
01:07:01,280 --> 01:07:02,880
LUNG CANCER, NEXT SLIDE THIS IS

1786
01:07:02,880 --> 01:07:06,320
AN ANIMATED SLIDE, WE ARE ALL

1787
01:07:06,320 --> 01:07:09,680
EXCITED THAT THE NEWS ABOUT LUNG

1788
01:07:09,680 --> 01:07:10,800
CANCER IS GREAT.

1789
01:07:10,800 --> 01:07:13,320
ESSENTIALLY YEAR-OVER-YEAR WE

1790
01:07:13,320 --> 01:07:16,800
ARE SEEING INCIDENCE AND

1791
01:07:16,800 --> 01:07:18,840
MORTALITY FROM LUNG CANCER GOING

1792
01:07:18,840 --> 01:07:20,360
DOWN SEQUENTIALLY.

1793
01:07:20,360 --> 01:07:22,400
THIS FIRST MAP TELLS YOU THAT

1794
01:07:22,400 --> 01:07:24,960
STORY HOE IS NOT UNIFORM.

1795
01:07:24,960 --> 01:07:27,320
IN AGGREGATE YES INDEED THE NEWS

1796
01:07:27,320 --> 01:07:28,440
IS GREAT BUT LUNG CANCER AS WE

1797
01:07:28,440 --> 01:07:31,440
KNOW IS A CANCER OF DISPARITY,

1798
01:07:31,440 --> 01:07:33,040
DEEP RED IN THE FIRST MAP OR

1799
01:07:33,040 --> 01:07:35,520
STATES WITH HIGHEST PER CAPITA

1800
01:07:35,520 --> 01:07:37,320
LUNG CANCER MORTALITY STATISTICS

1801
01:07:37,320 --> 01:07:42,760
YOU SEE MOSTLY CLUSTERED IN THE

1802
01:07:42,760 --> 01:07:43,280
SOUTHERN MIDWESTERN UNITED

1803
01:07:43,280 --> 01:07:43,520
STATES.

1804
01:07:43,520 --> 01:07:46,120
SECOND MAP TELLS YOU WHY, THAT

1805
01:07:46,120 --> 01:07:48,160
IS THE TOBACCO CONSUMPTION MAP

1806
01:07:48,160 --> 01:07:50,680
OF AMERICA AND THIRD MAP SHOWS

1807
01:07:50,680 --> 01:07:54,240
YOU THAT AT THE COUNTY LEVEL

1808
01:07:54,240 --> 01:07:56,440
STORIES EVEN WORSE.

1809
01:07:56,440 --> 01:07:59,200
SO GREEN AND DEEPER GREEN ARE

1810
01:07:59,200 --> 01:08:00,360
COUNTIES WHICH YEAR-OVER-YEAR

1811
01:08:00,360 --> 01:08:02,600
LUNG CANCER MORTALITY INDEED HAS

1812
01:08:02,600 --> 01:08:05,600
BEEN GOING DOWN, RED PINK PURPLE

1813
01:08:05,600 --> 01:08:09,200
AND DEEPER RED PINK PURPLE ARE

1814
01:08:09,200 --> 01:08:13,000
COUNTIES WHICH THE STORY IS THE

1815
01:08:13,000 --> 01:08:13,960
ON SCHISM LUNG CANCER INCIDENCE

1816
01:08:13,960 --> 01:08:16,840
MORTALITY STILL GOING UP AND THE

1817
01:08:16,840 --> 01:08:18,560
CIRCLE, BLUE CIRCLE SHOWS YOU

1818
01:08:18,560 --> 01:08:20,600
THE COUNTIES THAT ARE COVERED BY

1819
01:08:20,600 --> 01:08:25,240
MY HEALTHCARE SYSTEM.

1820
01:08:25,240 --> 01:08:27,480
SO -- NEXT SLIDE.

1821
01:08:27,480 --> 01:08:30,160
THE BAPTIST MEMORIAL HEALTHCARE

1822
01:08:30,160 --> 01:08:33,200
CORPORATION IS A NOT FOR PROFIT

1823
01:08:33,200 --> 01:08:34,680
HEALTHCARE SYSTEM DEPLOYED

1824
01:08:34,680 --> 01:08:36,440
ACROSS THREE STATES AT HEART OF

1825
01:08:36,440 --> 01:08:37,960
CANCER MORTALITY BELT OF THE

1826
01:08:37,960 --> 01:08:39,040
UNITED STATES, MISSISSIPPI

1827
01:08:39,040 --> 01:08:41,640
ARKANSAS TENNESSEE.

1828
01:08:41,640 --> 01:08:44,880
BUT OUR POPULATION SPILLS OUT TO

1829
01:08:44,880 --> 01:08:47,200
SIX STATES INCLUDING KENTUCKY,

1830
01:08:47,200 --> 01:08:49,720
ALABAMA, AND MISSOURI.

1831
01:08:49,720 --> 01:08:51,760
STATES WITH SOME OF THE HIGHEST

1832
01:08:51,760 --> 01:08:54,600
PER CAPITA LUNG CANCER MORTALITY

1833
01:08:54,600 --> 01:08:57,280
STATISTICS SO BAPTIST AS A

1834
01:08:57,280 --> 01:08:59,040
SINGLE HEALTHCARE SYSTEM

1835
01:08:59,040 --> 01:09:03,280
DEPLOYED ACROSS THREE STATES HAS

1836
01:09:03,280 --> 01:09:06,800
12 TO 1300 ANNUAL LUNG CANCER

1837
01:09:06,800 --> 01:09:07,280
CASES.

1838
01:09:07,280 --> 01:09:11,880
TO PUT THAT IN PERSPECTIVE IN

1839
01:09:11,880 --> 01:09:14,000
BAPTIST WHERE A STATE WE WOULD

1840
01:09:14,000 --> 01:09:16,360
HAVE MORE LUNG CANCER CASES

1841
01:09:16,360 --> 01:09:19,400
EVERY YEAR THAN 12 OF THE 50

1842
01:09:19,400 --> 01:09:20,000
UNITED STATES.

1843
01:09:20,000 --> 01:09:20,800
ONE OF THE POINTS IS THE

1844
01:09:20,800 --> 01:09:23,960
CHALLENGE IS TREMENDOUS AND THE

1845
01:09:23,960 --> 01:09:25,040
OPPORTUNITY IS GREAT.

1846
01:09:25,040 --> 01:09:28,920
NEXT SLIDE.

1847
01:09:28,920 --> 01:09:32,560
HOW DOES ONE TACKLE A WE COULD

1848
01:09:32,560 --> 01:09:33,640
PROBLEM AS LUNG CANCER.

1849
01:09:33,640 --> 01:09:38,000
THE PUBLIC HEALTH CHAL LENG OF

1850
01:09:38,000 --> 01:09:41,800
OUR AGE TAKING POPULATION

1851
01:09:41,800 --> 01:09:43,200
PERSPECTIVE IF WE WERE TO DEPLOY

1852
01:09:43,200 --> 01:09:47,120
OUR RESOURCES, GREATEST RETURN

1853
01:09:47,120 --> 01:09:49,160
ON INVESTMENT, THIS POPULATION

1854
01:09:49,160 --> 01:09:50,720
IMPACT TELLS YOU HOW WE GO ABOUT

1855
01:09:50,720 --> 01:09:51,640
DOING IT.

1856
01:09:51,640 --> 01:09:54,560
WE WOULD DO EVERYTHING WE COULD

1857
01:09:54,560 --> 01:09:55,680
TO KEEP PEOPLE FROM SMOKING AND

1858
01:09:55,680 --> 01:09:59,280
HELP THOSE WHO DO SMOKE TO QUIT.

1859
01:09:59,280 --> 01:10:00,760
WE WOULD DO EVERYTHING WE COULD

1860
01:10:00,760 --> 01:10:03,880
TO FIND LUNG CANCER EARLY WHEN

1861
01:10:03,880 --> 01:10:07,160
WE COULD BE CURED, WE ARE

1862
01:10:07,160 --> 01:10:09,440
EXCITED SCREENING HEALTHY PEOPLE

1863
01:10:09,440 --> 01:10:13,680
CERTAIN AGE WITH CERTAIN TOBACCO

1864
01:10:13,680 --> 01:10:16,000
HISTORY DOES ALLOW US O CATCH

1865
01:10:16,000 --> 01:10:17,400
LUNG CANCER EARLY WITH SCREENING

1866
01:10:17,400 --> 01:10:23,800
TEST ONCE A YEAR CT STAMP, THAT

1867
01:10:23,800 --> 01:10:25,280
SEEMS NICE BUT ONE OF THE THINGS

1868
01:10:25,280 --> 01:10:27,840
WE ALSO DEMONSTRATED IS THAT OF

1869
01:10:27,840 --> 01:10:30,160
ALL MANY, MANY MILLIONS OF

1870
01:10:30,160 --> 01:10:32,360
IMAGING THAT WE DO FOR MANY

1871
01:10:32,360 --> 01:10:33,600
DIFFERENT REASONS EVERY YEAR IF

1872
01:10:33,600 --> 01:10:35,600
WE WERE TO PAY PARTICULAR

1873
01:10:35,600 --> 01:10:39,240
ATTENTION TO THE ONE THAT SHOW

1874
01:10:39,240 --> 01:10:42,440
PRESENCE OF POTENTIAL LIMA LEG

1875
01:10:42,440 --> 01:10:43,200
FANTASTIC LESIONS WE COULD ALSO

1876
01:10:43,200 --> 01:10:46,200
USE A SORT OF SECOND HARVEST

1877
01:10:46,200 --> 01:10:48,640
APPROACH IDENTIFY LUNG CANCER

1878
01:10:48,640 --> 01:10:51,720
EARLIER THAT GIVES US RESULTS

1879
01:10:51,720 --> 01:10:53,720
THAT ARE VERY SIMILAR TO WHAT WE

1880
01:10:53,720 --> 01:10:54,560
GET FROM SCREENING.

1881
01:10:54,560 --> 01:10:59,000
SO THIS MANAGEMENT OF INCIDENTAL

1882
01:10:59,000 --> 01:11:00,560
DETECTED LUNG NODULES THERE IS

1883
01:11:00,560 --> 01:11:02,680
BUSINESS OF LUNG CANCER BEING SO

1884
01:11:02,680 --> 01:11:03,760
COMPLICATED THE TREATMENT

1885
01:11:03,760 --> 01:11:05,440
DECISION MAKING PROCESS CAN BE

1886
01:11:05,440 --> 01:11:06,920
COMPLICATED.

1887
01:11:06,920 --> 01:11:09,120
AND OFTEN TIMES LEADS TO BAD

1888
01:11:09,120 --> 01:11:09,480
DECISION.

1889
01:11:09,480 --> 01:11:11,080
ONE OF THE CHALLENGES IS HOW DO

1890
01:11:11,080 --> 01:11:13,640
WE MAKE SURE THE RIGHT PATIENT

1891
01:11:13,640 --> 01:11:14,880
GETS RIGHT TREATMENT AT THE

1892
01:11:14,880 --> 01:11:15,600
RIGHT TIME.

1893
01:11:15,600 --> 01:11:18,760
THOSE WHO ARE FORTUNATE ENOUGH

1894
01:11:18,760 --> 01:11:21,000
TO GET THE MAIN TREATMENT WHICH

1895
01:11:21,000 --> 01:11:22,640
IS SURGERY, HOW DO WE ENSURE

1896
01:11:22,640 --> 01:11:24,000
SURGERY WHEN DONE IS DONE RIGHT

1897
01:11:24,000 --> 01:11:25,880
TO GIVE PATIENT THE GREATEST

1898
01:11:25,880 --> 01:11:28,320
OPPORTUNITY TO REAP THE BENEFIT

1899
01:11:28,320 --> 01:11:29,040
OF EARLY DETECTION.

1900
01:11:29,040 --> 01:11:30,480
THERE IS THE CHALLENGE OF ALL

1901
01:11:30,480 --> 01:11:32,600
THE OTHER THINGS TO DO WITH THE

1902
01:11:32,600 --> 01:11:34,440
PATHOLOGY AND THEN FINALLY THIS

1903
01:11:34,440 --> 01:11:37,560
BUSINESS OF GIVING PALLIATIVE

1904
01:11:37,560 --> 01:11:39,880
SYSTEMIC THERAPY TO PATIENTS

1905
01:11:39,880 --> 01:11:41,320
WITH ADVANCED DISEASE WHICH IS

1906
01:11:41,320 --> 01:11:44,000
WHAT MOST ONCOLOGISTS DO.

1907
01:11:44,000 --> 01:11:45,680
SO WE HAVE TAKEN THE APPROACH WE

1908
01:11:45,680 --> 01:11:48,880
WILL DEPLOY SEVEN SPECIFIC

1909
01:11:48,880 --> 01:11:51,800
PROGRAMS HORIZONTALLY AND

1910
01:11:51,800 --> 01:11:52,440
VERTICALLY.

1911
01:11:52,440 --> 01:11:55,840
VIRTUALLY METROPOLITAN AND

1912
01:11:55,840 --> 01:11:56,960
DISSYSTEMNATING THIS

1913
01:11:56,960 --> 01:11:58,520
HORIZONTALLY ACROSS THE

1914
01:11:58,520 --> 01:12:00,120
HEALTHCARE SYSTEM --

1915
01:12:00,120 --> 01:12:00,520
DISSEMINATING.

1916
01:12:00,520 --> 01:12:02,600
WE ARE TAKING A RIGOROUS THREE

1917
01:12:02,600 --> 01:12:05,360
TIER APPROACH, THAT WE WANT TO

1918
01:12:05,360 --> 01:12:07,160
MAKE SURE THAT WE UNDERSTAND THE

1919
01:12:07,160 --> 01:12:08,920
POPULATIONS NEEDS USING

1920
01:12:08,920 --> 01:12:11,240
POPULATION SCIENCE, WE WANT TO

1921
01:12:11,240 --> 01:12:12,400
USE TEAM SCIENCE TO PUT TOGETHER

1922
01:12:12,400 --> 01:12:14,920
THE MULTI-DISCIPLINARY TEAM

1923
01:12:14,920 --> 01:12:16,920
MEMBERS WHO WILL HELP DEPLOY

1924
01:12:16,920 --> 01:12:18,480
THESE PROGRAMS AND WE WANT TO

1925
01:12:18,480 --> 01:12:20,600
USE IMPLEMENTATION SCIENCE TO

1926
01:12:20,600 --> 01:12:22,800
MAKE SURE THE PROGRAMS GET

1927
01:12:22,800 --> 01:12:24,200
MAXIMALLY DEPLOYED IN ALL THE

1928
01:12:24,200 --> 01:12:28,320
PLACES WHERE THEY ARE NEEDED SO

1929
01:12:28,320 --> 01:12:29,160
NOBODY GETS LEFT BEHIND.

1930
01:12:29,160 --> 01:12:31,680
I'M GOING TO GIVE YOU SNAP SHOTS

1931
01:12:31,680 --> 01:12:36,640
OF FOUR OF THESE SEVEN PROGRAMS.

1932
01:12:36,640 --> 01:12:38,680
FIRST WE WILL TALK SCREENING WE

1933
01:12:38,680 --> 01:12:40,800
KNOW LOW DOSE SCREENING CT

1934
01:12:40,800 --> 01:12:42,200
SCREENING SAVES LIVES, CHALLENGE

1935
01:12:42,200 --> 01:12:43,640
NOW IS CAN YOU DO THIS AT HOME

1936
01:12:43,640 --> 01:12:44,680
AND DO IT SAFELY AND

1937
01:12:44,680 --> 01:12:45,720
EFFECTIVELY.

1938
01:12:45,720 --> 01:12:48,200
WE SEE THAT THERE IS A

1939
01:12:48,200 --> 01:12:50,960
TREMENDOUS IMPLEMENTATION

1940
01:12:50,960 --> 01:12:52,600
CHALLENGE WITH LOW DOSE CT SCAN,

1941
01:12:52,600 --> 01:12:57,000
THIS IS SHOWING YOU AT THE STATE

1942
01:12:57,000 --> 01:13:02,200
LEVEL AT LEAST AS RECENTLY AS

1943
01:13:02,200 --> 01:13:06,280
2017, 2018, IT IS 3405% ELIGIBLE

1944
01:13:06,280 --> 01:13:07,640
PATIENTS WHO HAVE BEEN ABLE TO

1945
01:13:07,640 --> 01:13:09,800
GET A SCREENING TEST.

1946
01:13:09,800 --> 01:13:12,440
WHAT IS STARTLING IS THAT THE

1947
01:13:12,440 --> 01:13:16,200
PLACES WITH HIGHEST PER CAPITA

1948
01:13:16,200 --> 01:13:18,280
MORTALITY STATISTICS ARE THE ONE

1949
01:13:18,280 --> 01:13:19,120
BEING LEFT BEHIND.

1950
01:13:19,120 --> 01:13:20,960
YOU WILL SEE WITHIN THAT CIRCLE

1951
01:13:20,960 --> 01:13:24,600
THAT THE STATES IF YOU GO BACK,

1952
01:13:24,600 --> 01:13:27,440
PLEASE, ONE STEP THE STATES I

1953
01:13:27,440 --> 01:13:29,360
POINTED OUT, ALABAMA TENNESSEE

1954
01:13:29,360 --> 01:13:30,800
MISSISSIPPI ARKANSAS WEST

1955
01:13:30,800 --> 01:13:32,200
VIRGINIA, THE PLACES WITH SOME

1956
01:13:32,200 --> 01:13:34,600
OF THE HIGHEST PER CAPITA LUNG

1957
01:13:34,600 --> 01:13:36,880
CANCER MORTALITY STATISTICS WHO

1958
01:13:36,880 --> 01:13:38,240
NEED EARLY DETECTION THE MOST

1959
01:13:38,240 --> 01:13:43,000
ARE ALSO THE ONES AT THE LOWER

1960
01:13:43,000 --> 01:13:44,800
END OF THAT RED LINE AND STATE

1961
01:13:44,800 --> 01:13:47,400
OF KENTUCKY IS POSITIVE OUTLIER.

1962
01:13:47,400 --> 01:13:49,200
THEY HAVE BEEN ABLE TO FIGURE

1963
01:13:49,200 --> 01:13:49,680
SOMETHING OUT.

1964
01:13:49,680 --> 01:13:50,160
NEXT SLIDE.

1965
01:13:50,160 --> 01:13:52,240
SO THE CHALLENGE THEN IS IF

1966
01:13:52,240 --> 01:13:53,960
SCREENING IS DIFFICULT TO DO

1967
01:13:53,960 --> 01:13:56,040
WHAT ELSE CAN WE DO BESIDES TRY

1968
01:13:56,040 --> 01:14:00,400
TO DEPLOY LOW DOSE SCREENING CT

1969
01:14:00,400 --> 01:14:01,400
INFRASTRUCTURE, ONE THING WE

1970
01:14:01,400 --> 01:14:04,560
HAVE SHOWN IS IF WE DO THIS

1971
01:14:04,560 --> 01:14:06,680
ALGORITHMIC MANAGEMENT OF

1972
01:14:06,680 --> 01:14:08,560
INCIDENTALLY DETECTED LUNG

1973
01:14:08,560 --> 01:14:09,800
NODULES WE CAN FIND LUNG CANCER

1974
01:14:09,800 --> 01:14:10,960
EARLY WHEN WE CAN DO SOMETHING

1975
01:14:10,960 --> 01:14:12,320
ABOUT IT SO I'M JUST GOING TO

1976
01:14:12,320 --> 01:14:14,800
SHOW YOU REAL QUICK THREE

1977
01:14:14,800 --> 01:14:16,800
DIFFERENT PROGRAMS, WITHIN MY

1978
01:14:16,800 --> 01:14:20,400
HEALTHCARE SYSTEM.

1979
01:14:20,400 --> 01:14:25,040
GREEN IS PATIENTS INTO THE

1980
01:14:25,040 --> 01:14:26,080
INCIDENTAL LUNG NODULE PROGRAM,

1981
01:14:26,080 --> 01:14:28,800
BLUE ARE PATIENTS MOVE INTO THE

1982
01:14:28,800 --> 01:14:31,600
SCREENING PROGRAM AND JUST TO

1983
01:14:31,600 --> 01:14:33,360
CONTEXTUALIZE THIS, BLACK

1984
01:14:33,360 --> 01:14:35,280
PATIENTS REFER TO OUR

1985
01:14:35,280 --> 01:14:36,080
MULTI-DISCIPLINARY THORACIC

1986
01:14:36,080 --> 01:14:38,760
PROGRAM SO THE FIRST OF THE

1987
01:14:38,760 --> 01:14:41,480
THREE PLOTS SHOWS YOU PERSONS

1988
01:14:41,480 --> 01:14:43,400
ENROLLED INTO THE PROGRAM, FOR

1989
01:14:43,400 --> 01:14:45,640
EVERY ONE PERSON WE WE HAVE PUT

1990
01:14:45,640 --> 01:14:47,360
INTO THE SCREENING PROGRAM WE

1991
01:14:47,360 --> 01:14:49,600
HAVE APPROXIMATELY THREE PERSONS

1992
01:14:49,600 --> 01:14:53,120
IN THE INCIDENTAL LUNG NODULE

1993
01:14:53,120 --> 01:14:53,360
PROGRAM.

1994
01:14:53,360 --> 01:14:55,920
THE SECOND PLOT SHOWS YOU

1995
01:14:55,920 --> 01:14:57,400
ACCUMULATED NUMBERS OF PERSONS

1996
01:14:57,400 --> 01:14:59,200
DIAGNOSED WITH LUNG CANCER LIEU

1997
01:14:59,200 --> 01:15:03,080
THESE THREE PROGRAMS AND YOU SEE

1998
01:15:03,080 --> 01:15:05,240
AGAIN GREEN, THE NODULE PROGRAM

1999
01:15:05,240 --> 01:15:07,520
COMPARED TO BLUE, THE SCREENING

2000
01:15:07,520 --> 01:15:09,000
PROGRAM, HERE THE RATIO IS ONE

2001
01:15:09,000 --> 01:15:11,800
TO FIVE FOR LUNG CANCER PATIENT

2002
01:15:11,800 --> 01:15:13,680
FOLLOWED BY SCREENING WE ARE

2003
01:15:13,680 --> 01:15:14,960
FINDING FIVE LUNG CANCER

2004
01:15:14,960 --> 01:15:16,840
PATIENTS THROUGH THE NODULE

2005
01:15:16,840 --> 01:15:17,880
PROGRAM.

2006
01:15:17,880 --> 01:15:20,280
THE THIRD PLOT SHOWS YOU WHAT WE

2007
01:15:20,280 --> 01:15:21,720
REALLY WANT TO FIND, WHICH IS

2008
01:15:21,720 --> 01:15:23,320
STAGE ONE OR TWO LUNG CANCER AND

2009
01:15:23,320 --> 01:15:26,080
YOU CAN SEE ONCE AGAIN THAT

2010
01:15:26,080 --> 01:15:29,200
BETWEEN THE BLUE SCREEN PROGRAM

2011
01:15:29,200 --> 01:15:31,280
AND GREEN THE NODULE PROGRAM,

2012
01:15:31,280 --> 01:15:34,000
THE RELATIONSHIP IS EVEN MORE

2013
01:15:34,000 --> 01:15:41,680
SKEWED IN FAVOR OF THE PROGRAM.

2014
01:15:41,680 --> 01:15:46,080
SO HOW DO THESE COMPARE IN TERMS

2015
01:15:46,080 --> 01:15:46,920
OF CAGE DISTRIBUTION?

2016
01:15:46,920 --> 01:15:51,280
THE COLOR CODING IS THE SAME

2017
01:15:51,280 --> 01:15:55,000
A. BLUE BEING LOW DOSE CT, GREEN

2018
01:15:55,000 --> 01:15:57,120
BEING -- YOU SEE APPROXIMATELY

2019
01:15:57,120 --> 01:15:58,800
60% OF PATIENTS DIAGNOSED WITH

2020
01:15:58,800 --> 01:16:01,760
LUNG CANCER THROUGH THE TWO

2021
01:16:01,760 --> 01:16:03,440
EARLY DETECTION PROGRAMS ONE OR

2022
01:16:03,440 --> 01:16:05,040
WHO LUNG CANCER WHICH IS WHAT UP

2023
01:16:05,040 --> 01:16:12,000
TO SEE, BUT YOU SIGH IN THE

2024
01:16:12,000 --> 01:16:13,960
LOWER BAR RAC NUMBER OF PERSONS

2025
01:16:13,960 --> 01:16:15,360
DIAGNOSED WITH EARLY STAGE LUNG

2026
01:16:15,360 --> 01:16:17,160
CANCER SIGNIFICANTLY HIGHER

2027
01:16:17,160 --> 01:16:18,840
THROUGH THE NODULE PROGRAM THAN

2028
01:16:18,840 --> 01:16:21,960
THROUGH THE BLUE.

2029
01:16:21,960 --> 01:16:23,560
SCREENING PROGRAM.

2030
01:16:23,560 --> 01:16:24,880
THE POINT OF EARLY DETECTION IS

2031
01:16:24,880 --> 01:16:29,080
TO BE ABLE TO OFFER PEOPLE

2032
01:16:29,080 --> 01:16:32,520
CURATIVE SURGICAL RESECTION SO

2033
01:16:32,520 --> 01:16:35,560
THE TWO DIE GRAMS ON THE RIGHT

2034
01:16:35,560 --> 01:16:36,880
HAND SIDE, UPPER ONE GIVES YOU

2035
01:16:36,880 --> 01:16:38,240
DISTRIBUTION OF PATIENT

2036
01:16:38,240 --> 01:16:39,600
DIAGNOSED WITH LUNG CANCER

2037
01:16:39,600 --> 01:16:42,680
THROUGH EACH OF THE THREE

2038
01:16:42,680 --> 01:16:44,800
PROGRAMS WHO HAD SURGICAL

2039
01:16:44,800 --> 01:16:45,680
RESECTION AS SOLE TREATMENT,

2040
01:16:45,680 --> 01:16:49,040
THESE ARE EARLIEST OF PATIENTS,

2041
01:16:49,040 --> 01:16:52,120
FIRST THREE BARS SHOWS YOU THE

2042
01:16:52,120 --> 01:16:53,120
TWO EARLY DETECTION PROGRAMS

2043
01:16:53,120 --> 01:16:55,320
DOING ABOUT SAME, THE SECOND

2044
01:16:55,320 --> 01:16:56,920
TRIPLET OF BARS INCLUDE PATIENTS

2045
01:16:56,920 --> 01:16:59,200
WITH SURGERY IRRESPECTIVE OF ANY

2046
01:16:59,200 --> 01:17:01,520
ADDITIONAL TREATMENT THEY HAD TO

2047
01:17:01,520 --> 01:17:02,760
GET.

2048
01:17:02,760 --> 01:17:04,560
THE THIRD SHOWS PATIENTS WHO HAD

2049
01:17:04,560 --> 01:17:07,400
SURGERY AND/OR WHO HAD RADIATION

2050
01:17:07,400 --> 01:17:08,600
THERAPY ALSO CURATIVE INTENT.

2051
01:17:08,600 --> 01:17:10,120
YOU SEE THE RELATIONSHIP REMAINS

2052
01:17:10,120 --> 01:17:14,120
THE SAME.

2053
01:17:14,120 --> 01:17:16,560
BUT LOWER BAR GRAPHS SHOW YOU

2054
01:17:16,560 --> 01:17:18,080
THE SHEER NUMBER OF PERSONS WE

2055
01:17:18,080 --> 01:17:20,600
ARE TALKING ABOUT, THROUGH THE

2056
01:17:20,600 --> 01:17:23,200
NODULE PROGRAM SIGNIFICANTLY

2057
01:17:23,200 --> 01:17:25,000
HIGHER SEVERAL FOLD HIGHER THAN

2058
01:17:25,000 --> 01:17:25,840
THROUGH THE SCREEN PROGRAM.

2059
01:17:25,840 --> 01:17:32,040
NEXT SLIDE.

2060
01:17:32,040 --> 01:17:35,000
SO WE ALSO DEMONSTRATE THAT

2061
01:17:35,000 --> 01:17:38,160
TYPES OF PEOPLE COMING IN

2062
01:17:38,160 --> 01:17:40,960
THROUGH THESE PROGRAMS ARE

2063
01:17:40,960 --> 01:17:41,880
DIFFERENT SOMEWHAT.

2064
01:17:41,880 --> 01:17:44,480
I WILL SHOW THAT.

2065
01:17:44,480 --> 01:17:45,720
THE RACIAL DISTRIBUTION OF THE

2066
01:17:45,720 --> 01:17:47,040
LUNG CANCER PATIENTS VERY

2067
01:17:47,040 --> 01:17:47,440
DIFFERENT.

2068
01:17:47,440 --> 01:17:50,600
I REMIND YOU THAT THE NATIONAL

2069
01:17:50,600 --> 01:17:54,480
LUNG SCREENING TRIAL MANAGE TO

2070
01:17:54,480 --> 01:17:56,400
ENROLL 5% AFRICAN AMERICANS INTO

2071
01:17:56,400 --> 01:17:57,840
THAT TRIAL.

2072
01:17:57,840 --> 01:18:00,520
WE HAVE FOUND OUT SUBSEQUENTLY,

2073
01:18:00,520 --> 01:18:02,640
ACTUALLY SCREENING IS EVEN MORE

2074
01:18:02,640 --> 01:18:04,400
BENEFICIAL FOR AFRICAN AMERICANS

2075
01:18:04,400 --> 01:18:07,880
THAN OTHER RACES.

2076
01:18:07,880 --> 01:18:09,000
THE NUMBERS IN THE CIRCLE SHOW

2077
01:18:09,000 --> 01:18:11,040
YOU THE PERCENTAGES OF THE

2078
01:18:11,040 --> 01:18:13,280
PEOPLE DIAGNOSED WITH LUNG

2079
01:18:13,280 --> 01:18:15,960
CANCER THROUGH THE PROGRAMS I

2080
01:18:15,960 --> 01:18:17,800
DEMONSTRATED SO 16% OF THE

2081
01:18:17,800 --> 01:18:20,160
SCREEN PATIENTS WITH LUNG CANCER

2082
01:18:20,160 --> 01:18:23,040
WERE AFRICAN AMERICAN, IN THE

2083
01:18:23,040 --> 01:18:24,480
NODULE PROGRAM ALMOST 30% WHICH

2084
01:18:24,480 --> 01:18:27,480
IS SYSTEM TO WHAT WE FIND ACROSS

2085
01:18:27,480 --> 01:18:28,720
OUR HEALTH CARE SYSTEM AS A

2086
01:18:28,720 --> 01:18:29,400
WHOLE.

2087
01:18:29,400 --> 01:18:32,200
NEXT SLIDE.

2088
01:18:32,200 --> 01:18:38,480
WE FIND 13% PERSONS DIAGNOSE

2089
01:18:38,480 --> 01:18:40,520
WITH LUNG CANCER IN NODULE ARE

2090
01:18:40,520 --> 01:18:42,400
PEOPLE WHO NEVER SMOKED, PERSONS

2091
01:18:42,400 --> 01:18:44,760
NEVER ELIGIBLE FOR SCREENING I

2092
01:18:44,760 --> 01:18:45,800
FIGURING OUT ELIGIBILITY

2093
01:18:45,800 --> 01:18:47,360
CRITERIA TO MAKE IT EQUITABLE

2094
01:18:47,360 --> 01:18:50,160
FOR EVERYBODY AT RISK.

2095
01:18:50,160 --> 01:18:51,960
AND THEN THE LOWER RED CIRCLE

2096
01:18:51,960 --> 01:18:55,360
SHOWS YOU THAT THE -- OF THE

2097
01:18:55,360 --> 01:18:58,000
PEOPLE WHO QUIT SMOKING THE

2098
01:18:58,000 --> 01:18:59,680
MEDIAN QUIT DURATION FOR LUNG

2099
01:18:59,680 --> 01:19:02,000
CANCER PATIENTS IS 16 YEARS

2100
01:19:02,000 --> 01:19:04,160
MEANING MORE THAN HALF OF THESE

2101
01:19:04,160 --> 01:19:04,960
PATIENTS WOULD NOT HAVE BEEN

2102
01:19:04,960 --> 01:19:06,880
ELIGIBLE FOR SCREENING BECAUSE

2103
01:19:06,880 --> 01:19:10,320
THEY QUIT SMOKING TOO LONG AGO.

2104
01:19:10,320 --> 01:19:12,200
COLOR BEING YOU HAD TO BE EITHER

2105
01:19:12,200 --> 01:19:14,440
ACTIVE SMOKER OR IF YOU QUIT YOU

2106
01:19:14,440 --> 01:19:19,360
HAD TO BE WITHIN15 YEARS.

2107
01:19:19,360 --> 01:19:21,480
SO DIFFERENT PATIENTS, WE HAVE

2108
01:19:21,480 --> 01:19:25,360
NOW DISSEMINATED THESE PROGRAMS

2109
01:19:25,360 --> 01:19:26,800
ACROSS MULTIPLE SITES IN

2110
01:19:26,800 --> 01:19:27,800
HEALTHCARE SYSTEM.

2111
01:19:27,800 --> 01:19:34,040
AND I WANT TO SHOW YOU AS WE ARE

2112
01:19:34,040 --> 01:19:36,200
FLOODING ALL THE OTHER PARTS OF

2113
01:19:36,200 --> 01:19:37,400
HEALTHCARE SYSTEM NUMBERS OF

2114
01:19:37,400 --> 01:19:40,400
PERSONS DIAGNOSED, WITH LUNG

2115
01:19:40,400 --> 01:19:43,360
CANCER GOING UP YOU SEE THE

2116
01:19:43,360 --> 01:19:45,840
INFLECTION POINT IN 2020 IN THE

2117
01:19:45,840 --> 01:19:47,600
PEAK OF THE PANDEMIC NO LESS THE

2118
01:19:47,600 --> 01:19:51,040
NUMBER OF LUNG CANCER PATIENTS

2119
01:19:51,040 --> 01:19:52,960
DIAGNOSED THROUGH NODULE IS

2120
01:19:52,960 --> 01:19:54,240
RECOGNIZED A A FASTER RATED.

2121
01:19:54,240 --> 01:19:56,200
THE RATIO IS NOW ABOUT ONE TO

2122
01:19:56,200 --> 01:19:57,400
EIGHT.

2123
01:19:57,400 --> 01:19:58,880
ONE LUNG CANCER PATIENT FOUND IN

2124
01:19:58,880 --> 01:20:00,960
THE SCREENING PROGRAM, EIGHT

2125
01:20:00,960 --> 01:20:04,080
LUNG CANCER PATIENTS IN THE

2126
01:20:04,080 --> 01:20:05,720
NODULE PROGRAM.

2127
01:20:05,720 --> 01:20:07,560
SO THE GOAL IS TO FIND LUNG

2128
01:20:07,560 --> 01:20:08,280
CANCER EARLY.

2129
01:20:08,280 --> 01:20:10,600
NOW YOU FOUND THOSE PEOPLE WHO

2130
01:20:10,600 --> 01:20:13,200
ARE YOU GOING TO DO?

2131
01:20:13,200 --> 01:20:16,080
IDEALLY YOU WANT TO OFFER THEM

2132
01:20:16,080 --> 01:20:18,400
CURATIVE INTENT NEXT SLIDE BUT

2133
01:20:18,400 --> 01:20:20,400
THIS I WILL DEPRESS YOU A LITTLE

2134
01:20:20,400 --> 01:20:21,960
BIT BY SHOWING YOU WORK WE HAVE

2135
01:20:21,960 --> 01:20:24,320
DONE DEMONSTRATING THAT PATIENTS

2136
01:20:24,320 --> 01:20:26,760
WITH EARLY STAGE LUNG CANCER DO

2137
01:20:26,760 --> 01:20:28,240
NOT NECESSARILY GET TREATMENT

2138
01:20:28,240 --> 01:20:29,720
THEY NEED.

2139
01:20:29,720 --> 01:20:34,120
SO THE PRIMARY RECOMMENDED

2140
01:20:34,120 --> 01:20:35,880
TREATMENT OF COURSE IS SURGICAL

2141
01:20:35,880 --> 01:20:36,880
RESECTION.

2142
01:20:36,880 --> 01:20:41,760
THIS -- THE FIRST DIAGRAM SHOWS

2143
01:20:41,760 --> 01:20:42,880
YOU THE STATE LEVEL PROPORTION

2144
01:20:42,880 --> 01:20:44,320
OF PERSONS WITH STAGE ONE AND

2145
01:20:44,320 --> 01:20:46,120
TWO LUNG CANCER WHO HAVE

2146
01:20:46,120 --> 01:20:47,600
SURGICAL RESECTION.

2147
01:20:47,600 --> 01:20:51,240
YOU SEE IT IS AS LOWER, ABOUT

2148
01:20:51,240 --> 01:20:53,800
50% IN WYOMING, AS HIGH AS 80%

2149
01:20:53,800 --> 01:20:57,040
IN UTAH, MASSACHUSETTS AND OTHER

2150
01:20:57,040 --> 01:20:58,680
PLACES.

2151
01:20:58,680 --> 01:20:59,800
TENNESSEE IN THE MIDDLE,

2152
01:20:59,800 --> 01:21:01,040
MISSISSIPPI IS LOWER THAN THAT.

2153
01:21:01,040 --> 01:21:04,360
IF YOU LOOK AT THE COUNTY LEVEL

2154
01:21:04,360 --> 01:21:06,400
DISPARITY IS EVEN WORSE, RANGING

2155
01:21:06,400 --> 01:21:10,960
FROM 13% IN THE LOWER TO 92% IN

2156
01:21:10,960 --> 01:21:15,520
THE HIGHEST COUNTIES.

2157
01:21:15,520 --> 01:21:17,080
WHAT IS GOING ON COLOR BARS ON

2158
01:21:17,080 --> 01:21:20,280
THE RIGHT SIDE SHOW YOU WITHIN A

2159
01:21:20,280 --> 01:21:23,560
CERTAIN HEALTHCARE SYSTEM WITH

2160
01:21:23,560 --> 01:21:26,440
MA I YOUR HOSPITALS IN DIFFERENT

2161
01:21:26,440 --> 01:21:29,240
STATES, HOW THE QUESTION WHAT IS

2162
01:21:29,240 --> 01:21:32,360
GOING ON GOT ANSWERED SO EACH

2163
01:21:32,360 --> 01:21:33,840
BAR REPRESENTS ALL LUNG CANCER

2164
01:21:33,840 --> 01:21:38,000
PATIENTS STAGE ONE OR TWO

2165
01:21:38,000 --> 01:21:39,000
DISEASE WITHIN A CERTAIN

2166
01:21:39,000 --> 01:21:39,840
HOSPITAL WITHIN THE SAME

2167
01:21:39,840 --> 01:21:41,520
HEALTHCARE SYSTEM, WE SEE FIVE

2168
01:21:41,520 --> 01:21:45,880
DIFFERENT BARS THERE.

2169
01:21:45,880 --> 01:21:47,000
SOD EVERYBODY IDEALLY

2170
01:21:47,000 --> 01:21:47,920
RECOMMENDED TREATMENT IS

2171
01:21:47,920 --> 01:21:48,640
SURGICAL RESECTION.

2172
01:21:48,640 --> 01:21:49,960
THE PROPORTIONS THAT GOT

2173
01:21:49,960 --> 01:21:52,960
SURGICAL RESECTION ARE IN THE

2174
01:21:52,960 --> 01:21:53,920
BLUE LOWER END OF THE BAR.

2175
01:21:53,920 --> 01:21:55,320
YOU CAN SEE HOW DIFFERENT IT IS.

2176
01:21:55,320 --> 01:21:57,600
IT IS AS LOW AS 30% IN CERTAIN

2177
01:21:57,600 --> 01:21:58,400
HOSPITAL WITHIN THE SAME

2178
01:21:58,400 --> 01:21:59,280
HEALTHCARE SYSTEM.

2179
01:21:59,280 --> 01:22:02,200
TO HIGHER THAN 60% IN OTHERS.

2180
01:22:02,200 --> 01:22:05,600
WHAT IS REALLY DISTURBING IS THE

2181
01:22:05,600 --> 01:22:08,640
UPPER BLUE, UPPER MOST BLUE,

2182
01:22:08,640 --> 01:22:10,440
PATIENTS WITH TERRIBLE LUNG

2183
01:22:10,440 --> 01:22:12,160
CANCER WHO NEVER GOT TREATMENT

2184
01:22:12,160 --> 01:22:12,600
BEFORE THEY DIED.

2185
01:22:12,600 --> 01:22:18,200
YOU SEE HOW IT IS ALMOST 40% IN

2186
01:22:18,200 --> 01:22:20,600
HOSPITAL 3 AND LESS THAN 5% IN

2187
01:22:20,600 --> 01:22:27,880
THE MDC.

2188
01:22:27,880 --> 01:22:29,200
WHAT IS GOING ON?

2189
01:22:29,200 --> 01:22:30,520
>> IF YOU CAN WRAP UP IN TWO

2190
01:22:30,520 --> 01:22:31,040
MINUTES.

2191
01:22:31,040 --> 01:22:31,840
>> OKAY.

2192
01:22:31,840 --> 01:22:32,280
EXCELLENT.

2193
01:22:32,280 --> 01:22:36,440
SO WHAT I'M GOING TO SHOW YOU IS

2194
01:22:36,440 --> 01:22:38,960
THE RED BARS IN THE OTHER

2195
01:22:38,960 --> 01:22:41,560
DIAGRAM SHOWS YOU PATIENTS WHO

2196
01:22:41,560 --> 01:22:42,400
NEVER GOT TREATMENT.

2197
01:22:42,400 --> 01:22:46,840
AND WHAT THIS TELLS YOU IS THAT

2198
01:22:46,840 --> 01:22:48,760
MULTI-DISCIPLINARY CARE,

2199
01:22:48,760 --> 01:22:49,960
INTERDISCIPLINARY CARE DECISION

2200
01:22:49,960 --> 01:22:51,680
MAKING GIVES YOU BETTER ODDS OF

2201
01:22:51,680 --> 01:22:54,360
THE RIGHT TREATMENT AND THAT

2202
01:22:54,360 --> 01:22:56,600
TRANSLATES TO SIGNIFICANTLY

2203
01:22:56,600 --> 01:22:58,720
BETTER SURVIVAL GREEN

2204
01:22:58,720 --> 01:23:05,960
MULTI-CARE, BLUE MET --

2205
01:23:05,960 --> 01:23:07,400
METROPOLITAN AND OUR CHALLENGE

2206
01:23:07,400 --> 01:23:09,400
NOW IS DISSEMINATE CARE ACROSS

2207
01:23:09,400 --> 01:23:13,400
THE HEALTHCARE SYSTEM.

2208
01:23:13,400 --> 01:23:14,640
YOU GET PATIENTS EARLY STAGE NOW

2209
01:23:14,640 --> 01:23:16,800
YOU WANT TO GIVE SURGICAL

2210
01:23:16,800 --> 01:23:17,960
RESECTION, BIGGEST PROBLEM WITH

2211
01:23:17,960 --> 01:23:21,800
SURGICAL RESECTION IS MOST OFTEN

2212
01:23:21,800 --> 01:23:24,920
DONE FOR YOU SO THE BAR GRAPH

2213
01:23:24,920 --> 01:23:27,000
SHOWS YOU LOOKING AT THE SERE

2214
01:23:27,000 --> 01:23:29,880
DATABASE, THE PROPORTION OF

2215
01:23:29,880 --> 01:23:31,800
PATIENTS WITH NUMBER OF LYMPH

2216
01:23:31,800 --> 01:23:33,560
NODES EXAMINED AND JUST SHOWS

2217
01:23:33,560 --> 01:23:36,960
YOU THE VAST -- THE MODEL NUMBER

2218
01:23:36,960 --> 01:23:38,840
OF EXAMINE AFTER SURGICAL

2219
01:23:38,840 --> 01:23:39,600
RESECTION IN THE UNITED STATES

2220
01:23:39,600 --> 01:23:40,560
IS ZERO.

2221
01:23:40,560 --> 01:23:41,560
THE MOST IMPORTANT INFORMATION

2222
01:23:41,560 --> 01:23:44,840
YOU NEED TO MAKE SUBSEQUENT

2223
01:23:44,840 --> 01:23:46,720
DECISIONS NOT USUALLY -- 18%

2224
01:23:46,720 --> 01:23:47,800
RESECTION.

2225
01:23:47,800 --> 01:23:49,320
SO WE HAVE DONE WORK TRYING TO

2226
01:23:49,320 --> 01:23:57,480
IMPROVE ON THAT.

2227
01:23:57,480 --> 01:23:59,720
RESECTIONS THAT MEET NCCN

2228
01:23:59,720 --> 01:24:01,160
GUIDELINES RED IS SURVIVAL,

2229
01:24:01,160 --> 01:24:03,000
RESECTIONS THAT FAIL TO DO SO

2230
01:24:03,000 --> 01:24:03,800
STICK WITH BLUE THAT IS

2231
01:24:03,800 --> 01:24:04,240
SURVIVAL.

2232
01:24:04,240 --> 01:24:05,920
BIG DIFFERENCE.

2233
01:24:05,920 --> 01:24:09,360
AND WHAT WE SHOW IS THAT IN OUR

2234
01:24:09,360 --> 01:24:12,200
HEALTHCARE SYSTEM FROM 2004 TO

2235
01:24:12,200 --> 01:24:15,200
2008, 34% RESECTION MAKE NCCN

2236
01:24:15,200 --> 01:24:16,760
GUIDELINES WITH INTERVENION

2237
01:24:16,760 --> 01:24:20,320
WITH LYMPH NODE KIT WE HAVE BEEN

2238
01:24:20,320 --> 01:24:21,600
SEQUENTIALLY ABLE TO IMPROVE

2239
01:24:21,600 --> 01:24:22,680
THAT NOT ONLY IN OUR HEALTHCARE

2240
01:24:22,680 --> 01:24:24,800
SYSTEM BUT ACROSS EIGHT

2241
01:24:24,800 --> 01:24:29,040
DIFFERENT HEALTHCARE SYSTEMS ALL

2242
01:24:29,040 --> 01:24:31,440
SYSTEMS WITHIN FIVE CONTIGUOUS

2243
01:24:31,440 --> 01:24:32,480
HOSPITAL REGIONS.

2244
01:24:32,480 --> 01:24:37,320
I WILL JUST QUICKLY SHOW YOU

2245
01:24:37,320 --> 01:24:40,040
THAT THIS KIT IMPROVES PRO,

2246
01:24:40,040 --> 01:24:42,080
PROOF PATIENT WHOSE GET NCCN

2247
01:24:42,080 --> 01:24:42,800
GUIDELINE COMPLIANCE SURGERY.

2248
01:24:42,800 --> 01:24:47,120
THAT MAKES A BIG DIFFERENCE TO

2249
01:24:47,120 --> 01:24:49,200
SURVIVAL, UPPER LINE RED

2250
01:24:49,200 --> 01:24:51,040
COMPARED TO PATIENTS WITH

2251
01:24:51,040 --> 01:24:52,960
SURGERY WITHOUT INTERVENTION,

2252
01:24:52,960 --> 01:24:58,280
THE KIT WHICH IS BLUE.

2253
01:24:58,280 --> 01:24:59,960
SO WE INTEND TO DO DIFFERENCES

2254
01:24:59,960 --> 01:25:02,200
ANALYSIS LOOKING AT THE CASHMAN

2255
01:25:02,200 --> 01:25:04,800
AREA POPULATION BASELINE AND

2256
01:25:04,800 --> 01:25:07,280
SOMETIME FUTURE LOOKING AT THE

2257
01:25:07,280 --> 01:25:11,120
POPULATION LEVEL OUTCOMES OF

2258
01:25:11,120 --> 01:25:12,520
LUNG CANCER CARE WITH HYPOTHESIS

2259
01:25:12,520 --> 01:25:15,880
WE CAN REDUCE MORTALITY BY

2260
01:25:15,880 --> 01:25:18,480
IMPLEMENTING THESE PROGRAMS.

2261
01:25:18,480 --> 01:25:19,800
NEXT SLIDE.

2262
01:25:19,800 --> 01:25:21,680
MY LAST SLIDE IS MY THANK YOU

2263
01:25:21,680 --> 01:25:22,160
SLIDE.

2264
01:25:22,160 --> 01:25:24,040
I CERTAINLY WANT TO MAKE SURE I

2265
01:25:24,040 --> 01:25:25,320
ACKNOWLEDGE THAT A LOT OF THIS

2266
01:25:25,320 --> 01:25:26,800
WORK WAS SUPPORTED BY FUNDING

2267
01:25:26,800 --> 01:25:27,840
FROM THE NATIONAL INSTITUTES OF

2268
01:25:27,840 --> 01:25:28,320
HEALTH.

2269
01:25:28,320 --> 01:25:32,880
THANK YOU.

2270
01:25:32,880 --> 01:25:34,040
>> THANKS, WONDERFUL

2271
01:25:34,040 --> 01:25:35,960
PRESENTATION AND REALLY

2272
01:25:35,960 --> 01:25:37,560
IMPORTANT AREA THAT WE REALLY

2273
01:25:37,560 --> 01:25:41,120
NEED TO GET TO.

2274
01:25:41,120 --> 01:25:43,680
WE HAVE A REALLY IMPORTANT BREAK

2275
01:25:43,680 --> 01:25:46,160
AND I THINK WE NEED TO -- WE

2276
01:25:46,160 --> 01:25:50,400
WILL WORK I THINK WITH TO ENSURE

2277
01:25:50,400 --> 01:25:54,560
WE LEAVE THAT TIME FOR

2278
01:25:54,560 --> 01:25:55,200
DISCUSSION.

2279
01:25:55,200 --> 01:25:57,920
>> WE ARE TAKING A BREAK NOW.

2280
01:25:57,920 --> 01:26:00,600
SO TAKE A COUPLE OF QUESTIONS.

2281
01:26:00,600 --> 01:26:02,680
>> OKAY SO I KNOW OTIS HAD A

2282
01:26:02,680 --> 01:26:04,480
QUESTION AND I KNOW MARGARET HAD

2283
01:26:04,480 --> 01:26:05,120
A QUESTION AS WELL.

2284
01:26:05,120 --> 01:26:11,440
SO I WILL START WITH OTIS.

2285
01:26:11,440 --> 01:26:14,040
>> THANK YOU, WONDERFUL

2286
01:26:14,040 --> 01:26:15,840
PRESENTATION, ENJOYED IT.

2287
01:26:15,840 --> 01:26:18,400
MY QUESTION IS, IT SEEMS TO ME

2288
01:26:18,400 --> 01:26:19,960
THERE ARE SOME HOSPITALS THAT

2289
01:26:19,960 --> 01:26:24,160
ARE STARTING TO OFFER SPIRAL CT

2290
01:26:24,160 --> 01:26:25,960
SCREEN OF THE LUNG THAT IN MY

2291
01:26:25,960 --> 01:26:27,400
OPINION MAYBE OUGHT NOT BE

2292
01:26:27,400 --> 01:26:28,400
OFFERING BECAUSE THEY DON'T HAVE

2293
01:26:28,400 --> 01:26:31,160
THE RESOURCES TO DO SOME OF THE

2294
01:26:31,160 --> 01:26:34,400
WORK UP FOR POSITIVES, THEY

2295
01:26:34,400 --> 01:26:37,240
DON'T HAVE THE THORACIC SURGEONS

2296
01:26:37,240 --> 01:26:38,400
TO DO TREATMENT AND FREQUENTLY

2297
01:26:38,400 --> 01:26:40,200
TELL PEOPLE YOU HAVE AN

2298
01:26:40,200 --> 01:26:41,680
ABNORMALITY, THIS IS A LIST OF

2299
01:26:41,680 --> 01:26:48,760
PLACES YOU SHOULD GO TO.

2300
01:26:48,760 --> 01:26:51,360
HAVE YOU SEEN THAT HAPPENING?

2301
01:26:51,360 --> 01:26:53,200
>> YEAH SO I THINK THE CHALLENGE

2302
01:26:53,200 --> 01:26:57,240
OF LUNG CANCER OF COURSE IS THAT

2303
01:26:57,240 --> 01:27:01,000
THOUGH LOW DOSE SCREENING CTs

2304
01:27:01,000 --> 01:27:03,760
GIVE YOU THE OPPORTUNITY TO FIND

2305
01:27:03,760 --> 01:27:05,000
PATIENTS EARLY AND DO THE RIGHT

2306
01:27:05,000 --> 01:27:06,040
THING FOR THAT.

2307
01:27:06,040 --> 01:27:09,040
IT IS A NEEDLE IN A HAY STACK

2308
01:27:09,040 --> 01:27:11,640
PROBLEM.

2309
01:27:11,640 --> 01:27:14,280
GIANT HAY TACK AND THE CHALLENGE

2310
01:27:14,280 --> 01:27:19,120
IF WE DID THIS RECKLESSLY WE

2311
01:27:19,120 --> 01:27:20,400
WOULD TEAR UP MORE LIVES THAN

2312
01:27:20,400 --> 01:27:21,000
SAVE.

2313
01:27:21,000 --> 01:27:26,040
SO THE CHALLENGE IS TO PUT

2314
01:27:26,040 --> 01:27:28,720
INFRASTRUCTURE TO PUT DOWN

2315
01:27:28,720 --> 01:27:31,040
INFRASTRUCTURE IN A WAY THAT YOU

2316
01:27:31,040 --> 01:27:35,160
CAN LURE PEOPLE IN, SORT THEM

2317
01:27:35,160 --> 01:27:36,800
ACCURATELY, TRIAGE THEM INTO THE

2318
01:27:36,800 --> 01:27:38,600
PATHWAYS OF CARE THAT THEY NEED

2319
01:27:38,600 --> 01:27:42,840
SO THOSE WHO ARE ENDANGERED GET

2320
01:27:42,840 --> 01:27:44,880
RESCUED BY HIGH QUALITY CARE AND

2321
01:27:44,880 --> 01:27:46,880
THOSE WHO NEED TO BE LEFT ALONE

2322
01:27:46,880 --> 01:27:48,200
GET LEFT ALONE.

2323
01:27:48,200 --> 01:27:50,040
THIS IS NOT SOMETHING THAT YOU

2324
01:27:50,040 --> 01:27:54,040
CAN EXPECT EVERYBODY TO BE ABLE

2325
01:27:54,040 --> 01:27:55,480
TO DO BY BUYING CT SCANNER

2326
01:27:55,480 --> 01:27:56,760
PLUGGING IN AND DOING IT.

2327
01:27:56,760 --> 01:28:00,400
THAT IS WHY THE TEAM SCIENCE

2328
01:28:00,400 --> 01:28:02,520
ASPECT AND IMPLEMENTATION

2329
01:28:02,520 --> 01:28:04,440
SCIENCE ASPECT ARE VITALLY

2330
01:28:04,440 --> 01:28:07,840
IMPORTANT TO THIS PROJECT.

2331
01:28:07,840 --> 01:28:09,520
WHY WE USE RIGOROUS SCIENCE

2332
01:28:09,520 --> 01:28:14,480
WITHIN A COMMUNITY BASED

2333
01:28:14,480 --> 01:28:15,920
HEALTHCARE SYSTEM YOU CAN'T DO

2334
01:28:15,920 --> 01:28:17,800
CT SCANNER AND SAY MEDICARE PAY

2335
01:28:17,800 --> 01:28:18,760
FOR IT ALREADY WE START DOING

2336
01:28:18,760 --> 01:28:22,040
THIS, YOU HAVE TO HAVE THE HUMAN

2337
01:28:22,040 --> 01:28:23,400
RESOURCES TO DO THE RIGHT THING

2338
01:28:23,400 --> 01:28:27,040
FOR THE RIGHT PATIENT AT THE

2339
01:28:27,040 --> 01:28:29,080
RIGHT TIME.

2340
01:28:29,080 --> 01:28:31,400
>> 15 SECONDS, ORIGINAL STUDY

2341
01:28:31,400 --> 01:28:33,720
THAT TOLD US THAT LUNG CANCER

2342
01:28:33,720 --> 01:28:36,840
SCREENING REDUCES RISK OF DEATH

2343
01:28:36,840 --> 01:28:39,920
BY 20% SHOW THAT FOR EVERY 5.4

2344
01:28:39,920 --> 01:28:44,920
LIVES SAVED, ONE PERSON DIED

2345
01:28:44,920 --> 01:28:47,320
DURING BIOPSY AND WORK UP OF

2346
01:28:47,320 --> 01:28:49,120
ABNORMALS SO I JUST KEEP THAT IN

2347
01:28:49,120 --> 01:28:50,080
MIND WHAT YOU JUST SAID.

2348
01:28:50,080 --> 01:28:51,680
THANK YOU.

2349
01:28:51,680 --> 01:28:53,960
>> SO WE HAVE MARGARET THEN

2350
01:28:53,960 --> 01:28:55,800
WE'LL HAVE TO MOVE ON.

2351
01:28:55,800 --> 01:28:57,560
>> I JUST HAD A SIMPLE QUESTION,

2352
01:28:57,560 --> 01:29:00,240
I DIDN'T FULLY UNDERSTAND IT WAS

2353
01:29:00,240 --> 01:29:01,600
AN EXCELLENT INTRIGUING

2354
01:29:01,600 --> 01:29:02,320
PRESENTATION BY THE WAY.

2355
01:29:02,320 --> 01:29:04,760
I DIDN'T FULLY UNDERSTAND THE

2356
01:29:04,760 --> 01:29:06,400
THREE GROUPS YOU BEGAN YOUR

2357
01:29:06,400 --> 01:29:09,800
PRESENTATION WITH, THE SCREENING

2358
01:29:09,800 --> 01:29:16,400
GROUP IS CLEAR, NOT SURE WHAT

2359
01:29:16,400 --> 01:29:20,240
YOU MEAN BY NODULE, THEY WERE

2360
01:29:20,240 --> 01:29:22,120
SCREENS THEN THE NODULE SO I

2361
01:29:22,120 --> 01:29:23,000
DIDN'T UNDERSTAND HOW YOU

2362
01:29:23,000 --> 01:29:24,280
DIFFERENTIATED THE TWO AND I

2363
01:29:24,280 --> 01:29:26,040
PRESUME THOSE SEEM IN THE

2364
01:29:26,040 --> 01:29:27,840
MULTI-DISCIPLINARY CLINIC WERE

2365
01:29:27,840 --> 01:29:28,560
SYMPTOMATIC PATIENTS.

2366
01:29:28,560 --> 01:29:29,520
RIGHT OR WRONG?

2367
01:29:29,520 --> 01:29:33,080
>> YES, THANK YOU,.

2368
01:29:33,080 --> 01:29:34,680
GREAT QUESTION.

2369
01:29:34,680 --> 01:29:38,400
THE NODULE PATIENTS ARE PEOPLE

2370
01:29:38,400 --> 01:29:42,800
WHO HAD RADIOLOGY STUDY FOR

2371
01:29:42,800 --> 01:29:48,880
MYRIAD OF REASONS.

2372
01:29:48,880 --> 01:29:49,520
WHY WERE WE WERE TRYING TO

2373
01:29:49,520 --> 01:29:51,760
RESCUE FROM DYING AVOIDING

2374
01:29:51,760 --> 01:29:53,400
INJURIES YOU HAD, IT'S HELPFUL

2375
01:29:53,400 --> 01:29:55,560
TO SHOW BY THE WAY THERE IS A

2376
01:29:55,560 --> 01:29:56,160
SPOT THERE.

2377
01:29:56,160 --> 01:29:57,480
WHAT HAPPENS IS RADIOLOGIST

2378
01:29:57,480 --> 01:30:00,240
MENTIONS IT BUT WE ARE SO

2379
01:30:00,240 --> 01:30:01,520
DISTRACTED BY HE HAD HEART

2380
01:30:01,520 --> 01:30:04,040
ATTACK, MAJOR TRAUMA, WHATEVER,

2381
01:30:04,040 --> 01:30:06,720
TAKE CARE OF THAT AND THREE

2382
01:30:06,720 --> 01:30:08,960
YEARS LATER DYING OF STAGE 4

2383
01:30:08,960 --> 01:30:11,840
LUNG CANCER SO THE NODULE

2384
01:30:11,840 --> 01:30:16,400
PROGRAM ACTUALLY IN A VERY

2385
01:30:16,400 --> 01:30:17,600
PURPOSEFUL WAY COVERS UP ALL

2386
01:30:17,600 --> 01:30:20,600
THESE RADIOLOGY REPORTS USING

2387
01:30:20,600 --> 01:30:23,440
KEY WORDS THEN WE HAVE A TEAM OF

2388
01:30:23,440 --> 01:30:24,600
NAVIGATORS WHO COME IN BEHIND

2389
01:30:24,600 --> 01:30:29,880
AND USING A GUIDELINE, SOCIETY

2390
01:30:29,880 --> 01:30:32,200
GUIDELINES, TRIAGE PATIENTS INTO

2391
01:30:32,200 --> 01:30:34,440
DIFFERENT -- AND HIGH RISK ONES

2392
01:30:34,440 --> 01:30:35,440
GET BENEFIT OF ONGOING

2393
01:30:35,440 --> 01:30:37,120
SURVEILLANCE.

2394
01:30:37,120 --> 01:30:37,720
THAT'S THE DIFFERENCE BETWEEN

2395
01:30:37,720 --> 01:30:40,520
THEM.

2396
01:30:40,520 --> 01:30:42,360
>> SEEN IN THE CLINIC

2397
01:30:42,360 --> 01:30:42,640
SYMPTOMATIC.

2398
01:30:42,640 --> 01:30:45,040
>> WE JUST USE MULTI-DAY COHORT

2399
01:30:45,040 --> 01:30:47,840
TO HELP US CONTEXTUALIZE TO

2400
01:30:47,840 --> 01:30:49,200
EARLY DETECTION.

2401
01:30:49,200 --> 01:30:52,680
THEY ARE CONVENTIONAL PEOPLE

2402
01:30:52,680 --> 01:30:54,480
WHOM DAMAGE LUNG CANCER CAME IN.

2403
01:30:54,480 --> 01:31:00,760
IT IS BIAS IN ANALYSIS THE

2404
01:31:00,760 --> 01:31:02,600
MULTI-DAY COHORT DOES BETTER

2405
01:31:02,600 --> 01:31:03,760
THAN AVERAGE PERSON ON THE

2406
01:31:03,760 --> 01:31:04,960
STREET WITH LUNG CANCER.

2407
01:31:04,960 --> 01:31:07,240
>> SO IF ANYONE HAS ANY

2408
01:31:07,240 --> 01:31:08,440
ADDITIONAL QUESTIONS PLEASE TYPE

2409
01:31:08,440 --> 01:31:09,760
IN THE CHAT.

2410
01:31:09,760 --> 01:31:15,560
RAY, IF YOU CAN PERUSE THE CHAT

2411
01:31:15,560 --> 01:31:16,840
AND ADDRESS COMMENTS OR

2412
01:31:16,840 --> 01:31:17,760
QUESTIONS, THAT WOULD BE

2413
01:31:17,760 --> 01:31:18,560
HELPFUL.

2414
01:31:18,560 --> 01:31:20,400
I'M NOW GOING TO PASS THE PODIUM

2415
01:31:20,400 --> 01:31:24,000
OVER TO KEITH TO LEAD THE NEXT

2416
01:31:24,000 --> 01:31:25,440
SERIES OF DISCUSSIONS AND NEXT

2417
01:31:25,440 --> 01:31:25,840
SESSION.

2418
01:31:25,840 --> 01:31:26,640
THANK YOU ALL.

2419
01:31:26,640 --> 01:31:29,200
>> THANKS, JOHN.

2420
01:31:29,200 --> 01:31:30,680
SO WE HAVE TO WORK FOR OUR

2421
01:31:30,680 --> 01:31:31,800
BREAK, WE HAVE TWO CONCEPTS TO

2422
01:31:31,800 --> 01:31:32,840
GET THROUGH BEFORE WE MAKE IT TO

2423
01:31:32,840 --> 01:31:34,960
THE BREAK.

2424
01:31:34,960 --> 01:31:36,840
START TO TRAIN US TO USE OUR

2425
01:31:36,840 --> 01:31:41,200
TIME EFFICIENTLY, PAULETTE

2426
01:31:41,200 --> 01:31:43,400
ENGINEERING AAGENDA YOU ARE GET

2427
01:31:43,400 --> 01:31:44,600
CONSULTED ON HIGH LEVEL

2428
01:31:44,600 --> 01:31:49,200
DECISIONS LIKE THAT.

2429
01:31:49,200 --> 01:31:51,520
REMIND YOU BRIEFLY BSA MEMBERS

2430
01:31:51,520 --> 01:31:53,760
STAY CONNECT AND IF YOU WILL

2431
01:31:53,760 --> 01:31:56,840
ALSO ON SCREEN THAT WAY WE CAN

2432
01:31:56,840 --> 01:31:58,200
COUNT YOUR PRESENCE WHEN WE GET

2433
01:31:58,200 --> 01:32:01,040
TO VOTING FOR THOSE THAT ARE

2434
01:32:01,040 --> 01:32:05,000
MOTION FOR APPROVAL CONCURRENCE

2435
01:32:05,000 --> 01:32:07,720
WE WILL COUNT YOU APPROVING

2436
01:32:07,720 --> 01:32:09,360
CONCURRENCE BY SIMPLE PRESENCE

2437
01:32:09,360 --> 01:32:11,400
AND COLLECT NO VOTES.

2438
01:32:11,400 --> 01:32:12,840
DISAPPROVAL OR NON-CONCURRENCE

2439
01:32:12,840 --> 01:32:14,320
VOTES IN THAT CIRCUMSTANCE SO

2440
01:32:14,320 --> 01:32:16,520
ONE IMPORTANT POINT AND NCAB

2441
01:32:16,520 --> 01:32:17,880
COLLEAGUES REMINDER THAT WE

2442
01:32:17,880 --> 01:32:20,960
WELCOME YOUR PARTICIPATION IN

2443
01:32:20,960 --> 01:32:21,320
DISCUSSION.

2444
01:32:21,320 --> 01:32:24,680
THESE CONCEPTS EVEN THOUGH IT

2445
01:32:24,680 --> 01:32:29,560
WILL BE LET'S JUMP IN T. CONCEPT

2446
01:32:29,560 --> 01:32:32,760
IS NEW RFA/COOPERATIVE AGREEMENT

2447
01:32:32,760 --> 01:32:34,760
PEDIATRIC IMMUNOTHERAPY NETWORK,

2448
01:32:34,760 --> 01:32:36,640
DR. SINGH PRESENTING THE

2449
01:32:36,640 --> 01:32:38,160
SUBCOMMITTEE IS CHAIRED BY BOB

2450
01:32:38,160 --> 01:32:41,960
AND SUPPORTED BY BOB SCHRIBER

2451
01:32:41,960 --> 01:32:42,480
AND MYSELF.

2452
01:32:42,480 --> 01:32:44,400
UNABLE O JOIN IN PERSON BUT ABLE

2453
01:32:44,400 --> 01:32:46,120
TO PARTICIPATE IN THE DISCUSSION

2454
01:32:46,120 --> 01:32:47,800
TO PROVIDE FEEDBACK.

2455
01:32:47,800 --> 01:32:50,920
WE WILL INITIATE THE DISCUSSION

2456
01:32:50,920 --> 01:32:52,720
AFTER DR. SINGH'S PRESENTATION.

2457
01:32:52,720 --> 01:32:53,720
TAKE IT AWAY.

2458
01:32:53,720 --> 01:32:55,800
>> THANK YOU, DR. FLAHERTY.

2459
01:32:55,800 --> 01:32:56,760
GOOD AFTERNOON, EVERYONE.

2460
01:32:56,760 --> 01:32:59,040
IT IS MY PLEASURE TO PRESENT THE

2461
01:32:59,040 --> 01:33:00,560
PEDIATRIC IMMUNOTHERAPY NETWORK

2462
01:33:00,560 --> 01:33:03,560
ON BEHALF OF MY COLLEAGUES FROM

2463
01:33:03,560 --> 01:33:04,960
THE DIVISION OF CANCER BIOLOGY

2464
01:33:04,960 --> 01:33:06,120
AND CANCER TREATMENT AND

2465
01:33:06,120 --> 01:33:06,600
DIAGNOSIS.

2466
01:33:06,600 --> 01:33:09,280
NEXT SLIDE PLEASE.

2467
01:33:09,280 --> 01:33:10,840
PEDIATRIC CANCER IN

2468
01:33:10,840 --> 01:33:12,400
IMMUNOTHERAPY STRATEGIES ARE

2469
01:33:12,400 --> 01:33:14,000
VERY DIFFERENT FROM ADULT.

2470
01:33:14,000 --> 01:33:15,440
PEDIATRIC CANCER MOSTLY ARISE

2471
01:33:15,440 --> 01:33:17,240
FROM MISAPPROPRIATION OF NORMAL

2472
01:33:17,240 --> 01:33:18,720
DEVELOPMENT AND PROCESSES.

2473
01:33:18,720 --> 01:33:23,560
AND THESE CANCERS TEND TO BE

2474
01:33:23,560 --> 01:33:25,320
ORIGIN VERSUS -- CANCERS

2475
01:33:25,320 --> 01:33:26,720
EPITHELIAL AND THERE IS YEARS OF

2476
01:33:26,720 --> 01:33:27,960
ENVIRONMENTAL EXPOSURE LEADING

2477
01:33:27,960 --> 01:33:30,120
TO DNA DAMAGE.

2478
01:33:30,120 --> 01:33:32,560
PEDIATRIC CANCER HAVE LESS

2479
01:33:32,560 --> 01:33:34,600
EXPOSURE OF THE ENVIRONMENT,

2480
01:33:34,600 --> 01:33:36,920
LOOK IN THE FIGURE BELOW THE

2481
01:33:36,920 --> 01:33:38,520
MEDIAN MUTATION FOR PEDIATRIC

2482
01:33:38,520 --> 01:33:40,840
TUMOR IN THE MAGENTA BAR IS MUCH

2483
01:33:40,840 --> 01:33:42,520
LOWER COMPARED TO THE GREEN BAR

2484
01:33:42,520 --> 01:33:45,600
FOR ADULT TUMORS.

2485
01:33:45,600 --> 01:33:46,880
BECAUSE OF THE LOW MUTATION

2486
01:33:46,880 --> 01:33:48,400
BURDEN THERE IS LIMITED SUCCESS

2487
01:33:48,400 --> 01:33:50,400
WITH IMMUNE CHECK POINT

2488
01:33:50,400 --> 01:33:51,560
INHIBITORS WITH EXCEPTION OF

2489
01:33:51,560 --> 01:33:54,320
VERY SMALL SUBSET OF PATIENTS

2490
01:33:54,320 --> 01:33:57,320
SHOWN IN THE -- BELOW WHICH ARE

2491
01:33:57,320 --> 01:33:58,920
PATIENTS MISMATCH REPAIR

2492
01:33:58,920 --> 01:33:59,400
DEFICIENCY.

2493
01:33:59,400 --> 01:34:01,080
THESE PATIENTS RESPOND TO IMMUNE

2494
01:34:01,080 --> 01:34:03,600
CHECK POINT INHIBITORS.  

2495
01:34:03,600 --> 01:34:06,080
PEDIATRIC TUMORS HAVE DIFFERENT

2496
01:34:06,080 --> 01:34:08,920
IMMUNE INFILTRATES AND

2497
01:34:08,920 --> 01:34:10,440
CLASSIFIED THE NODULE CORED

2498
01:34:10,440 --> 01:34:13,120
TUMORS SOME EXAMPLES OF

2499
01:34:13,120 --> 01:34:14,120
IMMUNOTHERAPIES WHICH HAVE BEEN

2500
01:34:14,120 --> 01:34:15,600
SUCCESSFUL TO SOME DEGREE IN

2501
01:34:15,600 --> 01:34:20,280
CHILDREN ARE LISTED HERE.

2502
01:34:20,280 --> 01:34:22,280
MUCH FEWER COMPARED TO

2503
01:34:22,280 --> 01:34:23,720
IMMUNOTHERAPY FOR ADULT

2504
01:34:23,720 --> 01:34:25,960
INCLUDING CD 19 TARGETED CAR

2505
01:34:25,960 --> 01:34:27,960
T-CELLS, MONOCLONAL ANTIBODIES

2506
01:34:27,960 --> 01:34:31,480
FOR GD 2 AND CD 20, ANTIBODY

2507
01:34:31,480 --> 01:34:33,840
DRUG CONJUGATES.

2508
01:34:33,840 --> 01:34:37,520
AS YOU CAN SEE MOST SUCCESSFUL

2509
01:34:37,520 --> 01:34:38,920
ONES IN CHILDREN RELY ON --

2510
01:34:38,920 --> 01:34:41,000
COMMUNITY VERSUS THE ONE BY

2511
01:34:41,000 --> 01:34:43,240
ENHANCING TUMOR IMMUNOGENICITY

2512
01:34:43,240 --> 01:34:47,880
SUCH AS CHECK POINT INHIBITORS.

2513
01:34:47,880 --> 01:34:50,440
ANOTHER POINT, OUT OF FIVE

2514
01:34:50,440 --> 01:34:52,880
EXAMPLES OF THEM, ONLY ONE

2515
01:34:52,880 --> 01:34:54,400
MONOCLONAL ANTIBODY IS INDICATED

2516
01:34:54,400 --> 01:34:56,400
SOLID TUMOR INDICATION.

2517
01:34:56,400 --> 01:34:57,960
PEDIATRIC SOLID TUMORS REMAIN

2518
01:34:57,960 --> 01:35:00,320
AREA OF UNMET CLINICAL NEED AND

2519
01:35:00,320 --> 01:35:02,120
THAT'S WHY THIS CONCEPT IS

2520
01:35:02,120 --> 01:35:08,680
FOCUSED ON SOLID TUMORS.

2521
01:35:08,680 --> 01:35:10,160
FORTUNATELY THERE HAS BEEN SOME

2522
01:35:10,160 --> 01:35:12,320
SUCCESSFUL IMMUNOTHERAPY IN

2523
01:35:12,320 --> 01:35:14,880
HUMAN MALIGNANCY YOU MAY BE

2524
01:35:14,880 --> 01:35:16,280
FAMILIAR WITH ON THE TOP LEFT,

2525
01:35:16,280 --> 01:35:18,440
WHO WAS TREATED WITH CD 19 CAR

2526
01:35:18,440 --> 01:35:20,280
T-CELLS FOR REFRACTORY AND

2527
01:35:20,280 --> 01:35:24,400
RELAPSE LEUKEMIA AND SINCE THEN

2528
01:35:24,400 --> 01:35:25,520
MANY MORE CHILDREN TREAT WITH

2529
01:35:25,520 --> 01:35:27,400
IMMUNOTHERAPY ESPECIALLY WORKING

2530
01:35:27,400 --> 01:35:28,400
MALIGNANCIES AS YOU CAN SEE THE

2531
01:35:28,400 --> 01:35:31,080
TOP RIGHT.

2532
01:35:31,080 --> 01:35:31,960
UNFORTUNATELY SIMILAR SUCCESS

2533
01:35:31,960 --> 01:35:33,960
NOT ACHIEVED FOR SOLID BRAIN

2534
01:35:33,960 --> 01:35:35,960
TUMORS, IF YOU LOOK AT THE EVENT

2535
01:35:35,960 --> 01:35:37,720
FREE SURVIVAL IN THE BOTTOM

2536
01:35:37,720 --> 01:35:40,200
RIGHT HIGH RISK NEUROBLASTOMA

2537
01:35:40,200 --> 01:35:42,120
STILL IN THE RANGE 40 TO 06% AND

2538
01:35:42,120 --> 01:35:44,760
FOR BRAIN TUMORS LIKE DIPG LESS

2539
01:35:44,760 --> 01:35:46,560
THAN TWO YEARS FROM THE TIME OF

2540
01:35:46,560 --> 01:35:53,600
INITIAL DIAGNOSIS.

2541
01:35:53,600 --> 01:35:54,880
PEDIATRIC SOLID BRAIN TUMORS

2542
01:35:54,880 --> 01:35:58,440
HAVE UNIQUE CHALLENGES.

2543
01:35:58,440 --> 01:36:00,800
TUMORS ARE RARE TUMORS BUT DOES

2544
01:36:00,800 --> 01:36:02,280
POSE ADDITIONAL CHALLENGE FOR

2545
01:36:02,280 --> 01:36:04,080
CLINICIANS AND INVESTIGATORS

2546
01:36:04,080 --> 01:36:05,200
STUDY BECAUSE THERE ARE LIMITED

2547
01:36:05,200 --> 01:36:06,200
PATIENTS FOR ANY GIVEN TUMOR

2548
01:36:06,200 --> 01:36:09,200
INDICATION TO FOLLOW.

2549
01:36:09,200 --> 01:36:11,280
SPECIMEN AVAILABILITY IS

2550
01:36:11,280 --> 01:36:13,800
LIMITED, THERE ARE ADDITIONAL

2551
01:36:13,800 --> 01:36:15,200
CONSIDERATIONS ON AMOUNT AND

2552
01:36:15,200 --> 01:36:16,960
FREQUENCY OF SPECIMEN COLLECTION

2553
01:36:16,960 --> 01:36:18,200
AND LONGITUDINAL SAMPLING COULD

2554
01:36:18,200 --> 01:36:20,360
BE A PROBLEM.

2555
01:36:20,360 --> 01:36:21,600
MONITORING RESPONSE TO THERAPY

2556
01:36:21,600 --> 01:36:23,760
CAN GET VERY CHALLENGING, FOR

2557
01:36:23,760 --> 01:36:27,880
INSTANCE IMAGING WHO NEED

2558
01:36:27,880 --> 01:36:29,360
ANESTHETIZE PATIENTS THEY DON'T

2559
01:36:29,360 --> 01:36:30,480
UNDERSTAND HOW DEVELOPING IMMUNE

2560
01:36:30,480 --> 01:36:33,160
SYSTEM IN CHILDREN AFFECT THEIR

2561
01:36:33,160 --> 01:36:34,160
RESPONSE FOR RESISTANCE TO

2562
01:36:34,160 --> 01:36:35,480
IMMUNE THERAPIES.

2563
01:36:35,480 --> 01:36:37,680
THE TUMOR MICROENVIRONMENT IS

2564
01:36:37,680 --> 01:36:39,280
VERY POORLY UNDERSTOOD,

2565
01:36:39,280 --> 01:36:42,160
ESPECIALLY FOR BRAIN TUMORS.

2566
01:36:42,160 --> 01:36:44,960
I ALLUDED TO THE MUTATION BURDEN

2567
01:36:44,960 --> 01:36:48,240
AND THESE BEING IMMUNOCORED

2568
01:36:48,240 --> 01:36:49,960
TUMORS BECAUSE OF BODIES OF KIDS

2569
01:36:49,960 --> 01:36:51,840
ARE GROWING THERE IS INCREASE

2570
01:36:51,840 --> 01:36:54,360
FOR THERAPEUTIC TOXICITY

2571
01:36:54,360 --> 01:36:55,760
INCLUDING NEUROTOXICITY FOR

2572
01:36:55,760 --> 01:36:57,120
DEVELOPING BRAIN.

2573
01:36:57,120 --> 01:36:59,040
SIMILAR TOP ADULT THERE IS LACK

2574
01:36:59,040 --> 01:37:00,960
OF APPROPRIATE MODEL SYSTEMS,

2575
01:37:00,960 --> 01:37:03,960
YOU HAVE TO CONSIDER TUMOR

2576
01:37:03,960 --> 01:37:04,880
HETEROGENEITY, BLOOD BRAIN

2577
01:37:04,880 --> 01:37:06,200
BARRIER FOR BRAIN TUMORS AND

2578
01:37:06,200 --> 01:37:08,440
LACK OF NON-TUMOR TARGETS.

2579
01:37:08,440 --> 01:37:11,360
NEXT SLIDE PLEASE.

2580
01:37:11,360 --> 01:37:12,920
WE RECENTLY PERFORMED A

2581
01:37:12,920 --> 01:37:15,920
PORTFOLIO ANALYSIS FOR GRANTS IN

2582
01:37:15,920 --> 01:37:17,480
PEDIATRIC SOLID TUMOR

2583
01:37:17,480 --> 01:37:19,360
IMMUNOTHERAPY AND THERE ARE ONLY

2584
01:37:19,360 --> 01:37:20,280
31 GRANTS IN THIS AREA.

2585
01:37:20,280 --> 01:37:24,800
WE DO REALIZE THERE IS A NEED TO

2586
01:37:24,800 --> 01:37:25,840
INCREASE BOTH IN THE

2587
01:37:25,840 --> 01:37:31,080
PRE-CLINICAL AS WELL AS CLINICAL

2588
01:37:31,080 --> 01:37:34,960
SPACE RECENTLY PUBLISHED AN RFI

2589
01:37:34,960 --> 01:37:36,800
REQUEST FOR INFORMATION TOGETHER

2590
01:37:36,800 --> 01:37:38,920
IN PUT FROM THE RESEARCH

2591
01:37:38,920 --> 01:37:39,480
COMMUNITY.

2592
01:37:39,480 --> 01:37:41,840
RECEIVED A VERY GOOD RESPONSE,

2593
01:37:41,840 --> 01:37:43,080
SEVERAL OPPORTUNITIES WERE

2594
01:37:43,080 --> 01:37:44,960
IDENTIFIED WHERE NCI COULD HELP.

2595
01:37:44,960 --> 01:37:46,000
SOME OF THE TOPICS ARE LISTED

2596
01:37:46,000 --> 01:37:48,800
HERE.

2597
01:37:48,800 --> 01:37:51,840
A NEED FOR TARGETED ANGIOGENIC

2598
01:37:51,840 --> 01:37:53,120
ANECDOTES BINDERS AND

2599
01:37:53,120 --> 01:37:54,600
IMMUNOTHERAPY AGENTS,

2600
01:37:54,600 --> 01:37:57,680
ELUCIDATION OF IMMUNE INVASION

2601
01:37:57,680 --> 01:37:59,040
MECHANISMS, PEDIATRIC

2602
01:37:59,040 --> 01:38:00,040
PRE-CLINICAL MODEL ESPECIALLY

2603
01:38:00,040 --> 01:38:02,400
BRAIN TUMORS, RESOURCES FOR

2604
01:38:02,400 --> 01:38:05,440
DEVELOPING PROTEIN THERAPEUTICS

2605
01:38:05,440 --> 01:38:07,840
IND STUDIES AND CPMG

2606
01:38:07,840 --> 01:38:09,320
MANUFACTURING.

2607
01:38:09,320 --> 01:38:11,520
PREDICTIVE BIOMARKERS ANALYTICAL

2608
01:38:11,520 --> 01:38:12,840
TECHNOLOGIES FOR IMMUNE

2609
01:38:12,840 --> 01:38:13,680
MONITORING AND OPPORTUNITIES FOR

2610
01:38:13,680 --> 01:38:14,600
REVERSE TRANSLATION.

2611
01:38:14,600 --> 01:38:17,120
SO IN RESPONSE TO THE INPUT FROM

2612
01:38:17,120 --> 01:38:20,280
THE RFI, AS WELL AS INPUT FROM

2613
01:38:20,280 --> 01:38:25,800
THE NCI WE ARE PROPOSING THIS

2614
01:38:25,800 --> 01:38:27,640
NEW NETWORK CALLED PEDIATRIC

2615
01:38:27,640 --> 01:38:28,640
IMMUNOTHERAPY NETWORK.

2616
01:38:28,640 --> 01:38:30,560
THE PURPOSE OF WHICH WILL BE TO

2617
01:38:30,560 --> 01:38:32,200
DEVELOP TRANSLATABLE NOVEL

2618
01:38:32,200 --> 01:38:34,000
IMMUNOTHERAPY APPROACHES FOR

2619
01:38:34,000 --> 01:38:35,720
CHILDREN AND ADULTS WITH SOLID

2620
01:38:35,720 --> 01:38:37,840
TUMORS INCLUDING BRAIN TUMORS.

2621
01:38:37,840 --> 01:38:40,200
THE FOCUS OF PIN AS YOU CAN SEE

2622
01:38:40,200 --> 01:38:41,960
IN THE DIAGRAM WILL BE FROM

2623
01:38:41,960 --> 01:38:43,880
BASIC RESEARCH, LEADING TO

2624
01:38:43,880 --> 01:38:45,480
DISCOVERY VALIDATION

2625
01:38:45,480 --> 01:38:46,560
PRE-CLINICAL ALL WAY UP TO

2626
01:38:46,560 --> 01:38:47,800
CLINICAL TRIALS.

2627
01:38:47,800 --> 01:38:49,880
AND REVERSE TRANSLATION STUDIES

2628
01:38:49,880 --> 01:38:51,920
IN WHICH YOU CAN TAKE CLINICAL

2629
01:38:51,920 --> 01:38:53,680
SPECIMENS BACK TO LAB TO DO

2630
01:38:53,680 --> 01:38:55,800
BASIC PRE-CLINICAL AND

2631
01:38:55,800 --> 01:38:57,200
CONFIRMATORY STUDIES WILL ALSO

2632
01:38:57,200 --> 01:38:58,600
BE PART OF PIN.

2633
01:38:58,600 --> 01:39:03,360
NEXT SLIDE PLEASE.

2634
01:39:03,360 --> 01:39:05,640
THE SLIDE LISTS EXAMPLES OF

2635
01:39:05,640 --> 01:39:07,000
PROJECTS WHICH COULD BE PART OF

2636
01:39:07,000 --> 01:39:09,840
PIN DISCOVERY OF NOVEL ANTIGENS,

2637
01:39:09,840 --> 01:39:11,840
AND ANALYSIS OF PEDIATRIC

2638
01:39:11,840 --> 01:39:13,640
SPECIFIC IMMUNE RESPONSE, IMMUNE

2639
01:39:13,640 --> 01:39:16,200
PROFILING OF SOLID TUMORS,

2640
01:39:16,200 --> 01:39:18,480
STRATEGIES TO MODULATE PEDIATRIC

2641
01:39:18,480 --> 01:39:19,960
TUMOR MICROENVIRONMENT,

2642
01:39:19,960 --> 01:39:21,200
DEVELOPMENT TESTING AND

2643
01:39:21,200 --> 01:39:22,880
OPTIMIZATION OF PRE-CLINICAL

2644
01:39:22,880 --> 01:39:24,800
AGENTS, AND DIVERSE TRANSLATION

2645
01:39:24,800 --> 01:39:26,160
STUDIES USED IN CLINICAL

2646
01:39:26,160 --> 01:39:27,480
SPECIMENS TO INTERROGATE

2647
01:39:27,480 --> 01:39:28,520
MECHANISMS OF ACTION OR

2648
01:39:28,520 --> 01:39:34,200
RESISTANCE TO IMMUNE THERAPY.

2649
01:39:34,200 --> 01:39:37,680
SLIDE SHOWS PROPOSED -- WE

2650
01:39:37,680 --> 01:39:39,720
ANTICIPATE 6 TO 8 UO 1 AWARDS

2651
01:39:39,720 --> 01:39:40,920
STEERING COMMITTEE WILL CONSIST

2652
01:39:40,920 --> 01:39:43,880
OF INVESTIGATORS OF THESE U 1

2653
01:39:43,880 --> 01:39:45,720
PROJECTS AND NCI STAFF, PATIENT

2654
01:39:45,720 --> 01:39:48,960
ADVOCATES AND ADDITIONAL FUNDED

2655
01:39:48,960 --> 01:39:50,080
RESEARCHERS WILL BE EVIDENCE

2656
01:39:50,080 --> 01:39:51,840
ASSOCIATED MEMBERS AND

2657
01:39:51,840 --> 01:39:52,760
ADMINISTRATIVE COORDINATION WILL

2658
01:39:52,760 --> 01:39:55,200
BE PROVIDED BY ONE OF THE UO 1

2659
01:39:55,200 --> 01:39:56,640
SITES IN PARTNERSHIP WITH THE

2660
01:39:56,640 --> 01:39:57,000
NCI.

2661
01:39:57,000 --> 01:40:00,400
NEXT SLIDE PLEASE.

2662
01:40:00,400 --> 01:40:02,960
THIS SLIDE SHOWS HOW PIN CAN

2663
01:40:02,960 --> 01:40:04,160
INTERACT WITH OTHER

2664
01:40:04,160 --> 01:40:05,400
COMPLIMENTARY PEDIATRIC CANCER

2665
01:40:05,400 --> 01:40:07,640
NETWORKS AT THAT TIME NCI.

2666
01:40:07,640 --> 01:40:09,800
NCI HAS A WIDE SPECTRUM OF

2667
01:40:09,800 --> 01:40:11,600
PEDIATRIC PROGRAMS SUCH AS PIN

2668
01:40:11,600 --> 01:40:13,360
CAN BENEFIT AND INTERACT WITH

2669
01:40:13,360 --> 01:40:15,800
DATA INITIATIVES LIKE THE

2670
01:40:15,800 --> 01:40:17,960
CHILDHOOD CANCER INITIATIVE CCD

2671
01:40:17,960 --> 01:40:18,120
ISH.

2672
01:40:18,120 --> 01:40:21,200
MOON SHOT INITIATED PROGRAMS

2673
01:40:21,200 --> 01:40:23,600
SUCH AS FUSION ONCO PROTEIN AS

2674
01:40:23,600 --> 01:40:25,080
DRIVERS FOR CHILDHOOD CANCER,

2675
01:40:25,080 --> 01:40:27,120
ANOTHER MOON SHOT PROGRAM DIDDA,

2676
01:40:27,120 --> 01:40:29,360
FOCUSED ON IMMUNOTHERAPY.

2677
01:40:29,360 --> 01:40:33,960
NATURAL HISTORY STUDIES LIKE --

2678
01:40:33,960 --> 01:40:35,880
AGENTS CAN UNDERGO TESTING AND

2679
01:40:35,880 --> 01:40:36,600
PRE-CLINICAL TESTING PROGRAMS

2680
01:40:36,600 --> 01:40:38,600
LIKE THE PIVOT PROGRAM.

2681
01:40:38,600 --> 01:40:40,720
AGENTS DISCOVERED IN PIN CAN

2682
01:40:40,720 --> 01:40:42,840
ADVANCE INTO CLINICAL TRIALS

2683
01:40:42,840 --> 01:40:45,800
THROUGH THESE SUCH AS CHILDREN'S

2684
01:40:45,800 --> 01:40:47,720
ONCOLOGY GROUP, BLASTOMA, BRAIN

2685
01:40:47,720 --> 01:40:49,920
TUMOR CONSORTIUM AND THE EARLY

2686
01:40:49,920 --> 01:40:51,960
PHASE CLINICAL TRIAL NETWORK.

2687
01:40:51,960 --> 01:40:53,160
INVESTIGATORS FROM PIN CAN ALSO

2688
01:40:53,160 --> 01:40:56,320
APPLY TO THE NEXT PROGRAM OR USE

2689
01:40:56,320 --> 01:41:01,720
OTHER NCI RESOURCES.

2690
01:41:01,720 --> 01:41:03,280
THIS SLIDE SHOWS COMPARISON OF

2691
01:41:03,280 --> 01:41:04,960
PIN WITH CURRENT MOON SHOT

2692
01:41:04,960 --> 01:41:06,640
INITIATIVE DIDDN.

2693
01:41:06,640 --> 01:41:08,400
AS DR. SINGH MENTIONED IN HER

2694
01:41:08,400 --> 01:41:10,480
TALK YESTERDAY, PIN IS BUILDING

2695
01:41:10,480 --> 01:41:13,400
UPON THE ACCOMPLISHMENTS OF THE

2696
01:41:13,400 --> 01:41:15,080
IDDA GIVEN UNMET CLINICAL NEED,

2697
01:41:15,080 --> 01:41:17,400
THE FOCUS OF PIN WILL BE

2698
01:41:17,400 --> 01:41:18,960
RESTRICTED TO SOLID TUMORS

2699
01:41:18,960 --> 01:41:20,520
INCLUDING BRAIN TUMORS, THERE

2700
01:41:20,520 --> 01:41:22,480
WILL BE ENHANCE FOCUS ON

2701
01:41:22,480 --> 01:41:24,280
TRANSLATION IN ADDITION TO

2702
01:41:24,280 --> 01:41:25,800
DISCOVERY AND DEVELOPMENT AND

2703
01:41:25,800 --> 01:41:27,960
THE EARLIEST ANTICIPATED START

2704
01:41:27,960 --> 01:41:30,520
DATE IS SEPTEMBER 2023.

2705
01:41:30,520 --> 01:41:33,760
NEXT SLIDE PLEASE.

2706
01:41:33,760 --> 01:41:36,080
WE ANTICIPATE SIX TO EIGHT UO 1

2707
01:41:36,080 --> 01:41:39,200
AWARDS WITH EACH AWARD TO BE

2708
01:41:39,200 --> 01:41:40,760
AROUND 765 TOTAL COST WE DO

2709
01:41:40,760 --> 01:41:42,760
REQUEST MONEY FOR ADMINISTRATIVE

2710
01:41:42,760 --> 01:41:44,080
SUPPLEMENTS AND NETWORK SUPPORT

2711
01:41:44,080 --> 01:41:46,200
WITH A TOTAL NETWORK COST FOR

2712
01:41:46,200 --> 01:41:47,680
FIVE YEARS TO BE 30 MILLION.

2713
01:41:47,680 --> 01:41:50,280
NEXT SLIDE PLEASE.

2714
01:41:50,280 --> 01:41:52,600
WE NEED AN RFA MECHANISM, THIS

2715
01:41:52,600 --> 01:41:54,240
IS AN AREA UPON SCIENTIFIC AND

2716
01:41:54,240 --> 01:41:54,880
CLINICAL NEED.

2717
01:41:54,880 --> 01:41:56,800
THERE ARE ONLY 31 GRANTS IN THIS

2718
01:41:56,800 --> 01:41:57,280
AREA.

2719
01:41:57,280 --> 01:41:59,360
CURRENTLY THERE'S NO SPECIALIZED

2720
01:41:59,360 --> 01:42:01,200
PEER REVIEW IN A SINGLE RECEIPT

2721
01:42:01,200 --> 01:42:03,160
DATE ALLOW FOR FUNDING OFF THE

2722
01:42:03,160 --> 01:42:07,960
NETWORK.

2723
01:42:07,960 --> 01:42:10,640
WE NEED A MECHANISM NCI STAFF

2724
01:42:10,640 --> 01:42:11,640
PARTICIPATE IN STEERING

2725
01:42:11,640 --> 01:42:12,920
COMMITTEE MEETINGS, WE ARE OPEN

2726
01:42:12,920 --> 01:42:15,120
TO DISCUSS CURRENT CHALLENGES,

2727
01:42:15,120 --> 01:42:16,720
PROVIDE OVERALL ADVICE AND

2728
01:42:16,720 --> 01:42:17,080
DIRECTION.

2729
01:42:17,080 --> 01:42:19,920
AND FOSTER COLLABORATION.

2730
01:42:19,920 --> 01:42:21,240
AND THERE WILL BE FUNDS

2731
01:42:21,240 --> 01:42:23,680
AVAILABLE TO ENHANCE

2732
01:42:23,680 --> 01:42:24,760
INTRANETWORK COLLABORATION.

2733
01:42:24,760 --> 01:42:26,840
NCI STAFF EDUCATE STEERING

2734
01:42:26,840 --> 01:42:28,200
COMMITTEE MEMBERS OF USE OF NCI

2735
01:42:28,200 --> 01:42:31,320
RESOURCES AS WELL AS OTHER

2736
01:42:31,320 --> 01:42:34,600
PEDIATRIC PROGRAMS.

2737
01:42:34,600 --> 01:42:36,600
THE SLIDE LISTS THE CRITERIA

2738
01:42:36,600 --> 01:42:39,400
WHICH CAN BE USED TO JUDGE

2739
01:42:39,400 --> 01:42:42,400
SUCCESS OF PIN AND FIVE YEAR

2740
01:42:42,400 --> 01:42:43,920
AGREEMENT THESE MAY INCLUDE

2741
01:42:43,920 --> 01:42:45,160
DISCOVERY DEVELOPMENT AND

2742
01:42:45,160 --> 01:42:47,200
VALIDATION OF NOVEL TARGETS,

2743
01:42:47,200 --> 01:42:48,520
PRE-CLINICAL TESTING AND

2744
01:42:48,520 --> 01:42:50,760
DEVELOPMENT OF SINGLE OR

2745
01:42:50,760 --> 01:42:52,480
COMBINATION OF AGENTS, NOVEL

2746
01:42:52,480 --> 01:42:54,240
MECHANISTIC INSIGHT INTO THE

2747
01:42:54,240 --> 01:42:55,400
TUMOR MICROENVIRONMENT RESPONSE

2748
01:42:55,400 --> 01:42:59,160
OR RESISTANCE, CONDUCTIVE IND

2749
01:42:59,160 --> 01:43:00,840
ENABLING STUDIES AND PROMOTION

2750
01:43:00,840 --> 01:43:02,560
OF NOVEL AGENTS INTO A PILOT

2751
01:43:02,560 --> 01:43:03,320
CLINICAL TRIAL.

2752
01:43:03,320 --> 01:43:06,120
THE DATA WOULD LIKE -- WITH THAT

2753
01:43:06,120 --> 01:43:07,880
LISTENING AND SPECIAL THANKS TO

2754
01:43:07,880 --> 01:43:12,800
THE SUBCOMMITTEE MEMBERS DR.

2755
01:43:12,800 --> 01:43:14,280
FLAHERTY, AND WE HAVE INCLUDED

2756
01:43:14,280 --> 01:43:15,640
THEIR COMMENTS IN THE SLIDES

2757
01:43:15,640 --> 01:43:16,160
PRESENT.

2758
01:43:16,160 --> 01:43:17,280
WITH THAT I WILL BE HAPPY TO

2759
01:43:17,280 --> 01:43:18,000
TAKE QUESTIONS.

2760
01:43:18,000 --> 01:43:21,160
>> GREAT.

2761
01:43:21,160 --> 01:43:21,560
THANK YOU.

2762
01:43:21,560 --> 01:43:23,880
BOB WOULD YOU LIKE TO GET US

2763
01:43:23,880 --> 01:43:24,120
STARTD?

2764
01:43:24,120 --> 01:43:26,480
>> THANK YOU, DR. FLAHERTY AND

2765
01:43:26,480 --> 01:43:29,880
SINGH, THANK YOU FOR THAT

2766
01:43:29,880 --> 01:43:30,480
PRESENTATION.

2767
01:43:30,480 --> 01:43:31,600
I WOULD SAY QUITE SIMPLY THE

2768
01:43:31,600 --> 01:43:32,280
ONLY COMMENT FROM THE

2769
01:43:32,280 --> 01:43:33,200
SUBCOMMITTEE YOU DIDN'T INCLUDE

2770
01:43:33,200 --> 01:43:35,200
WAS THAT WE THOUGHT THIS WAS

2771
01:43:35,200 --> 01:43:36,600
ABSOLUTELY WONDERFUL AND IT'S

2772
01:43:36,600 --> 01:43:38,320
WELL CONCEIVE AND WELL EXECUTED.

2773
01:43:38,320 --> 01:43:40,080
SO I WILL JUST ECHO A FEW

2774
01:43:40,080 --> 01:43:40,600
THINGS.

2775
01:43:40,600 --> 01:43:42,960
THIS IS DIFFERENT BIOLOGY.

2776
01:43:42,960 --> 01:43:44,400
AND SCIENTIFIC CONSIDERATION,

2777
01:43:44,400 --> 01:43:45,560
MADE THAT HAVE CLEAR.

2778
01:43:45,560 --> 01:43:49,600
THE PORTFOLIO TO NCI IS HER 2

2779
01:43:49,600 --> 01:43:50,000
MAMMAL.

2780
01:43:50,000 --> 01:43:51,800
THIS LEVERAGES WHERE MOON SHOT

2781
01:43:51,800 --> 01:43:53,960
HAS TAKEN US PARTICULARLY FROM

2782
01:43:53,960 --> 01:43:54,960
DISCOVER INTO CLINIC.

2783
01:43:54,960 --> 01:43:58,960
SO THIS IS -- THAT SLIDE

2784
01:43:58,960 --> 01:44:01,560
COMPARING THE DIDN TO ME IS THE

2785
01:44:01,560 --> 01:44:04,200
MOST IMPORTANT SLIDE, CONSENSUS

2786
01:44:04,200 --> 01:44:06,280
DRIVEN DATA DRIVEN 6 TO 8 UO

2787
01:44:06,280 --> 01:44:10,960
1s WITH NCI AND UO 1 TEAMS

2788
01:44:10,960 --> 01:44:12,600
ORGANIZING THEMSELVES LEVERAGING

2789
01:44:12,600 --> 01:44:14,280
NATIONAL PEDIATRIC GROUPS WITH

2790
01:44:14,280 --> 01:44:16,160
SUCCESS METRICS, WHAT MORE COULD

2791
01:44:16,160 --> 01:44:19,440
YOU ASK, WE SUPPORT THE U RFA AS

2792
01:44:19,440 --> 01:44:21,640
PROPOSED, I WILL LET KEITH ADD

2793
01:44:21,640 --> 01:44:24,840
HIS THOUGHTS.

2794
01:44:24,840 --> 01:44:26,440
>> JUST TO EMPHASIZE THE POINT I

2795
01:44:26,440 --> 01:44:27,680
THINK WE ARE ALL PERFECTLY WELL

2796
01:44:27,680 --> 01:44:32,600
AWARE OF, THIS IS AG AREA WHERE

2797
01:44:32,600 --> 01:44:35,240
EXTERNAL ACTIVITY EXTERNAL TO

2798
01:44:35,240 --> 01:44:37,160
NCI IS UNDERINVESTED IN.

2799
01:44:37,160 --> 01:44:38,680
THAT IS TRUE SO MUCH OF

2800
01:44:38,680 --> 01:44:42,000
PEDIATRIC ONCOLOGY BUT CERTAINLY

2801
01:44:42,000 --> 01:44:47,400
WHAT IS UNIQUE IMMUNOTHERAPY

2802
01:44:47,400 --> 01:44:48,600
STRATEGIES FOR THE PEDIATRIC

2803
01:44:48,600 --> 01:44:50,080
POPULATION SO AREA OF O UNMET

2804
01:44:50,080 --> 01:44:52,200
NEED THAT IS UNDERATTENDED TO.

2805
01:44:52,200 --> 01:44:55,840
AND MAYBE JUST UNDERSCORE POINT

2806
01:44:55,840 --> 01:44:57,080
ABOUT THE MECHANISM AND

2807
01:44:57,080 --> 01:44:59,200
APPROACH, I THINK THIS IS A

2808
01:44:59,200 --> 01:45:00,880
MODEL THAT WORKED WELL IN RECENT

2809
01:45:00,880 --> 01:45:02,600
YEARS AT NCI IN TERMS OF

2810
01:45:02,600 --> 01:45:05,360
COORDINATING THIS NETWORK OF UO

2811
01:45:05,360 --> 01:45:07,600
1s, ALLOWING NCI LEADERSHIP TO

2812
01:45:07,600 --> 01:45:10,880
BE CENTRALLY INVOLVED SO I THINK

2813
01:45:10,880 --> 01:45:12,680
THAT METHOD IS VERY WELL TESTED

2814
01:45:12,680 --> 01:45:15,360
IN ONCOLOGY AND I THINK IS VERY

2815
01:45:15,360 --> 01:45:17,240
APT FOR THIS PROPOSAL AS WELL.

2816
01:45:17,240 --> 01:45:21,960
OTHERWISE NOTHING ELSE TO ADD.

2817
01:45:21,960 --> 01:45:22,600
HAM PI TO TAKE OTHER QUESTIONS

2818
01:45:22,600 --> 01:45:25,480
OR COMMENTS FROM BSA OR NCAB

2819
01:45:25,480 --> 01:45:26,560
MEMBERS.

2820
01:45:26,560 --> 01:45:30,600
HAPPY.

2821
01:45:30,600 --> 01:45:32,840
>> I JUST PUT A COMMENT QUESTION

2822
01:45:32,840 --> 01:45:36,720
IN THE CHAT JUST TO HIGHLIGHT WE

2823
01:45:36,720 --> 01:45:38,240
HAVE SUCH A -- WE HAVE A LONG

2824
01:45:38,240 --> 01:45:40,240
WAY TO GO WITH OUR FUNDING LINE

2825
01:45:40,240 --> 01:45:44,280
SO I HOPE UO 1s WOULDEN

2826
01:45:44,280 --> 01:45:47,400
COURAGE OR WON'T SAY REQUIRE,

2827
01:45:47,400 --> 01:45:50,200
BUT NEW INVESTIGATOR YOUNG

2828
01:45:50,200 --> 01:45:53,280
INVESTIGATORS IS I THINK WE NEED

2829
01:45:53,280 --> 01:45:55,440
TO EMPHASIZE SUPPORTING THEM.

2830
01:45:55,440 --> 01:45:56,760
>> THANK YOU FOR THE COMMENT.

2831
01:45:56,760 --> 01:46:01,680
YES.

2832
01:46:01,680 --> 01:46:03,640
>> VERY EXCITE #-D TO SEE THIS,

2833
01:46:03,640 --> 01:46:07,360
IT IS A DESPERATELY NEEDED

2834
01:46:07,360 --> 01:46:08,440
INITIATIVE.

2835
01:46:08,440 --> 01:46:10,720
SO WONDERING IF THERE WILL BE

2836
01:46:10,720 --> 01:46:11,840
SPECIFIC SELECTION OF THE COMP

2837
01:46:11,840 --> 01:46:13,440
MEN TARTY OF PROJECTS

2838
01:46:13,440 --> 01:46:15,800
REPRESENTED -- COMPLIMENTARITY

2839
01:46:15,800 --> 01:46:17,920
IN THE CLUSTER OF UO 1s OR

2840
01:46:17,920 --> 01:46:20,080
JUST TAKING THE STRONGEST UO 1,

2841
01:46:20,080 --> 01:46:22,200
ARE YOU LOOKING FOR PARTICUAR

2842
01:46:22,200 --> 01:46:23,360
THEMES YOU OUTLINE NUMBER OF

2843
01:46:23,360 --> 01:46:24,800
THEMES THAT WOULD BE ADDRESSED

2844
01:46:24,800 --> 01:46:25,840
BY DIFFERENT ONES.

2845
01:46:25,840 --> 01:46:29,280
AND ALSO HOW THE COORDINATING

2846
01:46:29,280 --> 01:46:32,200
CENTER WILL ACTIVELY FACILITATE

2847
01:46:32,200 --> 01:46:34,520
EXCHANGE OF REAGENTS PERHAPS

2848
01:46:34,520 --> 01:46:35,400
ACROSS DIFFERENT GROUPS

2849
01:46:35,400 --> 01:46:36,960
PARTICULARLY MODEL SYSTEMS WHICH

2850
01:46:36,960 --> 01:46:39,280
ARE REALLY CRITICAL FOR PROPER

2851
01:46:39,280 --> 01:46:41,720
STUDIES TO BE CONDUCTED.

2852
01:46:41,720 --> 01:46:43,600
>> THANK YOU, DR. BAKER.

2853
01:46:43,600 --> 01:46:44,000
GREAT QUESTION.

2854
01:46:44,000 --> 01:46:46,800
SO IN TERMS OF THE PROJECT WHICH

2855
01:46:46,800 --> 01:46:49,920
WILL BE CONSIDERED, APPLICATIONS

2856
01:46:49,920 --> 01:46:51,680
HAVE TO BE MERITORIOUS, NAY WILL

2857
01:46:51,680 --> 01:46:54,200
UNDERGO A THOROUGH REVIEW

2858
01:46:54,200 --> 01:46:54,720
PROCESS.

2859
01:46:54,720 --> 01:46:55,920
IN TERMS OF PREPARING THE

2860
01:46:55,920 --> 01:46:58,400
FUNDING PLAN WE WILL LOOK AT OUR

2861
01:46:58,400 --> 01:46:59,240
PROGRAM PORTFOLIO OF GRANTS

2862
01:46:59,240 --> 01:47:02,200
WHICH IS ALREADY FUNDED AND

2863
01:47:02,200 --> 01:47:05,000
WHERE THE GAPS ARE.

2864
01:47:05,000 --> 01:47:06,360
THERE WILL BE CONSIDERATION AND

2865
01:47:06,360 --> 01:47:09,440
NCI STAFF WILL WORK BASED ON

2866
01:47:09,440 --> 01:47:10,200
REVIEWS AND EVERYTHING.

2867
01:47:10,200 --> 01:47:15,000
IN TERMS OF THE COORDINATION, WE

2868
01:47:15,000 --> 01:47:17,120
ARE REQUESTING ADMINISTRATIVE

2869
01:47:17,120 --> 01:47:18,880
COORDINATION LIKE MOST SLEEPER

2870
01:47:18,880 --> 01:47:20,280
MEETING SUPPORT AND OTHER THINGS

2871
01:47:20,280 --> 01:47:21,960
BUT THERE WILL BE A STEERING

2872
01:47:21,960 --> 01:47:24,280
COMMITTEE BASED ON WHICH WILL BE

2873
01:47:24,280 --> 01:47:27,160
BY THE NCI STAFF AS WELL AS

2874
01:47:27,160 --> 01:47:29,040
INVESTIGATORS FROM THESE UO 1

2875
01:47:29,040 --> 01:47:32,600
SITES, THOSE WILL BE ACTIVELY

2876
01:47:32,600 --> 01:47:34,600
INVOLVED FOR INSTANCE MAKING

2877
01:47:34,600 --> 01:47:39,400
SURE FACILITATING ACCESS TO

2878
01:47:39,400 --> 01:47:41,200
RESOURCES OR PREVIOUS EXPERIENCE

2879
01:47:41,200 --> 01:47:43,520
WITH THE IDDN, ALL THE

2880
01:47:43,520 --> 01:47:45,760
INVESTIGATORS, REALLY WORK VERY

2881
01:47:45,760 --> 01:47:48,880
WELL IN THESE SORTS OF NETWORK.

2882
01:47:48,880 --> 01:47:52,200
AND THEY ARE VERY HAPPY TO

2883
01:47:52,200 --> 01:47:52,600
COLLABORATE.

2884
01:47:52,600 --> 01:47:53,840
THOSE INTERNETWORK

2885
01:47:53,840 --> 01:47:56,240
COLLABORATIONS WITH SUPPLEMENTS

2886
01:47:56,240 --> 01:47:58,800
FUNDS REALLY HELP TO ENHANCE

2887
01:47:58,800 --> 01:48:00,880
COLLABORATION EVEN FURTHER.

2888
01:48:00,880 --> 01:48:03,560
IN TERMS OF KNOWLEDGE ABOUT

2889
01:48:03,560 --> 01:48:06,640
OTHER PROGRAMS, NCS STAFF IS

2890
01:48:06,640 --> 01:48:07,760
HAPPY TO PROVIDE MORE

2891
01:48:07,760 --> 01:48:10,360
INFORMATION IF APPLICATION TO

2892
01:48:10,360 --> 01:48:13,560
THE NEXT PROGRAM OR EARLY PHASE

2893
01:48:13,560 --> 01:48:14,640
CLINICAL TRIALS, SO WEAPON A

2894
01:48:14,640 --> 01:48:21,240
BROAD TEAM OF EXPERTISE ON THIS.

2895
01:48:21,240 --> 01:48:22,160
>> JOHN.

2896
01:48:22,160 --> 01:48:23,840
>> THANK YOU.

2897
01:48:23,840 --> 01:48:25,320
I KNOW SOMETIMES IT IS DIFFICULT

2898
01:48:25,320 --> 01:48:28,560
AND WE THINK ABOUT SORT OF THE

2899
01:48:28,560 --> 01:48:29,920
CONCEPT OF INTEGRATION WE THINK

2900
01:48:29,920 --> 01:48:32,080
ABOUT ADULT RISK PEDIATRIC

2901
01:48:32,080 --> 01:48:35,240
BECAUSE WE KNOW THOSE THINGS CAN

2902
01:48:35,240 --> 01:48:37,720
BE VERY DIFFERENT BUT THINK

2903
01:48:37,720 --> 01:48:39,440
LARGE NETWORKS WITH STRONG FOCUS

2904
01:48:39,440 --> 01:48:44,400
ON BIOLOGY AND UNDERSTANDING OF

2905
01:48:44,400 --> 01:48:45,680
IMMUNOTHERAPEUTICS, ARE THERE --

2906
01:48:45,680 --> 01:48:47,600
IS THERE ANY INTEGRATION WITH

2907
01:48:47,600 --> 01:48:49,160
ANYTHING GOING ON ON THE ADULT

2908
01:48:49,160 --> 01:49:00,400
SIDE?

2909
01:49:00,400 --> 01:49:01,920
RIGHT NOW WE HAVE NOT BUT I CAN

2910
01:49:01,920 --> 01:49:02,960
GIVE AN EXAMPLE OF PREVIOUS

2911
01:49:02,960 --> 01:49:04,120
BECAUSE WE ARE PLANNING WHAT

2912
01:49:04,120 --> 01:49:07,280
GOES ON AT THE IOTN WHICH IS A

2913
01:49:07,280 --> 01:49:09,200
BIG NETWORK -- WHICH IS A VERY

2914
01:49:09,200 --> 01:49:10,560
BIG MOON SHOT INITIATED NETWORK

2915
01:49:10,560 --> 01:49:12,720
ON THE ADULT SIDE.

2916
01:49:12,720 --> 01:49:14,680
IN THE PAST TO GIVE AN EXAMPLE,

2917
01:49:14,680 --> 01:49:19,120
WE HOPE TO BUILD UPON A SIMILAR

2918
01:49:19,120 --> 01:49:20,920
COLLABORATION LIKE WE JUST HAD

2919
01:49:20,920 --> 01:49:24,440
OUR ENROLL MEETING WHICH WAS A

2920
01:49:24,440 --> 01:49:26,520
MEETING BETWEEN DIDDN

2921
01:49:26,520 --> 01:49:31,600
INVESTIGATORS IOTN K-9 FOR

2922
01:49:31,600 --> 01:49:32,120
PANCREATIC CANCER.

2923
01:49:32,120 --> 01:49:35,080
SO THERE IS A LOT OF SCIENTIFIC

2924
01:49:35,080 --> 01:49:37,560
EXCHANGE.

2925
01:49:37,560 --> 01:49:41,720
AND COLLABORATION BETWEEN ADULT

2926
01:49:41,720 --> 01:49:43,400
AND PEDIATRIC SO WITH THE

2927
01:49:43,400 --> 01:49:46,200
CURRENT FUNDED NIDDN AND ITTN

2928
01:49:46,200 --> 01:49:49,080
THERE'S FUTURE PROGRAMS IN ADULT

2929
01:49:49,080 --> 01:49:51,760
SIDE AND WE DO HOPE TO CONNECT

2930
01:49:51,760 --> 01:49:53,960
WITH THEM AND WE HAVE SEEN VERY

2931
01:49:53,960 --> 01:49:55,960
FRUITFUL COLLABORATION IN THE

2932
01:49:55,960 --> 01:50:02,400
PAST AND HOPE TO CONTINUE THAT.

2933
01:50:02,400 --> 01:50:03,920
>> MIGHT I ADD THE DIFFERENCES

2934
01:50:03,920 --> 01:50:05,240
ARE A LITTLE MORE STRAIGHT

2935
01:50:05,240 --> 01:50:07,520
FORWARD FOR SMALL MOLECULE AND

2936
01:50:07,520 --> 01:50:08,760
ANTIBODIES, FOR CELLULAR

2937
01:50:08,760 --> 01:50:14,200
IMMUNOTHERAPY IT IS HARDER.

2938
01:50:14,200 --> 01:50:17,200
THIS IS AREA NCI GIVE AS LOT OF

2939
01:50:17,200 --> 01:50:18,800
THOUGHT AND SPACE FOR US TO DO

2940
01:50:18,800 --> 01:50:20,080
MORE SO WE HAVE BEEN WORKING

2941
01:50:20,080 --> 01:50:21,640
THROUGH THOSE ISSUES OF

2942
01:50:21,640 --> 01:50:23,080
COORDINATION WITH ADULTS AND

2943
01:50:23,080 --> 01:50:24,560
CHILDREN AROUND CELLULAR

2944
01:50:24,560 --> 01:50:25,480
IMMUNOTHERAPY, PARTICULARLY

2945
01:50:25,480 --> 01:50:28,920
SUCCESSFUL TO DATE, WHERE THERE

2946
01:50:28,920 --> 01:50:31,000
IS REAL FUTURE OPPORTUNITY.

2947
01:50:31,000 --> 01:50:33,120
>> THANKS ALL FOR THE EXCELLENT

2948
01:50:33,120 --> 01:50:33,880
QUESTIONS.

2949
01:50:33,880 --> 01:50:35,560
LET'S MOVE TO VOTING.

2950
01:50:35,560 --> 01:50:45,600
BOB WOULD YOU MAKE A MOTION?

2951
01:50:45,600 --> 01:50:46,640
>> MOVE TO APPROVE 6789

2952
01:50:46,640 --> 01:50:48,480
>> I WILL STAND ASIDE FOR A

2953
01:50:48,480 --> 01:50:49,720
SECOND AND ASK ANOTHER BSA

2954
01:50:49,720 --> 01:50:50,120
MEMBER TO SECOND.

2955
01:50:50,120 --> 01:50:51,200
>> I WILL SECOND.

2956
01:50:51,200 --> 01:50:52,400
>> THANK YOU.

2957
01:50:52,400 --> 01:51:03,120
ANY FURTHER DISCUSSION?

2958
01:51:03,120 --> 01:51:03,960
SO VERY GOOD.

2959
01:51:03,960 --> 01:51:05,520
MOTION ON THE TABLE TO APPROVE

2960
01:51:05,520 --> 01:51:08,640
ONLY LOOKING FOR DISAPPROVALS SO

2961
01:51:08,640 --> 01:51:10,840
PLEASE VOICE THAT OR RAISE YOUR

2962
01:51:10,840 --> 01:51:12,920
HAND.

2963
01:51:12,920 --> 01:51:19,200
OR BOTH BSA MEMBERS ONLY.

2964
01:51:19,200 --> 01:51:23,200
SEEING NO HANDS, PAULETTE AND

2965
01:51:23,200 --> 01:51:28,080
ANY ABSTENTIONS?

2966
01:51:28,080 --> 01:51:29,960
NOD UNANIMOUS APPROVAL NO

2967
01:51:29,960 --> 01:51:30,440
ABSTENTIONS.

2968
01:51:30,440 --> 01:51:30,840
PAULETTE.

2969
01:51:30,840 --> 01:51:33,400
WE ARE MOVING ON TO THE SECOND

2970
01:51:33,400 --> 01:51:34,800
CONCEPT OF THE DAY.

2971
01:51:34,800 --> 01:51:37,600
THIS IS A NEW RFA INTEGRATE

2972
01:51:37,600 --> 01:51:40,400
HEALTH DISPARITIES INTO

2973
01:51:40,400 --> 01:51:42,600
IMMUNOONCOLOGY RESEARCH.

2974
01:51:42,600 --> 01:51:45,160
DR. WILLIAM KUO IS PRESENTING

2975
01:51:45,160 --> 01:51:46,760
AND SUBCOMMITTEE CHAIRED BY --

2976
01:51:46,760 --> 01:51:51,960
AND SUPPORTED BY BOB VONDERHYDE.

2977
01:51:51,960 --> 01:51:53,440
PLEASE GO AHEAD.

2978
01:51:53,440 --> 01:51:55,720
>> THIS CONCEPT ON INTEGRATING

2979
01:51:55,720 --> 01:51:57,600
HEALTH DISPARITIES INTO

2980
01:51:57,600 --> 01:51:59,600
IMMUNO-ONCOLOGY RESEARCH IS A

2981
01:51:59,600 --> 01:52:01,200
JOINT PROGRAM BETWEEN THE

2982
01:52:01,200 --> 01:52:02,840
DIVISION OF CANCER BIOLOGY AND

2983
01:52:02,840 --> 01:52:04,800
CENTER TO REDUCE CANCER HEALTH

2984
01:52:04,800 --> 01:52:05,520
DISPARITIES.

2985
01:52:05,520 --> 01:52:09,720
WITH CRITICAL INPUTS FROM

2986
01:52:09,720 --> 01:52:12,520
TIFFANY WALLACE AND NELSON.

2987
01:52:12,520 --> 01:52:16,440
WE THANKS DR.S SPRAWLY AND VON

2988
01:52:16,440 --> 01:52:17,320
DER HYDREA FLECKED IN THIS

2989
01:52:17,320 --> 01:52:22,720
CONSENT.

2990
01:52:22,720 --> 01:52:24,760
OUTSTANDING CANCER GAPS AND

2991
01:52:24,760 --> 01:52:26,200
HEALTH DISPARITIES ARE EVIDENT

2992
01:52:26,200 --> 01:52:27,760
IN MULTI-LAYERED IMPEDIMENTS AND

2993
01:52:27,760 --> 01:52:29,440
ACCESS TO CARE AND SIGNIFICANT

2994
01:52:29,440 --> 01:52:30,920
DRIVERS CONTRIBUTING TO HEALTH

2995
01:52:30,920 --> 01:52:34,600
DISPARITIES.

2996
01:52:34,600 --> 01:52:36,560
INTERDISCIPLINARY RESEARCH AND

2997
01:52:36,560 --> 01:52:37,960
IMPLEMENTATION SCIENCE GAPS

2998
01:52:37,960 --> 01:52:39,680
INCLUDE RACISM SOCIOECONOMIC

2999
01:52:39,680 --> 01:52:44,000
STATUS AND GEOGRAPHIC ORIGIN.

3000
01:52:44,000 --> 01:52:47,640
DESPITE RECENT ADVANCES IN

3001
01:52:47,640 --> 01:52:49,880
IMMUNO-ONCOLOGY HERE IN REFERRED

3002
01:52:49,880 --> 01:52:53,120
TO IO TUMOR IMMUNOLOGY, HEALTH

3003
01:52:53,120 --> 01:52:54,200
DISPARITIES PERSIST AND NEED TO

3004
01:52:54,200 --> 01:52:56,760
BE ADDRESSED IN THE IRB RESEARCH

3005
01:52:56,760 --> 01:52:57,160
ECOSYSTEM.

3006
01:52:57,160 --> 01:53:00,600
IT IS IMPERATIVE TO TAP THESE

3007
01:53:00,600 --> 01:53:02,600
MULTI-LAYER PROBLEMS THROUGH

3008
01:53:02,600 --> 01:53:03,840
COMPLIMENTARY BASIC RESEARCH

3009
01:53:03,840 --> 01:53:05,320
FOCUSED AT THE INTERSECTION

3010
01:53:05,320 --> 01:53:06,800
BETWEEN HEALTH DISPARITIES AND

3011
01:53:06,800 --> 01:53:09,040
IO RESEARCH.

3012
01:53:09,040 --> 01:53:10,760
IN ADDITION TO ACCESS TO CARE

3013
01:53:10,760 --> 01:53:11,760
AND IMPLEMENTATION SCIENCE GAPS

3014
01:53:11,760 --> 01:53:14,440
THERE IS A CRITICAL NEED FOR

3015
01:53:14,440 --> 01:53:15,240
COMPLIMENTARY BASIC SCIENCE

3016
01:53:15,240 --> 01:53:16,680
RESEARCH.

3017
01:53:16,680 --> 01:53:18,680
FROM THE DIVISION OF CANCER

3018
01:53:18,680 --> 01:53:20,760
BIOLOGY PERSPECTIVES, BASIC

3019
01:53:20,760 --> 01:53:22,320
SCIENCE CHALLENGES AND CANCER

3020
01:53:22,320 --> 01:53:24,640
HEALTH DISPARITIES INCLUDE

3021
01:53:24,640 --> 01:53:26,800
COMPLEX AND OVERLAPPING

3022
01:53:26,800 --> 01:53:29,560
BIOLOGICAL IMMUNOLOGICAL FACTORS

3023
01:53:29,560 --> 01:53:31,200
IMPACTING DISPARITY.

3024
01:53:31,200 --> 01:53:32,800
DIFFICULTY OR DIFFICULT TO

3025
01:53:32,800 --> 01:53:34,520
ACCESS SUFFICIENTLY POWERED OR

3026
01:53:34,520 --> 01:53:36,640
WELL CURATED SPECIMENS, LOWER

3027
01:53:36,640 --> 01:53:38,200
NUMBERS OF UNDER-REPRESENTED

3028
01:53:38,200 --> 01:53:39,120
GROUPS RECRUITED TO CLINICAL

3029
01:53:39,120 --> 01:53:41,600
TRIALS.

3030
01:53:41,600 --> 01:53:43,720
THUS THE B 6 SCIENCE OBJECTIVES

3031
01:53:43,720 --> 01:53:45,040
INTEGRATE HEALTH DISPARITIES

3032
01:53:45,040 --> 01:53:46,600
THROUGHOUT THE NCI IO RESEARCH

3033
01:53:46,600 --> 01:53:48,640
CONTINUUM.

3034
01:53:48,640 --> 01:53:52,480
WE ACKNOWLEDGE THIS IS A

3035
01:53:52,480 --> 01:53:55,400
MULTI-FACETTED RESEARCH GAP AND

3036
01:53:55,400 --> 01:53:56,080
WE ARE STARTING WITH BASIC

3037
01:53:56,080 --> 01:54:01,800
SCIENCE.  SHOWN HERE ARE

3038
01:54:01,800 --> 01:54:04,720
EXAMPLES OF RESEARCH GAPS AT THE

3039
01:54:04,720 --> 01:54:05,960
INTERSECTION OF HEALTH

3040
01:54:05,960 --> 01:54:08,200
DISPARITIES AND IO.

3041
01:54:08,200 --> 01:54:09,840
UNDERSTANDING INFLAMMATORY

3042
01:54:09,840 --> 01:54:12,800
METABOLIC IMMUNE PROFILES OF

3043
01:54:12,800 --> 01:54:13,480
IMMUNOTHERAPY TREATMENT AND

3044
01:54:13,480 --> 01:54:14,200
RESPONSE ACROSS

3045
01:54:14,200 --> 01:54:16,600
UNDER-REPRESENTED POPULATIONS,

3046
01:54:16,600 --> 01:54:17,960
INVESTIGATING GENETIC IMMUNE

3047
01:54:17,960 --> 01:54:19,400
SIGNATURES INFILTRATES AND

3048
01:54:19,400 --> 01:54:21,240
DISTINCT TUMOR IMMUNE

3049
01:54:21,240 --> 01:54:22,360
MICROENVIRONMENTS THAT MAY

3050
01:54:22,360 --> 01:54:24,000
UNDERLIE -- THAT MAY CONTRIBUTE

3051
01:54:24,000 --> 01:54:28,480
TO CANCER HEALTH DISPARITIES.

3052
01:54:28,480 --> 01:54:29,680
SHOWN HERE ARE MOM OR SPECIFIC

3053
01:54:29,680 --> 01:54:32,680
SPECIFIC GRANULAR RESEARCH

3054
01:54:32,680 --> 01:54:34,200
EXAMPLES CHARGE RISING UNIQUE OR

3055
01:54:34,200 --> 01:54:36,120
IMMUNE INFILTRATE PROFILES

3056
01:54:36,120 --> 01:54:36,920
ACROSS AFRICAN AMERICAN AND

3057
01:54:36,920 --> 01:54:39,040
CAUCASIAN PATIENTS.

3058
01:54:39,040 --> 01:54:39,840
UNDERSTANDING HOW DISTINCT

3059
01:54:39,840 --> 01:54:41,320
GENETIC AND IMMUNE SIGNATURES IN

3060
01:54:41,320 --> 01:54:43,440
THE TUMOR MICROENVIRONMENT ARE

3061
01:54:43,440 --> 01:54:44,880
ASSOCIATED WITH COLON CANCER

3062
01:54:44,880 --> 01:54:47,120
DISPARITIES.

3063
01:54:47,120 --> 01:54:50,200
DEVELOPING ANIMAL MODEL THAT

3064
01:54:50,200 --> 01:54:51,160
RECAPITULATE THE BREADTH OF

3065
01:54:51,160 --> 01:54:52,920
IMMUNE RESPONSES ACROSS

3066
01:54:52,920 --> 01:54:54,600
UNDER-REPRESENTED POPULATION AND

3067
01:54:54,600 --> 01:54:56,080
CHARACTERIZING DISPARITIES IN

3068
01:54:56,080 --> 01:54:57,040
IMMUNOTHERAPY RESPONSE

3069
01:54:57,040 --> 01:54:58,600
RESISTANCE AND IMMUNE RELATED

3070
01:54:58,600 --> 01:55:02,280
ADVERSE EVENTS.

3071
01:55:02,280 --> 01:55:03,600
WITH REPRODUCIBILITY WE STARTED

3072
01:55:03,600 --> 01:55:05,640
BY LOOKING A THE NCI PORTFOLIO

3073
01:55:05,640 --> 01:55:08,800
LOOKING AT PO 1 AS AN EXAMPLE OF

3074
01:55:08,800 --> 01:55:10,040
MULTI-DISCIPLINARY PROJECTS.

3075
01:55:10,040 --> 01:55:12,560
AND AS OUR PO 1 BEING SUBMIT

3076
01:55:12,560 --> 01:55:13,720
WITH HEALTH DISPARITIES AND

3077
01:55:13,720 --> 01:55:17,480
IMMUNOTHERAPY.

3078
01:55:17,480 --> 01:55:21,040
FROM FY 2017 TO 2021, 333

3079
01:55:21,040 --> 01:55:24,240
INVESTIGATOR INITIATED UO 1

3080
01:55:24,240 --> 01:55:25,960
APPLICATIONS WERE SUBMITTED.

3081
01:55:25,960 --> 01:55:28,600
18% APPLICATIONS SUBMITTED SHOWN

3082
01:55:28,600 --> 01:55:30,000
IN THE GREEN SLICE WERE FOCUSED

3083
01:55:30,000 --> 01:55:32,440
ON IMMUNOTHERAPY OR

3084
01:55:32,440 --> 01:55:33,480
IMMUNO-ONCOLOGY.

3085
01:55:33,480 --> 01:55:34,840
UNFORTUNATELY NONE OF THESE HAD

3086
01:55:34,840 --> 01:55:36,640
A HEALTH DISPARITIES COMPONENT.

3087
01:55:36,640 --> 01:55:40,600
ON THE FLIP SIDE, THE 1.5

3088
01:55:40,600 --> 01:55:42,960
PERCENT APPLICATIONS SUBMITTED

3089
01:55:42,960 --> 01:55:44,720
FOCUSED ON HEALTH DISPARITIES,

3090
01:55:44,720 --> 01:55:48,560
NONE OF THESE HAD IMMUNOLOGY

3091
01:55:48,560 --> 01:55:49,440
COMPONENT.

3092
01:55:49,440 --> 01:55:50,760
SO THESE DATA SUGGEST THAT THERE

3093
01:55:50,760 --> 01:55:53,040
IS A POTENTIAL POOL OF

3094
01:55:53,040 --> 01:55:54,960
APPLICANTS REFOCUSED TO FULLY

3095
01:55:54,960 --> 01:55:56,400
INTEGRATE HEALTH DISPARITIES TO

3096
01:55:56,400 --> 01:56:01,080
IMMUNO-ONCOLOGY RESEARCH.

3097
01:56:01,080 --> 01:56:02,520
SO THIS PORTFOLIO ANALYSIS

3098
01:56:02,520 --> 01:56:04,320
INDICATES THERE IS POTENTIAL

3099
01:56:04,320 --> 01:56:06,000
APPLICANT POOL FOR STUDYING

3100
01:56:06,000 --> 01:56:07,840
HEALTH DISPARITIES IN IO.

3101
01:56:07,840 --> 01:56:09,840
HOWEVER MULTI-DISCIPLINARY THAT

3102
01:56:09,840 --> 01:56:10,960
INCORPORATE HEALTH DISPARITIES

3103
01:56:10,960 --> 01:56:14,680
RESEARCH REMAIN UNMET NEED.

3104
01:56:14,680 --> 01:56:17,320
PROGRAM PROPOSE FOLLOWING

3105
01:56:17,320 --> 01:56:19,000
SOLUTION, TACKLING COMPLEXITIES

3106
01:56:19,000 --> 01:56:20,400
REQUIRES A MULTI-PRONG

3107
01:56:20,400 --> 01:56:21,280
PROGRAMMATIC APPROACH TO

3108
01:56:21,280 --> 01:56:23,280
INTEGRATE HEALTH DISPARITIES

3109
01:56:23,280 --> 01:56:25,200
INTO IO RESEARCH.

3110
01:56:25,200 --> 01:56:26,960
FIRST ONGOING BASIC

3111
01:56:26,960 --> 01:56:28,080
TRANSLATIONAL RESEARCH PROJECT

3112
01:56:28,080 --> 01:56:30,760
SUPPORTED THROUGH THE NCI AND

3113
01:56:30,760 --> 01:56:32,600
SECOND FOCUS OF THIS CONCEPT TO

3114
01:56:32,600 --> 01:56:34,600
SUPPORT FEASIBILITY AND PLANNING

3115
01:56:34,600 --> 01:56:36,600
PROJECT TO STUDY -- STRENGTHEN

3116
01:56:36,600 --> 01:56:38,040
STUDIES FROM MULTI-DISCIPLINARY

3117
01:56:38,040 --> 01:56:39,880
PROJECT SUCH AS PO 1.

3118
01:56:39,880 --> 01:56:42,600
NEXT SLIDE PLEASE.

3119
01:56:42,600 --> 01:56:44,360
SO THE AS SEPARATIONAL GOAL IS

3120
01:56:44,360 --> 01:56:47,480
TO BUILD A COHORT OF IO PO 1s

3121
01:56:47,480 --> 01:56:49,600
WITH INTEGRATED HEALTH

3122
01:56:49,600 --> 01:56:50,400
DISPARITIES RESEARCH.

3123
01:56:50,400 --> 01:56:54,160
THIS IS A HIGH BAR IN PO 1

3124
01:56:54,160 --> 01:56:55,760
INTEGRATION TRACK RECORD OF

3125
01:56:55,760 --> 01:57:01,720
COLLABORATIONS AND PUBLICATIONS.

3126
01:57:01,720 --> 01:57:04,160
SO SUCCESSFUL MULTI-DISCIPLINARY

3127
01:57:04,160 --> 01:57:06,040
RESEARCH WILL REQUIRE

3128
01:57:06,040 --> 01:57:07,840
FOUNDATIONAL FEASIBILITY

3129
01:57:07,840 --> 01:57:08,320
PROJECTS.

3130
01:57:08,320 --> 01:57:10,440
THIS CAN BE DONE THROUGH

3131
01:57:10,440 --> 01:57:14,200
SUPPORTING ONGOING PROGRAMS OR

3132
01:57:14,200 --> 01:57:15,960
NOTICE OF SPECIAL INTEREST, THIS

3133
01:57:15,960 --> 01:57:16,680
IS NOT ENOUGH.

3134
01:57:16,680 --> 01:57:20,600
IN THE NEXT SLIDE WE WILL

3135
01:57:20,600 --> 01:57:22,360
PROPOSE P 20s WRITE ARE

3136
01:57:22,360 --> 01:57:24,000
FEASIBILITY PLANNING STUDIES TO

3137
01:57:24,000 --> 01:57:25,600
BUILD COLLABORATION APPROPRIATE

3138
01:57:25,600 --> 01:57:27,200
SAMPLE SETS GENERATE PRELIMINARY

3139
01:57:27,200 --> 01:57:30,800
DATA FOR SUBSEQUENT APPLICATION

3140
01:57:30,800 --> 01:57:32,240
SUB MISSION.

3141
01:57:32,240 --> 01:57:34,160
SO WHAT ARE P 20s?

3142
01:57:34,160 --> 01:57:35,800
GRANTS TO SUPPORT PLANNING OR

3143
01:57:35,800 --> 01:57:37,280
FEASIBILITY STUDIES TO INTEGRATE

3144
01:57:37,280 --> 01:57:40,120
HEALTH DISPARITIES INTO MULTI-DI

3145
01:57:40,120 --> 01:57:41,040
PLENARY IO RESEARCH STUDIES.

3146
01:57:41,040 --> 01:57:43,160
IT IS EXPECTED PRELIMINARY

3147
01:57:43,160 --> 01:57:44,920
STUDIES FROM THE P 20 TO ENABLE

3148
01:57:44,920 --> 01:57:46,720
DEVELOPMENT OF INVESTIGATOR

3149
01:57:46,720 --> 01:57:48,840
INITIATED MULTI-DISCIPLINARY

3150
01:57:48,840 --> 01:57:51,800
PROJECTS SUCH AS PO 1

3151
01:57:51,800 --> 01:57:54,280
MULTI-DISCIPLINARY RO1.

3152
01:57:54,280 --> 01:57:55,600
RESEARCH SPOKE MAY INCLUDE

3153
01:57:55,600 --> 01:57:57,400
INITIAL STUDIES, TO ESTABLISH

3154
01:57:57,400 --> 01:57:59,400
SUFFICIENTLY POWERED OR WELL

3155
01:57:59,400 --> 01:58:01,520
CURATIVE SPECIMENS FROM GROUPS

3156
01:58:01,520 --> 01:58:03,560
UNDER-REPRESENTED IN CLINICAL

3157
01:58:03,560 --> 01:58:04,920
TRIALS, FEASIBILITY OR PILOT

3158
01:58:04,920 --> 01:58:06,720
STUDIES TO TEST EXPLORATORY OR

3159
01:58:06,720 --> 01:58:08,800
NOVEL HYPOTHESES ON IMMUNE

3160
01:58:08,800 --> 01:58:10,080
MECHANISMS, IMMUNE RESPONSE OR

3161
01:58:10,080 --> 01:58:11,800
TREATMENT RESPONSE RESISTANCE

3162
01:58:11,800 --> 01:58:13,440
THAT MAY CONTRIBUTE TO HELP

3163
01:58:13,440 --> 01:58:15,400
CANCER HEALTH DISPARITIES.

3164
01:58:15,400 --> 01:58:16,600
RESEARCH MAY ALSO INCLUDE

3165
01:58:16,600 --> 01:58:18,720
PLANNING STUDIES TO BUILD

3166
01:58:18,720 --> 01:58:19,920
COLLABORATIVE TEAMS GENERATE

3167
01:58:19,920 --> 01:58:21,720
RESOURCES SUCH AS TOOLS AND

3168
01:58:21,720 --> 01:58:25,040
REAGENTS AND COLLABORATIVE

3169
01:58:25,040 --> 01:58:26,400
RESEARCH INFRASTRUCTURE.

3170
01:58:26,400 --> 01:58:28,640
NEXT SLIDE.

3171
01:58:28,640 --> 01:58:30,400
FOR THE P 20 THE SPECIFIC

3172
01:58:30,400 --> 01:58:31,840
REQUIREMENT ARE THE INTEGRATION

3173
01:58:31,840 --> 01:58:34,160
OF UNDERSERVED POPULATIONS.

3174
01:58:34,160 --> 01:58:36,400
THIS IS AND EXPANDED SCOPE AND

3175
01:58:36,400 --> 01:58:39,000
RESPONSE TO THE BSA REVIEW

3176
01:58:39,000 --> 01:58:41,400
RECOMMENDATIONS TO BE INCLUSIVE

3177
01:58:41,400 --> 01:58:44,360
OF SOCIOECONOMIC STATUS AND

3178
01:58:44,360 --> 01:58:45,720
GEOGRAPHIC ORIGIN.

3179
01:58:45,720 --> 01:58:47,280
THE OTHER REQUIREMENT FOR THESE

3180
01:58:47,280 --> 01:58:51,480
P 20s IS THEY SHOULD BE

3181
01:58:51,480 --> 01:58:52,800
MULTI-DI PLENARY TEAMS WITH

3182
01:58:52,800 --> 01:58:53,800
COMPLIMENTARY EXPERTISE WITH

3183
01:58:53,800 --> 01:58:55,720
CANCER DISPARITIES AND IO

3184
01:58:55,720 --> 01:58:56,440
RESEARCH.

3185
01:58:56,440 --> 01:59:00,000
WE ARE REQUESTING A MODEST

3186
01:59:00,000 --> 01:59:02,800
BUDGET FOR TWO YEARS CAPPED

3187
01:59:02,800 --> 01:59:04,480
250,000-DOLLAR DIRECT COSTS PER

3188
01:59:04,480 --> 01:59:05,520
YEAR.

3189
01:59:05,520 --> 01:59:06,640
SO $1 MILLION TOTAL COST FOR

3190
01:59:06,640 --> 01:59:07,160
YEAR ONE.

3191
01:59:07,160 --> 01:59:09,120
AS JUSTIFICATION FOR RFA THERE

3192
01:59:09,120 --> 01:59:11,480
IS NO NIH P 20 PARENT

3193
01:59:11,480 --> 01:59:12,960
ANNOUNCEMENT AND IMPORTANTLY AS

3194
01:59:12,960 --> 01:59:14,840
AN RFA WILL ENABLE US TO HAVE

3195
01:59:14,840 --> 01:59:17,400
SPECIFIC REQUIREMENTS FOR

3196
01:59:17,400 --> 01:59:18,800
RESPONSIVENESS DESCRIBED ABOVE

3197
01:59:18,800 --> 01:59:20,960
AND SPECIFIC REVIEW CRITERIA.

3198
01:59:20,960 --> 01:59:24,600
THE IMPETUS FOR THESE P 20 IS

3199
01:59:24,600 --> 01:59:26,680
BUILT -- THE IMPETUS FOR THIS IS

3200
01:59:26,680 --> 01:59:28,040
BUILT ON THE SPORES P 20 AS A

3201
01:59:28,040 --> 01:59:29,640
MODEL.

3202
01:59:29,640 --> 01:59:32,760
NEXT SLIDE.

3203
01:59:32,760 --> 01:59:35,000
CRITICAL TO SUCCESS FOR THE P 20

3204
01:59:35,000 --> 01:59:36,840
SCIENTIFIC OUTREACH PROGRAM

3205
01:59:36,840 --> 01:59:38,080
COORDINATION THIS IS

3206
01:59:38,080 --> 01:59:40,320
PRE-APPLICATION OUTREACH TO BOTH

3207
01:59:40,320 --> 01:59:42,440
HEALTH DISPARITIES AND

3208
01:59:42,440 --> 01:59:43,000
IMMUNO-ONCOLOGY RESEARCH

3209
01:59:43,000 --> 01:59:45,440
COMMUNITIES SUCH AS AACR AND

3210
01:59:45,440 --> 01:59:47,440
PROGRAM COORDINATION BETWEEN CRC

3211
01:59:47,440 --> 01:59:49,680
AND DBCB STAFF.

3212
01:59:49,680 --> 01:59:52,320
FOR EVALUATION CRITERIA, METRICS

3213
01:59:52,320 --> 01:59:54,320
OF SUCCESS WE HOPE TO SEE

3214
01:59:54,320 --> 01:59:56,520
ESTABLISHMENT OF COMPLIMENTARY

3215
01:59:56,520 --> 01:59:57,640
MULTI-DISCIPLINARY RESEARCH

3216
01:59:57,640 --> 01:59:58,640
TEAMS WITH STRENGTH CANCER

3217
01:59:58,640 --> 02:00:02,160
HEALTH DISPARITIES AND IO

3218
02:00:02,160 --> 02:00:03,320
RESEARCH PRE-APPLICATION OR

3219
02:00:03,320 --> 02:00:05,200
SUBMISSION OF WELL INTEGRATED

3220
02:00:05,200 --> 02:00:06,000
MULTI-DISCIPLINARY RESEARCH

3221
02:00:06,000 --> 02:00:08,000
PROJECTS SUCH AS PO 1 OR RO1, IF

3222
02:00:08,000 --> 02:00:10,640
THE P 20 TEAM IS DEVELOPING AN

3223
02:00:10,640 --> 02:00:12,120
INVESTIGATOR INITIATED PROGRAM

3224
02:00:12,120 --> 02:00:15,080
PROJECT OR PO 1 HAS P 20 TEAM

3225
02:00:15,080 --> 02:00:17,720
FORMED ADVISORY BOARD TO REVIEW

3226
02:00:17,720 --> 02:00:19,600
INITIAL PO 1 SUBMISSION.

3227
02:00:19,600 --> 02:00:22,040
I WILL TRACK PUBLICATION AND

3228
02:00:22,040 --> 02:00:24,920
METRICS OF COLLABORATION.

3229
02:00:24,920 --> 02:00:26,600
NEXT SLIDE.

3230
02:00:26,600 --> 02:00:31,800
SO WE THINK DR.S SPRAWLEY AND

3231
02:00:31,800 --> 02:00:36,840
VON DEER HYDE FOR THE CRAW
CRITICAL

3232
02:00:36,840 --> 02:00:38,880
REVIEW OF THIS PROJECT.

3233
02:00:38,880 --> 02:00:41,960
HEALTH DISPARITIES ARE ROOTED IN

3234
02:00:41,960 --> 02:00:44,200
ACCESS TO CARE FACTORS AND NOT

3235
02:00:44,200 --> 02:00:44,880
UNDERLYING BIOLOGY.

3236
02:00:44,880 --> 02:00:46,680
WE AGREE ACCESS TO CARE AND

3237
02:00:46,680 --> 02:00:49,400
QUALITY OF TREATMENT ARE

3238
02:00:49,400 --> 02:00:50,520
PARAMOUNT PROBLEMS TO BE

3239
02:00:50,520 --> 02:00:52,000
ADDRESSD BY THE BROADER RESEARCH

3240
02:00:52,000 --> 02:00:52,800
COMMUNITY.

3241
02:00:52,800 --> 02:00:55,160
WE ACKNOWLEDGE RACISM CAN LEAD

3242
02:00:55,160 --> 02:00:56,800
TO BIOLOGICAL EFFECT THAT CAN

3243
02:00:56,800 --> 02:00:59,040
LEAD TO HEALTH DISPARITIES.

3244
02:00:59,040 --> 02:01:02,360
AND SIMPLY IMMUNOLOGIC RESPONSES

3245
02:01:02,360 --> 02:01:04,800
MAY VARY BASED ON ENVIRONMENTAL

3246
02:01:04,800 --> 02:01:07,120
INFLUENCES INCLUDING RACISM

3247
02:01:07,120 --> 02:01:10,320
SOCIO POLITICAL FACTORS POVERTY

3248
02:01:10,320 --> 02:01:13,000
MAL NUTRITION AND GEOGRAPHIC

3249
02:01:13,000 --> 02:01:13,400
ORIGIN.

3250
02:01:13,400 --> 02:01:14,960
TAKING THESE FACTORS INTO

3251
02:01:14,960 --> 02:01:16,400
CONSIDERATION, THE SCOPE OF THE

3252
02:01:16,400 --> 02:01:18,040
P 20 PILOT PROGRAM EXTENDS

3253
02:01:18,040 --> 02:01:22,400
BEYOND ACCESS FACTORS ALONE AND

3254
02:01:22,400 --> 02:01:25,400
DESIGNED TO COMPLIMENTARILY HELP

3255
02:01:25,400 --> 02:01:28,440
BY BIOLOGY IMMUNOLOGY INTERACT

3256
02:01:28,440 --> 02:01:29,760
WITH COMPLEX INTERRELATED

3257
02:01:29,760 --> 02:01:31,560
CONTRIBUTORS TO IO RELATED

3258
02:01:31,560 --> 02:01:34,560
DISPARITIES.

3259
02:01:34,560 --> 02:01:39,760
SECOND, ACCESS TO CARE RACISM

3260
02:01:39,760 --> 02:01:40,840
SOCIOECONOMIC GEOGRAPHIC CAN BE

3261
02:01:40,840 --> 02:01:41,600
ADDRESSED.

3262
02:01:41,600 --> 02:01:44,480
THIS P 25 PROGRAM WILL ELICIT

3263
02:01:44,480 --> 02:01:45,600
COMPLIMENTARY MULTI-DISCIPLINARY

3264
02:01:45,600 --> 02:01:48,240
RESEARCH TEAMS TO ADDRESS THESE

3265
02:01:48,240 --> 02:01:49,000
MULTI-LAYERED PROGRAMS.

3266
02:01:49,000 --> 02:01:51,040
THE P 20 ALSO ENABLES

3267
02:01:51,040 --> 02:01:52,840
FEASIBILITY AND PILOT STUDIES TO

3268
02:01:52,840 --> 02:01:55,800
ENABLE EXPLORATION OF NOVEL HIGH

3269
02:01:55,800 --> 02:01:59,000
RISK HYPOTHESES AND THUS ENABLE

3270
02:01:59,000 --> 02:02:02,360
STUDIES AT THE INTERSEXUALITY OF

3271
02:02:02,360 --> 02:02:04,160
THESE MULTIPLE COMPONENTS.

3272
02:02:04,160 --> 02:02:08,560
THE NEXT SLIDE IS THE LAST

3273
02:02:08,560 --> 02:02:09,080
SLIDE.

3274
02:02:09,080 --> 02:02:11,960
I WILL PAUSE AND WELCOME

3275
02:02:11,960 --> 02:02:13,320
DISCUSSION.

3276
02:02:13,320 --> 02:02:14,680
>> THANK YOU VERY MUCH.

3277
02:02:14,680 --> 02:02:18,280
>> I WANT TO THANK DR. COOL AND

3278
02:02:18,280 --> 02:02:20,800
DR. HOULIHAN.

3279
02:02:20,800 --> 02:02:22,120
YOU GUYS REALLY DID LISTEN TO

3280
02:02:22,120 --> 02:02:22,600
US.

3281
02:02:22,600 --> 02:02:24,600
I APPRECIATE THAT.

3282
02:02:24,600 --> 02:02:28,960
I HAD SOME INITIAL CONCERNS

3283
02:02:28,960 --> 02:02:31,800
ABOUT THE EXCLUSION OF SOCIALLY

3284
02:02:31,800 --> 02:02:36,160
DEPRIVED POPULATIONS OR LITTLE

3285
02:02:36,160 --> 02:02:38,000
BIT SOUNDED MORE LIKE RACE WAS

3286
02:02:38,000 --> 02:02:40,160
NOT A SOCIO POLITICAL CAT

3287
02:02:40,160 --> 02:02:42,000
FORRIZATION BUT BIOLOGICAL

3288
02:02:42,000 --> 02:02:43,400
CATEGORIZATION, BUT THE TEAM

3289
02:02:43,400 --> 02:02:45,920
TOOK THOSE AND WENT BACK AND

3290
02:02:45,920 --> 02:02:46,520
REDID THINGS.

3291
02:02:46,520 --> 02:02:47,640
I LOVE THIS.

3292
02:02:47,640 --> 02:02:49,360
I THINK IT IS GREAT.

3293
02:02:49,360 --> 02:02:53,080
I FULLY ENDORSE IT.

3294
02:02:53,080 --> 02:02:57,560
DR. VON DEER HYDE AND DR.

3295
02:02:57,560 --> 02:03:01,200
DAVENY, HOW DO YOU FEEL?

3296
02:03:01,200 --> 02:03:03,320
>> I AGREE THIS IS VASTLY

3297
02:03:03,320 --> 02:03:03,800
IMPROVED.

3298
02:03:03,800 --> 02:03:11,160
AND APPRECIATE YOUR INTEGRATING

3299
02:03:11,160 --> 02:03:11,760
COMMENTS AND GIVEN TIGHT TIME

3300
02:03:11,760 --> 02:03:16,840
LINE THAT YOU HAD TO WORK WITH.

3301
02:03:16,840 --> 02:03:20,640
I DO HAVE A COUPLE OF QUESTIONS

3302
02:03:20,640 --> 02:03:25,720
MAYBE PERHAPS ONE MORE LIKE IN A

3303
02:03:25,720 --> 02:03:27,720
CONCEPT ITSELF IS ENORMOUSLY

3304
02:03:27,720 --> 02:03:29,760
IMPORTANT BUT I THINK I STRUGGLE

3305
02:03:29,760 --> 02:03:31,840
WITH WHAT IS AN UNDERLYING

3306
02:03:31,840 --> 02:03:34,280
PREMISE BEHIND IT, ONE, BUT ALSO

3307
02:03:34,280 --> 02:03:37,440
IS YOUR IDEA TO FOCUS THIS ON

3308
02:03:37,440 --> 02:03:39,680
EFFECTIVENESS IMMUNOTHERAPY OR

3309
02:03:39,680 --> 02:03:41,480
IS IT ABOUT IMPLEMENTING

3310
02:03:41,480 --> 02:03:43,640
ADDITIONAL IMMUNOTHERAPY?

3311
02:03:43,640 --> 02:03:45,360
I THINK THOSE ARE DIFFERENCES

3312
02:03:45,360 --> 02:03:47,360
AND WE TALKED ALSO ABOUT I LIKE

3313
02:03:47,360 --> 02:03:48,480
FOR YOUR TEAM TO MAYBE TALK A

3314
02:03:48,480 --> 02:03:51,280
LITTLE BIT ABOUT WHETHER THIS IS

3315
02:03:51,280 --> 02:03:53,280
HEALTH DISPARITIES RESEARCH

3316
02:03:53,280 --> 02:03:54,200
GENERICALLY OR YOU HAVE

3317
02:03:54,200 --> 02:03:56,120
POPULATIONS OF FOCUS IN MIND.

3318
02:03:56,120 --> 02:04:00,200
BECAUSE I DO THINK WHEN WE THROW

3319
02:04:00,200 --> 02:04:02,520
TO CAP IT OUT, -- THROW THE

3320
02:04:02,520 --> 02:04:04,000
CARPET OUT WE MAY CATCH FLIES

3321
02:04:04,000 --> 02:04:05,360
FROM DIFFERENT PLACES IF WE TRY

3322
02:04:05,360 --> 02:04:07,680
TO FOCUS MORE NARROWLY, KNOWING

3323
02:04:07,680 --> 02:04:10,560
WE HAVE A BIG PROBLEM OUT THERE,

3324
02:04:10,560 --> 02:04:12,000
I THINK IT WILL GIVE US BETTER

3325
02:04:12,000 --> 02:04:15,560
CHANCE OF KNOWING IF PROGRAM WE

3326
02:04:15,560 --> 02:04:16,800
HAVE UNDERTAKEN IS EFFECTIVE.

3327
02:04:16,800 --> 02:04:20,000
BUT I DO THINK THE QUESTION

3328
02:04:20,000 --> 02:04:21,320
WHETHER IT IS AN EFFECTIVENESS

3329
02:04:21,320 --> 02:04:24,440
ISSUE THIS IS TRYING TO ADDRESS

3330
02:04:24,440 --> 02:04:26,880
AND I GUESS INCLUSIVENESS ISSUE

3331
02:04:26,880 --> 02:04:28,000
IMPLEMENTATION ISSUE BUT THIS

3332
02:04:28,000 --> 02:04:31,080
NEEDS TO BE A LITTLE CLEARER FOR

3333
02:04:31,080 --> 02:04:33,040
YOU TO BE ABLE TO VOUCH FOR

3334
02:04:33,040 --> 02:04:38,640
SUCCESS OF THIS INITIATIVE.

3335
02:04:38,640 --> 02:04:40,080
SO I SHARE ENTHUSIASM BUT I

3336
02:04:40,080 --> 02:04:42,480
STILL HAVE SOME QUESTIONS THAT

3337
02:04:42,480 --> 02:04:43,560
ILY WILL BE IMPORTANT TO

3338
02:04:43,560 --> 02:04:43,800
CONSIDER.

3339
02:04:43,800 --> 02:04:45,000
>> SURE.

3340
02:04:45,000 --> 02:04:46,400
THOSE ARE GREAT COMMENTS AND WE

3341
02:04:46,400 --> 02:04:47,600
WILL CERTAINLY TAKE IT INTO

3342
02:04:47,600 --> 02:04:48,000
CONSIDERATION.

3343
02:04:48,000 --> 02:04:51,080
I THINK IN GENERAL, WE WANT TO

3344
02:04:51,080 --> 02:04:52,600
BE INCLUSIVE OF ALL THESE

3345
02:04:52,600 --> 02:04:53,360
FACTORS.

3346
02:04:53,360 --> 02:04:54,800
WE ARE NOT BEING TOO

3347
02:04:54,800 --> 02:04:56,120
PRESCRIPTIVE AT THIS POINT IN

3348
02:04:56,120 --> 02:04:59,280
TERMS OF LOOKING AT TREATMENT

3349
02:04:59,280 --> 02:05:00,240
OUTCOMES.

3350
02:05:00,240 --> 02:05:05,120
WE CERTAINLY -- BASED ON PRIOR

3351
02:05:05,120 --> 02:05:07,000
PROGRAMS, WE -- IMMUNO-ONCOLOGY

3352
02:05:07,000 --> 02:05:08,800
LANDS SCAPE, WE ARE INTERESTED

3353
02:05:08,800 --> 02:05:11,360
IN BOTH PREVENTION AND TREATMENT

3354
02:05:11,360 --> 02:05:15,800
AND SO I THINK WE ARE WILLING TO

3355
02:05:15,800 --> 02:05:19,200
CONSIDER EVERYTHING.

3356
02:05:19,200 --> 02:05:21,080
THAT -- IMMUNE FACTORS OR

3357
02:05:21,080 --> 02:05:22,200
FACTORS THAT IMPACT

3358
02:05:22,200 --> 02:05:28,480
IMMUNO-ONCOLOGY P

3359
02:05:28,480 --> 02:05:31,960
>> THIS IS A -- THIS WAS NOT A

3360
02:05:31,960 --> 02:05:35,560
STRAIGHT FORWARD DISCUSSION.

3361
02:05:35,560 --> 02:05:41,520
THERE IS A LOT PACKED IN HERE.

3362
02:05:41,520 --> 02:05:45,680
SO THE NOTION OF UNDERSTANDING

3363
02:05:45,680 --> 02:05:48,280
INTERSECTION I THINK WE LIKE

3364
02:05:48,280 --> 02:05:50,040
USING A -- FOR PEOPLE TO START

3365
02:05:50,040 --> 02:05:51,360
GETTING TOOLS TOGETHER AND TEAMS

3366
02:05:51,360 --> 02:05:54,200
TOGETHER MAKES SENSE.

3367
02:05:54,200 --> 02:05:55,360
I DON'T KNOW WHAT YOU ARE GOING

3368
02:05:55,360 --> 02:05:56,400
TO GET.

3369
02:05:56,400 --> 02:06:00,320
NOT SURE WE -- THIS IS A LITTLE

3370
02:06:00,320 --> 02:06:03,880
BIT LIKE WIDE OPEN.

3371
02:06:03,880 --> 02:06:05,600
SO I THINK -- RAISED THIS ISSUE.

3372
02:06:05,600 --> 02:06:08,680
MAYBE THAT IS THE POINT TO SORT

3373
02:06:08,680 --> 02:06:11,360
OF -- LET THE EXTRAMURAL

3374
02:06:11,360 --> 02:06:13,440
COMMUNITY BE INNOVATIVE AND

3375
02:06:13,440 --> 02:06:14,800
CREATIVE TOGETHER WITH NOVEL

3376
02:06:14,800 --> 02:06:20,200
TEAMS AND START ASKING KEY

3377
02:06:20,200 --> 02:06:20,640
QUESTIONS.

3378
02:06:20,640 --> 02:06:22,200
I DON'T KNOW WHAT ANGLE PEOPLE

3379
02:06:22,200 --> 02:06:22,920
WILL TAKE.

3380
02:06:22,920 --> 02:06:24,600
NOT SURE NECESSARILY GOING TO

3381
02:06:24,600 --> 02:06:26,280
TAKE BIOLOGICAL ANGLE OR

3382
02:06:26,280 --> 02:06:27,000
SOCIOECONOMIC ANGLE, I DON'T

3383
02:06:27,000 --> 02:06:28,000
KNOW.

3384
02:06:28,000 --> 02:06:32,880
MAYBE WE THINK THAT IS OKAY.

3385
02:06:32,880 --> 02:06:36,080
BUT WE DON'T KNOW TWO A FEW

3386
02:06:36,080 --> 02:06:38,320
THINGS LIKE WHAT IS THE RESPONSE

3387
02:06:38,320 --> 02:06:41,880
TO CHECK POINT THERAPY FOR

3388
02:06:41,880 --> 02:06:44,800
PATIENTS WITH METASTATIC LUNG

3389
02:06:44,800 --> 02:06:47,200
CANCER IF BLACK OR WHITE OR

3390
02:06:47,200 --> 02:06:48,960
HISPANIC, ALL OTHER THINGS BEING

3391
02:06:48,960 --> 02:06:49,440
EQUAL.

3392
02:06:49,440 --> 02:06:52,040
IF WE KNEW THAT, STUDY THAT OR

3393
02:06:52,040 --> 02:06:53,520
DO WE NEED TO STUDY THAT.

3394
02:06:53,520 --> 02:06:56,280
I'M OKAY WITH GETTING GOING, AS

3395
02:06:56,280 --> 02:06:57,560
OTIS SAID BUT I JUST THINK WE

3396
02:06:57,560 --> 02:07:00,720
NEED TO KEEP AN EYE ON

3397
02:07:00,720 --> 02:07:02,120
SHARPENING A LENS HERE AND

3398
02:07:02,120 --> 02:07:03,160
KNOWING WHAT THIS -- WHAT YOU

3399
02:07:03,160 --> 02:07:07,640
ARE REALLY TRYING TO OBTAIN.

3400
02:07:07,640 --> 02:07:14,800
A LITTLE BIT LIKE/GOOD BUT, BUT.

3401
02:07:14,800 --> 02:07:16,760
>> THAT IS ABSOLUTELY FAIR, THAT

3402
02:07:16,760 --> 02:07:19,200
IS WHY THIS IS A PILOT PROGRAM.

3403
02:07:19,200 --> 02:07:20,880
WE LEAVE TO INVESTIGATOR BASED

3404
02:07:20,880 --> 02:07:22,040
ON STRENGTH AND THEIR RESEARCH

3405
02:07:22,040 --> 02:07:23,520
AND THE COLLABORATIVE TEAMS THEY

3406
02:07:23,520 --> 02:07:27,800
CAN PUT TOGETHER.

3407
02:07:27,800 --> 02:07:29,600
ED TO PUT FORWARD TWO YEAR PILOT

3408
02:07:29,600 --> 02:07:33,160
PROJECTS IN TERMS OF NARROWING

3409
02:07:33,160 --> 02:07:35,680
IT IS A GOAL DESCRIBED OF HAVING

3410
02:07:35,680 --> 02:07:37,040
LARGER MULTI-DISCIPLINARY

3411
02:07:37,040 --> 02:07:38,200
RESEARCH PROJECTS AND HOW THEY

3412
02:07:38,200 --> 02:07:41,400
GET THERE.

3413
02:07:41,400 --> 02:07:43,200
SO IT IS FIRST STEP BUT WE SOME

3414
02:07:43,200 --> 02:07:49,200
POINT WANT TO FOCUS THE RESERGE.

3415
02:07:49,200 --> 02:07:51,680
>> THIS IS THE SMALLEST PROPOSAL

3416
02:07:51,680 --> 02:07:53,440
IN OUR DISCUSSIONS YESTERDAY TO

3417
02:07:53,440 --> 02:07:53,840
TODAY.

3418
02:07:53,840 --> 02:07:56,040
SO JUST TO BE LEER CLEAR IT IS

3419
02:07:56,040 --> 02:07:57,600
TOE IN THE WATER RELATIVELY

3420
02:07:57,600 --> 02:07:58,640
SPEAKING.

3421
02:07:58,640 --> 02:08:00,200
YOUR LANDSCAPE ANALYSIS MAKES A

3422
02:08:00,200 --> 02:08:00,800
POWERFUL POINT.

3423
02:08:00,800 --> 02:08:02,480
YOU DON'T KNOW WHAT YOU GET

3424
02:08:02,480 --> 02:08:04,200
BECAUSE THERE IS NO FUNDING IN

3425
02:08:04,200 --> 02:08:09,200
THIS AREA RIGHT NOW.

3426
02:08:09,200 --> 02:08:10,680
SOD CHALLENGING TO KNOW WHAT THE

3427
02:08:10,680 --> 02:08:17,120
PROFILE PATTERN WOULD BE, JOHN,

3428
02:08:17,120 --> 02:08:21,600
ANDREW, THE TWO OF YOU.

3429
02:08:21,600 --> 02:08:22,840
MOTIONING AND VOTING JOHN.

3430
02:08:22,840 --> 02:08:24,560
>> COUPLE OF POINTS.

3431
02:08:24,560 --> 02:08:27,880
I'M HIGHLY ENTHUSIASTIC.

3432
02:08:27,880 --> 02:08:29,200
ONLY THING NOT ENTHUSIASTIC

3433
02:08:29,200 --> 02:08:32,120
ABOUT IS HOW LITTLE MONEY

3434
02:08:32,120 --> 02:08:32,760
REQUESTED.

3435
02:08:32,760 --> 02:08:37,200
>> SO MANY HYPOTHESES THAT ARE

3436
02:08:37,200 --> 02:08:39,120
THAT HAVE DRIVEN BIOMEDICAL

3437
02:08:39,120 --> 02:08:40,760
RESEARCH, DRIVING TODAY CREATED

3438
02:08:40,760 --> 02:08:43,040
BACK IN THE '80s AND '90s.

3439
02:08:43,040 --> 02:08:44,960
SOMEONE HAD AN IDEA, SOMEONE HAD

3440
02:08:44,960 --> 02:08:47,040
A QUESTION AND WITHOUT HAVING AN

3441
02:08:47,040 --> 02:08:49,520
OPPORTUNITY TO ASK THE QUESTION

3442
02:08:49,520 --> 02:08:51,000
AND ANSWER IT, WE WOULDN'T BE

3443
02:08:51,000 --> 02:08:52,640
FOLLOWING UP ON A LOT OF THE

3444
02:08:52,640 --> 02:08:54,800
WORK THAT'S LEADING AND GUIDING

3445
02:08:54,800 --> 02:08:57,200
US TODAY IN BIOMEDICAL RESEARCH.

3446
02:08:57,200 --> 02:08:58,600
WITHOUT A DOUBT WE HAVE TO HAVE

3447
02:08:58,600 --> 02:09:03,000
THE OPPORTUNITY TO EXPLORE SO

3448
02:09:03,000 --> 02:09:05,080
MANY GAPS IN THIS AREA PRESENTED

3449
02:09:05,080 --> 02:09:09,160
AT ASCO AND WRITTEN UP IN ACR

3450
02:09:09,160 --> 02:09:11,400
CONFERENCES WITH IMMUNO-ONCOLOGY

3451
02:09:11,400 --> 02:09:14,520
DRIVING CANCER THERAPY TODAY.

3452
02:09:14,520 --> 02:09:16,120
KNOWING SO LITTLE ABOUT THE

3453
02:09:16,120 --> 02:09:18,840
SIMILARITIES AND THE

3454
02:09:18,840 --> 02:09:19,560
DIFFERENCES.

3455
02:09:19,560 --> 02:09:22,000
SO I'M HIGHLY ENTHUSIASTIC ABOUT

3456
02:09:22,000 --> 02:09:23,880
THESE TYPES OF EXPLORATORY

3457
02:09:23,880 --> 02:09:26,320
APPROACHES TO BEGIN TO ADDRESS

3458
02:09:26,320 --> 02:09:27,360
THESE ISSUES.

3459
02:09:27,360 --> 02:09:31,440
I ALSO THINK WE HAVE TO BE

3460
02:09:31,440 --> 02:09:34,440
CAREFUL, I TOLDLY AGREE

3461
02:09:34,440 --> 02:09:36,560
FOUNDATION OF DISPARITIES ARE

3462
02:09:36,560 --> 02:09:37,360
SOCIOECONOMIC AND SOCIAL BUT IT

3463
02:09:37,360 --> 02:09:39,360
IS NOT THE ONLY THING.

3464
02:09:39,360 --> 02:09:40,560
THEIR DISPARITIES BOTH IN

3465
02:09:40,560 --> 02:09:45,280
INCIDENCE AND RISK AND OUTCOMES.

3466
02:09:45,280 --> 02:09:47,720
THERE IS A STRONG BIOLOGICAL

3467
02:09:47,720 --> 02:09:49,600
FACTOR TO DISPARITY ASSOCIATED

3468
02:09:49,600 --> 02:09:52,360
WITH RISK AND PREVALENCE BUT

3469
02:09:52,360 --> 02:09:54,360
DISPARITY IN OUTCOMES COULD BE

3470
02:09:54,360 --> 02:09:56,720
ALSO ECONOMICS AND VICE VERSA.

3471
02:09:56,720 --> 02:09:58,720
SO I THINK WE HAVE TO BE CAREFUL

3472
02:09:58,720 --> 02:10:00,120
SOMETIMES WHEN WE JUST SAY IT IS

3473
02:10:00,120 --> 02:10:02,360
ALL ONE THING AND JUST SOLVE

3474
02:10:02,360 --> 02:10:05,320
THIS ONE THING WE SOLVE ALL

3475
02:10:05,320 --> 02:10:05,720
PROBLEMS.

3476
02:10:05,720 --> 02:10:07,920
THESE ARE MULTI-FACTORAL ISSUES

3477
02:10:07,920 --> 02:10:11,760
THE ONLY THING I WOULD SUGGEST

3478
02:10:11,760 --> 02:10:14,400
LILLIAN IS THAT WHEN YOU ARE

3479
02:10:14,400 --> 02:10:16,600
DEVELOPING EVERY RFA OR -- HAS

3480
02:10:16,600 --> 02:10:18,600
DESCRIPTIONS OF THESE ARE THE

3481
02:10:18,600 --> 02:10:20,000
TYPES OF PROPOSALS WE ARE

3482
02:10:20,000 --> 02:10:20,800
LOOKING FOR.

3483
02:10:20,800 --> 02:10:22,400
THEY ARE USUALLY A SERIES OF

3484
02:10:22,400 --> 02:10:22,880
BULLETS.

3485
02:10:22,880 --> 02:10:26,040
YOU CAN BEGIN TO GUIDE POTENTIAL

3486
02:10:26,040 --> 02:10:29,760
APPLICANTS TO THE TYPE OF GRANTS

3487
02:10:29,760 --> 02:10:31,840
AND PROGRAMS YOU ARE LOOKING FOR

3488
02:10:31,840 --> 02:10:33,160
TO BE DEVELOPED SO WE CAN

3489
02:10:33,160 --> 02:10:34,960
ADDRESS SOME OF THOSE ISSUES

3490
02:10:34,960 --> 02:10:36,720
AROUND WHAT ARE WE GOING TO GET

3491
02:10:36,720 --> 02:10:38,560
BY PROVIDING LEAST SOME GUIDANCE

3492
02:10:38,560 --> 02:10:41,000
IN THE ANNOUNCEMENT TO POTENTIAL

3493
02:10:41,000 --> 02:10:41,400
APPLICANTS.

3494
02:10:41,400 --> 02:10:44,200
BUT I THINK THAT IT IS LONG

3495
02:10:44,200 --> 02:10:46,080
OVERDUE AND REALLY EXCITED ABOUT

3496
02:10:46,080 --> 02:10:46,520
THIS.

3497
02:10:46,520 --> 02:10:48,320
>> CORRECT ME IF I'M WRONG.

3498
02:10:48,320 --> 02:10:51,600
YOU PUT THE GEOGRAPHIC ORIGIN

3499
02:10:51,600 --> 02:10:56,400
PHRASE IN THERE.

3500
02:10:56,400 --> 02:11:00,280
TO ANSWER JOHN'S FIRST POINT HOW

3501
02:11:00,280 --> 02:11:02,840
IT'S NOT JUST SOCIOECONOMIC --

3502
02:11:02,840 --> 02:11:04,520
MOVE FROM RACE AND AREA OF

3503
02:11:04,520 --> 02:11:08,360
GEOGRAPHIC ORIGIN.

3504
02:11:08,360 --> 02:11:11,720
>> WE DON'T WANT THROW BABY OUT

3505
02:11:11,720 --> 02:11:12,360
WITH BAST WATER, THERE COULD BE

3506
02:11:12,360 --> 02:11:16,120
ISSUES RELATIVE TO STRUCTURE

3507
02:11:16,120 --> 02:11:18,120
BUILT ENVIRONMENT THAT IMPACT

3508
02:11:18,120 --> 02:11:19,560
PHYSIOLOGY AND BIOLOGY SO YOU

3509
02:11:19,560 --> 02:11:22,440
HAVE TO CONSIDER BOTH CONCEPTS,

3510
02:11:22,440 --> 02:11:23,600
RACE AS WELL AS GEOGRAPHIC

3511
02:11:23,600 --> 02:11:24,560
ORIGIN.

3512
02:11:24,560 --> 02:11:27,200
>> IF I MAY, I THINK JOHN YOU

3513
02:11:27,200 --> 02:11:28,920
YOU MAKE IT IMPORTANT TO POINT

3514
02:11:28,920 --> 02:11:31,000
ABOUT BIOLOGY BUT EVERY TIME

3515
02:11:31,000 --> 02:11:33,200
THAT WORK COMES UP IT SEEMS TO

3516
02:11:33,200 --> 02:11:34,440
TRIGGER SOMETHING IMMEDIATE THAT

3517
02:11:34,440 --> 02:11:36,200
FORCES ME TO RESPOND.

3518
02:11:36,200 --> 02:11:39,440
IT IS IMPORTANT FOR US TO BE

3519
02:11:39,440 --> 02:11:40,880
CLEAR THERE ARE NOT REAL

3520
02:11:40,880 --> 02:11:42,000
BIOLOGICAL DIFFERENCE THAT DRIVE

3521
02:11:42,000 --> 02:11:44,800
DISPARITIES.

3522
02:11:44,800 --> 02:11:44,920
IN

3523
02:11:44,920 --> 02:11:46,480
>> I TOTALLY DISAGREE.

3524
02:11:46,480 --> 02:11:49,480
>> YOU CAN DISAGREE BUT THERE

3525
02:11:49,480 --> 02:11:52,000
ARE DIFFERENCE IN GENETICS BUT

3526
02:11:52,000 --> 02:11:53,680
BIOLOGICAL DIFFERENCES ARE

3527
02:11:53,680 --> 02:11:55,320
DRIVEN BY ENVIRONMENTAL

3528
02:11:55,320 --> 02:11:57,320
EXPOSURES AND ADVERSE SECOND

3529
02:11:57,320 --> 02:11:57,840
SENSES.

3530
02:11:57,840 --> 02:12:01,040
THOSE WE CAN AGREE ON, BUT WHEN

3531
02:12:01,040 --> 02:12:02,160
WE TALK BIOLOGY, --

3532
02:12:02,160 --> 02:12:03,520
>> GENETICS IS BIOLOGY.

3533
02:12:03,520 --> 02:12:04,880
THAT'S MY ONLY POINT.

3534
02:12:04,880 --> 02:12:06,600
(OVERLAPPING SPEAKERS)

3535
02:12:06,600 --> 02:12:07,640
(OVERLAPPING SPEAKERS)

3536
02:12:07,640 --> 02:12:09,600
(OVERLAPPING SPEAKERS)

3537
02:12:09,600 --> 02:12:12,040
>> LET'S MOVE ON.

3538
02:12:12,040 --> 02:12:17,600
>> ANDREW, I JUST WANT TO SAY I

3539
02:12:17,600 --> 02:12:19,200
THINK THIS IS THE -- YOU ARE

3540
02:12:19,200 --> 02:12:21,480
GOING TO OPEN THERE'S SO MUCH

3541
02:12:21,480 --> 02:12:22,800
INTEREST TO INFORMATION, THAT IT

3542
02:12:22,800 --> 02:12:24,280
IS GOING TO COME OUT OF THIS

3543
02:12:24,280 --> 02:12:28,000
BECAUSE WE KNOW IN EVERY DAY

3544
02:12:28,000 --> 02:12:29,680
PRACTICE THAT WE TREAT THE SAME

3545
02:12:29,680 --> 02:12:31,920
WITH THE SAME DIAGNOSIS SAME

3546
02:12:31,920 --> 02:12:33,600
CHEMOTHERAPY AND I CAN TELL YOU

3547
02:12:33,600 --> 02:12:35,160
THAT THERE ARE MANY AFRICAN

3548
02:12:35,160 --> 02:12:37,000
AMERICAN HISPANC PATIENTS ARE

3549
02:12:37,000 --> 02:12:38,400
NOT RESPONDING TO THE SAME

3550
02:12:38,400 --> 02:12:40,200
TREATMENT THAT I GIVE FOR ONE

3551
02:12:40,200 --> 02:12:42,800
DISEASE AT THE SAME TIME.

3552
02:12:42,800 --> 02:12:47,680
WE ALSO KNOW THAT BLACK PATIENTS

3553
02:12:47,680 --> 02:12:50,720
BLACK THAT HAVE NOT -- FOR

3554
02:12:50,720 --> 02:12:55,080
EXAMPLE AS MA ASTHMA, THEY DON'T
HAVE

3555
02:12:55,080 --> 02:12:57,960
THE SAME RECEPTORS TO RESPOND TO

3556
02:12:57,960 --> 02:12:59,160
AL BEAUTY ROLL SO WE ARE

3557
02:12:59,160 --> 02:13:00,960
LEARNING THERE ARE BIOLOGICAL

3558
02:13:00,960 --> 02:13:02,400
DIFFERENCES RELATED TO THE

3559
02:13:02,400 --> 02:13:04,200
CONTINENT THAT YOU WERE BORN IN

3560
02:13:04,200 --> 02:13:06,200
AND THE ENVIRONMENT OF THAT

3561
02:13:06,200 --> 02:13:06,480
CONTINENT.

3562
02:13:06,480 --> 02:13:07,840
SO I THINK WE ARE

3563
02:13:07,840 --> 02:13:09,320
UNDERESTIMATING A LITTLE BIT

3564
02:13:09,320 --> 02:13:10,880
SAYING MAY NOT BE BIOLOGICAL,

3565
02:13:10,880 --> 02:13:12,360
MAY NOT FIND ANYTHING, U THINK

3566
02:13:12,360 --> 02:13:14,160
YOU FIND A TON ONCE YOU START

3567
02:13:14,160 --> 02:13:15,560
LOOKING.

3568
02:13:15,560 --> 02:13:17,800
AND I JUST THINK WE REALLY --

3569
02:13:17,800 --> 02:13:19,400
THE COMMENT MAY NOT BE ENOUGH

3570
02:13:19,400 --> 02:13:21,440
MONEY WE ARE GOING TO FUND NOT

3571
02:13:21,440 --> 02:13:23,120
GOING TO BE ENOUGH MONEY BECAUSE

3572
02:13:23,120 --> 02:13:26,400
THERE WILL BE INTERESTING

3573
02:13:26,400 --> 02:13:27,400
PROPOSALS BASED ON GETTING THIS

3574
02:13:27,400 --> 02:13:28,000
INFORMATION.

3575
02:13:28,000 --> 02:13:28,760
IT IS BIOLOGIC.

3576
02:13:28,760 --> 02:13:30,360
SOME OF IT IS SOCIOECONOMIC BUT

3577
02:13:30,360 --> 02:13:43,520
A LOT OF IT IS BIOLOGIC.

3578
02:13:43,520 --> 02:13:45,360
>> IT IS UNDERFUNDED, IT IS

3579
02:13:45,360 --> 02:13:46,000
FASCINATING.

3580
02:13:46,000 --> 02:13:48,080
LET'S TAKE IT AWAY FROM RACE.

3581
02:13:48,080 --> 02:13:49,520
SOCIAL DETERMINANTS OF HEALTH

3582
02:13:49,520 --> 02:13:51,600
DETERMINE YOUR MICROBIOME, YOUR

3583
02:13:51,600 --> 02:13:54,400
MICROBIOME TERMS YOUR RESPONSE.

3584
02:13:54,400 --> 02:13:56,000
WE NEED MORE WORK IN THIS AREA.

3585
02:13:56,000 --> 02:14:00,120
WE DON'T HAVE TO TALK ABOUT

3586
02:14:00,120 --> 02:14:00,920
UNDER-REPRESENTED.

3587
02:14:00,920 --> 02:14:05,760
I THINK THE WAY OTIS REFRAMED

3588
02:14:05,760 --> 02:14:08,040
IT, IN TERMS OF SOCIAL

3589
02:14:08,040 --> 02:14:10,200
DETERMINANTS OF HEALTH AND

3590
02:14:10,200 --> 02:14:11,600
IMMUNO-ONCOLOGY, THIS IS WORTH

3591
02:14:11,600 --> 02:14:12,960
INVESTING IN.

3592
02:14:12,960 --> 02:14:14,880
>> AGREED AND IN FUTURE

3593
02:14:14,880 --> 02:14:16,800
CONVERSATIONS WE CAN DISCUSS

3594
02:14:16,800 --> 02:14:17,920
ABOUT HOW MUCH MORE INVESTMENT

3595
02:14:17,920 --> 02:14:19,280
THERE SHOULD BE IN THIS AREA.

3596
02:14:19,280 --> 02:14:23,000
THERE'S CONSENSUS THERE.

3597
02:14:23,000 --> 02:14:23,760
CAN I ASK FOR A MOTION?

3598
02:14:23,760 --> 02:14:26,520
>> I WOULD LIKE TO MAKE A MOTION

3599
02:14:26,520 --> 02:14:27,280
WE ACCEPT THIS -- A

3600
02:14:27,280 --> 02:14:28,360
RECOMMENDATION THAT WE ACCEPT

3601
02:14:28,360 --> 02:14:30,000
THIS, IF IT IS POSSIBLE I ALSO

3602
02:14:30,000 --> 02:14:31,480
LOU I CAN TO MAKE A

3603
02:14:31,480 --> 02:14:32,960
RECOMMENDATION PERHAPS THE NCI

3604
02:14:32,960 --> 02:14:34,720
WOULD COME BACK TO THIS BODY IN

3605
02:14:34,720 --> 02:14:38,000
TWO OR LEE YEARS WITH AN UPDATE.

3606
02:14:38,000 --> 02:14:38,760
>> GREAT.

3607
02:14:38,760 --> 02:14:43,400
I HEAR THAT AS APPROVAL.

3608
02:14:43,400 --> 02:14:46,600
>> AGAIN (OVERLAPPING SPEAKERS)

3609
02:14:46,600 --> 02:14:47,480
(OVERLAPPING SPEAKERS)

3610
02:14:47,480 --> 02:14:50,240
>> CAN I GET A SECOND?

3611
02:14:50,240 --> 02:14:52,000
>> OTIS CAN YOU CLARIFY WHAT YOU

3612
02:14:52,000 --> 02:14:53,280
MEAN UP DAY, REPORT WHAT HAPPENS

3613
02:14:53,280 --> 02:14:55,400
WITH THE P 20 MECHANISM?

3614
02:14:55,400 --> 02:14:56,160
>> YES.

3615
02:14:56,160 --> 02:14:59,040
>> VERY GOOD.

3616
02:14:59,040 --> 02:15:00,440
-- SECONDED THAT, ANY FURTHER

3617
02:15:00,440 --> 02:15:07,000
DISCUSSION?

3618
02:15:07,000 --> 02:15:08,600
THIS IS A NEW CONCEPT SO

3619
02:15:08,600 --> 02:15:09,920
APPROVAL IS WHAT -- IS THE

3620
02:15:09,920 --> 02:15:11,920
MOTION ON THE TABLE.

3621
02:15:11,920 --> 02:15:14,080
ONLY COLLECTING BSA MEMBER

3622
02:15:14,080 --> 02:15:15,200
DISAPPROVALS IF THERE ARE ANY

3623
02:15:15,200 --> 02:15:21,800
PLEASE VOICE OR RAISE YOUR HAND.

3624
02:15:21,800 --> 02:15:23,280
I SEE NONE, PAULETTE.

3625
02:15:23,280 --> 02:15:29,560
ANY ABSTENTIONS?

3626
02:15:29,560 --> 02:15:30,760
SO UNANIMOUS APPROVAL NO

3627
02:15:30,760 --> 02:15:33,360
ABSTENTIONS.

3628
02:15:33,360 --> 02:15:34,000
PAULETTE.

3629
02:15:34,000 --> 02:15:35,560
WE GO TO BREAK.

3630
02:15:35,560 --> 02:15:35,760
GREAT.

3631
02:15:35,760 --> 02:15:37,280
OKAY.

3632
02:15:37,280 --> 02:15:40,400
SO STAY ON YOUR SCREENS, PLEASE,

3633
02:15:40,400 --> 02:15:42,560
BSA NCAB MEMBERS.

3634
02:15:42,560 --> 02:15:51,760
BUT WE WILL NOW ENTER THE BREAK.

3635
02:15:51,760 --> 02:15:55,200
>> KEITH, TOGETHER TO GIVE

3636
02:15:55,200 --> 02:15:55,720
RETURN TIME.

3637
02:15:55,720 --> 02:15:57,640
20 MINUTES.

3638
02:15:57,640 --> 02:16:01,560
>> 2:35.

3639
02:16:01,560 --> 02:16:03,960
>> RESUME THE CONCEPT REVIEW, WE

3640
02:16:03,960 --> 02:16:07,080
HAVE A THIRD CON REISSUE RFA.

3641
02:16:07,080 --> 02:16:08,760
DATA RESOURCE FOR ANALYZING

3642
02:16:08,760 --> 02:16:10,320
SUPPORTING BLOOD AND MARROW

3643
02:16:10,320 --> 02:16:11,440
TRANSPLANTS.

3644
02:16:11,440 --> 02:16:12,600
AND CELLULAR IMMUNOTHERAPY

3645
02:16:12,600 --> 02:16:13,160
RESEARCH.

3646
02:16:13,160 --> 02:16:15,600
BE PRESENTED BY DR. LORI

3647
02:16:15,600 --> 02:16:16,600
HENDERSON, SUBCOMMITTEE IS

3648
02:16:16,600 --> 02:16:24,920
CHAIRED BY MIKE DEISICH AND BOB

3649
02:16:24,920 --> 02:16:26,960
SCHREIBER, WHO ALSO COULDN'T

3650
02:16:26,960 --> 02:16:28,200
JOIN TODAY.

3651
02:16:28,200 --> 02:16:29,440
LORI GO AHEAD WITH YOUR

3652
02:16:29,440 --> 02:16:30,120
PRESENTATION.

3653
02:16:30,120 --> 02:16:31,360
>> THANK YOU FOR GIVING THE

3654
02:16:31,360 --> 02:16:32,160
OPPORTUNITY TO PRESENT THIS

3655
02:16:32,160 --> 02:16:34,040
CONCEPT.

3656
02:16:34,040 --> 02:16:37,280
WHICH SEEKS TO REISSUE THE

3657
02:16:37,280 --> 02:16:38,440
LIMITED COMPETITION RFA.

3658
02:16:38,440 --> 02:16:40,840
THAT RENEWS CENTER FOR

3659
02:16:40,840 --> 02:16:42,760
INTERNATIONAL BLOOD AND MARROW

3660
02:16:42,760 --> 02:16:44,560
TRANSPLANT RESEARCH REGISTRY

3661
02:16:44,560 --> 02:16:49,840
WHICH IS MORE COMMONLY KNOWN AS

3662
02:16:49,840 --> 02:16:52,360
CRDNTR, IT IS DATA RESOURCE

3663
02:16:52,360 --> 02:16:54,560
ANALYZE BLOOD SUPPORTS BONE

3664
02:16:54,560 --> 02:16:56,160
MARROW TRANSPLANT CELLULAR

3665
02:16:56,160 --> 02:16:57,200
THERAPY RESEARCH.

3666
02:16:57,200 --> 02:17:01,200
NEXT SLIDE, PLEASE.

3667
02:17:01,200 --> 02:17:05,840
THE CMDR IS FUNDED BY NCI MORE

3668
02:17:05,840 --> 02:17:09,160
THAN 30 YEARS WITH SUPPORT FROM

3669
02:17:09,160 --> 02:17:13,480
HEART LUNG AND BLOOD AND ALLERGY

3670
02:17:13,480 --> 02:17:16,880
INFECTIOUS DISEASE INSTITUTE IT

3671
02:17:16,880 --> 02:17:19,960
HAS BECOME A WORLD LEADING

3672
02:17:19,960 --> 02:17:22,080
RESOURCE THAT CAPTURES THE

3673
02:17:22,080 --> 02:17:24,160
INFORMATION OF HE MAN POIETIC

3674
02:17:24,160 --> 02:17:26,200
STEM CELL TRANSPLANT AND

3675
02:17:26,200 --> 02:17:28,200
ADOPTIVE CELL THERAPIES,

3676
02:17:28,200 --> 02:17:30,760
SPECIFICALLY WITH REGARDS TO US.

3677
02:17:30,760 --> 02:17:33,560
IT IS ESSENTIAL FOR RESEARCHERS

3678
02:17:33,560 --> 02:17:36,480
CLINICIANS AROUND FARM SUIT CELL

3679
02:17:36,480 --> 02:17:39,480
COMPANIES THAT HAVE TO MEET

3680
02:17:39,480 --> 02:17:41,480
ONGOING HHS PROGRAMS, SUCH AS

3681
02:17:41,480 --> 02:17:43,720
THE STEM CELL THERAPEUTIC

3682
02:17:43,720 --> 02:17:45,800
OUTCOMES DATABASE WHICH IS

3683
02:17:45,800 --> 02:17:48,440
MANAGED BY HRSA AND THE LONG

3684
02:17:48,440 --> 02:17:50,240
TERM FOLLOW-UP STUDIES AND CAR

3685
02:17:50,240 --> 02:17:51,280
T-CELL PRODUCTS WHICH IS

3686
02:17:51,280 --> 02:17:55,160
REQUIRED BY THE FDA AS WELL AS

3687
02:17:55,160 --> 02:17:57,680
THE EVIDENCE DEVELOPMENT

3688
02:17:57,680 --> 02:17:59,160
INITIATIVES FOR INSURANCE COVERS

3689
02:17:59,160 --> 02:18:01,000
BY C, MANYS THE NETWORK ALSO

3690
02:18:01,000 --> 02:18:05,560
CONDUCTS STUDIES AND WHICH

3691
02:18:05,560 --> 02:18:06,800
INFORMS CLINICAL TRIALS AND

3692
02:18:06,800 --> 02:18:07,920
PRACTICE, THAT ARE ASSOCIATED

3693
02:18:07,920 --> 02:18:11,840
WITH THE TREATMENT OF MALIGNANT

3694
02:18:11,840 --> 02:18:13,480
NON-MALIGNANT LUNG DISORDERS AND

3695
02:18:13,480 --> 02:18:15,840
EVOLVED OVER TIME TO MEET THE

3696
02:18:15,840 --> 02:18:17,440
MEDICAL NEEDS OF THESE DEMANDS.

3697
02:18:17,440 --> 02:18:20,320
SO IN THE NEXT FEW SLIDESLY

3698
02:18:20,320 --> 02:18:21,560
HIGHLIGHT SOME KEY

3699
02:18:21,560 --> 02:18:22,880
ACCOMPLISHMENTS IN WHICH TO

3700
02:18:22,880 --> 02:18:25,840
INITIATE DISCUSSION OF NOW AS

3701
02:18:25,840 --> 02:18:28,560
REQUESTED BY THREE OF THE CORE

3702
02:18:28,560 --> 02:18:29,160
BSA MEMBERS.

3703
02:18:29,160 --> 02:18:33,760
NEXT SLIDE PLEASE.

3704
02:18:33,760 --> 02:18:36,320
THE CURRENT U 24 GRANT AWARDED

3705
02:18:36,320 --> 02:18:39,720
IN 2018 AND HAS SINCE THEN MET

3706
02:18:39,720 --> 02:18:41,800
MANY RFA REQUIREMENTS FOR

3707
02:18:41,800 --> 02:18:43,920
DEVELOPING AND UTILIZING THE

3708
02:18:43,920 --> 02:18:45,360
REGISTRY AS SHOWN HERE.

3709
02:18:45,360 --> 02:18:47,920
AMONG THESE ACCOMPLISHMENTS THEY

3710
02:18:47,920 --> 02:18:50,360
WERE REALLY GROUND BREAKING

3711
02:18:50,360 --> 02:18:52,800
IMPROVEMENTS THAT MARK A HUGE

3712
02:18:52,800 --> 02:18:55,720
STEP FORWARD FOR THE REGISTRY.

3713
02:18:55,720 --> 02:18:57,160
THIS INCLUDED SUBSTANTIAL

3714
02:18:57,160 --> 02:19:00,040
INCREASE IN ENROLLMENT BY IS

3715
02:19:00,040 --> 02:19:01,880
ABOUT 72,000 NEW PATIENTS THAT

3716
02:19:01,880 --> 02:19:05,600
NOT ONLY RECEIVED ALLOGENEIC

3717
02:19:05,600 --> 02:19:07,720
AUTOLOGOUS AND ADAPTIVE CELL

3718
02:19:07,720 --> 02:19:09,720
THERAPY FOR TRANSPLANT

3719
02:19:09,720 --> 02:19:11,200
PROCEDURES BUT ALSO ADOPTED CELL

3720
02:19:11,200 --> 02:19:14,920
THERAPY THAT WAS USED IN PRIMARY

3721
02:19:14,920 --> 02:19:19,160
THERAPY TO TREAT HEMATOLOGIC

3722
02:19:19,160 --> 02:19:19,720
MALIGNANCY.

3723
02:19:19,720 --> 02:19:21,320
AS A RESULT THE DATABASE

3724
02:19:21,320 --> 02:19:23,600
CONTAINS INFORMATION MORE THAN

3725
02:19:23,600 --> 02:19:29,160
575,000 PATIENTS.

3726
02:19:29,160 --> 02:19:31,960
IN MARCH LAST YEAR THEY ADAPTED

3727
02:19:31,960 --> 02:19:34,560
DATA COLLECTION PROCESSES, AND

3728
02:19:34,560 --> 02:19:38,200
THIS WAS DETAILED INFORMATION

3729
02:19:38,200 --> 02:19:40,520
DIAGNOSIS TREATMENT AND OUTCOMES

3730
02:19:40,520 --> 02:19:42,840
OF SARS COV-2 INFECTION AND

3731
02:19:42,840 --> 02:19:45,280
INTEND WAS TO SEE DETERMINE

3732
02:19:45,280 --> 02:19:47,280
IMPACT OF UPON TRANSPLANT

3733
02:19:47,280 --> 02:19:51,280
PRACTICES AS WELL AS SURVIVAL.

3734
02:19:51,280 --> 02:19:53,480
THERE WAS FIVE PUBLICATIONS THAT

3735
02:19:53,480 --> 02:19:57,360
HAVE BEEN PRODUCED SO FAR, AMONG

3736
02:19:57,360 --> 02:20:03,000
THE 297 PUBLICATIO PUBLICATIONS
AND THE

3737
02:20:03,000 --> 02:20:05,240
SAME TIME PUBLICATIONS FOCUSED

3738
02:20:05,240 --> 02:20:08,320
ON REAL WORLD ISSUES WITH

3739
02:20:08,320 --> 02:20:10,640
REGARDS TO TRANSPLANTS.

3740
02:20:10,640 --> 02:20:13,160
LAST BUT NOT LEAST DATA

3741
02:20:13,160 --> 02:20:14,480
TRANSFORMATION TEAM ACTUALLY

3742
02:20:14,480 --> 02:20:17,480
DEVELOPED THE TECHNOLOGY

3743
02:20:17,480 --> 02:20:19,320
PLATFORM AND SEVEN DATA SHARING

3744
02:20:19,320 --> 02:20:21,560
APPS TO EXPEDITE DATA COLLECTION

3745
02:20:21,560 --> 02:20:25,880
AS WELL AS TRANSMISSION AND THIS

3746
02:20:25,880 --> 02:20:27,600
CREATED SAVE VALUABLE TIME AND

3747
02:20:27,600 --> 02:20:29,760
COST FOR TRANSPLANT CENTERS.

3748
02:20:29,760 --> 02:20:31,160
ESPECIALLY WITH CENTERS THAT

3749
02:20:31,160 --> 02:20:34,360
REPORT MILLIONS OF DATA POINTS

3750
02:20:34,360 --> 02:20:41,760
PER YEAR, NEXT SLIDE PLEASE.

3751
02:20:41,760 --> 02:20:43,960
ANOTHER HALLMARK ACHIEVEMENT WAS

3752
02:20:43,960 --> 02:20:45,640
ESTABLISHMENT OF PUBLIC PRIVATE

3753
02:20:45,640 --> 02:20:47,360
PARTNERSHIPS TO CHECK CAR T-CELL

3754
02:20:47,360 --> 02:20:50,400
THERAPY DATA USED TO TREAT

3755
02:20:50,400 --> 02:20:51,480
HEMATOLOGIC MALIGNANCIES.

3756
02:20:51,480 --> 02:20:53,000
THE REGISTRY WAS ADAPTED IN

3757
02:20:53,000 --> 02:20:55,560
RESPONSE TO A SPECIAL REQUEST

3758
02:20:55,560 --> 02:20:59,760
FROM THE FDA TO NCI TO USE THE

3759
02:20:59,760 --> 02:21:01,680
CIBMTR FOR POST MARKET STUDIES.

3760
02:21:01,680 --> 02:21:03,680
THESE POST MARKET STUDIES

3761
02:21:03,680 --> 02:21:05,880
REQUIRE 15 YEARS FOLLOW-UP

3762
02:21:05,880 --> 02:21:07,240
SAFETY ADVOCACY INFORMATION ON

3763
02:21:07,240 --> 02:21:11,080
THE CAR T-CELL PRODUCTS AND IN

3764
02:21:11,080 --> 02:21:13,760
TURN CIBMETER WILL GIVE ACCESS

3765
02:21:13,760 --> 02:21:16,120
TO CLINICIANS STAKEHOLDERS TO

3766
02:21:16,120 --> 02:21:18,440
ADVANCE ADOPTIVE CELL THERAPY

3767
02:21:18,440 --> 02:21:19,400
RESEARCH.

3768
02:21:19,400 --> 02:21:21,600
THERE ARE NOW FIVE POST MARKET

3769
02:21:21,600 --> 02:21:23,400
STUDIES UNDERWAY AND IN ADDITION

3770
02:21:23,400 --> 02:21:25,400
TO THAT, THERE ARE OTHER NCI

3771
02:21:25,400 --> 02:21:27,200
FUNDED COLLABORATORS THAT ARE

3772
02:21:27,200 --> 02:21:29,320
ALSO PROVIDING CAR T-CELL

3773
02:21:29,320 --> 02:21:31,760
RESEARCH DATA SETS FOR SECONDARY

3774
02:21:31,760 --> 02:21:35,800
RESEARCH THAT WILL BE AVAILABLE

3775
02:21:35,800 --> 02:21:37,120
UPON COMPLETION.

3776
02:21:37,120 --> 02:21:38,600
THIS SPECIFICALLY REFERRING TO

3777
02:21:38,600 --> 02:21:42,360
THE AIDS MALIGNANCY CONSORTIA,

3778
02:21:42,360 --> 02:21:44,080
CONSORTIUM AND BLOOD MARROW

3779
02:21:44,080 --> 02:21:45,840
TRANSPLANT -- THE BLOOD MARROW

3780
02:21:45,840 --> 02:21:47,760
CLINICAL TRIALS NETWORK AS WELL

3781
02:21:47,760 --> 02:21:48,600
AS NATIONAL CLINICAL TRIALS

3782
02:21:48,600 --> 02:21:53,040
NETWORK.

3783
02:21:53,040 --> 02:21:55,840
NEXT SLIDE PLEASE.

3784
02:21:55,840 --> 02:21:59,200
THE NETWORK IS ALSO VERY

3785
02:21:59,200 --> 02:22:01,120
SUCCESSFUL PROGRAM WHERE LINKING

3786
02:22:01,120 --> 02:22:03,920
DATA SETS HAS INFORMED CLINICAL

3787
02:22:03,920 --> 02:22:06,160
PRACTICE, AS ILLUSTRATED HERE IN

3788
02:22:06,160 --> 02:22:07,000
THESE TWO EXAMPLES.

3789
02:22:07,000 --> 02:22:10,120
THE FIRST STUDY REAL WORLD DATA

3790
02:22:10,120 --> 02:22:13,560
WAS COLLECTED FROM TWO NOVARTIS

3791
02:22:13,560 --> 02:22:16,520
POST MARKET STUDIES THAT

3792
02:22:16,520 --> 02:22:19,520
ACTUALLY CONFIRM SAFETY AND EF

3793
02:22:19,520 --> 02:22:21,000
EFFICACY FINDINGS OF THE HE

3794
02:22:21,000 --> 02:22:23,600
WILLIANA TRIAL FOR PEDIATRIC

3795
02:22:23,600 --> 02:22:26,800
LYMPHOBLASTIC LEUKEMIA AS WELL

3796
02:22:26,800 --> 02:22:30,880
AS JULIA TRIAL FOR NONHODGKINS

3797
02:22:30,880 --> 02:22:31,240
LYMPHOMA.

3798
02:22:31,240 --> 02:22:33,400
THE RESULTS THE TREATMENT WERE

3799
02:22:33,400 --> 02:22:34,960
SAFE AND TOLERABLE WHEN USING

3800
02:22:34,960 --> 02:22:36,720
STANDARD DRUG THERAPIES TO

3801
02:22:36,720 --> 02:22:40,560
MITIGATE THE OVERREACTIVE IMMUNE

3802
02:22:40,560 --> 02:22:43,120
INFLAMMATORY RESPONSE ALSO

3803
02:22:43,120 --> 02:22:45,280
SIMILAR WITH REGARDS TO SURVIVAL

3804
02:22:45,280 --> 02:22:47,040
SO WHAT THIS SHOWS IS THE

3805
02:22:47,040 --> 02:22:48,480
ABILITY TO TRANSLATE THE

3806
02:22:48,480 --> 02:22:51,040
TREATMENT INTO PRACTICE.

3807
02:22:51,040 --> 02:22:55,800
THE SECOND STUDY, IS A LARGE

3808
02:22:55,800 --> 02:22:58,760
MULTI-OMIC PROJECT THAT IS

3809
02:22:58,760 --> 02:23:02,400
DESIGNED TO IDENTIFY GENETIC

3810
02:23:02,400 --> 02:23:05,360
EPIGENETIC PROTEOMIC SIGNATURES,

3811
02:23:05,360 --> 02:23:07,600
THAT MAY PREDICT SURVIVAL

3812
02:23:07,600 --> 02:23:09,440
OUTCOMES FOR MILD DYSPLASTIC

3813
02:23:09,440 --> 02:23:10,560
SYNDROME PATIENTS THAT ARE

3814
02:23:10,560 --> 02:23:12,840
RECEIVING ALLOGENEIC TRANSPLANT.

3815
02:23:12,840 --> 02:23:16,840
THE FIRST STEP IN THIS

3816
02:23:16,840 --> 02:23:19,160
MULTI-STATE PROGRAM WAS TO

3817
02:23:19,160 --> 02:23:22,760
ANALYZE DATA FROM 1500 HEALTHY

3818
02:23:22,760 --> 02:23:25,640
DATA DONOR AND MDS RECIPIENT

3819
02:23:25,640 --> 02:23:29,680
SPECIMENS TO LOOK AT THE GENETIC

3820
02:23:29,680 --> 02:23:31,360
MUTATIONS AND RESULTS WERE THEY

3821
02:23:31,360 --> 02:23:33,240
FOUND THAT THE PROGNOSIS WAS

3822
02:23:33,240 --> 02:23:36,760
POOR FOR PATIENTS THAT HAD TP 3

3823
02:23:36,760 --> 02:23:39,640
MUTATION AS WELL AS THE RAS AND

3824
02:23:39,640 --> 02:23:41,640
JACK 2 PATHWAY MUTATIONS THAT

3825
02:23:41,640 --> 02:23:45,640
WERE DUE TO TRANSPLANT

3826
02:23:45,640 --> 02:23:47,760
COMPLICATIONS OR RELAPSE.

3827
02:23:47,760 --> 02:23:50,120
ADVERSE EFFECT OF THE RAS

3828
02:23:50,120 --> 02:23:52,880
MUTATIONS CAN ALSO BE OVERCOME

3829
02:23:52,880 --> 02:23:54,440
TO CERTAIN DEGREE BY USING THE

3830
02:23:54,440 --> 02:23:56,680
HIGH INTENSITY PRE-TREATMENT

3831
02:23:56,680 --> 02:23:57,640
CONDITION.

3832
02:23:57,640 --> 02:23:58,760
SO THE PROCORRECT NOT MOVING

3833
02:23:58,760 --> 02:24:01,760
FORWARD TO LOOK AT PROTEOMIC

3834
02:24:01,760 --> 02:24:03,080
PROFILING, TO BE ABLE TO

3835
02:24:03,080 --> 02:24:04,640
IDENTIFY THE BENEFITS OF

3836
02:24:04,640 --> 02:24:06,720
TRANSPLANT PROCEDURES AND

3837
02:24:06,720 --> 02:24:08,120
UNDERSTAND WHAT -- UNDER WHAT

3838
02:24:08,120 --> 02:24:09,680
CONDITIONS.

3839
02:24:09,680 --> 02:24:12,760
NEXT SLIDE PLEASE.

3840
02:24:12,760 --> 02:24:17,440
SO WHERE DO WE GO FROM HERE.

3841
02:24:17,440 --> 02:24:19,360
NCI PROPOSES TO MAINTAIN CURRENT

3842
02:24:19,360 --> 02:24:22,200
ORGANIZATIONAL PRACTICES AND THE

3843
02:24:22,200 --> 02:24:24,880
ONGOING DATA COLLECTION AND AS

3844
02:24:24,880 --> 02:24:27,760
WELL AS TO ENSURE WE MAINTAIN

3845
02:24:27,760 --> 02:24:29,960
FOCUS ON THESE SPECIAL

3846
02:24:29,960 --> 02:24:31,680
INITIATIVES AND SUPPORT OF THE

3847
02:24:31,680 --> 02:24:33,560
HHS PROGRAMS.

3848
02:24:33,560 --> 02:24:35,480
THIS IS ESPECIALLY IMPORTANT

3849
02:24:35,480 --> 02:24:41,160
BECAUSE WE -- THE NUMBER OF

3850
02:24:41,160 --> 02:24:43,080
CELLULAR THERAPIES EXPECTED WITH

3851
02:24:43,080 --> 02:24:44,440
REGARDS TO THE LONG TERM

3852
02:24:44,440 --> 02:24:48,640
FOLLOW-UP STUDIES, WILL IT BE

3853
02:24:48,640 --> 02:24:49,920
SUBSTANTIAL OVER THE NEXT COUPLE

3854
02:24:49,920 --> 02:24:52,920
OF YEARS.

3855
02:24:52,920 --> 02:24:55,040
ALSO WHAT WE ARE TO POSING IS A

3856
02:24:55,040 --> 02:24:56,600
NEW DIRECTION THAT WILL REQUIRE

3857
02:24:56,600 --> 02:24:59,040
MORE STRENGTHENING ACADEMIC

3858
02:24:59,040 --> 02:25:02,760
PARTNER AND PRIVATE PARTNER

3859
02:25:02,760 --> 02:25:04,240
RELATIONSHIPS IS TO COLLECT

3860
02:25:04,240 --> 02:25:06,120
ADOPTIVE CELL THERAPIES FOR

3861
02:25:06,120 --> 02:25:06,960
SOLID TUMORS.

3862
02:25:06,960 --> 02:25:10,920
ALL THIS WHILE STILL PROVIDING

3863
02:25:10,920 --> 02:25:12,040
THE NECESSARY SUPPORT

3864
02:25:12,040 --> 02:25:12,960
STATISTICAL SUPPORT FOR TRIALS

3865
02:25:12,960 --> 02:25:19,160
AND OTHER RESEARCH STUDIES.

3866
02:25:19,160 --> 02:25:23,200
THANK YOU FOR YOUR ATTENTION

3867
02:25:23,200 --> 02:25:26,000
>> THANK YOU VERY MUCH.

3868
02:25:26,000 --> 02:25:27,560
MIKE, ARE YOU LEAD THE

3869
02:25:27,560 --> 02:25:28,000
DISCUSSION?

3870
02:25:28,000 --> 02:25:28,440
>> YES.

3871
02:25:28,440 --> 02:25:33,040
CAN YOU HEAR ME?

3872
02:25:33,040 --> 02:25:34,080
CAN YOU HEAR ME?

3873
02:25:34,080 --> 02:25:38,320
>> BE YES, G GO AHEAD MIKE.

3874
02:25:38,320 --> 02:25:44,920
>> I WILL SPEAK ON BEHALF OF DR.

3875
02:25:44,920 --> 02:25:47,560
FABRIS HARBOR AND MEAT WE E

3876
02:25:47,560 --> 02:25:48,600
REVIEWED IT AND THOUGHT IT WAS

3877
02:25:48,600 --> 02:25:52,160
AN OUTSTANDING EXCEPTIONAL

3878
02:25:52,160 --> 02:25:52,800
PROGRAM, MON STRAITED ACTIVITY,

3879
02:25:52,800 --> 02:25:56,000
ALL THE CHARACTERISTICS OF A

3880
02:25:56,000 --> 02:25:56,720
GOOD CON SOURCEIAL PROGRAM OF

3881
02:25:56,720 --> 02:26:00,240
IMPACT IN A VERY UNIQUE NICHE.

3882
02:26:00,240 --> 02:26:02,080
ITS COLLECTION OF BIOSPECIMENS

3883
02:26:02,080 --> 02:26:04,960
AND DATA AND SHARING COMMUNITY

3884
02:26:04,960 --> 02:26:07,280
AND LINK TO GENERAL PROTEOMICS

3885
02:26:07,280 --> 02:26:08,640
ARE COB TON GARAGE LATEDED FROM

3886
02:26:08,640 --> 02:26:09,080
THE NCI.

3887
02:26:09,080 --> 02:26:10,760
THE ONLY REASON WE WANTED TO

3888
02:26:10,760 --> 02:26:13,440
HAVE IT PRESENTED HERE IS TO

3889
02:26:13,440 --> 02:26:14,920
HAVE THE PROGRAM WHAT IS A GOOD

3890
02:26:14,920 --> 02:26:15,920
EXAMPLE OF WHAT CAN BE DONE AT

3891
02:26:15,920 --> 02:26:16,760
THE NCI.

3892
02:26:16,760 --> 02:26:19,720
I WILL HAND IT TO MY COLLEAGUES

3893
02:26:19,720 --> 02:26:22,480
SYLVIA AND BOB SCHRIEBER.

3894
02:26:22,480 --> 02:26:24,880
BOB IS NOT HERE BECAUSE OF

3895
02:26:24,880 --> 02:26:26,880
FAMILY EMERGENCY SO SYLVIA.

3896
02:26:26,880 --> 02:26:30,560
>> MICHAEL, THAT WAS TERRIFIC.

3897
02:26:30,560 --> 02:26:32,160
DR. HENDERSON THANK YOU FOR THAT

3898
02:26:32,160 --> 02:26:33,320
PRESENTATION.

3899
02:26:33,320 --> 02:26:37,080
COMPLETELY AGREE, THIS IS REALLY

3900
02:26:37,080 --> 02:26:38,480
REMARKABLE PROGRAM AND I THINK

3901
02:26:38,480 --> 02:26:41,160
IT IS A MODEL PROGRAM.

3902
02:26:41,160 --> 02:26:43,080
THE SUCCESSES WITH THE

3903
02:26:43,080 --> 02:26:44,840
BIOSPECIMEN COLLECTION AND DATA

3904
02:26:44,840 --> 02:26:48,360
SHARING AND THE DATA LINKAGES

3905
02:26:48,360 --> 02:26:51,520
ARE VERY EXCITING TO SEE AND WE

3906
02:26:51,520 --> 02:26:53,400
WERE -- WE REALLYING HOW IT WAS

3907
02:26:53,400 --> 02:26:54,520
IMPORTANT FOR THE COMMITTEES TO

3908
02:26:54,520 --> 02:26:55,040
HEAR ABOUT IT.

3909
02:26:55,040 --> 02:26:58,600
SO THANK YOU.

3910
02:26:58,600 --> 02:26:59,880
>> ANY FURTHER QUESTIONS OR

3911
02:26:59,880 --> 02:27:02,840
COMMENTS?

3912
02:27:02,840 --> 02:27:06,240
GO AHEAD TIM.

3913
02:27:06,240 --> 02:27:07,280
HEMATOPOIETIC MALIGNANCY, THE

3914
02:27:07,280 --> 02:27:10,320
FIELD WOULD BE LOST WITHOUT THIS

3915
02:27:10,320 --> 02:27:11,000
RESOURCE.

3916
02:27:11,000 --> 02:27:13,520
ONE OF THE FINEST EXAMPLES HOW

3917
02:27:13,520 --> 02:27:16,600
NCI SUPPORT FOR LARGE COLLECTIVE

3918
02:27:16,600 --> 02:27:18,720
RESEARCH COLLABORATION HAS BEEN

3919
02:27:18,720 --> 02:27:19,880
TRANSPERFORMTIVE AND SO CRITICAL

3920
02:27:19,880 --> 02:27:21,560
FOR EVERYTHING THAT WE DO.

3921
02:27:21,560 --> 02:27:25,480
THANKS.

3922
02:27:25,480 --> 02:27:31,000
>> UNIQUE NICHE REALLY SPANNING

3923
02:27:31,000 --> 02:27:32,240
SPECTRUM OF THINGS NCI WANTS TO

3924
02:27:32,240 --> 02:27:35,000
HANDLE IN EXTREMELY GROUP

3925
02:27:35,000 --> 02:27:40,720
GRATEFUL OPPORTUNITY FOR

3926
02:27:40,720 --> 02:27:41,040
COLLABORATORS.

3927
02:27:41,040 --> 02:27:43,320
>> SEEING NO OTHER HANDS, LET'S

3928
02:27:43,320 --> 02:27:45,000
MOVE TO VOTING.

3929
02:27:45,000 --> 02:27:46,360
MIKE COULD YOU MAKE A MOTION.

3930
02:27:46,360 --> 02:27:49,920
>> MAKE A MOTION TO ACCEPT

3931
02:27:49,920 --> 02:27:51,480
RENEWAL OF THIS.

3932
02:27:51,480 --> 02:27:53,560
AND WITH STRONG KUDOS.

3933
02:27:53,560 --> 02:27:56,360
>> THAT IS A BIG CONCURRENCE

3934
02:27:56,360 --> 02:27:58,880
MOTION SYLVIA, SECOND THAT?

3935
02:27:58,880 --> 02:28:01,280
>> SECOND.

3936
02:28:01,280 --> 02:28:07,560
>> SO GIVEN THAT READY FOR

3937
02:28:07,560 --> 02:28:12,680
DISCUSSION MOTION IS FOR

3938
02:28:12,680 --> 02:28:13,280
CONCURRENCE.

3939
02:28:13,280 --> 02:28:17,400
THAT WILL BE YOUR DEFAULT MODE.

3940
02:28:17,400 --> 02:28:19,440
PSA MEMBERS NOT ON SCREEN,

3941
02:28:19,440 --> 02:28:21,440
ANYONE VOTING NOT CONCUR VOICE

3942
02:28:21,440 --> 02:28:27,920
THAT OR RAISE YOUR HAND.

3943
02:28:27,920 --> 02:28:29,480
I SEE NONE.

3944
02:28:29,480 --> 02:28:35,760
ANY ABSTENTIONS.

3945
02:28:35,760 --> 02:28:37,120
SO NO ABSTENTIONS.

3946
02:28:37,120 --> 02:28:39,560
>> OKAY.

3947
02:28:39,560 --> 02:28:43,200
SO WE HAVE ANOTHER REISSUANCE

3948
02:28:43,200 --> 02:28:44,640
RFA TO KEEP THE LANGUAGE IN MIND

3949
02:28:44,640 --> 02:28:44,840
THERE.

3950
02:28:44,840 --> 02:28:46,800
THIS IS A PATIENT DERIVED

3951
02:28:46,800 --> 02:28:48,160
XENOGRAPH DEVELOPMENT AND TRIALS

3952
02:28:48,160 --> 02:28:50,560
CENTER NETWORK.

3953
02:28:50,560 --> 02:28:52,640
U 54 MECHANISM PDX DATA COMMONS

3954
02:28:52,640 --> 02:28:54,560
AND COORDINATING CENTER

3955
02:28:54,560 --> 02:28:57,240
PRESENTED BY DR. MOSCOW,

3956
02:28:57,240 --> 02:29:04,920
SUBCOMMITTEE CHAIR BY DAVE

3957
02:29:04,920 --> 02:29:09,360
SEDRANSKI, AND MIKE BECICH.

3958
02:29:09,360 --> 02:29:10,760
I BELIEVE DAVID COULDN'T BE WITH

3959
02:29:10,760 --> 02:29:12,560
US SO DR. MICHAEL WITH

3960
02:29:12,560 --> 02:29:13,880
DISCUSSION SO JEFF WHY DON'T YOU

3961
02:29:13,880 --> 02:29:14,840
GET GOING WITH THE PRESENTATION.

3962
02:29:14,840 --> 02:29:15,840
>> THANK YOU, GOOD AFTERNOON.

3963
02:29:15,840 --> 02:29:17,960
AND THANK YOU FOR THE

3964
02:29:17,960 --> 02:29:19,080
OPPORTUNITY TO PRESENT OUR

3965
02:29:19,080 --> 02:29:22,960
REQUEST FOR REISSUANCE OF RFAs

3966
02:29:22,960 --> 02:29:27,960
TO CONTINUE PDX NET COMPOSED OF

3967
02:29:27,960 --> 02:29:31,440
PDX AND TRIALS ACCEPTOR U 24

3968
02:29:31,440 --> 02:29:31,880
AWARD.

3969
02:29:31,880 --> 02:29:33,440
THIS IS A JOINT PROGRAM BETWEEN

3970
02:29:33,440 --> 02:29:35,240
THE DIVISION OF CANCER TREATMENT

3971
02:29:35,240 --> 02:29:38,120
AND DIAGNOSIS AND THE CENTER TO

3972
02:29:38,120 --> 02:29:38,960
REDUCE CANCER HEALTH

3973
02:29:38,960 --> 02:29:42,760
DISPARITIES.

3974
02:29:42,760 --> 02:29:44,960
THE ORIGINAL GOALS OF THE PDX

3975
02:29:44,960 --> 02:29:47,360
NET IN 2017 WHEN IT WAS FIRST

3976
02:29:47,360 --> 02:29:52,560
SET UP WERE TO TEST THERAPEUTIC

3977
02:29:52,560 --> 02:29:54,680
STRATEGIES AND LARGE SCALE CLECS

3978
02:29:54,680 --> 02:29:56,360
TO PROVIDE PRE-CLINICAL IN VIVO

3979
02:29:56,360 --> 02:29:57,760
EVIDENCE TO SUPPORT NOVEL EARLY

3980
02:29:57,760 --> 02:29:59,800
BASED CLINICAL TRIALS TO ADDRESS

3981
02:29:59,800 --> 02:30:01,280
CRITICAL SCIENTIFIC ISSUES

3982
02:30:01,280 --> 02:30:05,160
RELATED TO USE OF PDX MODELS OF

3983
02:30:05,160 --> 02:30:06,480
CLINICAL BENEFIT THROUGH

3984
02:30:06,480 --> 02:30:08,360
COLLABORATIVE NETWORK STRUCTURE

3985
02:30:08,360 --> 02:30:11,360
PDX NET AND CONTRIBUTE NEW PDX

3986
02:30:11,360 --> 02:30:13,600
MODEL TO NCI PATIENT DERIVED

3987
02:30:13,600 --> 02:30:15,600
MODEL REPOSITORY FOR

3988
02:30:15,600 --> 02:30:16,760
DISTRIBUTION OF WIDER RESEARCH

3989
02:30:16,760 --> 02:30:18,800
COMMUNITY.

3990
02:30:18,800 --> 02:30:22,240
WHEN ADDITIONAL PDCs WERE

3991
02:30:22,240 --> 02:30:23,440
GOWNED THE NET WORK THROUGH

3992
02:30:23,440 --> 02:30:25,160
CENTER OF REDUCE CANCER HEALTH

3993
02:30:25,160 --> 02:30:26,520
DISPARITIES WE ADD ADDITIONAL

3994
02:30:26,520 --> 02:30:28,720
GOALS TO INCREASE THE DIVERSE

3995
02:30:28,720 --> 02:30:30,480
REPRESENTATION AND STUDY OF

3996
02:30:30,480 --> 02:30:32,040
RACIAL ETHNIC MINORITY

3997
02:30:32,040 --> 02:30:33,920
POPULATIONS IN PDX NET AND

3998
02:30:33,920 --> 02:30:36,120
REPRESENTATION IN THE PDMR AND

3999
02:30:36,120 --> 02:30:37,920
TO ADVANCE CANCER HEALTH

4000
02:30:37,920 --> 02:30:41,880
DISPARITIES RESEARCH.

4001
02:30:41,880 --> 02:30:43,520
THIS H IS THE CURRENT STRUCTURE

4002
02:30:43,520 --> 02:30:49,080
OF PDX NET BY THREE RFAs WITH

4003
02:30:49,080 --> 02:30:50,680
THE -- WHICH WILL ULTIMATELY NOW

4004
02:30:50,680 --> 02:30:54,440
BE REDUCED TO TWO RFAs, THE

4005
02:30:54,440 --> 02:30:55,560
ORIGINAL FOUR ARE SHOWN ON THE

4006
02:30:55,560 --> 02:30:58,360
LEFT WITH TWO ADDITIONAL PDC

4007
02:30:58,360 --> 02:30:59,960
BROUGHT IN A YEAR LATER THROUGH

4008
02:30:59,960 --> 02:31:02,760
THE CRCHD, ALL INTERACTING WITH

4009
02:31:02,760 --> 02:31:06,400
THE COORDINATING CENTER AND THE

4010
02:31:06,400 --> 02:31:08,000
PDMR REPOSITORY.

4011
02:31:08,000 --> 02:31:10,840
THE ENTIRE NETWORK INTERACTED

4012
02:31:10,840 --> 02:31:12,400
WITH OTHER LABORATORY BASE

4013
02:31:12,400 --> 02:31:14,080
INVESTIGATORS TO A SUPPLEMENT

4014
02:31:14,080 --> 02:31:16,960
PROGRAM AND WITH THE ETCTN AND

4015
02:31:16,960 --> 02:31:19,560
OTHER NCI CLINICAL NETWORKS FOR

4016
02:31:19,560 --> 02:31:22,080
CLINICAL TRANSLATION OF

4017
02:31:22,080 --> 02:31:25,400
EXPERIMENTAL RESULTS.

4018
02:31:25,400 --> 02:31:28,080
THE ACCOMPLISHMENTS IN THE FIRST

4019
02:31:28,080 --> 02:31:29,520
CYCLE INCLUDED THE COLLABORATION

4020
02:31:29,520 --> 02:31:33,160
WITH CRCHD TO BRING IN THEIR TWO

4021
02:31:33,160 --> 02:31:36,440
ADDITIONAL PETCs FOCUSED ON

4022
02:31:36,440 --> 02:31:38,760
DISPARITY RESEARCH P. IT REALLY

4023
02:31:38,760 --> 02:31:40,120
DID DEVELOP A CULTURE

4024
02:31:40,120 --> 02:31:41,760
COLLABORATION AMONG ALL GRANTEES

4025
02:31:41,760 --> 02:31:43,320
WITH MULTIPLE COLLABORATIVE

4026
02:31:43,320 --> 02:31:44,560
RESEARCH PROJECTS.

4027
02:31:44,560 --> 02:31:46,560
I THINK THAT THE INVESTIGATORS

4028
02:31:46,560 --> 02:31:48,720
IN THE NETWORK CAPITALIZE ON

4029
02:31:48,720 --> 02:31:50,480
NETWORK STRUCTURE AND RESOURCE

4030
02:31:50,480 --> 02:31:52,560
TO TRULY COLLABORATE ON NETWORK

4031
02:31:52,560 --> 02:31:54,960
WIDE RESEARCH PROJECTS INCLUDING

4032
02:31:54,960 --> 02:31:56,960
DEMONSTRATION MULTI-CENTER

4033
02:31:56,960 --> 02:31:58,880
EXPERIMENTAL REPRODUCIBILITY OF

4034
02:31:58,880 --> 02:32:01,320
DRUG RESPONSE STUDIES USING PDX

4035
02:32:01,320 --> 02:32:02,560
MODEL DEMONSTRATION OF COPY

4036
02:32:02,560 --> 02:32:05,160
NUMBER ALTERATION FIDELITY AND

4037
02:32:05,160 --> 02:32:09,200
SUCCESS PDX PASSAGES TAKING

4038
02:32:09,200 --> 02:32:12,240
NETWORK AND SHOWING IDENTICAL

4039
02:32:12,240 --> 02:32:13,960
RESULTS DEMONSTRATION OF

4040
02:32:13,960 --> 02:32:16,240
THERAPEUTIC TARGET PATHWAY

4041
02:32:16,240 --> 02:32:18,160
IDENTIFICATION AND ONGOING COST

4042
02:32:18,160 --> 02:32:19,920
NETWORK COLLABORATIVE STUDY OF

4043
02:32:19,920 --> 02:32:22,000
GREAT EFFICACY EVALUATION

4044
02:32:22,000 --> 02:32:23,720
METHODS IN PDX MODELS TO

4045
02:32:23,720 --> 02:32:25,040
DETERMINE HOW WE MIGHT SET

4046
02:32:25,040 --> 02:32:27,520
STANDARDS FROM MEANINGFUL

4047
02:32:27,520 --> 02:32:30,480
REPORTING OF DRUG RESPONSE

4048
02:32:30,480 --> 02:32:31,040
EXPERIMENTS.

4049
02:32:31,040 --> 02:32:33,280
THESE COLLABORATIVE PROJECTS IN

4050
02:32:33,280 --> 02:32:37,760
THEIR SUCCESS HAS NOW LED TO TEN

4051
02:32:37,760 --> 02:32:40,240
ACTIVE INTERNETWORK

4052
02:32:40,240 --> 02:32:41,360
COLLABORATIONS THAT ARE BY THE

4053
02:32:41,360 --> 02:32:44,400
COORDINATING CENTER.

4054
02:32:44,400 --> 02:32:47,520
IN ADDITION THE INVESTIGATORS

4055
02:32:47,520 --> 02:32:50,320
DONATED 690 UNIQUE MODELS TO THE

4056
02:32:50,320 --> 02:32:53,960
PDMR MOST ARE IN PROCESS IS OF

4057
02:32:53,960 --> 02:32:54,560
EXPANDING PRIORITIZATION PRIOR

4058
02:32:54,560 --> 02:32:55,840
TO PUBLIC DISTRIBUTION.

4059
02:32:55,840 --> 02:32:57,960
PRE-CLINICAL EVIDENCE DEVELOPED

4060
02:32:57,960 --> 02:32:59,760
FROM 10CTEP LOI.

4061
02:32:59,760 --> 02:33:02,040
A WEBSITE FOR INTERNAL NETWORK

4062
02:33:02,040 --> 02:33:02,920
COLLABORATION BUT ALSO FOR

4063
02:33:02,920 --> 02:33:05,920
PUBLIC ACCESS TO OUR DATA AND TO

4064
02:33:05,920 --> 02:33:07,080
SOPs.

4065
02:33:07,080 --> 02:33:08,840
AND AS DR. SHAW WAS MENTIONS A

4066
02:33:08,840 --> 02:33:11,320
FEW DAYS COLLABORATION REQUIRE

4067
02:33:11,320 --> 02:33:13,560
DATA SHARING REQUIRE DEVELOPMENT

4068
02:33:13,560 --> 02:33:15,760
OF TOOLS TO FACILITATE IT AND

4069
02:33:15,760 --> 02:33:18,280
THAT CERTAINLY BEEN THE CASE,

4070
02:33:18,280 --> 02:33:20,720
COLLABORATIVE PROJECTS FROM

4071
02:33:20,720 --> 02:33:23,280
WITHIN PDX NET AND RESULTED IN

4072
02:33:23,280 --> 02:33:26,360
15 VALIDATED WORK FLOWS, THAT WE

4073
02:33:26,360 --> 02:33:27,800
USE TO FACILITATE THE

4074
02:33:27,800 --> 02:33:29,160
COLLABORATIVE PROJECTS WHICH ARE

4075
02:33:29,160 --> 02:33:32,200
NOW ALSO SHARED WITH THE PDX

4076
02:33:32,200 --> 02:33:34,280
SUPPORT.

4077
02:33:34,280 --> 02:33:37,320
ALSO THE RESEARCH GRANTS

4078
02:33:37,320 --> 02:33:38,960
ORIGINAL RESEARCH PROJECTS

4079
02:33:38,960 --> 02:33:42,160
ONGOING AND 88 ORIGINAL

4080
02:33:42,160 --> 02:33:45,640
PUBLICATIONS HAVE BEEN PUBLISHED

4081
02:33:45,640 --> 02:33:49,760
FROM RESEARCH FROM PDX

4082
02:33:49,760 --> 02:33:52,960
INVESTIGATORS.

4083
02:33:52,960 --> 02:33:56,040
WE UNDERWENT EXTERNAL REVIEW OF

4084
02:33:56,040 --> 02:33:58,360
PDX NET REVIEWERS

4085
02:33:58,360 --> 02:33:58,880
ENTHUSIASTICALLY SUPPORTED

4086
02:33:58,880 --> 02:34:01,560
RENEWAL OF IT.

4087
02:34:01,560 --> 02:34:04,000
WITH SCORES AS YOU CAN SEE ON

4088
02:34:04,000 --> 02:34:08,240
THE ONE TO NINE RANGE FOR -- HA

4089
02:34:08,240 --> 02:34:11,560
WE USE FOR GRANT EVALUATION.

4090
02:34:11,560 --> 02:34:12,800
REVIEWSERS NOTED PROGRESS

4091
02:34:12,800 --> 02:34:15,040
DESCRIBING THE PROGRESS REPORT

4092
02:34:15,040 --> 02:34:16,400
WAS MADE ONLY AFTER THREE AND A

4093
02:34:16,400 --> 02:34:17,600
HALF YEARS AND TWO AND A HALF

4094
02:34:17,600 --> 02:34:24,720
YEARS IN THE CASE OF CHHD PDTC E

4095
02:34:24,720 --> 02:34:27,240
SO MADE DURING THE PANDEMIC

4096
02:34:27,240 --> 02:34:31,000
WHICH PLACED SEVERE PERSONNEL

4097
02:34:31,000 --> 02:34:31,720
RESTRICTIONS.

4098
02:34:31,720 --> 02:34:33,600
OUR DISCUSSION FOCUSED ON TUMOR

4099
02:34:33,600 --> 02:34:37,000
VOLUME ANALYSIS WORK AND

4100
02:34:37,000 --> 02:34:39,960
ENCOURAGED US TO WORK TO

4101
02:34:39,960 --> 02:34:44,200
ESTABLISH CONSENSUS METRICS FOR

4102
02:34:44,200 --> 02:34:45,960
DRUG RESPONSE, FOCUSING

4103
02:34:45,960 --> 02:34:46,840
SUPPLEMENT PROGRAM WITH

4104
02:34:46,840 --> 02:34:47,960
COLLABORATIONS FROM CLINICIAN

4105
02:34:47,960 --> 02:34:50,320
SCIENTIST AND WE DID DISCUSS

4106
02:34:50,320 --> 02:34:51,680
IMMUNO-ONCOLOGY ISSUES AND HOW

4107
02:34:51,680 --> 02:34:56,960
THEY MIGHT BE EVALUATED IN PDX

4108
02:34:56,960 --> 02:35:01,880
NET BUT IT IS COMPLICATED AND --

4109
02:35:01,880 --> 02:35:03,120
NEXT SLIDE.

4110
02:35:03,120 --> 02:35:07,960
WE RECEIVED INFORMATION FROM

4111
02:35:07,960 --> 02:35:09,440
SUBCOMMITTEE, AND THANKED THEM

4112
02:35:09,440 --> 02:35:10,800
FOR INPUT DEFINING DELIVERABLES

4113
02:35:10,800 --> 02:35:12,240
FOR THE SECOND GRANT CYCLE

4114
02:35:12,240 --> 02:35:13,600
INCLUDING DEVELOPMENT AND

4115
02:35:13,600 --> 02:35:14,920
APPLICATION OF DRUG RESPONSE

4116
02:35:14,920 --> 02:35:16,800
EVALUATION STANDARDS ACROSS PDX

4117
02:35:16,800 --> 02:35:18,800
NET APPLYING THEM IN OUR OWN

4118
02:35:18,800 --> 02:35:20,000
PUBLICATION -- IN THEIR OWN

4119
02:35:20,000 --> 02:35:21,680
PUBLICATIONS AND ADVOCATING FOR

4120
02:35:21,680 --> 02:35:23,840
ADOPTION ACROSS THE THE WIDER

4121
02:35:23,840 --> 02:35:28,360
RESEARCH COMMUNITY.

4122
02:35:28,360 --> 02:35:32,320
PROVIDE ROBUST DATA TO

4123
02:35:32,320 --> 02:35:32,920
PRIORITIZE 20 CLINICAL TRIALS

4124
02:35:32,920 --> 02:35:33,720
NCI CLINICAL TRIAL NETWORKS

4125
02:35:33,720 --> 02:35:35,120
WHICH IS REALLY CAN YOU BELIEVE

4126
02:35:35,120 --> 02:35:37,160
FROM THE FIRST CYCLE.

4127
02:35:37,160 --> 02:35:39,040
AND THIS THIRD POINT WAS TO

4128
02:35:39,040 --> 02:35:41,640
FOCUS OF OUR DISCUSSION WITH BSA

4129
02:35:41,640 --> 02:35:43,360
COMMITTEE MEMBERS REGARD MAKING

4130
02:35:43,360 --> 02:35:49,680
MORE STRATEGIC DOE NEIGHS TO

4131
02:35:49,680 --> 02:35:50,360
PDR.

4132
02:35:50,360 --> 02:35:52,960
THIS REFLECTS BY DEFINING HOW

4133
02:35:52,960 --> 02:35:55,960
PDX WILL BE MORE FOCUSED IN

4134
02:35:55,960 --> 02:35:59,080
DONATION FROM THE PDMR REQUIRING

4135
02:35:59,080 --> 02:36:02,480
GAPS IN REPOSITORY COLLECTION

4136
02:36:02,480 --> 02:36:03,960
AND METHODS TO ORCHESTRATE

4137
02:36:03,960 --> 02:36:05,600
TARGETED COLLECTIONS TO FILL

4138
02:36:05,600 --> 02:36:08,160
THOSE GAPS, TO INCLUDE RACIALLY

4139
02:36:08,160 --> 02:36:10,600
ETHNICALLY UNDERSERVED MODEL OR

4140
02:36:10,600 --> 02:36:12,320
MODELS FROM PATIENTS WHO ARE

4141
02:36:12,320 --> 02:36:14,360
CLINICALLY RELAMENTED OR WHO ARE

4142
02:36:14,360 --> 02:36:15,840
-- RELAPSED OR RESISTANT TO

4143
02:36:15,840 --> 02:36:16,360
THERAPY.

4144
02:36:16,360 --> 02:36:19,360
IN ADDITION, USING THE NETWORK

4145
02:36:19,360 --> 02:36:21,560
COLLABORATIVE PROJECT AS ENGINE

4146
02:36:21,560 --> 02:36:22,840
TO GUIDE DATA INTEGRATION

4147
02:36:22,840 --> 02:36:24,160
NETWORK SHOULD CONTINUE TO

4148
02:36:24,160 --> 02:36:27,400
CREATE METHODS AND WORK FLOWS TO

4149
02:36:27,400 --> 02:36:28,880
INTEGRATE COMPLEX OMIC DATA FROM

4150
02:36:28,880 --> 02:36:31,560
MULTIPLE SITES, DO A SEARCHABLE

4151
02:36:31,560 --> 02:36:33,760
DATABASE MODEL SECTION SELECTION

4152
02:36:33,760 --> 02:36:35,080
AND MAKE TOOLS PUBLICLY

4153
02:36:35,080 --> 02:36:37,600
AVAILABLABLE AND FACILITATE

4154
02:36:37,600 --> 02:36:38,760
PRODUCTIVE COLLABORATION BETWEEN

4155
02:36:38,760 --> 02:36:41,320
PX NET SCIENTIST AND EARLY PHASE

4156
02:36:41,320 --> 02:36:42,160
CLINICAL TRIALISTS.

4157
02:36:42,160 --> 02:36:45,240
NEXT SLID PLEASE.

4158
02:36:45,240 --> 02:36:48,960
SO THE U 54 WOULD BE REQUIRED TO

4159
02:36:48,960 --> 02:36:51,400
HAVE TWO RESEARCH PROJECTS AND

4160
02:36:51,400 --> 02:36:53,200
MECHANISM BASED DRUG

4161
02:36:53,200 --> 02:36:55,000
COMBINATIONS GENETICALLY OR

4162
02:36:55,000 --> 02:36:56,360
HISTOLOGICALLY DEFINE TUMOR SUB

4163
02:36:56,360 --> 02:36:57,720
GROUPS THAT EXPLORE RELATIONSHIP

4164
02:36:57,720 --> 02:36:59,360
WITH TUMOR CHARACTERISTICS AND

4165
02:36:59,360 --> 02:37:02,360
TUMOR DRUG RESPONSE.

4166
02:37:02,360 --> 02:37:03,960
CRCHD TRACK FOCUS ON MODELS

4167
02:37:03,960 --> 02:37:05,720
RELEVANT TO CANCER HEALTH

4168
02:37:05,720 --> 02:37:06,560
DISPARITIES.

4169
02:37:06,560 --> 02:37:09,320
EACH U 54 HAVE FOUR REQUIRED

4170
02:37:09,320 --> 02:37:11,240
CORES AND EXPECTATION RESEARCH

4171
02:37:11,240 --> 02:37:13,040
PROJECTS WOULD EMPLOY LARGE

4172
02:37:13,040 --> 02:37:14,920
SCALE PDX COLLECTIONS.

4173
02:37:14,920 --> 02:37:18,160
NEXT SLIDE.

4174
02:37:18,160 --> 02:37:21,400
THE U 24 WOULD HAVE TWO CORES

4175
02:37:21,400 --> 02:37:22,400
BIOINFORMATICS CORE, CONTINUE TO

4176
02:37:22,400 --> 02:37:24,280
WORK LEADING THE DEVELOPMENT AND

4177
02:37:24,280 --> 02:37:26,040
IMPLEMENTATION OF DATA STANDARDS

4178
02:37:26,040 --> 02:37:29,560
WORK FLOWS SOPs AND

4179
02:37:29,560 --> 02:37:31,480
HARMONIZATION DATA INTEGRATION

4180
02:37:31,480 --> 02:37:33,560
ACROSS THE DIFFERENT PEDCs AND

4181
02:37:33,560 --> 02:37:36,200
CONTINUE TO MAINTAIN WEBSITE AND

4182
02:37:36,200 --> 02:37:37,680
ADMINISTRATIVE CORE AS

4183
02:37:37,680 --> 02:37:39,720
LOGISTICAL AND ADMINISTRATIVE

4184
02:37:39,720 --> 02:37:40,160
CENTER.

4185
02:37:40,160 --> 02:37:43,840
NEXT SLIDE.

4186
02:37:43,840 --> 02:37:45,600
THE SUPPLEMENT PROGRAM IN THE

4187
02:37:45,600 --> 02:37:48,520
PAST IN THE FIRST CYCLE WAS

4188
02:37:48,520 --> 02:37:49,840
GIVEN TO LABORATORY SCIENTIST

4189
02:37:49,840 --> 02:37:52,160
OUTSIDE PDX NET TO COLLABORATE

4190
02:37:52,160 --> 02:37:55,360
WITH LABORATORY SCIENCE

4191
02:37:55,360 --> 02:37:57,800
INVESTIGATED WITHIN PDX NET AND

4192
02:37:57,800 --> 02:38:00,240
OVERALL THE PRODUCTIVITY WAS

4193
02:38:00,240 --> 02:38:03,000
FELT MODEST.

4194
02:38:03,000 --> 02:38:05,880
WE FELT EXTERNAL COMMITTEE FELT

4195
02:38:05,880 --> 02:38:08,360
THAT IT WOULD BE BEST TO

4196
02:38:08,360 --> 02:38:09,560
RESTRUCTURE THIS TO FACILITATE

4197
02:38:09,560 --> 02:38:11,360
INVESTIGATOR INITIATED CLINICAL

4198
02:38:11,360 --> 02:38:12,920
TRIALS BY PROVIDING CLINICIAN

4199
02:38:12,920 --> 02:38:17,160
SCIENTISTS ACCESS TODX NET FOR

4200
02:38:17,160 --> 02:38:18,400
PROPOSED THERAPIES,

4201
02:38:18,400 --> 02:38:20,400
COLLABORATION BETWEEN CLINICIAN

4202
02:38:20,400 --> 02:38:22,520
AND THE PDX NET INVESTIGATORS

4203
02:38:22,520 --> 02:38:26,880
COULD INCLUDE BIOMARKER

4204
02:38:26,880 --> 02:38:27,960
DEVELOPMENT INVESTIGATION

4205
02:38:27,960 --> 02:38:29,080
MECHANISM TO PDX RELATED

4206
02:38:29,080 --> 02:38:29,680
RESEARCH QUESTIONS.

4207
02:38:29,680 --> 02:38:31,920
NEXT SLIDE.

4208
02:38:31,920 --> 02:38:35,320
SO THE BENEFITS OF THE PROPOSED

4209
02:38:35,320 --> 02:38:38,440
FOA AND THE REISSUE IS THIS

4210
02:38:38,440 --> 02:38:40,480
NETWORKTRANSSENDS SILO

4211
02:38:40,480 --> 02:38:42,360
STRUCTURE OF PDX PROGRAMS THAT

4212
02:38:42,360 --> 02:38:44,240
IT CREATES INTEGRATED

4213
02:38:44,240 --> 02:38:45,920
COORDINATED COLLABORATIVE

4214
02:38:45,920 --> 02:38:47,800
NETWORK OF PDX CENTERS OF

4215
02:38:47,800 --> 02:38:49,360
EXCELLENCE TO ADDRESS MULTIPLE

4216
02:38:49,360 --> 02:38:50,960
SCIENTIFIC ISSUES, IT FOCUSES ON

4217
02:38:50,960 --> 02:38:52,640
THE DEVELOPMENT OF PRE-CLINICAL

4218
02:38:52,640 --> 02:38:55,160
IN VIVO EVIDENCE MORE RAPID

4219
02:38:55,160 --> 02:38:57,360
TRANSLATION TO INTEGRATION WITH

4220
02:38:57,360 --> 02:38:59,280
NCI CLINICAL NETWORKS, IT

4221
02:38:59,280 --> 02:39:01,160
CREATES HARMONIZE WORK FLOWS TO

4222
02:39:01,160 --> 02:39:03,800
FACILITATE COLLABORATION AND

4223
02:39:03,800 --> 02:39:06,160
SHARING THOSE SOP AND WORK FLOWS

4224
02:39:06,160 --> 02:39:10,560
WITH A COMMUNITY AND FACILITATES

4225
02:39:10,560 --> 02:39:13,200
MULTI-CENTER DONATION OF PDX

4226
02:39:13,200 --> 02:39:16,480
MODEL TO PD MARKET FILL IDENTIFY

4227
02:39:16,480 --> 02:39:17,440
RESOURCE GAPS.

4228
02:39:17,440 --> 02:39:19,560
IT IS A PURPOSE DRIVEN

4229
02:39:19,560 --> 02:39:20,880
CONSORTIUM FOR PRACTICAL

4230
02:39:20,880 --> 02:39:24,760
APPLICATION OF PDX BY

4231
02:39:24,760 --> 02:39:26,000
INTEGRATING PDX SCIENTIST.

4232
02:39:26,000 --> 02:39:28,160
THE NEXT PROGRAM IN CLINICAL

4233
02:39:28,160 --> 02:39:29,040
SCIENTIST AND CLINICAL TRIAL

4234
02:39:29,040 --> 02:39:30,840
NETWORK CREATING A COMPLETE

4235
02:39:30,840 --> 02:39:32,960
ENTERPRISE FOR DEVELOPMENT OF

4236
02:39:32,960 --> 02:39:33,960
PRECISION CANCER MEDICINE.

4237
02:39:33,960 --> 02:39:36,480
IT ADDRESSES OUR NEED FOR IN

4238
02:39:36,480 --> 02:39:38,040
VIVO EVIDENCE TO PRIORITIZE

4239
02:39:38,040 --> 02:39:40,200
TARGETED AGENT COMBINATIONS,

4240
02:39:40,200 --> 02:39:42,360
MOLECULARLY DEFINED TUMORS FOR

4241
02:39:42,360 --> 02:39:43,480
NCI CLINICAL TRIAL DEVELOMENT

4242
02:39:43,480 --> 02:39:45,040
AND IT COMPLIMENTS THE DIVISION

4243
02:39:45,040 --> 02:39:47,600
OF CANCER BIOLOGY PATIENT

4244
02:39:47,600 --> 02:39:49,040
DERIVED MODEL OF CANCER PROGRAM

4245
02:39:49,040 --> 02:39:51,280
WHICH FOCUSES ON THE BIOLOGY OF

4246
02:39:51,280 --> 02:39:54,680
PATIENT GUIDELINES.

4247
02:39:54,680 --> 02:39:55,200
NEXT SLIDE.

4248
02:39:55,200 --> 02:39:57,120
SO THIS IS THE BUDGET, THE

4249
02:39:57,120 --> 02:39:59,000
CURRENT FUNDING LEVEL IS

4250
02:39:59,000 --> 02:40:00,440
$10.5 MILLION A YEAR, CANCER

4251
02:40:00,440 --> 02:40:03,960
MOON SHOT PROGRAM AND WE HAVE

4252
02:40:03,960 --> 02:40:06,440
PROPOSED DECREASING TOTAL COSTS

4253
02:40:06,440 --> 02:40:08,120
TO $8 MILLION A YEAR DECREASING

4254
02:40:08,120 --> 02:40:09,560
THE NUMBER OF DEVELOPMENT AND

4255
02:40:09,560 --> 02:40:12,360
TRIAL CENTERS FROM 6 TO 5 AND

4256
02:40:12,360 --> 02:40:13,760
DECREASING THE BUDGET OR THE

4257
02:40:13,760 --> 02:40:15,840
COORDINATING CENTER AND -- OF

4258
02:40:15,840 --> 02:40:17,560
THE SUPPLEMENT PROGRAM.

4259
02:40:17,560 --> 02:40:22,520
NEXT SLIDE.

4260
02:40:22,520 --> 02:40:23,320
SO THANK YOU, VERY MUCH TO

4261
02:40:23,320 --> 02:40:24,440
ASSIST IN ANSWERING QUESTIONS

4262
02:40:24,440 --> 02:40:26,160
I'M HERE WITH TIFFANY WALLACE

4263
02:40:26,160 --> 02:40:28,000
FROM CENTER TO REDUCE CANCER

4264
02:40:28,000 --> 02:40:30,080
HEALTH DISPARITIES.

4265
02:40:30,080 --> 02:40:31,640
YVONNE FROM THE PATIENT GUIDE

4266
02:40:31,640 --> 02:40:33,640
MODEL REPOSITORY AND KIM

4267
02:40:33,640 --> 02:40:35,760
WITHERSPOON WHO IS OUR

4268
02:40:35,760 --> 02:40:36,760
INVESTIGATION DRUG BRANCH,

4269
02:40:36,760 --> 02:40:41,200
BRANCH MANAGEMENT SPECIALIST,

4270
02:40:41,200 --> 02:40:42,360
POOLS PAPERWORK TOGETHER.

4271
02:40:42,360 --> 02:40:44,080
THANK YOU VERY MUCH AND HAPPY TO

4272
02:40:44,080 --> 02:40:45,720
ANSWER QUESTIONS.

4273
02:40:45,720 --> 02:40:47,880
>> THANKS, JEFF.

4274
02:40:47,880 --> 02:40:51,600
SHOULD I CONFIRM IN THE

4275
02:40:51,600 --> 02:40:53,240
PARTICIPANT LIST -- IS NOT WITH

4276
02:40:53,240 --> 02:40:55,920
US SO DAVE CAN YOU GET US

4277
02:40:55,920 --> 02:40:56,160
STARTD?

4278
02:40:56,160 --> 02:40:58,960
>> THANK YOU, DR. MOSCOW,

4279
02:40:58,960 --> 02:40:59,880
TERRIFIC PRESENTATION, THANK YOU

4280
02:40:59,880 --> 02:41:01,680
SO MUCH FOR RESPONDING TO OUR

4281
02:41:01,680 --> 02:41:03,920
MANY QUESTIONS THAT WE HAD OF

4282
02:41:03,920 --> 02:41:04,520
THE PROGRAM.

4283
02:41:04,520 --> 02:41:05,960
IT IS ORIGINAL INTENTIONS WERE

4284
02:41:05,960 --> 02:41:09,160
AND WHAT YOU LEARNED DURING THE

4285
02:41:09,160 --> 02:41:12,080
PAST FOUR YEARS HOW YOU MODIFY

4286
02:41:12,080 --> 02:41:13,360
THINGS TO MEET THE GOALS OF WHY

4287
02:41:13,360 --> 02:41:15,640
IT WAS SET UP IN THE FIRST

4288
02:41:15,640 --> 02:41:16,040
PLACE.

4289
02:41:16,040 --> 02:41:18,800
I WANT TO START BY ADDRESSING

4290
02:41:18,800 --> 02:41:20,760
THE COVID PANDEMIC YOU TALKED

4291
02:41:20,760 --> 02:41:22,200
HOW INVESTIGATOR HAD A HARD TIME

4292
02:41:22,200 --> 02:41:24,000
MANAGING LARGE ANIMAL COLONIES

4293
02:41:24,000 --> 02:41:26,280
DURING THAT TIME BECAUSE OF

4294
02:41:26,280 --> 02:41:27,360
PERSONNEL LIMITATIONS THE OTHER

4295
02:41:27,360 --> 02:41:30,000
ISSUE, THIS IS A PROGRAM TOTALLY

4296
02:41:30,000 --> 02:41:31,160
DEPENDENT ON ACQUISITION OF

4297
02:41:31,160 --> 02:41:33,360
FRESH HUMAN TUMORS.

4298
02:41:33,360 --> 02:41:36,160
AND MOST CANCER SURGERIES

4299
02:41:36,160 --> 02:41:37,840
STOPPED ACROSS THE COUNTRY.

4300
02:41:37,840 --> 02:41:39,480
SO THE BIG HIT TO THIS PROGRAM

4301
02:41:39,480 --> 02:41:42,280
IS THERE WERE NO SAMPLES.

4302
02:41:42,280 --> 02:41:43,400
FOR 18 TO 24 MONTHS.

4303
02:41:43,400 --> 02:41:47,520
YET YOU STILL MADE 690 SAMPLES

4304
02:41:47,520 --> 02:41:51,360
WHICH SHOULDN'T BE OVERLOOKED.

4305
02:41:51,360 --> 02:41:52,120
SO THAT WAS GREAT.

4306
02:41:52,120 --> 02:41:54,640
THE CONCEPT OF PDX IS CAN WE

4307
02:41:54,640 --> 02:41:56,480
LEARN ABOUT HUMAN CANCER TO HELP

4308
02:41:56,480 --> 02:41:58,120
OTHER HUMANS WHO HAVE CANCER

4309
02:41:58,120 --> 02:42:00,560
LIKE THIS, AND/OR CAN WE HELP

4310
02:42:00,560 --> 02:42:01,880
THAT PATIENT WITH THIS CANCER?

4311
02:42:01,880 --> 02:42:05,080
CAN IT GO ALL THE WAY TO A

4312
02:42:05,080 --> 02:42:06,560
PERSONALIZED MEDICINE

4313
02:42:06,560 --> 02:42:06,840
APPLICATION?

4314
02:42:06,840 --> 02:42:08,680
THE PDX SPACE IT IS STILL

4315
02:42:08,680 --> 02:42:10,560
UNCLEAR BECAUSE IT TAKES

4316
02:42:10,560 --> 02:42:12,800
SOMEWHERE MORE THAN SIX UP TO 24

4317
02:42:12,800 --> 02:42:15,360
MONTHS GENERATE GOOD PDX LEVELS

4318
02:42:15,360 --> 02:42:19,200
WHERE YOU HAVE ENOUGH MICE SO

4319
02:42:19,200 --> 02:42:20,640
YOU CAN DO TREATMENT IN THERAPY

4320
02:42:20,640 --> 02:42:23,560
AS WELL AS COMBINATION THERAPY.

4321
02:42:23,560 --> 02:42:24,720
THE IMPORTANT POINTS THIS GROUP

4322
02:42:24,720 --> 02:42:26,960
IS WORKING ON IS STANDARDIZATION

4323
02:42:26,960 --> 02:42:27,560
SO THAT WE CAN ANSWER THAT

4324
02:42:27,560 --> 02:42:29,400
QUESTION.

4325
02:42:29,400 --> 02:42:31,040
SO AGAIN THE POINT OF HAVING

4326
02:42:31,040 --> 02:42:33,520
MULTIPLE SITES AROUND THE

4327
02:42:33,520 --> 02:42:35,520
COUNTRY, WILL IN FACT TRY TO

4328
02:42:35,520 --> 02:42:38,160
REPRODUCE THE SAME EXPERIMENT

4329
02:42:38,160 --> 02:42:39,800
WITH THE SAME MODELS.

4330
02:42:39,800 --> 02:42:41,400
IT IS TOTALLY ESSENTIAL.

4331
02:42:41,400 --> 02:42:42,960
RIGOR AND REPRODUCIBILITY

4332
02:42:42,960 --> 02:42:45,040
SOMETHING ON OUR GRANTS NOW

4333
02:42:45,040 --> 02:42:47,720
THANKS TO ALL OF US THINKING

4334
02:42:47,720 --> 02:42:49,720
ABOUT IT AND END ADOPTING IT,

4335
02:42:49,720 --> 02:42:51,560
THIS WILL ADDRESS IT IN

4336
02:42:51,560 --> 02:42:53,400
STANDARDIZATION OF PDX AS A

4337
02:42:53,400 --> 02:42:54,120
MODEL.

4338
02:42:54,120 --> 02:42:55,680
PERSONALIZING MEDICINE USING I

4339
02:42:55,680 --> 02:42:58,760
WOULD SAY IS A HARD SELL FOR A

4340
02:42:58,760 --> 02:43:00,920
LOT OF OUR PATIENTS, BUT WE WILL

4341
02:43:00,920 --> 02:43:02,720
ONLY GET TO THAT AFTER THE

4342
02:43:02,720 --> 02:43:04,160
STANDARDIZATION IS COMPLETE.

4343
02:43:04,160 --> 02:43:08,000
SO AGAIN THAT IS A HIGHLIGHT FOR

4344
02:43:08,000 --> 02:43:08,360
YOU.

4345
02:43:08,360 --> 02:43:10,280
I ORIGINALLY WHEN I LOOK AT

4346
02:43:10,280 --> 02:43:11,960
BUDGET AND THOUGHT HARD ABOUT IT

4347
02:43:11,960 --> 02:43:14,520
I WONDERED WHY THIS WASN'T 16

4348
02:43:14,520 --> 02:43:17,120
RO1 OPPOSED TO SIX PROJECTS.

4349
02:43:17,120 --> 02:43:21,320
AS I DUG INTO IT AND REALIZED IT

4350
02:43:21,320 --> 02:43:22,600
HAD THESE CORES TO DO THIS WORK

4351
02:43:22,600 --> 02:43:24,520
SO YOU CAN STANDARDIZE PROPERLY

4352
02:43:24,520 --> 02:43:27,040
I RETREATED FROM MY ORIGINAL

4353
02:43:27,040 --> 02:43:29,400
POSITION ON IT, TO PUT MORE

4354
02:43:29,400 --> 02:43:31,160
RO1s ON THE BOARD WHENEVER I

4355
02:43:31,160 --> 02:43:31,560
CAN.

4356
02:43:31,560 --> 02:43:33,640
I CAN'T DO THAT IN THIS SETTING,

4357
02:43:33,640 --> 02:43:35,120
STANDARDIZATION IS STILL THE

4358
02:43:35,120 --> 02:43:36,560
NUMBER ONE OBJECTIVE WE HAVE

4359
02:43:36,560 --> 02:43:37,640
HERE.

4360
02:43:37,640 --> 02:43:39,720
STANDARDIZED PROPERLY SO WE CAN

4361
02:43:39,720 --> 02:43:44,240
MOVE INTO ORIGINAL HYPOTHESIS

4362
02:43:44,240 --> 02:43:45,320
DIRECTED QUESTIONS.

4363
02:43:45,320 --> 02:43:47,600
THIS LAST PART THOUGH ABOUT WHAT

4364
02:43:47,600 --> 02:43:49,960
YOU WANT TO DO IN THE FUTURE AND

4365
02:43:49,960 --> 02:43:54,000
LINKING MORE TO ECTN,

4366
02:43:54,000 --> 02:43:54,720
INVESTIGATORS.

4367
02:43:54,720 --> 02:43:56,760
I THINK IS ALSO QUITE IMPORTANT

4368
02:43:56,760 --> 02:43:59,800
AND WILL ALLOW IN REAL TIME

4369
02:43:59,800 --> 02:44:01,200
THESE MODELS TO BE INCORPORATED

4370
02:44:01,200 --> 02:44:03,360
IN THE DESIGN OF TRIALS OPPOSED

4371
02:44:03,360 --> 02:44:04,880
TO AFTER SOMEONE READ IT IS

4372
02:44:04,880 --> 02:44:06,200
PAPER AFTER APPROVAL AND AFTER

4373
02:44:06,200 --> 02:44:09,840
THEY APPLY FOR SO I THINK THAT

4374
02:44:09,840 --> 02:44:12,840
IS A GOOD DIRECTION TO TAKE IT.

4375
02:44:12,840 --> 02:44:16,040
FINALLY THIS ISSUE ABOUT

4376
02:44:16,040 --> 02:44:18,160
DIVERSITY AND MODELS, IT IS A

4377
02:44:18,160 --> 02:44:20,000
HUGE PROBLEM EVEN PDX AS YOU

4378
02:44:20,000 --> 02:44:20,400
KNOW.

4379
02:44:20,400 --> 02:44:21,680
AS WE HAVE HEARD OVER THE LAST

4380
02:44:21,680 --> 02:44:24,360
TWO DAYS.

4381
02:44:24,360 --> 02:44:27,440
I WOULD SAY TO INCORPORATE THAT

4382
02:44:27,440 --> 02:44:29,760
EARLY ON WILL BE IMPORTANT GIVEN

4383
02:44:29,760 --> 02:44:31,720
PRESENTATION THESE LAST TWO

4384
02:44:31,720 --> 02:44:32,120
DAYS.

4385
02:44:32,120 --> 02:44:34,080
IT HAS AN EARLY ADOPTER OF THIS

4386
02:44:34,080 --> 02:44:36,920
I CAN TELL YOU WE ARE LEARNING A

4387
02:44:36,920 --> 02:44:38,560
LOT SOMETIMES, PROBABLY

4388
02:44:38,560 --> 02:44:40,080
HAVEMOGTO DO WITH MACRO

4389
02:44:40,080 --> 02:44:40,960
ENVIRONMENT WE ONLY KNOW BECAUSE

4390
02:44:40,960 --> 02:44:42,560
WE ARE MAKING THESE MODELS.

4391
02:44:42,560 --> 02:44:47,000
SO I'M GOING TO TURN OVER TO DR.

4392
02:44:47,000 --> 02:44:48,240
BESICH WHO WROTE DOWN POINTS

4393
02:44:48,240 --> 02:44:51,560
THAT LED TO IMPROVEMENT IN YOUR

4394
02:44:51,560 --> 02:44:51,920
PROTOCOL.

4395
02:44:51,920 --> 02:44:53,920
DAVID AND I DISCUSSED OFFLINE A

4396
02:44:53,920 --> 02:44:55,560
HEAD OF TIME, HIS MAIN CONCERN

4397
02:44:55,560 --> 02:44:57,240
IS CHAMPIONS ONCOLOGY, THERE YOU

4398
02:44:57,240 --> 02:44:58,760
HAVE THOUSANDS OF MODELS.

4399
02:44:58,760 --> 02:45:00,320
WHY COULDN'T ACADEMIC CALL THAT

4400
02:45:00,320 --> 02:45:03,880
A CHAMPIONS AND GET THINGS?

4401
02:45:03,880 --> 02:45:05,560
THE REASON I TALKED ABOUT

4402
02:45:05,560 --> 02:45:08,200
BEFORE, STANDARDIZATION.

4403
02:45:08,200 --> 02:45:09,560
INCORPORATION OF MODEL IN

4404
02:45:09,560 --> 02:45:12,720
PRACTICE ACROSS OUR COUNTRY.

4405
02:45:12,720 --> 02:45:14,040
DAVID IS RIGHT GETTING

4406
02:45:14,040 --> 02:45:15,040
LONGITUDINAL SAMPLES THAT YOU

4407
02:45:15,040 --> 02:45:17,720
WILL ALLOW SECOND PHASE WILL BE

4408
02:45:17,720 --> 02:45:19,280
IMPORTANT SO DRUG RESISTANCE CAN

4409
02:45:19,280 --> 02:45:20,320
BE STUDIED.

4410
02:45:20,320 --> 02:45:21,360
MIKE I DON'T KNOW IF YOU WANT TO

4411
02:45:21,360 --> 02:45:23,920
ADD ANYTHING TO THIS.

4412
02:45:23,920 --> 02:45:25,960
>> COMMENTS RIGHT ON POINT

4413
02:45:25,960 --> 02:45:26,960
DAVID, THANK YOU FOR GREAT

4414
02:45:26,960 --> 02:45:28,480
SUMMARY.

4415
02:45:28,480 --> 02:45:30,920
I THINK KEY ISSUE IS INs AND

4416
02:45:30,920 --> 02:45:33,440
OUTS OF THIS PROGRAM METRICS FOR

4417
02:45:33,440 --> 02:45:34,440
MOCH DATA IS SHARED HOW MANY

4418
02:45:34,440 --> 02:45:35,440
MODELS HAVE BEEN OUT THERE, WHAT

4419
02:45:35,440 --> 02:45:37,200
IS THE TIME LINE FOR DELIVERING

4420
02:45:37,200 --> 02:45:41,560
THOSE MODELS, TO THE CANCER

4421
02:45:41,560 --> 02:45:42,960
RESEARCH COMMUNITY AT LARGE.

4422
02:45:42,960 --> 02:45:44,120
THE INTERACTION BETWEEN THE

4423
02:45:44,120 --> 02:45:46,640
PEOPLE WHO ARE FUNDED ARE

4424
02:45:46,640 --> 02:45:47,040
SPECTACULAR.

4425
02:45:47,040 --> 02:45:48,160
ON THE OTHER HAND THIS IS

4426
02:45:48,160 --> 02:45:49,920
SUPPOSED TO BE FACILITY HELP

4427
02:45:49,920 --> 02:45:51,360
WITH BIG OUTBOUND ARROW THE REST

4428
02:45:51,360 --> 02:45:54,480
OF THE NCI COMMUNITY.

4429
02:45:54,480 --> 02:45:56,720
THERE HAVE BEEN SEVERAL PROGRAMS

4430
02:45:56,720 --> 02:45:59,280
WAITING FOR STUFF FUNDED ACROSS

4431
02:45:59,280 --> 02:46:00,920
THE NCI THAT WE ARE GOING TO

4432
02:46:00,920 --> 02:46:02,520
COUNT ON THESE MODELS AND ARE

4433
02:46:02,520 --> 02:46:04,560
STILL NOT GETTING THEM.

4434
02:46:04,560 --> 02:46:06,840
SO FOR ME THE INs AND OUTS

4435
02:46:06,840 --> 02:46:08,760
THAT NEED TO BE CAREFULLY

4436
02:46:08,760 --> 02:46:09,640
DOCUMENTED IN THIS PROGRAM,

4437
02:46:09,640 --> 02:46:11,840
CLEARLY THIS IS AN IMPORTANT

4438
02:46:11,840 --> 02:46:15,480
PART OF THE WAY WE CAN LOOK AT

4439
02:46:15,480 --> 02:46:18,000
WAYS TO DELIVER NEW DRUG TARGETS

4440
02:46:18,000 --> 02:46:21,760
AND TEST THEM GREAT PROMISE, BUT

4441
02:46:21,760 --> 02:46:25,960
I DO THINK IT IS A LONG TIME

4442
02:46:25,960 --> 02:46:27,720
BIOREPOSITORY SCIENTIST.

4443
02:46:27,720 --> 02:46:30,720
MENT THE PROOF IS NOT YET THERE

4444
02:46:30,720 --> 02:46:32,720
IMPACT OF OVERALL SCIENTIFIC

4445
02:46:32,720 --> 02:46:35,920
COMMUNITY AND NUMBER OF PATIENTS

4446
02:46:35,920 --> 02:46:37,760
IS QUITE SMALL.

4447
02:46:37,760 --> 02:46:45,960
>> THANK YOU, DR. BARKER.

4448
02:46:45,960 --> 02:46:47,760
SO I WANT TO FOLLOW UP ON THAT

4449
02:46:47,760 --> 02:46:50,960
POINT, MICHAEL.

4450
02:46:50,960 --> 02:46:53,720
YOU HAVE A U 54 MECHANISM AND U

4451
02:46:53,720 --> 02:46:54,080
24.

4452
02:46:54,080 --> 02:46:55,760
SO I NEED TO UNDERSTAND ARE YOU

4453
02:46:55,760 --> 02:46:57,640
JUST SETTING UP THE COORDINATING

4454
02:46:57,640 --> 02:47:00,280
CENTERS NOW OR CENTER AND DATA

4455
02:47:00,280 --> 02:47:01,800
COMMONS OR ARE THEY ALREADY IN

4456
02:47:01,800 --> 02:47:04,040
PLACE?

4457
02:47:04,040 --> 02:47:08,360
>> THERE WAS ALREADY HAS BEEN

4458
02:47:08,360 --> 02:47:10,280
2024 COORDINATING CENTER, IT WAS

4459
02:47:10,280 --> 02:47:12,800
A JOINT GRANT BETWEEN JACKSON

4460
02:47:12,800 --> 02:47:14,600
LABS AND SEVEN BRIDGES WHO DID

4461
02:47:14,600 --> 02:47:19,640
COORDINATED ALL THE INFORMATICS

4462
02:47:19,640 --> 02:47:20,760
AND INFRASTRUCTURE THAT WERE

4463
02:47:20,760 --> 02:47:25,160
NEEDED FOR ALL OF THIS.

4464
02:47:25,160 --> 02:47:27,000
SO THERE ISN'T REISSUANCE OF

4465
02:47:27,000 --> 02:47:27,800
THAT.

4466
02:47:27,800 --> 02:47:29,960
THAT'S IN EXISTENCE.

4467
02:47:29,960 --> 02:47:31,800
>> THE COORDINATING CENTER IS

4468
02:47:31,800 --> 02:47:32,160
EXISTENCE.

4469
02:47:32,160 --> 02:47:34,600
SO I WANT TO GET BACK TO THIS

4470
02:47:34,600 --> 02:47:36,200
QUESTION OF STANDARDIZATION.

4471
02:47:36,200 --> 02:47:39,560
THIS IS GOING TO BE CAREER GOAL

4472
02:47:39,560 --> 02:47:42,160
FOR THIS, TO WHAT EXTENT IS THE

4473
02:47:42,160 --> 02:47:45,040
COORDINATOR CENTER WORKING ON

4474
02:47:45,040 --> 02:47:48,800
THAT ISSUE?

4475
02:47:48,800 --> 02:47:51,160
>> I THINK THERE ARE A COUPLE OF

4476
02:47:51,160 --> 02:47:53,720
AREAS, FIRST THING THE GROUP DID

4477
02:47:53,720 --> 02:47:58,760
WAS TO TAKE MODELS FROM THE PDMR

4478
02:47:58,760 --> 02:48:05,440
AND THE DRUG AND SEE IF THEY CAN

4479
02:48:05,440 --> 02:48:07,480
EACH THE MODEL AND THE DRUG

4480
02:48:07,480 --> 02:48:10,360
THREE MODELS AND A DRUG AND TOLD

4481
02:48:10,360 --> 02:48:12,280
TO SEE WHICH TUMORS RESPOND TO

4482
02:48:12,280 --> 02:48:15,280
THE DRUG AND TO PLOT THEIR DATA

4483
02:48:15,280 --> 02:48:16,840
AND THEN Y'ALL PUT THE DATA

4484
02:48:16,840 --> 02:48:18,320
TOGETHER AND ONE OF THE FURTHER

4485
02:48:18,320 --> 02:48:21,240
THINGS WE LEARNED IS EVERYBODY

4486
02:48:21,240 --> 02:48:23,160
DID EXPERIMENTS DIFFERENTLY AND

4487
02:48:23,160 --> 02:48:24,960
THE DATA, EVERYTHING HAD TO BE

4488
02:48:24,960 --> 02:48:26,520
HARMONIZED BECAUSE IN ORDER TO

4489
02:48:26,520 --> 02:48:28,840
COMPARE THE DATA, YOU HAD

4490
02:48:28,840 --> 02:48:30,840
EVERYBODY DOING EVERYTHING

4491
02:48:30,840 --> 02:48:31,440
DIFFERENTLY.

4492
02:48:31,440 --> 02:48:34,560
TURNED OUT WHEN YOU FINALLY GOT

4493
02:48:34,560 --> 02:48:37,480
EVERYTHING DONE HARMONIZED WAY

4494
02:48:37,480 --> 02:48:39,600
YOU CAN SEE EVERYBODY ENDED UP

4495
02:48:39,600 --> 02:48:43,240
WITH THE SAME RESULT SO GREAT

4496
02:48:43,240 --> 02:48:45,240
BECAUSE EXPERIMENT WAS

4497
02:48:45,240 --> 02:48:47,160
REPRODUCIBLE BUT IT TOOK SOME

4498
02:48:47,160 --> 02:48:49,800
TIME TO FIGURE O THAT OUT

4499
02:48:49,800 --> 02:48:50,600
BECAUSE EVERYTHING AGAIN

4500
02:48:50,600 --> 02:48:52,640
EVERYBODY HAD DIFFERENT WAYS OF

4501
02:48:52,640 --> 02:48:56,200
REPORTING DATA MEASURING TUMORS

4502
02:48:56,200 --> 02:48:57,760
OF RECORDED DIFFERENT DATES,

4503
02:48:57,760 --> 02:48:58,880
EVERYTHING ABOUT THE WAY

4504
02:48:58,880 --> 02:49:00,200
EXPERIMENTS WERE DONE IN

4505
02:49:00,200 --> 02:49:01,640
DIFFERENT CENTERS WAS DIFFERENT.

4506
02:49:01,640 --> 02:49:07,360
SO I THINK WHAT -- PART IS --

4507
02:49:07,360 --> 02:49:09,520
HEN THE OTHER ISSUE THAT WE H

4508
02:49:09,520 --> 02:49:14,120
FOCUS ON NOW IS IF YOU LOOK AT

4509
02:49:14,120 --> 02:49:16,880
HOW PDX RESPONSE ARE REPORTED,

4510
02:49:16,880 --> 02:49:19,560
IN THE LITERATURE, IT IS ALL

4511
02:49:19,560 --> 02:49:20,840
OVER THE PLACE, EVERYBODY DOES

4512
02:49:20,840 --> 02:49:21,440
IT DIFFERENTLY.

4513
02:49:21,440 --> 02:49:23,200
AND THERE'S NO CONSENSUS ABOUT

4514
02:49:23,200 --> 02:49:25,360
WHAT IS A SIGNIFICANT RESPONSE

4515
02:49:25,360 --> 02:49:28,160
TO THERAPY AND HOW DO YOU

4516
02:49:28,160 --> 02:49:30,280
COMPARE ALL WE DO IT BY EYE BALL

4517
02:49:30,280 --> 02:49:31,560
BUT THERE IS NO STANDARDIZATION

4518
02:49:31,560 --> 02:49:32,600
FOR THAT.

4519
02:49:32,600 --> 02:49:34,360
SO I THINK A LOT OF WHAT WE ARE

4520
02:49:34,360 --> 02:49:36,840
TRYING TO DO INITIALLY IS TO TRY

4521
02:49:36,840 --> 02:49:39,040
TO STANDARDIZE HOW WE THINK

4522
02:49:39,040 --> 02:49:40,560
ABOUT A DRUG RESPONSE AND WHAT

4523
02:49:40,560 --> 02:49:42,280
IS A SIGNIFICANT DRUG RESPONSE

4524
02:49:42,280 --> 02:49:46,680
AND WHAT WOULD BE A POTENTIALLY

4525
02:49:46,680 --> 02:49:47,320
PRE-DICKTIVE RESPONSE SOMETHING

4526
02:49:47,320 --> 02:49:50,600
YOU WOULD BE SEEING IN

4527
02:49:50,600 --> 02:49:54,280
TRANSLATABLE TO THE CLINIC.

4528
02:49:54,280 --> 02:49:58,560
IT IS METHODS, IT IS ABOUT

4529
02:49:58,560 --> 02:50:00,760
DEFINITION, IT IS ABOUT HAVING A

4530
02:50:00,760 --> 02:50:03,760
COMMON UNDERSTANDING OF WHAT

4531
02:50:03,760 --> 02:50:05,960
DRUG RESPONSE IS MEANINGFUL.

4532
02:50:05,960 --> 02:50:08,160
HOW DO YOU CAPTURE THE DEPTH AND

4533
02:50:08,160 --> 02:50:09,760
DURATION OF RESPONSE OPPOSED TO

4534
02:50:09,760 --> 02:50:11,360
A STATISTICALLY DIFFERENT

4535
02:50:11,360 --> 02:50:12,920
MEASUREMENT OF A GROWTH RATE AT

4536
02:50:12,920 --> 02:50:14,520
ONE POINT IN TIME?

4537
02:50:14,520 --> 02:50:18,440
SO THESE ARE ALL ISSUES THAT

4538
02:50:18,440 --> 02:50:20,560
NETWORK IS TRYING TO DEAL WITH.

4539
02:50:20,560 --> 02:50:21,480
I DON'T KNOW -- I HOPE THAT

4540
02:50:21,480 --> 02:50:23,160
ANSWERS YOUR QUESTION.

4541
02:50:23,160 --> 02:50:24,400
>> THAT STARTS TO ANSWER THE

4542
02:50:24,400 --> 02:50:26,200
QUESTION, I KNOW IT IS A LONG

4543
02:50:26,200 --> 02:50:27,400
CONFERENCE SURE IN TERMS OF

4544
02:50:27,400 --> 02:50:28,760
CONTINUUM BUT THE OTHER QUESTION

4545
02:50:28,760 --> 02:50:31,960
WHAT PERCENTAGE, THESE ARE IDEAL

4546
02:50:31,960 --> 02:50:33,760
RESOURCES TO BUILD FOR THE

4547
02:50:33,760 --> 02:50:34,920
EXTRAMURAL COMMUNITY, VERY

4548
02:50:34,920 --> 02:50:36,640
SUPPORTIVE OF THESE.

4549
02:50:36,640 --> 02:50:39,680
THE U 54 IS THE BEST WAY TO DO

4550
02:50:39,680 --> 02:50:40,840
THIS.

4551
02:50:40,840 --> 02:50:42,800
CURIOUS WHAT PERCENTAGE OF

4552
02:50:42,800 --> 02:50:45,480
EXTRAMURAL INVESTIGATORS

4553
02:50:45,480 --> 02:50:47,720
PRESENTED A NOVEL, A COMBINATION

4554
02:50:47,720 --> 02:50:49,600
OF DRUGS OR DRUG TO BE TESTED

4555
02:50:49,600 --> 02:50:52,760
AND HAVE BEEN SUCCESSFULLY

4556
02:50:52,760 --> 02:50:53,800
TESTED TO DATE?

4557
02:50:53,800 --> 02:50:55,800
ANY EXTRAMURAL INVESTIGATORS

4558
02:50:55,800 --> 02:50:59,280
USING THIS RESOURCE YET?

4559
02:50:59,280 --> 02:51:01,880
>> SO I THINK -- SO IN TERMS OF

4560
02:51:01,880 --> 02:51:07,800
IF YOU ARE ASKING -- IF THE

4561
02:51:07,800 --> 02:51:09,160
RESOURCE IS TO THE SAY TORRS ARE

4562
02:51:09,160 --> 02:51:13,360
IS INVESTIGATORS BASICALLY

4563
02:51:13,360 --> 02:51:16,440
COMING UP WITH DRUG/WE CAN

4564
02:51:16,440 --> 02:51:18,360
TRANSLATE TO CLINIC THE ANSWER

4565
02:51:18,360 --> 02:51:21,000
IS YES.

4566
02:51:21,000 --> 02:51:22,520
AND THAT IS -- AND WE THINK WE

4567
02:51:22,520 --> 02:51:24,360
CAN ACCELERATE THAT BY

4568
02:51:24,360 --> 02:51:25,160
REPROGRAMMING THE SUPPLEMENT

4569
02:51:25,160 --> 02:51:29,840
PROGRAM.

4570
02:51:29,840 --> 02:51:32,640
SO WE DID TRY TO -- I THINK WHAT

4571
02:51:32,640 --> 02:51:34,520
MAYBE YOU ARE SUGGESTING IS

4572
02:51:34,520 --> 02:51:36,880
HAVING OTHER NON-PDX

4573
02:51:36,880 --> 02:51:40,040
INVESTIGATORS USE IT TO TEST

4574
02:51:40,040 --> 02:51:41,960
THEIR IDEAS THEY WORKED ON

4575
02:51:41,960 --> 02:51:43,960
SOMETHING, THEY DIDN'T HAVE PDX

4576
02:51:43,960 --> 02:51:47,640
RESOURCES COULD THEY USE PDX NET

4577
02:51:47,640 --> 02:51:50,960
FOR -- THAT WAS THE ORIGINAL

4578
02:51:50,960 --> 02:51:51,160
GOAL.

4579
02:51:51,160 --> 02:51:55,840
I HAVE TO SAY RLZ IT DIDN'T

4580
02:51:55,840 --> 02:51:59,480
WORK, A LOT OF PROJECTS THAT

4581
02:51:59,480 --> 02:52:02,960
JUST DIDN'T GO ANYWHERE, DIDN'T

4582
02:52:02,960 --> 02:52:05,480
SEEM TO EXPERIMENTS WOULD BE

4583
02:52:05,480 --> 02:52:06,960
DONE BUT NO FOLLOW THROUGH, SO

4584
02:52:06,960 --> 02:52:10,720
OVERALL WE THOUGHT THE -- THAT

4585
02:52:10,720 --> 02:52:11,840
IDEA WOULD SEEM GREAT AT THE

4586
02:52:11,840 --> 02:52:15,520
TIME IN PRACTICE THE OUTCOME OF

4587
02:52:15,520 --> 02:52:16,960
THOSE DIFFERENT PROJECTS, REALLY

4588
02:52:16,960 --> 02:52:20,400
DIDN'T SHOW THAT THAT WAS A

4589
02:52:20,400 --> 02:52:21,160
PRODUCTIVE WAY BECAUSE --

4590
02:52:21,160 --> 02:52:26,280
>> AS WE SAW FROM PRIOR

4591
02:52:26,280 --> 02:52:27,160
PRESENTATION, SOMETIME DEVELOP

4592
02:52:27,160 --> 02:52:29,600
THINGS IT TAKES TIME TO DEVELOP

4593
02:52:29,600 --> 02:52:32,560
CAPABILITY, IT IS A $49

4594
02:52:32,560 --> 02:52:34,440
INVESTMENT, GREAT TO SEE THE

4595
02:52:34,440 --> 02:52:35,560
ENTIRE COMMUNITY BENEFIT FROM

4596
02:52:35,560 --> 02:52:38,520
SOMETHING LIKE THIS.

4597
02:52:38,520 --> 02:52:40,600
>> WE HAVE TIME FOR ONE MORE

4598
02:52:40,600 --> 02:52:42,040
QUICK QUESTION, MAX YOU HAD YOUR

4599
02:52:42,040 --> 02:52:44,240
HAND UP FIRST SO GO WITH YOU.

4600
02:52:44,240 --> 02:52:46,760
WE CAN HOPEFULLY TRY TO ADD

4601
02:52:46,760 --> 02:52:48,360
JAMES TO THE CHAT.

4602
02:52:48,360 --> 02:52:49,440
GO AHEAD MATT.

4603
02:52:49,440 --> 02:52:51,720
>> GREAT TO BUILD THIS MODEL BUT

4604
02:52:51,720 --> 02:52:54,560
MY CONCERN IS THE BIOLOGY OF THE

4605
02:52:54,560 --> 02:52:56,000
MODEL AND HOW MUCH OF INVESTMENT

4606
02:52:56,000 --> 02:52:58,560
IS REALLY BEING MADE TO IMPROVE

4607
02:52:58,560 --> 02:53:00,560
THE MODELS RATHER THAN JUST MAKE

4608
02:53:00,560 --> 02:53:03,480
MORE MODELS FOR MORE PATIENTS.

4609
02:53:03,480 --> 02:53:05,680
FOR EXAMPLE YOU WENT BY QUICKLY

4610
02:53:05,680 --> 02:53:08,680
THE EXTERNAL GROUP RECOMMENDED

4611
02:53:08,680 --> 02:53:10,240
EXPANDING IMMUNE APPROACHES TO

4612
02:53:10,240 --> 02:53:12,440
THE POTENTIALLY HUMANIZED MICE

4613
02:53:12,440 --> 02:53:13,760
WITH HUMAN IMMUNE SYSTEM.

4614
02:53:13,760 --> 02:53:15,680
AND I THINK THAT THAT IS

4615
02:53:15,680 --> 02:53:17,760
BECOMING QUITE CONCLUSIVE THAT

4616
02:53:17,760 --> 02:53:19,960
RESPONSE TO DRUGS IS VERY

4617
02:53:19,960 --> 02:53:22,520
DIFFERENT IN IMMUNE COMPETENT

4618
02:53:22,520 --> 02:53:24,000
VERSUS IMMUNOCOMPROMISED

4619
02:53:24,000 --> 02:53:25,040
ANIMALS, MY CONCERN IS WE ARE

4620
02:53:25,040 --> 02:53:26,840
SPENDING A TREMENDOUS AMOUNT OF

4621
02:53:26,840 --> 02:53:28,600
MONEY WITH MODELS THAT MAY NOT

4622
02:53:28,600 --> 02:53:29,800
BE THAT REPRESENTATIVE OF WHAT

4623
02:53:29,800 --> 02:53:32,400
IS GOING ON, IF THEY ARE LACKING

4624
02:53:32,400 --> 02:53:33,880
THINGS LIKE IMMUNE SYSTEM.

4625
02:53:33,880 --> 02:53:36,880
I ALSO THINK MONEY NEEDS TO BE

4626
02:53:36,880 --> 02:53:38,320
SPENT TO COMPARE MODELS TO

4627
02:53:38,320 --> 02:53:41,240
ORGANOID MODELS.

4628
02:53:41,240 --> 02:53:43,040
WE HAVE TO KNOW HOW THEY COMPARE

4629
02:53:43,040 --> 02:53:45,240
WHAT'S THE DIFFERENCE AND WE

4630
02:53:45,240 --> 02:53:47,000
GENERATE ORGANOID MODELS THEY

4631
02:53:47,000 --> 02:53:48,560
JUST AS GOOD, NOT AS GOOD AND

4632
02:53:48,560 --> 02:53:51,880
CAN WE USE THOSE FOR OTHER

4633
02:53:51,880 --> 02:53:57,280
BIOETHIC STUDIES, BOTH ELEMENTS.

4634
02:53:57,280 --> 02:53:59,200
>> THE SECOND ONE FIRST ORGANOID

4635
02:53:59,200 --> 02:54:01,560
I THINK HAVE TO BE AN IMPORTANT

4636
02:54:01,560 --> 02:54:03,720
PART OF THIS CLEARLY WE HAVE TO

4637
02:54:03,720 --> 02:54:06,360
BE ABLE TO SCREEN EFFICIENTLY

4638
02:54:06,360 --> 02:54:08,560
AND THEN UNDERSTAND PREDICTIVE

4639
02:54:08,560 --> 02:54:11,920
HOW TO DO THAT, AGAIN

4640
02:54:11,920 --> 02:54:12,520
STANDARDIZATION CAN BE HELPFUL

4641
02:54:12,520 --> 02:54:15,880
WITH THAT APPROACH.

4642
02:54:15,880 --> 02:54:18,200
THAT'S PART OF THIS.

4643
02:54:18,200 --> 02:54:20,560
USE HAVE LARGE SCALE PDX

4644
02:54:20,560 --> 02:54:22,440
COLLECTIONS WE NEED A WAY OF

4645
02:54:22,440 --> 02:54:23,680
SUFFICIENTLY SCREENING AND WE

4646
02:54:23,680 --> 02:54:25,560
CAN'T DO THAT ALL WITHIN THE

4647
02:54:25,560 --> 02:54:27,120
EXPERIMENTS.

4648
02:54:27,120 --> 02:54:32,080
IN REGARD TO THE BIOLOGY OF OF

4649
02:54:32,080 --> 02:54:34,280
PATIENT DERIVED MODELS, STUDYING

4650
02:54:34,280 --> 02:54:36,960
THAT IS PART OF DIFFERENT

4651
02:54:36,960 --> 02:54:40,560
PROGRAM IN DIVISION OF CANCER

4652
02:54:40,560 --> 02:54:43,920
BIOLOGY SO I THINK THERE ARE

4653
02:54:43,920 --> 02:54:46,440
REALLY COMPLEX QUESTIONS, HOW DO

4654
02:54:46,440 --> 02:54:49,120
YOU INCORPORATE STRUGGLE

4655
02:54:49,120 --> 02:54:50,240
ELEMENTS AND IMMUNE SYSTEM

4656
02:54:50,240 --> 02:54:54,120
ELEMENTS INTO MODELS.

4657
02:54:54,120 --> 02:54:57,560
THAT'S REALLY UNDERSTANDING

4658
02:54:57,560 --> 02:54:59,600
ALTERING BIOLOGY IS JUST REALLY

4659
02:54:59,600 --> 02:55:02,560
THE FOCUS OF DIFFERENT GRANT

4660
02:55:02,560 --> 02:55:04,840
PROGRAMS, I THINK SO I THINK

4661
02:55:04,840 --> 02:55:07,400
THAT IS GOING ON, THIS IS REALLY

4662
02:55:07,400 --> 02:55:12,440
PROBABLY MORE LIKELY DAD

4663
02:55:12,440 --> 02:55:13,560
CATEGORY APPLIED SCIENCE OPPOSE

4664
02:55:13,560 --> 02:55:14,560
TO TRYING TO UNDERSTAND THE

4665
02:55:14,560 --> 02:55:17,080
BIOLOGY OF MODEL WHICH IS REALLY

4666
02:55:17,080 --> 02:55:21,440
IN DCP PROGRAM.

4667
02:55:21,440 --> 02:55:23,720
>> GOOD TOMMIC FOR FUTURE

4668
02:55:23,720 --> 02:55:24,080
DISCUSSION.

4669
02:55:24,080 --> 02:55:25,400
YOUR COMMENTS POINT IN THAT

4670
02:55:25,400 --> 02:55:26,040
DIRECTION ALSO.

4671
02:55:26,040 --> 02:55:28,920
LET'S MOVE TO VOTING KEEPING AN

4672
02:55:28,920 --> 02:55:29,680
EYE ON THE CLOCK.

4673
02:55:29,680 --> 02:55:33,040
THIS IS REISSUANCE SO LOOKING

4674
02:55:33,040 --> 02:55:36,160
FOR MOTION TO CONCUR OR NOT

4675
02:55:36,160 --> 02:55:38,000
CONCUR SO DAVE AS CHAIR.

4676
02:55:38,000 --> 02:55:40,040
>> I MOTION TO CONCUR.

4677
02:55:40,040 --> 02:55:42,400
THE COMMENTS OF MY COLLEAGUES

4678
02:55:42,400 --> 02:55:43,200
NOTWITHSTANDING THEIR CERTAINLY

4679
02:55:43,200 --> 02:55:46,560
LOT OF TUMOR MICROENVIRONMENT

4680
02:55:46,560 --> 02:55:48,360
TOPICS AND EXVIVO TALK ABOUT.

4681
02:55:48,360 --> 02:55:51,440
THIS IS REALLY GOING AFTER CELL

4682
02:55:51,440 --> 02:55:53,000
AUTONOMOUS TARGETS CAN THESE BE

4683
02:55:53,000 --> 02:55:55,160
USED TO GO AFTER CELL AUTONOMOUS

4684
02:55:55,160 --> 02:55:56,360
TARGETS THAT IS THE PLAN OF THIS

4685
02:55:56,360 --> 02:55:57,240
PROGRAM.

4686
02:55:57,240 --> 02:55:57,760
SO I CONCUR.

4687
02:55:57,760 --> 02:56:00,880
>> MIKE.

4688
02:56:00,880 --> 02:56:02,080
>> YES I CONCUR.

4689
02:56:02,080 --> 02:56:03,040
>> OKAY.

4690
02:56:03,040 --> 02:56:09,200
ANY FURTHER DISCUSSION?

4691
02:56:09,200 --> 02:56:12,360
OKAY MOTION ON THE TABLE IS A

4692
02:56:12,360 --> 02:56:12,760
CONCURRENCE.

4693
02:56:12,760 --> 02:56:14,160
LOOKING SPECIFICALLY FOR ANY

4694
02:56:14,160 --> 02:56:18,080
VOTES OF NON-CONCURRENCE FROM

4695
02:56:18,080 --> 02:56:18,600
BSA MEMBERS.

4696
02:56:18,600 --> 02:56:20,640
VOICE OR RAISE YOUR HAND.

4697
02:56:20,640 --> 02:56:21,920
MAX YOU HAVE YOUR HAND UP ON

4698
02:56:21,920 --> 02:56:23,680
YOUR SCREEN BUT I THINK THAT IS

4699
02:56:23,680 --> 02:56:29,560
LEFT OVER FROM YOUR QUESTION.

4700
02:56:29,560 --> 02:56:32,160
JUST CAME DOWN.

4701
02:56:32,160 --> 02:56:36,120
PAULETTE I SEE OR HEAR NONE.

4702
02:56:36,120 --> 02:56:37,320
ANY ABSTENTIONS?

4703
02:56:37,320 --> 02:56:39,840
NO ABSTENTIONS.

4704
02:56:39,840 --> 02:56:41,400
SO UNANIMOUS CONCURRENCE, NO

4705
02:56:41,400 --> 02:56:45,360
ABSTENTIONS PAULETTE.

4706
02:56:45,360 --> 02:56:46,800
SO WE MOVE TO LAST PROPOSALS OF

4707
02:56:46,800 --> 02:56:48,640
THE DAY, THIS IS A NEW PROGRAM

4708
02:56:48,640 --> 02:56:49,760
ANNOUNCEMENT JUST GOING TO

4709
02:56:49,760 --> 02:56:51,360
MENTION UP FRONT WE BUDGET ONLY

4710
02:56:51,360 --> 02:56:52,840
FIVE MINUTES FOR DISCUSSION.

4711
02:56:52,840 --> 02:56:54,400
WHEN WE GET THERE, TEN MINUTES

4712
02:56:54,400 --> 02:56:55,120
FOR PRESENTATION.

4713
02:56:55,120 --> 02:56:57,960
THIS IS SYSTEMATIC TESTING OF

4714
02:56:57,960 --> 02:56:59,640
RADIONUCLIDE IN PRE-CLINICAL

4715
02:56:59,640 --> 02:57:01,680
EXPERIMENTS DR. MICHAEL ESPE

4716
02:57:01,680 --> 02:57:03,680
WILL PRESENT SUBCOMMITTEE CHAIR

4717
02:57:03,680 --> 02:57:09,560
BY KAREN KNUDSEN AND SYLVIA AND

4718
02:57:09,560 --> 02:57:10,440
MIKE TAKE IT AWAY WITH YOUR

4719
02:57:10,440 --> 02:57:11,320
PRESENTATION.

4720
02:57:11,320 --> 02:57:13,160
>> THANKS, NED.

4721
02:57:13,160 --> 02:57:17,240
I'M JOINED BY DR. -- WHO MANAGES

4722
02:57:17,240 --> 02:57:22,000
THE NCI RADIO PHARMACEUTICAL

4723
02:57:22,000 --> 02:57:24,000
PORTFOLIO AND WITH THE RPT

4724
02:57:24,000 --> 02:57:24,560
COMMUNITY.

4725
02:57:24,560 --> 02:57:26,320
WE THANK THE BSA SUBCOMMITTEE

4726
02:57:26,320 --> 02:57:29,320
MEMBERS DR. KNUDSEN FOR THEIR

4727
02:57:29,320 --> 02:57:30,200
GUIDANCE WHICH I WILL TOUCH ON

4728
02:57:30,200 --> 02:57:33,560
AT THE END.

4729
02:57:33,560 --> 02:57:35,360
OUR CONCEPT STRIPE STANDS FOR

4730
02:57:35,360 --> 02:57:37,240
SYSTEMATIC TESTING OF RAID YES

4731
02:57:37,240 --> 02:57:38,640
NUCLIDE PRE-CLINICAL

4732
02:57:38,640 --> 02:57:39,080
EXPERIMENTS.

4733
02:57:39,080 --> 02:57:44,000
NEXT SLIDE.

4734
02:57:44,000 --> 02:57:45,960
WE ARE REQUESTING APPROVAL OF

4735
02:57:45,960 --> 02:57:48,040
PAR TO ADDRESS KNOWLEDGE GAPS

4736
02:57:48,040 --> 02:57:49,920
AND HOW RADIO PHARMACEUTICAL

4737
02:57:49,920 --> 02:57:52,920
THERAPY OR RPT AFFECTS BIOLOGY

4738
02:57:52,920 --> 02:57:54,040
OF CANCER CELLS, NORMAL CELLS

4739
02:57:54,040 --> 02:57:55,720
AND TUMOR MICROENVIRONMENT.

4740
02:57:55,720 --> 02:57:58,240
THROUGH THIS PAR WE SEEK TO

4741
02:57:58,240 --> 02:57:59,720
CATALYZE INTERDISCIPLINARY

4742
02:57:59,720 --> 02:58:01,080
COLLABORATIVE PROJECTS THAT WILL

4743
02:58:01,080 --> 02:58:02,760
SERVE TO STRENGTHEN THE

4744
02:58:02,760 --> 02:58:06,160
PRE-CLINICAL FOUNDATION OF THE

4745
02:58:06,160 --> 02:58:06,560
RPT.

4746
02:58:06,560 --> 02:58:08,440
NEXT SLIDE PLEASE.

4747
02:58:08,440 --> 02:58:09,640
THIS SLIDE COMPARES TO

4748
02:58:09,640 --> 02:58:11,480
APPROACHES IN IONIZING RADIATION

4749
02:58:11,480 --> 02:58:11,920
THERAPY.

4750
02:58:11,920 --> 02:58:14,360
ON THE LEFT IS EXTERNAL BEAM

4751
02:58:14,360 --> 02:58:16,040
WHERE INNOVATION IN THE FIELD IS

4752
02:58:16,040 --> 02:58:18,720
LARGELY DRIVEN BY DEVICES TO

4753
02:58:18,720 --> 02:58:22,000
PRECISELY DELIVER PHYSICAL DOSE.

4754
02:58:22,000 --> 02:58:23,560
HOWEVER, SPATIAL TARGETING CAN

4755
02:58:23,560 --> 02:58:25,640
BE LIMITED BY THE RESOLUTION OF

4756
02:58:25,640 --> 02:58:28,000
DIAGNOSTIC IMAGING.

4757
02:58:28,000 --> 02:58:29,480
EFFICACY IS LIMITED BY

4758
02:58:29,480 --> 02:58:30,760
INCIDENTAL INJURY TO NORMAL

4759
02:58:30,760 --> 02:58:31,760
TISSUES.

4760
02:58:31,760 --> 02:58:34,200
ON THE RIGHT YOU SEE RPT WHERE

4761
02:58:34,200 --> 02:58:35,680
IMPORTANTLY TARGETING IS BASED

4762
02:58:35,680 --> 02:58:39,000
ON TUMOR BIOLOGY AS DEPICTE
DEPICTED IN

4763
02:58:39,000 --> 02:58:43,280
THE FIGURE DRUG DELIVERLY

4764
02:58:43,280 --> 02:58:44,760
CELLULAR SCALE SETTING UP CROSS

4765
02:58:44,760 --> 02:58:47,960
FIRE DOSE TO TUMOR CELLS AND

4766
02:58:47,960 --> 02:58:49,760
TUMOR MICROENVIRONMENT RPT HAS

4767
02:58:49,760 --> 02:58:53,040
VOLATILITY IN LOCAL AND

4768
02:58:53,040 --> 02:58:54,840
MICROMETASTATIC DISEASE.

4769
02:58:54,840 --> 02:58:57,160
THE PHYSICS OF RADIONUCLIDE

4770
02:58:57,160 --> 02:58:59,160
PARTICLES USED IN RPT ARE WELL

4771
02:58:59,160 --> 02:58:59,680
KNOWN AND DISTINCT.

4772
02:58:59,680 --> 02:59:02,280
ONE WAY TO VISUALIZE THEM IS BY

4773
02:59:02,280 --> 02:59:03,840
ANALOGY TO CONSTRUCTION SITE.

4774
02:59:03,840 --> 02:59:05,560
ALPHA MISSIONS ARE LIKE A BULL

4775
02:59:05,560 --> 02:59:07,560
DOSER VERY POWERFUL AND

4776
02:59:07,560 --> 02:59:09,480
DESTRUCTIVE BUT SHORT RANGE.

4777
02:59:09,480 --> 02:59:11,200
BETA PARTICLES ARE LIKE BOB CAT

4778
02:59:11,200 --> 02:59:13,320
BUT LESS ENERGY TO TRAVEL

4779
02:59:13,320 --> 02:59:14,960
FURTHER TO MULTIPLE CELL

4780
02:59:14,960 --> 02:59:15,600
LENGTHS.

4781
02:59:15,600 --> 02:59:18,480
ELECTRONS ARE LIKE A JACKHAMMER

4782
02:59:18,480 --> 02:59:20,400
IMPACTING CLOSE PROXIMITY.

4783
02:59:20,400 --> 02:59:23,120
ON THE RIGHT WHICH IS MEANT TO

4784
02:59:23,120 --> 02:59:25,560
ILLUSTRATE HOW RPT ACTIONS ARE

4785
02:59:25,560 --> 02:59:27,760
FOUND IN THE TUMOR

4786
02:59:27,760 --> 02:59:28,480
MICROENVIRONMENT LIMITING

4787
02:59:28,480 --> 02:59:33,560
TOXICITY TO NORMAL TISSUE.

4788
02:59:33,560 --> 02:59:35,880
RADIO PHARMACEUTICAL THERAPY HAS

4789
02:59:35,880 --> 02:59:37,120
DESIRABLE MODULAR QUALITIES AS

4790
02:59:37,120 --> 02:59:40,360
ILLUSTRATED IN THE TABLE ON THE

4791
02:59:40,360 --> 02:59:42,520
LEFT, KNOWN PHYSICAL PROPERTIES

4792
02:59:42,520 --> 02:59:44,160
OF DIFFERENT RADIONUCLIDE

4793
02:59:44,160 --> 02:59:45,760
INCLUDE RANGE OF PARTICLE TYPES

4794
02:59:45,760 --> 02:59:48,040
WITH HALF LIVES THAT VARY FROM

4795
02:59:48,040 --> 02:59:50,040
HOURS TO DAYS AS DEPICTED ON THE

4796
02:59:50,040 --> 02:59:51,760
RIGHT THESE CHARACTERISTICS CAN

4797
02:59:51,760 --> 02:59:53,960
BE COMBINED WITH VARIETY OF

4798
02:59:53,960 --> 02:59:56,400
MOLECULAR TARGETING APPROACHES

4799
02:59:56,400 --> 02:59:58,400
INCLUDING NANOTECHNOLOGY OR

4800
02:59:58,400 --> 02:59:59,240
ENGINEER CANCER SPECIFIC

4801
02:59:59,240 --> 03:00:00,280
ANTIBODIES.

4802
03:00:00,280 --> 03:00:03,040
THESE DISCRETE COMPONENTS CAN

4803
03:00:03,040 --> 03:00:04,880
HAVE POTENTIAL TO BE BLENDED.

4804
03:00:04,880 --> 03:00:07,320
TO PAINTERS PALATE.

4805
03:00:07,320 --> 03:00:13,000
CREATE NOVEL STRATEGIES FIT TIE

4806
03:00:13,000 --> 03:00:13,640
DRESS SPECIFIC CANCER TREATMENT

4807
03:00:13,640 --> 03:00:13,840
NEEDS.

4808
03:00:13,840 --> 03:00:15,120
NEXT SLIDE PLEASE.

4809
03:00:15,120 --> 03:00:17,320
THE STATE OF ART FIELD IS TOP

4810
03:00:17,320 --> 03:00:17,680
LOADED.

4811
03:00:17,680 --> 03:00:19,040
AS SHOWN IN THE UPPER LEFT.

4812
03:00:19,040 --> 03:00:20,760
SEVERAL RPT AGENTS ARE HAVING

4813
03:00:20,760 --> 03:00:24,040
IMPACT IN THE CLINIC NOTABLY FOR

4814
03:00:24,040 --> 03:00:26,160
ENDOCRINE AND METASTATIC CANCER,

4815
03:00:26,160 --> 03:00:27,560
HOWEVER THE PRE-CLINICAL SPACE

4816
03:00:27,560 --> 03:00:29,440
IS QUITE LIMITED AND THINS OUT

4817
03:00:29,440 --> 03:00:30,520
AT BASE OF THE FIGURE.

4818
03:00:30,520 --> 03:00:32,200
ON THE RIGHT WE EMPHASIZE THAT

4819
03:00:32,200 --> 03:00:36,280
DEVELOPMENT AND PHARMA IS ALSO

4820
03:00:36,280 --> 03:00:37,960
LIMITED FOCUS ON MONOTHERAPIES

4821
03:00:37,960 --> 03:00:41,560
AND RPG TRIAL PROPOSALS RELY ON

4822
03:00:41,560 --> 03:00:43,280
EMPIRICAL DATA.

4823
03:00:43,280 --> 03:00:45,520
THE NCI RESEARCH PORTFOLIO RPT

4824
03:00:45,520 --> 03:00:48,160
IS COMPRISED OF 20 AWARDS,

4825
03:00:48,160 --> 03:00:50,040
FOCUSED ON THERAPEUTIC OR

4826
03:00:50,040 --> 03:00:52,600
IMAGING BASE OBJECTIVES, THERE'S

4827
03:00:52,600 --> 03:00:53,440
MINIMAL SUPPORT TOWARD

4828
03:00:53,440 --> 03:00:55,200
UNDERSTANDING RADIO BIOLOGY OF

4829
03:00:55,200 --> 03:00:55,560
RPT.

4830
03:00:55,560 --> 03:00:56,680
WE CALL THAT THE UNDERLYING

4831
03:00:56,680 --> 03:00:59,360
PREMISE OF RPT TO TUMOR BIOLOGY.

4832
03:00:59,360 --> 03:01:03,480
NEXT SLIDE PLEASE.

4833
03:01:03,480 --> 03:01:06,560
THEREFORE UNMET NEEDS AND

4834
03:01:06,560 --> 03:01:08,280
FOUNDATION PRE-CLINICAL RPT

4835
03:01:08,280 --> 03:01:11,160
RESEARCH STEM FROM DERTH OF RPT

4836
03:01:11,160 --> 03:01:12,960
STUDIES THAT LEVERAGE ADVANCE

4837
03:01:12,960 --> 03:01:16,000
OMICS CANCER MODELING ENABLING

4838
03:01:16,000 --> 03:01:17,680
CELL BIOLOGY TECHNOLOGIES, GAPS

4839
03:01:17,680 --> 03:01:21,360
NOTED BY RECENT CTAC RADIATION

4840
03:01:21,360 --> 03:01:23,160
ONTOLOGY WORKING GROUP REPORT.

4841
03:01:23,160 --> 03:01:24,560
SPECIALIZED EXPERTISE IN

4842
03:01:24,560 --> 03:01:26,320
LICENSURE FOR RAID YES NUCLIDE

4843
03:01:26,320 --> 03:01:29,360
USE CAN CREATE A THRESHOLD INTO

4844
03:01:29,360 --> 03:01:31,280
ALREADYPT RESEARCH, HAVING A

4845
03:01:31,280 --> 03:01:34,240
EFFECT ON RADIO BIOLOGISTS AND

4846
03:01:34,240 --> 03:01:36,240
CANCER BIOLOGISTS IN THE

4847
03:01:36,240 --> 03:01:36,760
PRE-CLINICAL SPACE.

4848
03:01:36,760 --> 03:01:41,280
NEXT SLIDE PLEASE.

4849
03:01:41,280 --> 03:01:44,640
TO ADDRESS THIS THE OBJECTIVE

4850
03:01:44,640 --> 03:01:46,000
ARCHIVE CATALYZE COLLABORATIVE

4851
03:01:46,000 --> 03:01:46,920
PROJECTS AS DEPICT MISDEMEANOR

4852
03:01:46,920 --> 03:01:48,600
THE UPPER RIGHT STRENGTHEN THE

4853
03:01:48,600 --> 03:01:50,480
PRE-CLINICAL FOUNDATION OF THE

4854
03:01:50,480 --> 03:01:53,040
RPT FIELD, THE STRIPE DAR

4855
03:01:53,040 --> 03:01:54,800
FACILITATE INTEGRATION OF RPT

4856
03:01:54,800 --> 03:01:57,280
INTO PRE-CLINICAL ORIENTED TUMOR

4857
03:01:57,280 --> 03:01:59,720
BIOLOGY EXPERIMENTS WITH HAVING

4858
03:01:59,720 --> 03:02:01,160
POTENTIAL TO IDENTIFY NEW

4859
03:02:01,160 --> 03:02:02,480
TARGETING STRATEGIES, AND

4860
03:02:02,480 --> 03:02:04,680
CONDUCT A MORE SYSTEMATIC

4861
03:02:04,680 --> 03:02:06,440
EXAMINATION OF DRUG RPT

4862
03:02:06,440 --> 03:02:07,160
COMBINATIONS.

4863
03:02:07,160 --> 03:02:12,040
NEXT SLIDE PLEASE.

4864
03:02:12,040 --> 03:02:14,280
WE PROPOSE USING PAR MECHANISM

4865
03:02:14,280 --> 03:02:17,480
TO SOLICIT RO1 AND R21

4866
03:02:17,480 --> 03:02:18,800
APPLICATIONS, WE WILL ENCOURAGE

4867
03:02:18,800 --> 03:02:20,720
COLLABORATIVE PROJECTS THAT

4868
03:02:20,720 --> 03:02:22,800
INTERSECT RPT AND PRE-CLINICAL

4869
03:02:22,800 --> 03:02:23,400
CANCER BIOLOGY.

4870
03:02:23,400 --> 03:02:26,440
úRAID YEAR AGO THERAPEUTICS AND

4871
03:02:26,440 --> 03:02:30,440
BIOLOGY STUDY SECTION AND

4872
03:02:30,440 --> 03:02:34,120
ENUMERATES HOW THEY REVIEW ABOUT

4873
03:02:34,120 --> 03:02:37,600
225 UNSOLICITED APPLICATIONS PER

4874
03:02:37,600 --> 03:02:39,800
YEAR.

4875
03:02:39,800 --> 03:02:42,440
ONLY A HANDFUL OF RPT RESEARCH

4876
03:02:42,440 --> 03:02:49,960
AWARDS MADE A YEAR.

4877
03:02:49,960 --> 03:02:51,320
NUCLEIC TO PORTFOLIO AND

4878
03:02:51,320 --> 03:02:53,320
CATALYZE A FIELD POISED FOR

4879
03:02:53,320 --> 03:02:54,640
IMPACT CANCER THERAPY IN NEW

4880
03:02:54,640 --> 03:02:55,120
WAYS.

4881
03:02:55,120 --> 03:02:58,000
NEXT SLIDE PLEASE.

4882
03:02:58,000 --> 03:03:00,960
THIS IS A FINAL SLIDE.

4883
03:03:00,960 --> 03:03:04,200
IN SUMMATION RPT TOOLBOX EXISTS

4884
03:03:04,200 --> 03:03:05,160
WITH DEMONSTRABLE SUCCESS IN

4885
03:03:05,160 --> 03:03:05,680
CLINIC.

4886
03:03:05,680 --> 03:03:09,400
THE BSA SUBCOMMITTEE ASKED US TO

4887
03:03:09,400 --> 03:03:10,920
EMPHASIZE THE FOLLOWING PAR CON

4888
03:03:10,920 --> 03:03:12,400
SUSPECT ADDRESS THE NEED TO

4889
03:03:12,400 --> 03:03:13,360
BOLSTER PRE-CLINICAL FOUNDATION

4890
03:03:13,360 --> 03:03:16,040
OF RPT AND RADIO BIOLOGY

4891
03:03:16,040 --> 03:03:18,280
RESEARCH WITH GOAL EXPANDING

4892
03:03:18,280 --> 03:03:19,400
DIVERSIFYING THE FIELD.

4893
03:03:19,400 --> 03:03:21,840
TO BE SPECIFIC ABOUT WHAT WOULD

4894
03:03:21,840 --> 03:03:24,160
SUCCESS LOOK LIKE, WE SEEK TO

4895
03:03:24,160 --> 03:03:25,800
ESTABLISH THE PORTFOLIO OF 6 TO

4896
03:03:25,800 --> 03:03:28,680
8 AWARDS FOCUSED ON BIOLOGY

4897
03:03:28,680 --> 03:03:30,800
BASED RPD TARGETING.

4898
03:03:30,800 --> 03:03:32,080
WHERE THESE DATA WOULD HAVE

4899
03:03:32,080 --> 03:03:35,040
POTENTIAL TO INFORM RATIONALE

4900
03:03:35,040 --> 03:03:36,360
FOR NEW CLINICAL TRIALS

4901
03:03:36,360 --> 03:03:37,360
CONCEPTS.

4902
03:03:37,360 --> 03:03:39,400
POSSIBLY EMERGING INTEREST IN ET

4903
03:03:39,400 --> 03:03:40,640
CTN TRIALS.

4904
03:03:40,640 --> 03:03:47,600
THANK YOU VERY MUCH.

4905
03:03:47,600 --> 03:03:49,400
>> THANK YOU VERY MUCH.

4906
03:03:49,400 --> 03:03:51,560
KAREN, COULD YOU LEAD US OFF IN

4907
03:03:51,560 --> 03:03:51,960
DISCUSSION.

4908
03:03:51,960 --> 03:03:53,760
>> GET US STARTED I WILL BE

4909
03:03:53,760 --> 03:03:54,560
BRIEF BECAUSE THERE WAS

4910
03:03:54,560 --> 03:03:57,360
SIGNIFICANT ENTHUSIASM FOR THIS

4911
03:03:57,360 --> 03:03:57,840
PAR.

4912
03:03:57,840 --> 03:03:59,760
DESPITE ADVANCES INCLUDING BUT

4913
03:03:59,760 --> 03:04:03,240
NOT LIMITED TO PSMA SUCCESS IN

4914
03:04:03,240 --> 03:04:06,000
PROSTATE CANCER, THERE'S A

4915
03:04:06,000 --> 03:04:08,800
UNDERFUNDING AS YOU SAW OF RADIO

4916
03:04:08,800 --> 03:04:10,280
PHARMACEUTICAL GRANTS IN

4917
03:04:10,280 --> 03:04:12,240
TRADITIONAL STUDY SECTIONS SO WE

4918
03:04:12,240 --> 03:04:13,920
PLOTTED THE -- APPLAUDED EFFORT

4919
03:04:13,920 --> 03:04:15,520
OF DR. ESPE AND GROUP TO PUT

4920
03:04:15,520 --> 03:04:16,960
TOGETHER A WELL CRAFTED PAR

4921
03:04:16,960 --> 03:04:19,360
CENTERED ON THIS FOUNDATIONAL

4922
03:04:19,360 --> 03:04:21,560
PRE-CLINICAL KNOWLEDGE WITH THE

4923
03:04:21,560 --> 03:04:24,080
GOAL TWOFOLD GOAL OF BRINGING TO

4924
03:04:24,080 --> 03:04:26,640
BEAR NEW POTENTIAL AGENTS IN THE

4925
03:04:26,640 --> 03:04:28,200
PRE-CLINICAL SPACE TO ULTIMATELY

4926
03:04:28,200 --> 03:04:31,000
GO TO THE PIPELINE BUT ALSO NEW

4927
03:04:31,000 --> 03:04:31,760
COMBINATIONS, THE QUESTIONS THAT

4928
03:04:31,760 --> 03:04:33,760
WE HAVE WHICH I THINK WERE

4929
03:04:33,760 --> 03:04:35,960
SATISFACTORILY ADDRESSED IN THE

4930
03:04:35,960 --> 03:04:37,880
PRESENTATION BUT ALSO IN OUR

4931
03:04:37,880 --> 03:04:38,960
MEETING, WENT TOWARD ENSURING

4932
03:04:38,960 --> 03:04:40,640
THAT WE HAD THE RIGHT REVIEWERS

4933
03:04:40,640 --> 03:04:42,240
IN THE POOL WITH THE RIGHT

4934
03:04:42,240 --> 03:04:44,680
COMPETENCY AND STUDY SECTION TO

4935
03:04:44,680 --> 03:04:46,880
ASSESS THE SCIENCE AND WE FEEL

4936
03:04:46,880 --> 03:04:48,320
CONFIDENT THE PROGRAM HADNA MIND

4937
03:04:48,320 --> 03:04:49,920
ALREADY.

4938
03:04:49,920 --> 03:04:51,360
SO I WILL -- THAT IN MIND

4939
03:04:51,360 --> 03:04:51,720
ALREADY.

4940
03:04:51,720 --> 03:04:53,120
I'M HIGHLY SUPPORTIVE OF THIS,

4941
03:04:53,120 --> 03:04:54,800
THIS IS AN IMPORTANT NEW AREA,

4942
03:04:54,800 --> 03:05:00,600
FOR WHICH I THINK WE NEED INT TO
INCREASE

4943
03:05:00,600 --> 03:05:02,680
THE PACE OF DISCOVERY.

4944
03:05:02,680 --> 03:05:04,040
I WILL ASK THE DOCTORS IF THEY

4945
03:05:04,040 --> 03:05:05,160
HAVE MORE TO ADD.

4946
03:05:05,160 --> 03:05:06,560
>> IN THE INTEREST OF TIME I

4947
03:05:06,560 --> 03:05:08,640
DON'T HAVE ANYTHING ELSE TO ADD.

4948
03:05:08,640 --> 03:05:12,640
KAREN SUMMARIZED IT WET.

4949
03:05:12,640 --> 03:05:16,040
>> I ECHO THAT I HAVE

4950
03:05:16,040 --> 03:05:17,760
SUPPORTIVE, I THINK ESPECIALLY

4951
03:05:17,760 --> 03:05:18,800
BRINGING PHARMACEUTICAL

4952
03:05:18,800 --> 03:05:19,480
SCIENTISTS TOGETHER IS

4953
03:05:19,480 --> 03:05:21,760
ABSOLUTELY NEEDED.

4954
03:05:21,760 --> 03:05:25,360
>> WE CLASSIFIED THIS AS A NO

4955
03:05:25,360 --> 03:05:25,960
BRAINER.

4956
03:05:25,960 --> 03:05:27,480
>> EXCELLENT.

4957
03:05:27,480 --> 03:05:29,400
ANY FURTHER BRIEF DISCUSSION?

4958
03:05:29,400 --> 03:05:38,640
QUESTIONS OR COMMENTS?

4959
03:05:38,640 --> 03:05:40,760
HEARING NONE LET'S MOVE TO

4960
03:05:40,760 --> 03:05:41,200
VOTING.

4961
03:05:41,200 --> 03:05:42,880
KAREN WOULD YOU MAKE A MOTION?

4962
03:05:42,880 --> 03:05:45,160
>> LIKE TO MAKE A MOTION TO FILL

4963
03:05:45,160 --> 03:05:47,000
IN THE CORRECT VERB APPROVE.

4964
03:05:47,000 --> 03:05:49,640
>> APPROVE.

4965
03:05:49,640 --> 03:05:51,280
>> EXCELLENT.

4966
03:05:51,280 --> 03:05:52,000
THANK YOU.

4967
03:05:52,000 --> 03:05:56,960
ANY FURTHER DISCUSSION?

4968
03:05:56,960 --> 03:05:57,560
OKAY.

4969
03:05:57,560 --> 03:06:00,040
MOTION ON THE TABLE IS TO

4970
03:06:00,040 --> 03:06:02,680
APPROVE ANY BSA MEMBERS

4971
03:06:02,680 --> 03:06:04,040
DISAPPROVE PLEASE VOICE THAT

4972
03:06:04,040 --> 03:06:11,160
VOTE BY RAISING YOUR HAND.

4973
03:06:11,160 --> 03:06:13,360
SEEING NONE, ANY ABSTENTIONS,

4974
03:06:13,360 --> 03:06:15,120
PAULETTE I'M GOING TO ABSTAIN

4975
03:06:15,120 --> 03:06:15,680
FROM THIS VOTE.

4976
03:06:15,680 --> 03:06:20,520
ANY OTHER ABSTENTION?

4977
03:06:20,520 --> 03:06:23,240
>> OKAY.

4978
03:06:23,240 --> 03:06:24,960
SO WE HAVE ONE ABSTENTION.

4979
03:06:24,960 --> 03:06:26,680
>> CORRECT.

4980
03:06:26,680 --> 03:06:27,440
OTHERWISE UNANIMOUS.

4981
03:06:27,440 --> 03:06:28,400
>> OKAY.

4982
03:06:28,400 --> 03:06:29,320
>> THANK YOU.

4983
03:06:29,320 --> 03:06:32,360
>> AND THAT WRAPS UP OUR CONCEPT

4984
03:06:32,360 --> 03:06:33,120
REVIEW TODAY.

4985
03:06:33,120 --> 03:06:35,080
>> NO IT DOESN'T.

4986
03:06:35,080 --> 03:06:42,840
ONE MORE CONCEPT.

4987
03:06:42,840 --> 03:06:45,400
>> IF I DON'T SEE RED I LOOK TO

4988
03:06:45,400 --> 03:06:46,240
JOHN TO TAKE OVER.

4989
03:06:46,240 --> 03:06:52,960
ONE MORE CONCEPT.

4990
03:06:52,960 --> 03:06:53,480
SORRY.

4991
03:06:53,480 --> 03:06:56,360
IF YOU WANT TO TAKE A TEN MINUTE

4992
03:06:56,360 --> 03:06:58,160
BREAK OR YOU CAN GO AND COME

4993
03:06:58,160 --> 03:07:01,840
BACK AND SO LET'S JUST KEEP

4994
03:07:01,840 --> 03:07:02,240
GOING.

4995
03:07:02,240 --> 03:07:06,080
IF THERE'S ANYONE WHO DISAGREES

4996
03:07:06,080 --> 03:07:11,200
WITH THAT, SAY NO.

4997
03:07:11,200 --> 03:07:14,200
>> PAULETTE, I DO HAVE ONE

4998
03:07:14,200 --> 03:07:15,920
QUESTION BEING NEW AT THIS.

4999
03:07:15,920 --> 03:07:18,760
IF YOU ARE INVOLVED WITH A

5000
03:07:18,760 --> 03:07:21,120
PROGRAM TO BE DISCUSSED THROUGH

5001
03:07:21,120 --> 03:07:23,080
A PROPOSAL AS INVESTIGATOR,

5002
03:07:23,080 --> 03:07:25,080
SHOULD I STEP OFF CALL OR WHAT

5003
03:07:25,080 --> 03:07:26,720
IS MY CONFLICT SITUATION THERE?

5004
03:07:26,720 --> 03:07:27,760
>> OKAY.

5005
03:07:27,760 --> 03:07:29,080
IS THIS TRAY?

5006
03:07:29,080 --> 03:07:30,320
>> THIS IS TREY.

5007
03:07:30,320 --> 03:07:34,320
>> I SENT YOU AN EMAIL A TAD

5008
03:07:34,320 --> 03:07:34,960
EARLIER TODAY.

5009
03:07:34,960 --> 03:07:35,360
>> I'M SORRY

5010
03:07:35,360 --> 03:07:36,200
>> I MISSED IT.

5011
03:07:36,200 --> 03:07:38,120
>> YOU DON'T HAVE TO LEAVE BUT

5012
03:07:38,120 --> 03:07:39,400
YOU SHOULD NOT PARTICIPATE IN

5013
03:07:39,400 --> 03:07:42,960
THE DISCUSSION.

5014
03:07:42,960 --> 03:07:46,120
ONCE YOU ARE FULLY APPOINTED YOU

5015
03:07:46,120 --> 03:07:48,680
CANNOT VOTE SO TODAY ALL I NEED

5016
03:07:48,680 --> 03:07:51,280
YOU TO DO IS SIT TIGHT.

5017
03:07:51,280 --> 03:07:51,680
>> WILL DO.

5018
03:07:51,680 --> 03:07:57,120
THANK YOU.

5019
03:07:57,120 --> 03:07:58,720
>> BACK TO BUSINESS, FINAL

5020
03:07:58,720 --> 03:07:59,760
CONCEPT.

5021
03:07:59,760 --> 03:08:03,840
IS A REISSUE RFA ENTITLED

5022
03:08:03,840 --> 03:08:05,000
INFORMATICS TECHNOLOGY FOR

5023
03:08:05,000 --> 03:08:06,800
CANCER RESEARCH, PRESENTED BY

5024
03:08:06,800 --> 03:08:10,320
DR. JULIE KLEMM, SUBCOMMITTEE IS

5025
03:08:10,320 --> 03:08:18,280
CHAIRED BY SILL VIEIA AND

5026
03:08:18,280 --> 03:08:20,840
SUPPORTED BY MIKE AND LISA.

5027
03:08:20,840 --> 03:08:22,080
>> THANK YOU FOR THIS

5028
03:08:22,080 --> 03:08:22,960
OPPORTUNITY TO PRESENT OUR

5029
03:08:22,960 --> 03:08:25,840
REQUEST TO REISSUE RFAs FOR

5030
03:08:25,840 --> 03:08:27,520
THE NCI'S INFORMATICS TECHNOLOGY

5031
03:08:27,520 --> 03:08:33,960
FOR CANCER RESEARCH PROGRAM.

5032
03:08:33,960 --> 03:08:36,200
IPCR IS A TRANSNCI PROGRAM TO

5033
03:08:36,200 --> 03:08:38,640
SUPPORT INVESTIGATOR INITIATED

5034
03:08:38,640 --> 03:08:40,160
INFORMATICS TECHNOLOGY

5035
03:08:40,160 --> 03:08:41,120
DEVELOPMENT DETERMINED BY

5036
03:08:41,120 --> 03:08:42,040
CRITICAL NEEDS IN CANCER

5037
03:08:42,040 --> 03:08:42,800
RESEARCH.

5038
03:08:42,800 --> 03:08:45,040
THE FUNDED PROJECTS SUPPORT A

5039
03:08:45,040 --> 03:08:46,200
RANGE OF CANCER RESEARCH

5040
03:08:46,200 --> 03:08:49,080
ACTIVITIES.

5041
03:08:49,080 --> 03:08:50,960
ALL TOOLS DEVELOPED ARE OPEN

5042
03:08:50,960 --> 03:08:53,360
SOURCE AND PROGRAMMATIC

5043
03:08:53,360 --> 03:08:55,040
ACTIVITIES PROMOTE

5044
03:08:55,040 --> 03:08:55,800
INTEROPERABILITY AND

5045
03:08:55,800 --> 03:08:56,560
DISSEMINATION OF SUPPORTED

5046
03:08:56,560 --> 03:09:01,800
TOOLS.

5047
03:09:01,800 --> 03:09:02,720
THE PROGRAM STRUCTURE SUPPORTS

5048
03:09:02,720 --> 03:09:05,040
ACTIVITY ACROSS THE INFORMATICS

5049
03:09:05,040 --> 03:09:06,600
DEVELOPMENT LIFE CYCLE THROUGH

5050
03:09:06,600 --> 03:09:09,440
COMPANION FUNDING OPPORTUNITIES.

5051
03:09:09,440 --> 03:09:11,560
FOUR RFAs SUPPORT INFORMATICS

5052
03:09:11,560 --> 03:09:13,640
TECHNOLOGY DEVELOPMENT.

5053
03:09:13,640 --> 03:09:16,160
AN R21 SUPPORTS DEVELOPMENT OF

5054
03:09:16,160 --> 03:09:17,760
INNOVATIVE METHODS AND

5055
03:09:17,760 --> 03:09:19,960
ALGORITHMS THE UO 1 SUPPORTS

5056
03:09:19,960 --> 03:09:21,400
EARLY STAGE TOOL DEVELOPMENT,

5057
03:09:21,400 --> 03:09:23,600
THE ADVANCE DEVELOPMENT U 24

5058
03:09:23,600 --> 03:09:25,600
SUPPORTS ENHANCEMENT AND

5059
03:09:25,600 --> 03:09:27,320
DISSEMINATION OF EMERGING

5060
03:09:27,320 --> 03:09:30,400
INFORMATICS TOOLS AND THE

5061
03:09:30,400 --> 03:09:31,760
SUSTAINMENTED U 24 SUPPORTS

5062
03:09:31,760 --> 03:09:33,280
ACCESSED MATURE INFORMATICS

5063
03:09:33,280 --> 03:09:33,960
RESOURCES.

5064
03:09:33,960 --> 03:09:36,760
THE UO 1 AND U 24 AWARDEES ARE

5065
03:09:36,760 --> 03:09:39,920
REQUIRED TO SET ASIDE 10% OF

5066
03:09:39,920 --> 03:09:42,160
ANNUAL BUDGET FOR COLLABORATIVE

5067
03:09:42,160 --> 03:09:42,600
ACTIVITIES.

5068
03:09:42,600 --> 03:09:44,880
THAT ARE PROPOSED POST AWARD.

5069
03:09:44,880 --> 03:09:46,640
IN ADDITION THE PROGRAM HAS A

5070
03:09:46,640 --> 03:09:48,880
NEW EDUCATION RESOURCE ADDED AT

5071
03:09:48,880 --> 03:09:50,960
THE LAST PROGRAM RENEWAL, TO

5072
03:09:50,960 --> 03:09:52,640
CONDUCT ACTIVITIES THAT ENGAGE

5073
03:09:52,640 --> 03:09:54,760
RESEARCH AND INFORMATICS

5074
03:09:54,760 --> 03:09:57,120
COMMUNITY TO USE AND EXTEND ITCR

5075
03:09:57,120 --> 03:09:59,880
TECHNOLOGIES.

5076
03:09:59,880 --> 03:10:01,440
THE PROGRAM OFFERED SERIES OF

5077
03:10:01,440 --> 03:10:02,360
COMPETITIVE REVISION TO SUPPORT

5078
03:10:02,360 --> 03:10:07,840
THE INCORPORATION OF ITCR FUNDED

5079
03:10:07,840 --> 03:10:12,960
TECHNOLOGY AND RO1 UO 1 AND U 24

5080
03:10:12,960 --> 03:10:14,600
PROJECTS.

5081
03:10:14,600 --> 03:10:18,560
SINCE THE INCEPTION IN 2013 ITCR

5082
03:10:18,560 --> 03:10:20,000
HAS IMPORTANT ESTABLISHMENTS IN

5083
03:10:20,000 --> 03:10:21,760
SEVERAL AREAS -- ACCOMPLISHMENTS

5084
03:10:21,760 --> 03:10:23,480
IN SEVERAL AREAS.

5085
03:10:23,480 --> 03:10:24,960
TOOLS SUPPORTING THE PROGRAM ARE

5086
03:10:24,960 --> 03:10:27,040
WIDELY USED INFORMATICS

5087
03:10:27,040 --> 03:10:28,160
RESOURCES IN CANCER RESEARCH

5088
03:10:28,160 --> 03:10:30,160
EVIDENCED BY CITATION AND USAGE

5089
03:10:30,160 --> 03:10:30,680
STATISTICS.

5090
03:10:30,680 --> 03:10:32,560
THIS TABLE SHOWS A FEW EXAMPLES

5091
03:10:32,560 --> 03:10:35,560
ACROSS VARIOUS RESEARCH DOMAINS

5092
03:10:35,560 --> 03:10:37,120
OF WIDELY USED RESOURCES

5093
03:10:37,120 --> 03:10:40,200
SUPPORTED THROUGH THE PROGRAM.

5094
03:10:40,200 --> 03:10:42,040
ITCR TOOLS SUPPORT IMPORTANT

5095
03:10:42,040 --> 03:10:44,160
ADVANCE ACROSS CANCER RESEARCH

5096
03:10:44,160 --> 03:10:45,840
CONTINUUM AND MANY OF THESE

5097
03:10:45,840 --> 03:10:48,920
ACTIVITIES ARE DIRECT SUPPORT OF

5098
03:10:48,920 --> 03:10:50,160
NCI SCIENTIFIC PROGRAMS.

5099
03:10:50,160 --> 03:10:52,080
THE PROGRAM IS FOSTERING

5100
03:10:52,080 --> 03:10:55,040
COMMUNITY OF PRACTICE IN CANCER

5101
03:10:55,040 --> 03:10:56,320
INFORMATICS THROUGH PROGRAMMATIC

5102
03:10:56,320 --> 03:10:58,320
EMPHASIS ON COLLABORATION AND

5103
03:10:58,320 --> 03:10:59,240
INTEROPERABILITY THAT SUPPORT

5104
03:10:59,240 --> 03:11:02,160
THROUGH THE SET ASIDES FUNDS.

5105
03:11:02,160 --> 03:11:03,800
FINALLY ITCR TOOLS HAVE HIGH

5106
03:11:03,800 --> 03:11:05,040
ADOPTION AND CITATION RATES

5107
03:11:05,040 --> 03:11:06,560
THROUGH EMPHASIS ON OUTREACH AND

5108
03:11:06,560 --> 03:11:08,640
TRAINING.

5109
03:11:08,640 --> 03:11:12,520
NEXT SLIDE PLEASE.

5110
03:11:12,520 --> 03:11:14,840
SINCE THE START OF THE PROGRAM

5111
03:11:14,840 --> 03:11:16,320
ITCR MADE 130 AWARDS AND THE

5112
03:11:16,320 --> 03:11:18,440
PORTFOLIO INCLUDES TOOLS THAT

5113
03:11:18,440 --> 03:11:20,240
SUPPORT WIDE RANGE OF DATA TYPES

5114
03:11:20,240 --> 03:11:22,360
REPRESENTED IN THIS TREE PLOT.

5115
03:11:22,360 --> 03:11:23,960
SOME OF THE MOST PROMINENT

5116
03:11:23,960 --> 03:11:24,960
TECHNOLOGIES TO SUPPORT

5117
03:11:24,960 --> 03:11:28,760
RADIOLOGY IMAGING MEDICAL INFOR

5118
03:11:28,760 --> 03:11:29,760
MA THEICS, GENOMICS AND

5119
03:11:29,760 --> 03:11:30,320
HISTOLOGY.

5120
03:11:30,320 --> 03:11:34,120
NEXT SLIDE.

5121
03:11:34,120 --> 03:11:35,560
THESE TOOLS SUPPORT VARIETY OF

5122
03:11:35,560 --> 03:11:37,000
DATA SCIENCE FUNCTIONS INCLUDING

5123
03:11:37,000 --> 03:11:40,120
DATA MANAGEMENT, VISUALIZATION

5124
03:11:40,120 --> 03:11:41,760
STATISTICAL AND MACHINE LEARNING

5125
03:11:41,760 --> 03:11:43,160
METHODS NATURAL LANGUAGE

5126
03:11:43,160 --> 03:11:45,600
PROCESSING, CLINICAL DECISION

5127
03:11:45,600 --> 03:11:46,160
SUPPORT, CLINICAL TRIALS

5128
03:11:46,160 --> 03:11:48,280
MATCHING.

5129
03:11:48,280 --> 03:11:50,400
NEXT SLIDE PLEASE.

5130
03:11:50,400 --> 03:11:52,400
THE PROGRAM MAINTAINS A CATALOG

5131
03:11:52,400 --> 03:11:54,960
OF ALL ITCR SUPPORTED TOOLS ON

5132
03:11:54,960 --> 03:11:56,120
THEIR WEBSITE THAT INCLUDE

5133
03:11:56,120 --> 03:11:58,760
POINTERS TO THE PROJECT WEBSITE,

5134
03:11:58,760 --> 03:12:00,720
CODE REPOSITORIES RUNNING

5135
03:12:00,720 --> 03:12:03,040
INSTANCES OF THE TOOLS, AND FOR

5136
03:12:03,040 --> 03:12:05,040
MANY SHORT EXPLAINER VIDEOS WITH

5137
03:12:05,040 --> 03:12:08,360
OVERVIEW OF THE TOOLS FUNDALTY.

5138
03:12:08,360 --> 03:12:11,160
NEXT SLIDE PLEASE.

5139
03:12:11,160 --> 03:12:13,320
TODAY COLLABORATIVE SET ASIDE

5140
03:12:13,320 --> 03:12:16,440
FUNDS SUPPORTED 50

5141
03:12:16,440 --> 03:12:17,160
COLLABORATIONS, MOST WHICH

5142
03:12:17,160 --> 03:12:19,760
BETWEEN ITCR SUPPORTED TOOLS AND

5143
03:12:19,760 --> 03:12:21,480
THIS IS FOSTERING THE EMERGENCE

5144
03:12:21,480 --> 03:12:23,360
OF ECOSYSTEM OF CANCER

5145
03:12:23,360 --> 03:12:25,000
INFORMATICS RESOURCES THAT

5146
03:12:25,000 --> 03:12:27,480
DEPICTED IN THIS NET WORK

5147
03:12:27,480 --> 03:12:28,720
DIAGRAM, IT WAS CONNECTIONS AND

5148
03:12:28,720 --> 03:12:31,120
COLLABORATION BETWEEN ITCR

5149
03:12:31,120 --> 03:12:31,560
TOOLS.

5150
03:12:31,560 --> 03:12:35,200
NEXT SLIDE PLEASE.

5151
03:12:35,200 --> 03:12:36,880
TO DISSEMINATE INFORMATION ABOUT

5152
03:12:36,880 --> 03:12:38,680
AVAILABILITY AND EXTENSIBILITY

5153
03:12:38,680 --> 03:12:41,760
OF ITCR TOOLS AN RESOURCES THE

5154
03:12:41,760 --> 03:12:43,680
INVESTIGATORS CONDUCT OUTREACH

5155
03:12:43,680 --> 03:12:45,880
AND TRAINING AND SUPPORTED

5156
03:12:45,880 --> 03:12:46,280
FUNDED TECHNOLOGY.

5157
03:12:46,280 --> 03:12:47,480
IN ADDITION TO THE ACTIVITIES

5158
03:12:47,480 --> 03:12:50,480
THAT ARE CONDUCTED WITHIN THE

5159
03:12:50,480 --> 03:12:53,680
INDIVIDUAL AWARDS ITCR TOOLS ARE

5160
03:12:53,680 --> 03:12:55,360
PROMOTED THROUGH PROGRAM WIDE

5161
03:12:55,360 --> 03:12:56,240
EFFORTS BEEN SPURRED THROUGH

5162
03:12:56,240 --> 03:12:58,440
TRAINING AND OUTREACH WORKING

5163
03:12:58,440 --> 03:12:58,840
GROUP.

5164
03:12:58,840 --> 03:13:00,520
THIS INCLUDED TWO FOCUS JOURNAL

5165
03:13:00,520 --> 03:13:01,760
ISSUES OF TECHNOLOGIES DEVELOPED

5166
03:13:01,760 --> 03:13:03,400
THROUGH THE PROGRAM, THE MOST

5167
03:13:03,400 --> 03:13:07,320
RECENT BEING FOCUS ISSUE OF JCO

5168
03:13:07,320 --> 03:13:09,320
CLINICAL CANCER INFORMATICS

5169
03:13:09,320 --> 03:13:10,960
WHICH TECH PEER REVIEW PAPERS

5170
03:13:10,960 --> 03:13:13,360
OF OVER 30 ITCR TOOLS AND

5171
03:13:13,360 --> 03:13:16,080
PROMOTED ITCR RESOURCES THROUGH

5172
03:13:16,080 --> 03:13:18,520
DEDICATED SECTIONS AT PROMINENT

5173
03:13:18,520 --> 03:13:19,960
SCIENTIFIC CONFERENCES, REGULAR

5174
03:13:19,960 --> 03:13:21,440
PARTICIPATION AND VARIOUS NCI

5175
03:13:21,440 --> 03:13:24,120
WEBINAR SERIES, AND THROUGH

5176
03:13:24,120 --> 03:13:24,720
SOCIAL MEDIA.

5177
03:13:24,720 --> 03:13:28,200
NEXT SLIDE PLEASE.

5178
03:13:28,200 --> 03:13:30,440
BASED ON THE EVALUATION

5179
03:13:30,440 --> 03:13:32,240
RECOMMENDATION FROM OUR 2018

5180
03:13:32,240 --> 03:13:34,680
RENEWAL, THE PROGRAM IS ADDED A

5181
03:13:34,680 --> 03:13:38,560
UA 5 EDUCATION RESOURCE WITH TWO

5182
03:13:38,560 --> 03:13:40,640
PRIMARY GOALS, TO PROVIDE IN

5183
03:13:40,640 --> 03:13:42,440
DEPTH COURSES ON TOPICS AND

5184
03:13:42,440 --> 03:13:44,880
CANCER INFORMATICS USING THE

5185
03:13:44,880 --> 03:13:46,680
ITCR TOOLS AS EXEMPLARS AND

5186
03:13:46,680 --> 03:13:48,560
PROVIDE GUIDANCE AND SUPPORT TO

5187
03:13:48,560 --> 03:13:50,120
INFORMATICS TOOL DEVELOPERS TO

5188
03:13:50,120 --> 03:13:52,160
FACILITATE DISSEMINATION OF BEST

5189
03:13:52,160 --> 03:13:53,720
PRACTICES FOR USER ENGAGEMENT

5190
03:13:53,720 --> 03:13:56,040
AND OUTREACH.

5191
03:13:56,040 --> 03:13:56,960
JOHNS HOPKINS UNIVERSITY

5192
03:13:56,960 --> 03:13:59,200
RECEIVED THIS AWARD IN SEPTEMBER

5193
03:13:59,200 --> 03:14:01,760
2020 AND HAS INITIATED THE ITCR

5194
03:14:01,760 --> 03:14:04,480
TRAINING NETWORK AND THE ITN

5195
03:14:04,480 --> 03:14:06,560
RELEASED MY COURSES LEADERSHIP

5196
03:14:06,560 --> 03:14:09,000
PER CANCER INFORMATICS RESEARCH

5197
03:14:09,000 --> 03:14:10,360
AND DOCUMENTATION AND USABILITY

5198
03:14:10,360 --> 03:14:11,720
WITH OTHERS BEING ROLLED OUT

5199
03:14:11,720 --> 03:14:18,120
ACROSS THE PERIOD OF AWARD.

5200
03:14:18,120 --> 03:14:19,640
IN PREPARATION FOR REQUESTING

5201
03:14:19,640 --> 03:14:21,880
THIS RENEWAL AND EVALUATION OF

5202
03:14:21,880 --> 03:14:24,880
ITCR PROGRAM WAS CONDUCTED IN

5203
03:14:24,880 --> 03:14:26,320
EARLY 2021, THIS REVIEW WAS LED

5204
03:14:26,320 --> 03:14:28,680
BY PANEL OF SCIENTISTS FROM THE

5205
03:14:28,680 --> 03:14:29,960
EXTRAMURAL COMMUNITY WITH

5206
03:14:29,960 --> 03:14:32,520
EXPERIENCE IN CANCER INFORMATICS

5207
03:14:32,520 --> 03:14:32,920
DEVELOPMENT.

5208
03:14:32,920 --> 03:14:35,160
THEIR FINDINGS WERE

5209
03:14:35,160 --> 03:14:36,360
OVERWHELMINGLY POSITIVE WITH

5210
03:14:36,360 --> 03:14:37,600
OVERALL RECOMMENDATION TO

5211
03:14:37,600 --> 03:14:40,600
CONTINUE THE PROGRAM AS

5212
03:14:40,600 --> 03:14:41,640
STRUCTURED.

5213
03:14:41,640 --> 03:14:42,560
ADDITIONAL RECOMMENDATIONS

5214
03:14:42,560 --> 03:14:44,440
INCLUDED CONTINUING TO PROMOTE

5215
03:14:44,440 --> 03:14:46,200
CLAN RATION AMONG TOOL

5216
03:14:46,200 --> 03:14:48,480
DEVELOPERS AND EMPHASIZE FUNDING

5217
03:14:48,480 --> 03:14:50,480
EMERGING TECHNOLOGIES TO KEEP

5218
03:14:50,480 --> 03:14:52,720
PACE WITH ADVANCE IN CANCER

5219
03:14:52,720 --> 03:14:53,720
RESEARCH.

5220
03:14:53,720 --> 03:14:54,680
OPINIONLY THE PANEL RECOMMENDED

5221
03:14:54,680 --> 03:14:56,120
THE PROGRAM MAXIMIZE THE VALUE

5222
03:14:56,120 --> 03:14:59,640
OF THE TECHNOLOGIES BY PROMOTING

5223
03:14:59,640 --> 03:15:01,240
INFORMATICS SKILL AND WORK FORCE

5224
03:15:01,240 --> 03:15:02,760
DEVELOPMENT, ADVANCING STANDARDS

5225
03:15:02,760 --> 03:15:05,200
DEVELOPMENT EVALUATION AND

5226
03:15:05,200 --> 03:15:06,760
DISSEMINATION OF TOOLS,

5227
03:15:06,760 --> 03:15:09,000
FOSTERING ACADEMIC INDUSTRY

5228
03:15:09,000 --> 03:15:10,600
PARTNERSHIPS AND WORKING TO

5229
03:15:10,600 --> 03:15:12,720
ENSURE TOOLS AND ALGORITHMS ARE

5230
03:15:12,720 --> 03:15:14,520
AT THE GOAL AND TRANS-- ETHICAL

5231
03:15:14,520 --> 03:15:18,400
AND TRANSPARENT.

5232
03:15:18,400 --> 03:15:21,120
BASED ON FINDINGS OF THE

5233
03:15:21,120 --> 03:15:22,000
EVALUATION PANEL AND PROGRA

5234
03:15:22,000 --> 03:15:24,000
IMPACT TO DATE WE PROPOSE TO

5235
03:15:24,000 --> 03:15:26,840
CONTINUE ITCR AS A TRANSNCI

5236
03:15:26,840 --> 03:15:28,560
PROGRAM IN SUPPORTIVE INNOVATIVE

5237
03:15:28,560 --> 03:15:30,560
INVESTIGATOR INITIATED RESEARCH

5238
03:15:30,560 --> 03:15:33,720
DRIVEN INFORMATICS TECHNOLOGY

5239
03:15:33,720 --> 03:15:35,080
DEVELOPMENT TO MEET OBJECTIVES

5240
03:15:35,080 --> 03:15:36,520
WE WILL CONTINUE TO EMPLOY A

5241
03:15:36,520 --> 03:15:37,880
MULTI-MECHANISM APPROACH TO

5242
03:15:37,880 --> 03:15:39,600
SUPPORT INFORMATICS TECHNOLOGY

5243
03:15:39,600 --> 03:15:40,960
DEVELOPMENT THROUGH THE USE OF

5244
03:15:40,960 --> 03:15:44,520
THE R21 UO 1 AND U 24

5245
03:15:44,520 --> 03:15:45,080
MECHANISMS.

5246
03:15:45,080 --> 03:15:46,640
WE PROPOSE TO CONTINUE TO MAKE

5247
03:15:46,640 --> 03:15:48,960
THE FOA CLINICAL TRIALS OPTIONAL

5248
03:15:48,960 --> 03:15:51,720
TO SUPPORT TECHNOLOGY VALIDATION

5249
03:15:51,720 --> 03:15:54,320
STUDIES THAT MEET NIH DEFINITION

5250
03:15:54,320 --> 03:15:54,760
OF CLINICAL TRIAL.

5251
03:15:54,760 --> 03:15:56,840
TO ADDRESS FEEDBACK FROM THE

5252
03:15:56,840 --> 03:15:58,280
EVALUATION PANEL REGARDING

5253
03:15:58,280 --> 03:16:00,760
RELATIVE EMPHASIS ON NEW EARLY

5254
03:16:00,760 --> 03:16:03,320
STAGE DEVELOPMENT THE ITCR

5255
03:16:03,320 --> 03:16:05,080
PROGRAM TODAY OPTIMIZE PROCESSES

5256
03:16:05,080 --> 03:16:08,560
TO PRIORITIZE MERITORIOUS UO 1

5257
03:16:08,560 --> 03:16:09,720
APPLICATIONS FOR INCLUSION AND

5258
03:16:09,720 --> 03:16:11,600
FUNDING PLANS AND PROMOTE

5259
03:16:11,600 --> 03:16:13,320
ACADEMIC SRI PARTNERSHIPS SBIR

5260
03:16:13,320 --> 03:16:15,560
WILL BE ENGAGED TO IDENTIFY

5261
03:16:15,560 --> 03:16:17,240
OPPORTUNITIES FOR COLLABORATION

5262
03:16:17,240 --> 03:16:19,280
WITH INDUSTRIAL PARTNERS FOR

5263
03:16:19,280 --> 03:16:21,360
DIRECTED YOU OUT REACH AND FOCUS

5264
03:16:21,360 --> 03:16:22,240
CONTRACT TOPICS.

5265
03:16:22,240 --> 03:16:23,880
WE ARE NOT PROPOSING TO RENEW

5266
03:16:23,880 --> 03:16:25,000
THE COMPETITIVE -- COMPETING

5267
03:16:25,000 --> 03:16:26,680
REVISIONS FOR THE ADOPTION OF

5268
03:16:26,680 --> 03:16:28,560
ITCR TECHNOLOGIES THAT WERE

5269
03:16:28,560 --> 03:16:30,320
INITIATE IN THE PREVIOUS

5270
03:16:30,320 --> 03:16:30,760
RENEWAL.

5271
03:16:30,760 --> 03:16:33,600
DUE TO LOW RESPONSE RATE TO

5272
03:16:33,600 --> 03:16:33,960
FOAs.

5273
03:16:33,960 --> 03:16:37,160
ADOPTION OF THE ITCR TOOLS WILL

5274
03:16:37,160 --> 03:16:38,720
CONTINUE TO BE VIGOROUSLY

5275
03:16:38,720 --> 03:16:41,000
PROMOTED THROUGH INVESTIGATOR

5276
03:16:41,000 --> 03:16:42,080
PROMOTED OUTREACH ACTIVITIES.

5277
03:16:42,080 --> 03:16:44,960
NEXT SLIDE.

5278
03:16:44,960 --> 03:16:47,920
THE BUDGET REQUESTING IS 8

5279
03:16:47,920 --> 03:16:49,320
MILLION PER YEAR FOR NEW AWARDS

5280
03:16:49,320 --> 03:16:51,680
AND WE ARE REQUESTING THREE

5281
03:16:51,680 --> 03:16:53,560
REISSUANCES THE ESTIMATED

5282
03:16:53,560 --> 03:16:54,960
DISTRIBUTION ACROSS MECHANISMS

5283
03:16:54,960 --> 03:16:55,800
AD SHOWN ON THE SLIDE.

5284
03:16:55,800 --> 03:16:58,840
NEXT SLIDE.

5285
03:16:58,840 --> 03:17:00,520
I WOULD LIKE TO THANK THE

5286
03:17:00,520 --> 03:17:02,760
SUBCOMMITTEE WHO REVIEWED THE

5287
03:17:02,760 --> 03:17:03,760
REQUEST FOR FEEDBACK AND

5288
03:17:03,760 --> 03:17:06,240
VALUABLE DISCUSSION.

5289
03:17:06,240 --> 03:17:08,120
FEEDBACK INCLUDED FURTHER

5290
03:17:08,120 --> 03:17:09,040
PRIORITIZING CONSIDERATIONS FOR

5291
03:17:09,040 --> 03:17:11,280
SUSTAINMENT OF THE ITCR

5292
03:17:11,280 --> 03:17:12,760
TECHNOLOGIES, WE DISCUSSED

5293
03:17:12,760 --> 03:17:14,880
SEVERAL MODELS FOR SUSTAINMENT

5294
03:17:14,880 --> 03:17:17,560
INCLUDING SUCCESSFUL COMPETITION

5295
03:17:17,560 --> 03:17:20,520
FOR CONTINUED NCI FUNDING,

5296
03:17:20,520 --> 03:17:21,240
COMMERCIALIZATION OR OTHER

5297
03:17:21,240 --> 03:17:22,760
INDUSTRY PARTNERSHIP AS WELL AS

5298
03:17:22,760 --> 03:17:25,320
FUNDING THROUGH OTHER SOURCES

5299
03:17:25,320 --> 03:17:25,880
INCLUDING POSSIBLE CLINICAL

5300
03:17:25,880 --> 03:17:28,320
TRIALS FOR MATURE TOOLS.

5301
03:17:28,320 --> 03:17:30,480
LIKE THE EVALUATION PANEL THE

5302
03:17:30,480 --> 03:17:32,240
BSA REVIEWERS RECOMMENDED

5303
03:17:32,240 --> 03:17:33,840
FOSTERING INDUSTRIAL

5304
03:17:33,840 --> 03:17:35,080
PARTNERSHIPS AND WHILE SEVERAL

5305
03:17:35,080 --> 03:17:36,680
INDIVIDUAL PROJECTS DO HAVE

5306
03:17:36,680 --> 03:17:38,360
INDUSTRY PARTNERS AS MENTION WE

5307
03:17:38,360 --> 03:17:40,560
DO PLAN TO PROGRAMATICALLY

5308
03:17:40,560 --> 03:17:42,240
ENGAGE WITH SBIR.

5309
03:17:42,240 --> 03:17:44,240
THE REVIEWERS NOTED THE

5310
03:17:44,240 --> 03:17:45,360
IMPORTANCE OF CONTINUING TO

5311
03:17:45,360 --> 03:17:47,480
ENSURE THAT ITCR SUPPORTED

5312
03:17:47,480 --> 03:17:49,320
DIVERSE AREAS OF CANCER RESEARCH

5313
03:17:49,320 --> 03:17:51,880
AND RECOMMENDED INCREASING THE

5314
03:17:51,880 --> 03:17:53,360
NUMBER OF CLINICAL TRANSLATIONAL

5315
03:17:53,360 --> 03:17:55,840
TOOLS IN THE PORTFOLIO.

5316
03:17:55,840 --> 03:17:57,360
WE DO RECOGNIZE THERE ARE

5317
03:17:57,360 --> 03:17:59,360
UNDER-REPRESENTED DOMAINS IN THE

5318
03:17:59,360 --> 03:18:00,560
PORTFOLIO AND MOST RECENTLY

5319
03:18:00,560 --> 03:18:03,200
WORKED WITH COLLEAGUES IN DCCPS

5320
03:18:03,200 --> 03:18:06,960
TO PUT UP RFI FOR MORE INPUT ON

5321
03:18:06,960 --> 03:18:08,040
TECHNOLOGY NEEDS FOR

5322
03:18:08,040 --> 03:18:08,960
EPIDEMIOLOGY AND POPULATION

5323
03:18:08,960 --> 03:18:10,400
RESEARCH TO INFORM FUTURE

5324
03:18:10,400 --> 03:18:12,560
RFAs.

5325
03:18:12,560 --> 03:18:13,600
FINALLY THE SUBCOMMITTEE

5326
03:18:13,600 --> 03:18:14,760
EMPHASIZED THE IMPORTANCE OF

5327
03:18:14,760 --> 03:18:17,320
INCREASING ENGAGEMENT WITH OTHER

5328
03:18:17,320 --> 03:18:17,720
NCI PROGRAMS.

5329
03:18:17,720 --> 03:18:20,760
NEXT SLIDE PLEASE.

5330
03:18:20,760 --> 03:18:22,960
WHEN WE LOOK ACROSS NCI

5331
03:18:22,960 --> 03:18:25,320
CONSORTIA WE SEE ITCR TECHNOLOGY

5332
03:18:25,320 --> 03:18:27,680
SUPPORTING RESEARCH WITHIN THESE

5333
03:18:27,680 --> 03:18:29,480
PROGRAMS AND THIS SLIDE SHOWS

5334
03:18:29,480 --> 03:18:31,280
SEVERAL EXAMPLES.

5335
03:18:31,280 --> 03:18:34,000
GOING FORWARD WE PLAN TO

5336
03:18:34,000 --> 03:18:36,640
INCREASE CANCER OUTREACH TO NCI

5337
03:18:36,640 --> 03:18:37,760
CONSORTIA AND CANCER CENTER.

5338
03:18:37,760 --> 03:18:40,120
NEXT SLIDE.

5339
03:18:40,120 --> 03:18:41,800
FINALLY I WOULD LIKE TO END BY

5340
03:18:41,800 --> 03:18:43,480
ACKNOWLEDGING THE NCI STAFF ON

5341
03:18:43,480 --> 03:18:45,920
ITCR PROGRAM TEAM THAT SUPPORTS

5342
03:18:45,920 --> 03:18:47,920
THIS TRANSNCI PROGRAM WHO I

5343
03:18:47,920 --> 03:18:48,560
REPRESENT TODAY.

5344
03:18:48,560 --> 03:18:49,760
WITH THAT I WOULD LIKE TO THANK

5345
03:18:49,760 --> 03:18:51,080
YOU AND I'M HAPPY TO TAKE ANY

5346
03:18:51,080 --> 03:18:55,160
QUESTIONS.

5347
03:18:55,160 --> 03:18:56,560
OPERATOR:  THANK YOU VERY MUCH

5348
03:18:56,560 --> 03:18:56,880
DR. KLEMM.

5349
03:18:56,880 --> 03:18:58,800
SYLVIA, LEAD THE DISCUSSION.

5350
03:18:58,800 --> 03:19:03,080
>> THANK YOU, DR. KLEMM FOR A

5351
03:19:03,080 --> 03:19:04,680
TERRIFIC PRESENTATION, MICHAEL

5352
03:19:04,680 --> 03:19:06,160
IAN AND I SERVE ON THE COMMITTEE

5353
03:19:06,160 --> 03:19:08,440
AND THIS IS REALLY EXCEPTIONAL

5354
03:19:08,440 --> 03:19:10,320
PROGRAM AND WE ARE UNANIMOUSLY

5355
03:19:10,320 --> 03:19:11,440
SUPPORT OF RENEWALS GOING

5356
03:19:11,440 --> 03:19:12,520
THROUGH DISCUSSION.

5357
03:19:12,520 --> 03:19:13,520
WE FELT A PRESENTATION VALUABLE

5358
03:19:13,520 --> 03:19:16,280
TO ENSURE THE BSA AND NCAB

5359
03:19:16,280 --> 03:19:18,320
MEMBERS ARE AWARE REMARKABLE

5360
03:19:18,320 --> 03:19:19,120
SUCCESS OF THIS PROGRAM.

5361
03:19:19,120 --> 03:19:20,880
WE HAD REALLY PRODUCTIVE HOUR

5362
03:19:20,880 --> 03:19:24,120
LONG MEETING WITH JULIE AND SHE

5363
03:19:24,120 --> 03:19:26,680
ITEMIZED DISCUSSION POINTS

5364
03:19:26,680 --> 03:19:28,520
REALLY AROUND PATHS OF LONG TERM

5365
03:19:28,520 --> 03:19:30,760
SUSTAINABILITY AND THE ITCR

5366
03:19:30,760 --> 03:19:32,080
FUNDED PROGRAMS INCREASE

5367
03:19:32,080 --> 03:19:35,760
PARTNERSHIPS WITH INDUSTRY,

5368
03:19:35,760 --> 03:19:37,520
INCREASE INTERACTION WITH OTHER

5369
03:19:37,520 --> 03:19:39,360
NCI PROGRAMS SPECIFICALLY TOWARD

5370
03:19:39,360 --> 03:19:42,200
SPORES AND CRSG TO HAVE MORE

5371
03:19:42,200 --> 03:19:46,200
EXPLICIT CONNECTION WITH ITCR.

5372
03:19:46,200 --> 03:19:48,880
AND TO EXPAND THE CLINICAL

5373
03:19:48,880 --> 03:19:50,880
TRANSLATIONAL INFORMATICS IN THE

5374
03:19:50,880 --> 03:19:53,160
ITCR PORTFOLIO WITH CLINICAL

5375
03:19:53,160 --> 03:19:53,560
PHENOTYPING.

5376
03:19:53,560 --> 03:19:59,840
IN CONCERT WITH CC SGAs SO

5377
03:19:59,840 --> 03:20:03,040
JUST VERY IN SUMMARY WE ARE VERY

5378
03:20:03,040 --> 03:20:04,400
SUPPORTIVE WE VIEW AS IMPORTANT

5379
03:20:04,400 --> 03:20:05,880
ASSET OF THE NCI AND PLACE FOR

5380
03:20:05,880 --> 03:20:07,760
CONTINUED INVESTMENT TO KEEP

5381
03:20:07,760 --> 03:20:08,800
PACE WITH ADVANCES IN DATA

5382
03:20:08,800 --> 03:20:11,080
SCIENCE.

5383
03:20:11,080 --> 03:20:15,000
THIS -- I WOULD LIKE TO INVITE

5384
03:20:15,000 --> 03:20:19,280
MY COLLEAGUE DR. BESICH.

5385
03:20:19,280 --> 03:20:21,040
>> GREAT SUMMARY.

5386
03:20:21,040 --> 03:20:24,480
IT IS A MODEL PROGRAM FOR THE

5387
03:20:24,480 --> 03:20:27,760
ENTIRE NIH WHERE IT COULD MOVE

5388
03:20:27,760 --> 03:20:29,440
TO EXCEPTIONAL FOR THE INFINITY

5389
03:20:29,440 --> 03:20:31,520
WOULD BE TO INTEGRATE MORE

5390
03:20:31,520 --> 03:20:33,720
DEEPLY WITH KEY NCI PROGRAMS

5391
03:20:33,720 --> 03:20:36,720
STILL TO ME IS LACKING SOME KIND

5392
03:20:36,720 --> 03:20:39,760
OF PRESCRIPTIVE PATH FOR ITCR TO

5393
03:20:39,760 --> 03:20:42,800
INTERACT WITH SPORES, TO

5394
03:20:42,800 --> 03:20:45,280
INTERACT WITH OTHER U 54

5395
03:20:45,280 --> 03:20:48,160
MECHANISMS WITH PROGRAM

5396
03:20:48,160 --> 03:20:50,040
PROJECTS, WITH SPORES WOULD BE

5397
03:20:50,040 --> 03:20:53,680
AN EXCEPTIONAL OLD STEP FORWARD

5398
03:20:53,680 --> 03:20:55,760
FOR THE NCI IN NOT TO BE SO

5399
03:20:55,760 --> 03:20:57,680
PRESCRIPTIVE TO MAKE SURE THAT

5400
03:20:57,680 --> 03:20:59,160
THAT HAPPENS.

5401
03:20:59,160 --> 03:21:01,800
I THINK BARRIER TO SUCCESS SO

5402
03:21:01,800 --> 03:21:05,680
THIS IS IS A MODEL PROGRAM

5403
03:21:05,680 --> 03:21:06,720
TESTIFY IN THELY REFUNDED AND

5404
03:21:06,720 --> 03:21:10,440
KUDOS TO JULIE AND CODER SHIP

5405
03:21:10,440 --> 03:21:11,960
BUT DEEPER INTEGRATION WITH

5406
03:21:11,960 --> 03:21:14,960
ITSELF NCI TAKE IT TO THE NEXT

5407
03:21:14,960 --> 03:21:25,720
LEVEL.

5408
03:21:25,720 --> 03:21:28,120
>> -- IS NOT HERE TODAY.

5409
03:21:28,120 --> 03:21:30,560
>> OPEN UP ANY FURTHER QUESTIONS

5410
03:21:30,560 --> 03:21:35,840
OR COMMENTS FROM MEMBERS?

5411
03:21:35,840 --> 03:21:39,480
>> THIS IS JOHN I ALSO THINK

5412
03:21:39,480 --> 03:21:42,920
THIS PROGRAM IS WELL SHUTEDDED

5413
03:21:42,920 --> 03:21:45,680
FOR CONSIDERING INTEGRATING WITH

5414
03:21:45,680 --> 03:21:48,560
-- PARTICULARLY ON THE TRAINING

5415
03:21:48,560 --> 03:21:49,320
SIDE, THINK ABOUT

5416
03:21:49,320 --> 03:21:51,200
UNDER-REPRESENTED MINORITY

5417
03:21:51,200 --> 03:21:52,560
TRAINEES I HAVE ALWAYS LOOKED AT

5418
03:21:52,560 --> 03:21:54,120
DATA SCIENCE AND INFORMATICS

5419
03:21:54,120 --> 03:21:55,560
WELL SUITED ESPECIALLY THINK

5420
03:21:55,560 --> 03:21:56,480
ABOUT FOR INSTANCE MINORITY

5421
03:21:56,480 --> 03:21:58,720
SERVING INSTITUTIONS, MIGHT NOT

5422
03:21:58,720 --> 03:22:00,160
BE A LOT OF INFRASTRUCTURE FOR

5423
03:22:00,160 --> 03:22:01,760
WET LAB RESEARCH BUT THERE COULD

5424
03:22:01,760 --> 03:22:04,080
BE A LOT OF INFRASTRUCTURE IN

5425
03:22:04,080 --> 03:22:08,720
PLACE FOR DRY LAB WORK A LOT

5426
03:22:08,720 --> 03:22:10,480
DONE IN THE CLOUD SO IT WOULD BE

5427
03:22:10,480 --> 03:22:13,680
GREAT TO SEE HOW YOU COULD WORK

5428
03:22:13,680 --> 03:22:16,680
TO ENHANCE TRAINING.

5429
03:22:16,680 --> 03:22:19,360
AROUND BIOINFORMATICS AN DATA

5430
03:22:19,360 --> 03:22:23,360
SCIENCE IN THOSE SETTINGS.

5431
03:22:23,360 --> 03:22:25,080
>> THE OPPORTUNITY TO MENTION

5432
03:22:25,080 --> 03:22:27,160
THE EDUCATION RESOURCE HAS

5433
03:22:27,160 --> 03:22:30,480
PARTICULAR FOCUS ON WORKING WITH

5434
03:22:30,480 --> 03:22:32,320
MINORITY SUPPORTING

5435
03:22:32,320 --> 03:22:33,360
INSTITUTIONS.

5436
03:22:33,360 --> 03:22:34,160
AND HAS PARTICULAR AIM AROUND

5437
03:22:34,160 --> 03:22:38,240
THAT.

5438
03:22:38,240 --> 03:22:40,240
>> OPPORTUNITY IS GROWING R 25

5439
03:22:40,240 --> 03:22:43,880
PROGRAM IN NCI SUPPLEMENTS, TO

5440
03:22:43,880 --> 03:22:45,240
BRING UNDER-REPRESENTED

5441
03:22:45,240 --> 03:22:47,800
MINORITIES IN TO STEM WITH TWO

5442
03:22:47,800 --> 03:22:49,520
Ms, SCIENCE TECHNOLOGY

5443
03:22:49,520 --> 03:22:53,000
ENGINEERING MATH AND MEDICINE TO

5444
03:22:53,000 --> 03:22:53,920
CANCER RESEARCH AND AGAIN IT IS

5445
03:22:53,920 --> 03:22:57,960
PLACE WHERE ITCR IS SILENT BUT

5446
03:22:57,960 --> 03:22:59,680
YOU SHOULD BE ENCOURAGED BECAUSE

5447
03:22:59,680 --> 03:23:01,200
YOU NEED TO START EARLY AT THIS

5448
03:23:01,200 --> 03:23:04,200
STAGE OF RECRUITING

5449
03:23:04,200 --> 03:23:06,480
UNDER-REPRESENTED SCIENCE --

5450
03:23:06,480 --> 03:23:08,920
SCIENTISTS WITH POTENTIAL INTO

5451
03:23:08,920 --> 03:23:09,800
THE FRAMEWORK.

5452
03:23:09,800 --> 03:23:11,600
WE HAD EXTRAORDINARY SUCCESS

5453
03:23:11,600 --> 03:23:14,480
WITH OUR R 25 DOING THAT THOUGH

5454
03:23:14,480 --> 03:23:16,920
NO LONGER ITCR FUNDED.

5455
03:23:16,920 --> 03:23:18,920
ANOTHER MISSED OPPORTUNITY TO

5456
03:23:18,920 --> 03:23:20,360
INTEGRATE PROGRAMS ACROSS THENY

5457
03:23:20,360 --> 03:23:23,160
THAT ITCR SHOULD BE ENCOURAGED

5458
03:23:23,160 --> 03:23:27,880
AND FUNDED.

5459
03:23:27,880 --> 03:23:29,800
>> COUPLE OF GOOD COMMENTS IN

5460
03:23:29,800 --> 03:23:33,200
TERMS OF POSSIBLE INTERACTION

5461
03:23:33,200 --> 03:23:34,640
WITH N CORP, ALSO A SUGGESTION

5462
03:23:34,640 --> 03:23:37,200
TO CONSIDER.

5463
03:23:37,200 --> 03:23:40,040
LET'S MOVE TO VOTING.

5464
03:23:40,040 --> 03:23:40,920
SYLVIA, MAKE A MOTION LOOKING

5465
03:23:40,920 --> 03:23:43,000
FOR CONCURRENCE OR

5466
03:23:43,000 --> 03:23:43,360
NON-CONCURRENCE.

5467
03:23:43,360 --> 03:23:44,800
>> I CONDITION CUR.

5468
03:23:44,800 --> 03:23:47,440
>> CAN I GET A SECOND -- CONCUR.

5469
03:23:47,440 --> 03:23:49,160
>> I'LL SECOND THAT STRONGLY.

5470
03:23:49,160 --> 03:23:50,240
>> THANK YOU.

5471
03:23:50,240 --> 03:23:56,960
ANY FURTHER DISCUSSION?

5472
03:23:56,960 --> 03:23:57,920
NO?

5473
03:23:57,920 --> 03:23:59,600
MOTION IS FOR CONCURRENCE.

5474
03:23:59,600 --> 03:24:02,800
BSA MEMBERS IF YOU VOTE TO NOT

5475
03:24:02,800 --> 03:24:05,600
CONCUR PLEASE VOICE THAT OR

5476
03:24:05,600 --> 03:24:11,320
RAISE YOUR HANDS.

5477
03:24:11,320 --> 03:24:11,960
I SEE NONE.

5478
03:24:11,960 --> 03:24:17,720
ANY ABSTENTIONS.

5479
03:24:17,720 --> 03:24:21,920
NO ABSTENTIONS,

5480
03:24:21,920 --> 03:24:24,680
>> IT'S UNANIMOUS NO

5481
03:24:24,680 --> 03:24:25,360
ABSTENTIONS.

5482
03:24:25,360 --> 03:24:27,640
WE ARE FINISHED WITH THE CONCEPT

5483
03:24:27,640 --> 03:24:28,080
CLEARANCES.

5484
03:24:28,080 --> 03:24:34,440
>> GREAT, JOHN BACK TO YOU.

5485
03:24:34,440 --> 03:24:41,080
>> SO I THINK WE NEXT ON THE

5486
03:24:41,080 --> 03:24:44,320
AGENDA IS ONGOING BUSINESS.

5487
03:24:44,320 --> 03:24:48,120
THERE WAS ONE NCAB SUBCOMMITTEE

5488
03:24:48,120 --> 03:24:50,320
MEETING ON DECEMBER 7 WHICH WAS

5489
03:24:50,320 --> 03:24:51,920
AD HOC SUBCOMMITTEE ON

5490
03:24:51,920 --> 03:24:53,360
EXPERIMENTAL THERAPEUTICS WHICH

5491
03:24:53,360 --> 03:25:02,360
IS CHAIRED BY TIM WADE.

5492
03:25:02,360 --> 03:25:03,360
SO I BELIEVE TIM WILL GIVE A

5493
03:25:03,360 --> 03:25:03,600
REPORT.

5494
03:25:03,600 --> 03:25:05,680
>> POINT OF ORDER, AT THE END OF

5495
03:25:05,680 --> 03:25:07,360
THE REPORT PAULETTE WE NEED A

5496
03:25:07,360 --> 03:25:09,400
MOTION A SECOND AND VOTE TO

5497
03:25:09,400 --> 03:25:12,960
APPROVE THIS MOTION.

5498
03:25:12,960 --> 03:25:14,920
>> THE BOARD WILL VOTE TO ACCEPT

5499
03:25:14,920 --> 03:25:17,280
THE REPORT.

5500
03:25:17,280 --> 03:25:17,520
JOHN --

5501
03:25:17,520 --> 03:25:20,240
>> ONLY NCAB.

5502
03:25:20,240 --> 03:25:22,080
ONLY NCAB MEMBERS WILL VOTE.

5503
03:25:22,080 --> 03:25:22,560
(OVERLAPPING SPEAKERS)

5504
03:25:22,560 --> 03:25:23,320
>> YES.

5505
03:25:23,320 --> 03:25:25,320
>> STILL HAVE A QUORUM.

5506
03:25:25,320 --> 03:25:28,480
>> YES, WE DO.

5507
03:25:28,480 --> 03:25:31,160
>> I SERVED ON THE BOARD, BEEN A

5508
03:25:31,160 --> 03:25:32,280
TREMENDOUS PLEASURE FOR SEVEN

5509
03:25:32,280 --> 03:25:34,040
AND A HALF YEARS.

5510
03:25:34,040 --> 03:25:36,520
I WILL TELL YOU THE ONLY THING

5511
03:25:36,520 --> 03:25:37,760
BETWEEN ME AND THE END OF MY

5512
03:25:37,760 --> 03:25:39,200
SERVICE TO THE BOARD THIS

5513
03:25:39,200 --> 03:25:39,760
REPORT.

5514
03:25:39,760 --> 03:25:41,800
I ASSURE YOU I'M GOING TO BE

5515
03:25:41,800 --> 03:25:45,800
SUCCINCT.

5516
03:25:45,800 --> 03:25:47,160
ABOUT YEAR AND A HALF AGO NED

5517
03:25:47,160 --> 03:25:50,640
ASKED ME TO CHAIR A SUBCOMMITTEE

5518
03:25:50,640 --> 03:25:52,320
ON EXPERIMENTAL THERAPEUTICS TO

5519
03:25:52,320 --> 03:25:54,760
GIVE ADVICE NCI HEEDER SHIP

5520
03:25:54,760 --> 03:25:57,120
ABOUT TOPICS THAT WERE HOT AND

5521
03:25:57,120 --> 03:26:01,720
THAT THE NCI IMMEDIATED TO

5522
03:26:01,720 --> 03:26:03,960
CONSIDER FOR BOARD MEMBERS TO

5523
03:26:03,960 --> 03:26:07,360
FOCUS ON THINGS THAT WOULD BE

5524
03:26:07,360 --> 03:26:09,560
RELEVANT FOR NCI INVESTMENT IN

5525
03:26:09,560 --> 03:26:11,040
THE NEAR FUTURE.

5526
03:26:11,040 --> 03:26:12,800
SO THE SUBCOMMITTEE MET AND

5527
03:26:12,800 --> 03:26:15,320
CONSIDERED A WIDE VARIETY OF

5528
03:26:15,320 --> 03:26:18,120
TOPICS AND WE PICKED TWO.

5529
03:26:18,120 --> 03:26:21,080
CELLULAR THERAPY, AND RATIONAL

5530
03:26:21,080 --> 03:26:23,960
DRUG DESIGN TO ADDRESS.

5531
03:26:23,960 --> 03:26:26,560
WE DID NOT HAVE ADEQUATE

5532
03:26:26,560 --> 03:26:27,600
EXPERTISE TO THE BOARD TO

5533
03:26:27,600 --> 03:26:29,520
EXPRESS IN A MEANINGFUL WAY SO

5534
03:26:29,520 --> 03:26:33,120
THEREFORE NCI STAFF PARTICULARLY

5535
03:26:33,120 --> 03:26:34,080
ROSE OR JENNA, EXECUTIVE

5536
03:26:34,080 --> 03:26:36,760
SECRETARY OF THE SUBCOMMITTEE,S

5537
03:26:36,760 --> 03:26:38,760
ORGANIZED WORKSHOPS FOR US TO

5538
03:26:38,760 --> 03:26:40,560
GATHER INFORMATION ABOUT THESE

5539
03:26:40,560 --> 03:26:42,720
TWO TOPICS.

5540
03:26:42,720 --> 03:26:44,160
SO THERE WERE TWO THAT WERE DONE

5541
03:26:44,160 --> 03:26:49,200
IN CELL THERAPY INCREDIBLY

5542
03:26:49,200 --> 03:26:50,560
VALUABLE IT WAS REASONABLY VAGUE

5543
03:26:50,560 --> 03:26:54,200
FORWARD TO GET PEOPLE'S IDEAS

5544
03:26:54,200 --> 03:26:55,560
ABOUT ISSUES INVOLVED IN

5545
03:26:55,560 --> 03:26:59,440
CELLULAR THERAPY FOR CANCER AND

5546
03:26:59,440 --> 03:27:01,760
THOSE WORKSHOPS LED TO REPORT

5547
03:27:01,760 --> 03:27:02,560
WITH SEVEN RECOMMENDATIONS WE

5548
03:27:02,560 --> 03:27:03,760
OFFER TO THE BOARD AND WERE

5549
03:27:03,760 --> 03:27:07,000
APPROVED EARLIER I YEAR.

5550
03:27:07,000 --> 03:27:08,880
THE SECOND TOPIC RATIONAL DRUG

5551
03:27:08,880 --> 03:27:10,680
DESIGN TURNED OUT MUCH, MUCH

5552
03:27:10,680 --> 03:27:11,960
MORE DIFFICULT.

5553
03:27:11,960 --> 03:27:14,960
IT IS A VERY, VERY LARGE AREA.

5554
03:27:14,960 --> 03:27:16,600
AGAIN WE DIDN'T HAVE ADEQUATE

5555
03:27:16,600 --> 03:27:18,040
EXPERTISE ON THE BOARD TO

5556
03:27:18,040 --> 03:27:20,360
EXPLORE THIS IN DETAIL.

5557
03:27:20,360 --> 03:27:23,160
SO ROSE AND HER COLLEAGUES AT

5558
03:27:23,160 --> 03:27:24,880
NCI WORKSHOP THAT WAS HELD ON

5559
03:27:24,880 --> 03:27:28,080
THE 18TH AND 19TH OF OCTOBER,

5560
03:27:28,080 --> 03:27:30,840
RASH MALL DRUG DESIGN, OVER 700

5561
03:27:30,840 --> 03:27:35,640
PEOPLE PARTICIPATED IN THE WORK

5562
03:27:35,640 --> 03:27:38,320
SHOPS AND NUMBER VERY PROMINENT

5563
03:27:38,320 --> 03:27:40,280
LEADERS IN THIS ARENA INCLUDING

5564
03:27:40,280 --> 03:27:44,600
LEADERS IN PHARMA PARTICIPATED.

5565
03:27:44,600 --> 03:27:46,520
THEY CONSIDER FOUR TOPICS

5566
03:27:46,520 --> 03:27:50,160
VIRTUAL BIOLOGY AND RELEVANCE OF

5567
03:27:50,160 --> 03:27:51,360
CRYOEM FOR THAT KIND OF

5568
03:27:51,360 --> 03:27:53,280
TECHNOLOGY FOR DRUG DESIGN, THEY

5569
03:27:53,280 --> 03:27:56,240
CONSIDERED MACHINE LEARNING

5570
03:27:56,240 --> 03:27:58,240
ARTIFICIAL INTELLIGENCE IN ITS

5571
03:27:58,240 --> 03:27:59,800
ROLE NOVEL MODALITIES FOR

5572
03:27:59,800 --> 03:28:01,680
EXPLORING RATIONAL DRUG DESIGN

5573
03:28:01,680 --> 03:28:05,360
AND TARGETED INTERROGATION.

5574
03:28:05,360 --> 03:28:06,920
THEY CAME UP WITH A LARGE NUMBER

5575
03:28:06,920 --> 03:28:09,320
OF IDEAS WHICH I WILL ATTEMPT TO

5576
03:28:09,320 --> 03:28:10,840
DISTILL INCREDIBLY BRIEFLY FOR

5577
03:28:10,840 --> 03:28:15,520
YOU THE NEXT COUPLE OF MINUTES.

5578
03:28:15,520 --> 03:28:18,920
THE OVERARCHING THEMES ABOUT

5579
03:28:18,920 --> 03:28:20,680
AREAS THAT WERE PROBLEMATIC IN

5580
03:28:20,680 --> 03:28:22,560
THIS ARENA WERE AS FOLLOWS.

5581
03:28:22,560 --> 03:28:25,680
SO NUMBER ONE WAS DATA SHARING

5582
03:28:25,680 --> 03:28:27,240
AND HOMAGE ANYIZATION.

5583
03:28:27,240 --> 03:28:29,480
THIS IS SEEN AS AN OBSTACLE IN

5584
03:28:29,480 --> 03:28:31,680
MANY WAYS, ESPECIALLY AS

5585
03:28:31,680 --> 03:28:33,320
PERTAINS TO DEVELOPING DATABASES

5586
03:28:33,320 --> 03:28:36,000
THAT CAN BE UTILIZED BY

5587
03:28:36,000 --> 03:28:37,520
ARTIFICIAL INTELLIGENCE MACHINE

5588
03:28:37,520 --> 03:28:38,960
LEARNING AL FOR RUT.

5589
03:28:38,960 --> 03:28:40,920
S THAT QUALITY OF DATA SETS AND

5590
03:28:40,920 --> 03:28:43,240
THE HARMONIZATION OF DATA SETS

5591
03:28:43,240 --> 03:28:46,560
IS ABSOLUTELY ESSENTIAL FOR

5592
03:28:46,560 --> 03:28:48,400
BEING EFFECTIVE IN TERMS OF

5593
03:28:48,400 --> 03:28:51,600
USING EXISTING DATA TO LOOK AT

5594
03:28:51,600 --> 03:28:53,080
RATIONAL DRUG DESIGN.

5595
03:28:53,080 --> 03:28:55,120
THE SECOND THING THAT WAS

5596
03:28:55,120 --> 03:28:58,880
ENORMOUS WAS REPRODUCIBILITY OF

5597
03:28:58,880 --> 03:29:02,160
STUDIES, REPRODUCIBILITY CRISIS

5598
03:29:02,160 --> 03:29:03,440
HOW THAT CAN BE ADDRESSED.

5599
03:29:03,440 --> 03:29:06,760
THIRD WAS THE UNIFICATION OF

5600
03:29:06,760 --> 03:29:07,920
INVESTIGATORS ON BOTH SIDES OF

5601
03:29:07,920 --> 03:29:09,040
THE STREET AND ACADEMIA AND

5602
03:29:09,040 --> 03:29:12,320
PHARMA.

5603
03:29:12,320 --> 03:29:15,080
THE LAST WAS THIS LONG STANDING

5604
03:29:15,080 --> 03:29:17,560
DILEMMA OF HOW TO GET AN IDEA TO

5605
03:29:17,560 --> 03:29:19,680
A PRODUCT, SO CALLED VALLEY OF

5606
03:29:19,680 --> 03:29:21,640
DEATH OF DRUG DEVELOPMENT

5607
03:29:21,640 --> 03:29:24,640
BETWEEN DISCOVERY OF LEAD

5608
03:29:24,640 --> 03:29:26,960
COMPOUNDS AND INITIAL TRIAL

5609
03:29:26,960 --> 03:29:28,240
DRUGS, GETTING SOMETHING TO

5610
03:29:28,240 --> 03:29:30,840
APPROVAL BY THE FDA.

5611
03:29:30,840 --> 03:29:34,600
THOSE ARE THE MAJOR THEMES

5612
03:29:34,600 --> 03:29:38,120
IDENTIFIED BY PARTICIPANTS IN

5613
03:29:38,120 --> 03:29:40,120
THESE WORKSHOP GROUPS, THERE WAS

5614
03:29:40,120 --> 03:29:40,800
SOME RECOMMENDATIONS THAT CAME

5615
03:29:40,800 --> 03:29:45,360
OUT WHICH I WILL SUMMARIZE FROM

5616
03:29:45,360 --> 03:29:47,160
A LOFT HERE THAT ARE RELEVANT

5617
03:29:47,160 --> 03:29:49,840
FROM THE NCI LEADERSHIP.

5618
03:29:49,840 --> 03:29:52,760
MAJOR CATEGORIES WERE TO REALLY

5619
03:29:52,760 --> 03:29:55,760
HI SERIOUSLY ABOUT NON-DRUGGABLE

5620
03:29:55,760 --> 03:29:57,200
TARGETS AND DEVELOP MECHANISMS

5621
03:29:57,200 --> 03:30:00,400
FOR EVALUATING NON-DRUGGABLE

5622
03:30:00,400 --> 03:30:01,480
TARGETS.

5623
03:30:01,480 --> 03:30:06,040
TO DEVELOP BETTER RESOURCES FOR

5624
03:30:06,040 --> 03:30:08,960
MEDICINAL CHEMISTRY COURSE.

5625
03:30:08,960 --> 03:30:12,760
TO INCREASE ACCESSIBILITY OF

5626
03:30:12,760 --> 03:30:15,200
LIBRARIES IN THE NEXT PROGRAM

5627
03:30:15,200 --> 03:30:17,400
AND CRYOEM SOMEWHAT LIMITED IN

5628
03:30:17,400 --> 03:30:18,560
MANY INSTITUTIONS BUT RESOURCES

5629
03:30:18,560 --> 03:30:21,400
AT THE NATIONAL LAB IN PREED

5630
03:30:21,400 --> 03:30:29,240
RICK ARFREDERICKARE EXTENSIVE
BUT OVERSAW 
SCRIBE

5631
03:30:29,240 --> 03:30:31,160
BUT WE NEED MORE LEVEL OF DATA

5632
03:30:31,160 --> 03:30:33,920
ABOUT LEVEL OF RESOURCES

5633
03:30:33,920 --> 03:30:34,800
AVAILABLE.

5634
03:30:34,800 --> 03:30:37,520
BETTER DEVELOPMENT OF MODEL LIKE

5635
03:30:37,520 --> 03:30:40,200
PDX AND APPROACHES FOR TARGETED

5636
03:30:40,200 --> 03:30:43,280
VALIDATION WHICH ARE KEY TO

5637
03:30:43,280 --> 03:30:44,280
MAKING SURE DRUG TARGETS ARE

5638
03:30:44,280 --> 03:30:45,640
GOING TO BE USEFUL AT THE END OF

5639
03:30:45,640 --> 03:30:48,560
THE DAY.

5640
03:30:48,560 --> 03:30:50,720
BETTER ACCESSIBILITY OF DNA

5641
03:30:50,720 --> 03:30:54,480
ENCODED LIBRARIES AND FRAGMENT

5642
03:30:54,480 --> 03:30:56,720
BASE DRUG DESIGN WHICH NOW ARE

5643
03:30:56,720 --> 03:31:01,960
NOT REALLY SOURCES OF RESOURCES

5644
03:31:01,960 --> 03:31:05,200
THAT ARE SUPPORTED BY THE NCI.

5645
03:31:05,200 --> 03:31:07,520
ONE THING THAT I THINK EVERYBODY

5646
03:31:07,520 --> 03:31:09,240
WAS CONCERNED ABOUT IS TRAINING

5647
03:31:09,240 --> 03:31:13,640
OF PEOPLE IN THIS DISMINUTE.

5648
03:31:13,640 --> 03:31:14,960
IF SOMETHING WERE INSTEAD OF

5649
03:31:14,960 --> 03:31:17,560
TRAINING OF YOUNG PEOPLE BEING

5650
03:31:17,560 --> 03:31:19,640
ACCENTUATED RECENTLY DECLINED,

5651
03:31:19,640 --> 03:31:23,440
MANY MEDICAL SCHOOLS HAVE SHIED

5652
03:31:23,440 --> 03:31:25,080
AWAY FROM DRUG DEVELOPMENT AND

5653
03:31:25,080 --> 03:31:26,400
FROM DEPARTMENTS OF

5654
03:31:26,400 --> 03:31:28,560
PHARMACOLOGY.

5655
03:31:28,560 --> 03:31:30,160
AND MANY YOUNG SCIENTISTS AND

5656
03:31:30,160 --> 03:31:31,560
PHYSICIAN SCIENTISTS ARE NOT

5657
03:31:31,560 --> 03:31:34,600
TRAINED IN THIS DISCIPLINE ANY

5658
03:31:34,600 --> 03:31:36,480
MORE THERE WAS A STRONG FEELING

5659
03:31:36,480 --> 03:31:38,920
THAT TRAINING IN THE NURTUREK OF

5660
03:31:38,920 --> 03:31:41,120
PEOPLE WHO ARE INTERESTED IN

5661
03:31:41,120 --> 03:31:43,560
THESE IDEAS IS INTERNAL MISSING

5662
03:31:43,560 --> 03:31:47,560
FEATURE OF THE CURRENT LANDSCAPE

5663
03:31:47,560 --> 03:31:49,320
AND SINCE THERE'S NO PRECEDENT

5664
03:31:49,320 --> 03:31:51,560
FOR THIS VERY CAREFUL THOUGHT

5665
03:31:51,560 --> 03:31:53,000
HOW TO DEVELOP THESE KINDS OF

5666
03:31:53,000 --> 03:31:54,440
TRAINING EXERCISES ARE GOING TO

5667
03:31:54,440 --> 03:31:56,920
BE NEEDED.

5668
03:31:56,920 --> 03:32:00,560
ALONG THOSE LINES AN IMPORTANT

5669
03:32:00,560 --> 03:32:03,640
ADDITIONAL IDEA IS THAT THESE

5670
03:32:03,640 --> 03:32:05,200
CONCEPTS REQUIRE TEAM BUILDING,

5671
03:32:05,200 --> 03:32:07,080
FROM THE BEGINNING TO THE END OF

5672
03:32:07,080 --> 03:32:09,160
THE PROCESS OF DRUG DEVELOPMENT

5673
03:32:09,160 --> 03:32:10,520
THERE'S MANY KINDS OF EXPERTISE

5674
03:32:10,520 --> 03:32:12,320
THAT ARE NEEDED.

5675
03:32:12,320 --> 03:32:15,880
AND IT IS VERY RARE EFFECTIVE

5676
03:32:15,880 --> 03:32:17,320
TEAMS ARE PRESENT ONE

5677
03:32:17,320 --> 03:32:18,880
INSTITUTION, GOING TO REQUIRE

5678
03:32:18,880 --> 03:32:21,080
ACROSS INSTITUTIONAL

5679
03:32:21,080 --> 03:32:22,760
COLLABORATION AND CROSS

5680
03:32:22,760 --> 03:32:24,040
DISCIPLINARY COLLABORATION TO

5681
03:32:24,040 --> 03:32:25,400
CREATE THE TEAMS NECESSARY TO

5682
03:32:25,400 --> 03:32:28,400
ADDRESS MANY OF THESE ISSUES.

5683
03:32:28,400 --> 03:32:30,960
ONE IMPORTANT CONCEPT THAT CAME

5684
03:32:30,960 --> 03:32:32,880
THROUGH IN OUR DISCUSSION ON

5685
03:32:32,880 --> 03:32:34,160
WEDNESDAY WAS INDIVIDUAL CANCER

5686
03:32:34,160 --> 03:32:36,160
CENTERS JUST DON'T HAVE THE

5687
03:32:36,160 --> 03:32:37,800
RESOURCES OR THE BANDWIDTH TO

5688
03:32:37,800 --> 03:32:41,240
DEVELOP THESE KINDS OF IDEAS.

5689
03:32:41,240 --> 03:32:43,880
FINALLY THE OTHER RESOURCE THAT

5690
03:32:43,880 --> 03:32:46,000
IS INADEQUATE AT THE MOMENT IS

5691
03:32:46,000 --> 03:32:47,280
COMPOUND LIBRARIES.

5692
03:32:47,280 --> 03:32:51,000
ONE ESPECIALLY THAT DESERVES

5693
03:32:51,000 --> 03:32:53,520
MORE ATTENTION THAT NED BROUGHT

5694
03:32:53,520 --> 03:32:54,920
UP WAS NATIONAL -- NATURAL

5695
03:32:54,920 --> 03:32:59,000
RESOURCE LIBRARY THAT EXISTS AT

5696
03:32:59,000 --> 03:33:01,360
THE NCI, PROBABLY UTILIZED AND

5697
03:33:01,360 --> 03:33:06,440
WHICH IS A RICH RESOURCE THAT NO

5698
03:33:06,440 --> 03:33:08,040
ONE KNOWS HOW TO GO AFTER.

5699
03:33:08,040 --> 03:33:09,920
SO THOSE ARE MAIN THINGS

5700
03:33:09,920 --> 03:33:12,040
COMMITTEE TOOK AWAY, I WANT TO

5701
03:33:12,040 --> 03:33:15,800
GIVE SPECIAL THANKS TO ROSE AND

5702
03:33:15,800 --> 03:33:18,240
TO VERMA WHO PUT TOGETHER THE

5703
03:33:18,240 --> 03:33:19,440
REPORT OF THE SUBCOMMITTEE AND

5704
03:33:19,440 --> 03:33:22,200
DID HEAVY LIFTING AND I'M GOING

5705
03:33:22,200 --> 03:33:24,920
TO STOP FOR A MINUTE AND -- HAS

5706
03:33:24,920 --> 03:33:26,320
THOUGHTS ABOUT THIS AND I WOULD

5707
03:33:26,320 --> 03:33:28,280
LIKE TO ALLOW HIM TO HAVE A FEW

5708
03:33:28,280 --> 03:33:29,720
MINUTES TO GIVE HIS TAKE ON THE

5709
03:33:29,720 --> 03:33:31,720
WORK THAT WE HAVE DONE.

5710
03:33:31,720 --> 03:33:32,880
NED.

5711
03:33:32,880 --> 03:33:35,560
>> THANK YOU, TIM.

5712
03:33:35,560 --> 03:33:38,040
I THOUGHT THAT WAS A TERRIFIC

5713
03:33:38,040 --> 03:33:40,600
SUMMARY OF BOTH EFFORTS.

5714
03:33:40,600 --> 03:33:43,480
THE -- I -- LIKE TIM I WAS

5715
03:33:43,480 --> 03:33:45,600
SURPRISED THAT CELLULAR

5716
03:33:45,600 --> 03:33:47,160
IMMUNOTHERAPY TURNED OUT MORE

5717
03:33:47,160 --> 03:33:47,560
STRAIGHT FORWARD.

5718
03:33:47,560 --> 03:33:49,360
WE THOUGHT OF THESE TOPICS TWO

5719
03:33:49,360 --> 03:33:50,840
THINGS WHERE I THOUGHT NCI USE

5720
03:33:50,840 --> 03:33:53,400
ADVICE AND THE ACTUAL OLDER

5721
03:33:53,400 --> 03:33:54,960
ISSUES AROUND MEDICINAL

5722
03:33:54,960 --> 03:33:57,080
CHEMISTRY SEEM IN SOME WAYS MORE

5723
03:33:57,080 --> 03:33:58,560
CHALLENGING FOR THE NCI WHERE TO

5724
03:33:58,560 --> 03:34:04,960
GO NEXT SO I APPRECIATE BOTH

5725
03:34:04,960 --> 03:34:08,240
REPORTS ARE IMPORTANT TO NCI AND

5726
03:34:08,240 --> 03:34:09,600
WE FEEL USEFUL AND CERTAINLY

5727
03:34:09,600 --> 03:34:11,320
GIVEN US A LOT TO THINK ABOUT.

5728
03:34:11,320 --> 03:34:15,160
WHAT I PROPOSE AT THIS TIME IS

5729
03:34:15,160 --> 03:34:18,080
THE SECOND REPORT TAKE BACK READ

5730
03:34:18,080 --> 03:34:19,400
CAREFULLY THINK THROUGH WHAT WE

5731
03:34:19,400 --> 03:34:21,560
CAN AND SHOULD DO HERE, I WOULD

5732
03:34:21,560 --> 03:34:31,520
PROPOSE WE REPORT BACK TO THE

5733
03:34:31,520 --> 03:34:32,120
JOINT BOARD NEURODATE HOW TO

5734
03:34:32,120 --> 03:34:33,280
RESPOND PARTICULARLY THE SECOND

5735
03:34:33,280 --> 03:34:35,080
ONE.

5736
03:34:35,080 --> 03:34:41,120
AND I THINK THAT -- TAKE IT FROM

5737
03:34:41,120 --> 03:34:42,080
THERE.

5738
03:34:42,080 --> 03:34:47,800
IN THAT INTERIM I THINK BEST WE

5739
03:34:47,800 --> 03:34:48,680
SHOULD LET THE SUBCOMMITTEE BE

5740
03:34:48,680 --> 03:34:49,960
DORMANT WHILE WE THINK ABOUT THE

5741
03:34:49,960 --> 03:34:51,800
NEXT ISSUES WHETHER WE NEED TO

5742
03:34:51,800 --> 03:34:53,040
TAKE ON NATURAL PRODUCTS OR

5743
03:34:53,040 --> 03:34:54,960
WHATEVER ELSE IS COMING ON LINE.

5744
03:34:54,960 --> 03:34:56,120
WE HAVE A LOT TO WORK THROUGH

5745
03:34:56,120 --> 03:34:59,640
NOW.

5746
03:34:59,640 --> 03:35:01,000
AS YOU CAN TELL THIS WAS WORK

5747
03:35:01,000 --> 03:35:03,640
AND SO I ALSO WANT TO CREDIT

5748
03:35:03,640 --> 03:35:04,640
THOSE INDIVIDUALS WHO PUT SO

5749
03:35:04,640 --> 03:35:07,840
MUCH TIME INTO IT.

5750
03:35:07,840 --> 03:35:10,560
NCI STAFF, EXTRAMURAL PEOPLE AND

5751
03:35:10,560 --> 03:35:13,440
PARTICULARLY TIM LEADER SHIP WAS

5752
03:35:13,440 --> 03:35:15,240
TERRIFIC IN THIS EFFORTS AND

5753
03:35:15,240 --> 03:35:16,960
EXEMPLARY AS SERVICE TO NCI AND

5754
03:35:16,960 --> 03:35:18,480
WE ARE SORRY HE IS LEAVING

5755
03:35:18,480 --> 03:35:20,720
BECAUSE HE'S SO GOOD AT THIS.

5756
03:35:20,720 --> 03:35:21,840
THANK YOU FOR STEWARDING A

5757
03:35:21,840 --> 03:35:26,800
THOUGHTFUL PROCESS AND GIVING US

5758
03:35:26,800 --> 03:35:29,400
SUCH GOOD ADVICE.

5759
03:35:29,400 --> 03:35:31,000
>> THE SUMMARY AVAILABLE FOR

5760
03:35:31,000 --> 03:35:37,160
EVERYBODY TO LOOK AT, SENT OUT

5761
03:35:37,160 --> 03:35:38,320
BY RICARDO THIS MORNING.

5762
03:35:38,320 --> 03:35:38,480
>>

5763
03:35:38,480 --> 03:35:41,600
>> THANKS, TIM.

5764
03:35:41,600 --> 03:35:44,320
ANY OTHER COMMENTS REGARDING THE

5765
03:35:44,320 --> 03:35:46,520
REPORT ON EXPERIENCAL

5766
03:35:46,520 --> 03:36:04,920
THERAPEUTICS?

5767
03:36:04,920 --> 03:36:07,560
>> I THINK MY COMMENTS CAN BE

5768
03:36:07,560 --> 03:36:09,680
DONE BY EMAIL, I THINK THERE WAS

5769
03:36:09,680 --> 03:36:11,120
SO MANY IMPORTANT ISSUES THAT

5770
03:36:11,120 --> 03:36:11,920
TIM JUST RAISED.

5771
03:36:11,920 --> 03:36:14,160
I WOULD RATHER DEFER FEW MINUTES

5772
03:36:14,160 --> 03:36:15,760
WE HAVE TO OTHERS WHO WANT TO

5773
03:36:15,760 --> 03:36:19,680
TALK ABOUT THEM.

5774
03:36:19,680 --> 03:36:21,440
>> JOHN THE ONLY THING TO ADD,

5775
03:36:21,440 --> 03:36:25,320
THIS IS SHELLEY IS THAT --

5776
03:36:25,320 --> 03:36:28,080
ACADEMIC MED CENTERS AN

5777
03:36:28,080 --> 03:36:29,240
UNIVERSITIES SHY FROM THIS

5778
03:36:29,240 --> 03:36:30,960
UNNECESSARILY.

5779
03:36:30,960 --> 03:36:35,240
IT IS JUST URBAN LE YEAR-END

5780
03:36:35,240 --> 03:36:37,320
UNIVERSITIES CAN'T DO THIS,

5781
03:36:37,320 --> 03:36:38,480
PURVIEW OF PHARMA.

5782
03:36:38,480 --> 03:36:41,680
I DON'T THINK THAT IS THE CASE.

5783
03:36:41,680 --> 03:36:45,120
TIM MAY BE RIGHT, IT NEEDS TO BE

5784
03:36:45,120 --> 03:36:47,360
MORE INTERINSTITUTIONAL BUT

5785
03:36:47,360 --> 03:36:49,160
CLEARLY WE HAVE A LOT OF SMART

5786
03:36:49,160 --> 03:36:52,680
PEOPLE IN OUR CHEMISTRY

5787
03:36:52,680 --> 03:36:55,040
DEPARTMENT AND PHARMACOLOGY

5788
03:36:55,040 --> 03:36:55,880
SCHOOLS, ACADEMIC INSTITUTION

5789
03:36:55,880 --> 03:36:59,600
SHOULD NOT SHY FROM THIS.

5790
03:36:59,600 --> 03:37:01,560
>> THERE IS A PLAUSIBILITY

5791
03:37:01,560 --> 03:37:03,480
BARRIER TO THIS.

5792
03:37:03,480 --> 03:37:04,520
THAT HAS BEEN IN PLACE FOR A

5793
03:37:04,520 --> 03:37:08,160
WHILE AND I THINK THAT

5794
03:37:08,160 --> 03:37:09,160
CONTRIBUTED TO ONE UNFORTUNATE

5795
03:37:09,160 --> 03:37:11,960
THING, THE LACK OF TRAINING OF

5796
03:37:11,960 --> 03:37:12,520
YOUNG SIGN IT ISES IN THIS

5797
03:37:12,520 --> 03:37:13,760
DISCIPLINE ESPECIALLY YOUNG

5798
03:37:13,760 --> 03:37:15,840
PHYSICIAN SCIENTISTS WHO REALLY

5799
03:37:15,840 --> 03:37:18,840
SEEM TO HAVE NO INTEREST IN THIS

5800
03:37:18,840 --> 03:37:20,760
KIND OF DRUG DEVELOPMENTAL

5801
03:37:20,760 --> 03:37:21,760
PROBLEM AT ALL.

5802
03:37:21,760 --> 03:37:24,200
IT IS JUST BEEN GIVEN TO PHARMA

5803
03:37:24,200 --> 03:37:25,880
AND SHOULDN'T BE -- I AGREE

5804
03:37:25,880 --> 03:37:27,760
COMPLETELY, IT IS TIME FOR THE

5805
03:37:27,760 --> 03:37:29,320
NCI TO TRY TO GET ITS ACT

5806
03:37:29,320 --> 03:37:30,680
TOGETHER AND FIGURE OUT WHAT

5807
03:37:30,680 --> 03:37:33,120
EXACTLY WILL BE THE BEST THING

5808
03:37:33,120 --> 03:37:35,000
TO SUPPORT.

5809
03:37:35,000 --> 03:37:37,000
I AGREE WITH NED THERE'S SO MANY

5810
03:37:37,000 --> 03:37:38,960
THINGS UNCOVERED BY THIS

5811
03:37:38,960 --> 03:37:39,960
PROCESS, IT WILL TAKE A WHILE

5812
03:37:39,960 --> 03:37:42,240
FOR THE NCI LEADERSHIP TO DIGEST

5813
03:37:42,240 --> 03:37:45,000
JUST WHAT WE LOOK AT ALREADY AND

5814
03:37:45,000 --> 03:37:47,000
COME UP WITH THINGS THAT ARE

5815
03:37:47,000 --> 03:37:51,600
RATIONAL TO SUPPORT.

5816
03:37:51,600 --> 03:37:54,520
>> THEY COULD BE COMPONENTS THAT

5817
03:37:54,520 --> 03:37:57,800
ARE REALLY ACADEMIC CENTERED BUT

5818
03:37:57,800 --> 03:38:00,040
THEN THE QUESTION BECOMES DARE

5819
03:38:00,040 --> 03:38:03,320
USE THE PHRASE PUBLIC PRIVATE

5820
03:38:03,320 --> 03:38:05,800
PARTNERSHIP.

5821
03:38:05,800 --> 03:38:08,440
TYPES OF MECHANISM THAT HELP

5822
03:38:08,440 --> 03:38:11,960
BUILD THESE MULTI-INSTITUTIONAL

5823
03:38:11,960 --> 03:38:13,680
PLATFORMS TO SUPPORT THIS TYPE

5824
03:38:13,680 --> 03:38:17,520
OF WORK.

5825
03:38:17,520 --> 03:38:18,720
ANY OTHER COMMENTS OR DISCUSSION

5826
03:38:18,720 --> 03:38:19,800
POINTS?

5827
03:38:19,800 --> 03:38:28,440
>> NCI - -- (OVERLAPPING
SPEAKERS)

5828
03:38:28,440 --> 03:38:30,160
>> I WAS A BIT CURIOUS.

5829
03:38:30,160 --> 03:38:31,840
NCI TENDS TO BE TRAILBLAZER IN

5830
03:38:31,840 --> 03:38:35,360
MANY OF THESE INITIATIVES BUT

5831
03:38:35,360 --> 03:38:37,560
INSTITUTES NIH THAT ARE DOING IN

5832
03:38:37,560 --> 03:38:39,680
DRUG DEVELOPMENT THAT COULD

5833
03:38:39,680 --> 03:38:41,960
PROVIDE THAT ROADMAP OR SOME

5834
03:38:41,960 --> 03:38:43,760
SORT OF WAY HOW THIS CAN BE

5835
03:38:43,760 --> 03:38:45,960
DONE, ACADEMIC INSTITUTIONS

5836
03:38:45,960 --> 03:38:47,640
PARTNER WITH DRUG DEVELOPMENT

5837
03:38:47,640 --> 03:38:51,400
NOT IN THAT AREA OBVIOUSLY BUT

5838
03:38:51,400 --> 03:38:52,640
CURIOUS ABOUT ANY OR OTHER

5839
03:38:52,640 --> 03:38:53,640
INSTITUTES NIH THAT MAY BE DOING

5840
03:38:53,640 --> 03:38:55,280
THIS WORK.

5841
03:38:55,280 --> 03:38:56,280
IN A MORE AGGRESSIVE WAY.

5842
03:38:56,280 --> 03:38:58,240
>> NCATS COMES TO MIND.

5843
03:38:58,240 --> 03:39:01,440
>> SO WE WORK CLOSELY WITH NCATS

5844
03:39:01,440 --> 03:39:02,800
ON HIGH THROUGH PUT SCREENING

5845
03:39:02,800 --> 03:39:05,360
AND ROBOT UK APPROACHES TO HIGH

5846
03:39:05,360 --> 03:39:06,800
THROUGH PUT SCREENING.

5847
03:39:06,800 --> 03:39:09,560
NCATS IS A MAJOR USER OF NATURAL

5848
03:39:09,560 --> 03:39:11,160
PRODUCTS LIBRARY SO THEY HAVE

5849
03:39:11,160 --> 03:39:12,840
REAL INTEREST IN THIS SPACE.

5850
03:39:12,840 --> 03:39:14,160
NIAID IS INTERESTED IN THIS

5851
03:39:14,160 --> 03:39:16,120
TOPIC AND THERE'S BEEN A LIVELY

5852
03:39:16,120 --> 03:39:19,000
SET OF DISCUSSIONS SOME AT NCI

5853
03:39:19,000 --> 03:39:22,120
LED BY DANA SINGER INDIVIDUALS

5854
03:39:22,120 --> 03:39:26,040
AT NIAID ABOUT NOVEL DATA

5855
03:39:26,040 --> 03:39:27,160
APPROACHES TO DRUG DISCOVERY

5856
03:39:27,160 --> 03:39:29,400
MACHINE LEARNING DRUG DISCOVERY

5857
03:39:29,400 --> 03:39:30,520
AND NOVEL APPROACHES TO

5858
03:39:30,520 --> 03:39:33,120
STRUCTURAL BIOLOGY.

5859
03:39:33,120 --> 03:39:35,760
THAT MULTIPLE IC INTEREST BOTH

5860
03:39:35,760 --> 03:39:39,680
BLESSING AND CURSE BECAUSE I

5861
03:39:39,680 --> 03:39:40,560
THINK THE LENGTH OF TIME TAKES

5862
03:39:40,560 --> 03:39:41,640
TO DO ANYTHING GOES UP WITH

5863
03:39:41,640 --> 03:39:45,080
SQUARE NUMBER OF ICs INVOLVED,

5864
03:39:45,080 --> 03:39:47,360
SO BUT I THINK IT IS ALSO IF

5865
03:39:47,360 --> 03:39:48,680
THERE IS ENOUGH TRANS-NIH

5866
03:39:48,680 --> 03:39:50,240
INTEREST AMAZING THINGS HAPPEN

5867
03:39:50,240 --> 03:39:51,600
LIKE COMMON FUND INITIATIVES SO

5868
03:39:51,600 --> 03:39:53,400
I THINK WE ARE LOOKING IN BOTH

5869
03:39:53,400 --> 03:39:54,760
APPROACHES WHAT SHOULD WE DO ON

5870
03:39:54,760 --> 03:39:56,160
OUR OWN AND WHAT NEEDS TO BE

5871
03:39:56,160 --> 03:40:02,400
TRANS-NIH.

5872
03:40:02,400 --> 03:40:03,880
>> PAULETTE, NEED YOUR HELP

5873
03:40:03,880 --> 03:40:09,280
HERE, ARE WE VOTING TO TABLE?

5874
03:40:09,280 --> 03:40:12,920
>> 

5875
03:40:12,920 --> 03:40:17,280
>> WE NEED TO CALL A MOTION TO

5876
03:40:17,280 --> 03:40:18,640
ACCEPT.

5877
03:40:18,640 --> 03:40:21,520
THEN A SECOND THEN A VOTE.

5878
03:40:21,520 --> 03:40:22,440
>> OKAY.

5879
03:40:22,440 --> 03:40:23,400
LET'S CALL FOR A MOTION TO

5880
03:40:23,400 --> 03:40:28,800
ACCEPT.

5881
03:40:28,800 --> 03:40:31,120
>> SO MOVED.

5882
03:40:31,120 --> 03:40:35,120
>> SECOND.

5883
03:40:35,120 --> 03:40:37,200
>> PROPERLY MOVED AND SECONDED.

5884
03:40:37,200 --> 03:40:46,760
DISCUSSION.

5885
03:40:46,760 --> 03:40:47,480
NEES.

5886
03:40:47,480 --> 03:40:47,760
ABSTENTIONS.

5887
03:40:47,760 --> 03:40:52,040
>> OR DO THE NAYS FIRST.

5888
03:40:52,040 --> 03:40:53,520
NO NAYS.

5889
03:40:53,520 --> 03:40:58,640
ANY ABSTENTION?

5890
03:40:58,640 --> 03:41:01,080
>> SO THE REPORT IS UNANIMOUSLY

5891
03:41:01,080 --> 03:41:02,760
ACCEPTED.

5892
03:41:02,760 --> 03:41:05,080
>> THE REPORT HAS BEEN

5893
03:41:05,080 --> 03:41:14,040
UNANIMOUSLY ACCEPTED.

5894
03:41:14,040 --> 03:41:23,080
>> NOW WE ARE MOVING ON TO -- --

5895
03:41:23,080 --> 03:41:24,280
YOU HAVE A BULLET TO READ.

5896
03:41:24,280 --> 03:41:28,160
>> ONE BULLET THE ANNUAL

5897
03:41:28,160 --> 03:41:29,160
REVIEWER CONCEPT REPORT IS

5898
03:41:29,160 --> 03:41:32,640
POSTED ON THE BSA MEMBERS ONLY

5899
03:41:32,640 --> 03:41:33,000
WEBSITE.

5900
03:41:33,000 --> 03:41:35,240
I DON'T KNOW IF I SHOULD BE

5901
03:41:35,240 --> 03:41:38,000
SAYING THIS OR KEITH BUT -- AND

5902
03:41:38,000 --> 03:41:41,560
AS REQUESTED PRIOR YEARS OF THE

5903
03:41:41,560 --> 03:41:42,520
REPORT HAVE ALSO BEEN ARCHIVED

5904
03:41:42,520 --> 03:41:45,560
TO BE ACCESSED AS WELL.

5905
03:41:45,560 --> 03:41:46,480
>> NEXT GOAL.

5906
03:41:46,480 --> 03:41:48,360
>> NEXT BULLET IS ARE THERE

5907
03:41:48,360 --> 03:41:50,720
OTHER ISSUES THAT YOU THINK THE

5908
03:41:50,720 --> 03:41:56,840
BOARD SHOULD BE ADDRESSING?

5909
03:41:56,840 --> 03:42:00,760
>> AT THIS POINT WE HAVE A BOARD

5910
03:42:00,760 --> 03:42:01,760
MEMBER WHO WOULD LIKE TO MAKE

5911
03:42:01,760 --> 03:42:02,160
COMMENTS.

5912
03:42:02,160 --> 03:42:02,760
SYLVIA.

5913
03:42:02,760 --> 03:42:04,440
>> I APPRECIATE THIS

5914
03:42:04,440 --> 03:42:05,040
OPPORTUNITY.

5915
03:42:05,040 --> 03:42:06,760
SO WE JUST FINISHED A DISCUSSION

5916
03:42:06,760 --> 03:42:09,080
ABOUT THE RENEWAL OF ITCR AND

5917
03:42:09,080 --> 03:42:10,840
OUR SUBCOMMITTEE AS YOU KNOW IS

5918
03:42:10,840 --> 03:42:11,880
UNANIMOUSLY SUPPORTIVE AND VERY

5919
03:42:11,880 --> 03:42:15,360
EXCITED ABOUT THE PROGRESS OF

5920
03:42:15,360 --> 03:42:16,960
ITCR.

5921
03:42:16,960 --> 03:42:18,880
AS WE DID ON OUR DISCUSSION NOW,

5922
03:42:18,880 --> 03:42:21,240
WE FOCUSED ON NEED FOR ITCR TO

5923
03:42:21,240 --> 03:42:26,560
CONNECT WITH OTHER NCI PROGRAMS.

5924
03:42:26,560 --> 03:42:29,760
AND THROUGH JULIE'S PRESENTATION

5925
03:42:29,760 --> 03:42:31,400
WE WERE SO SATISFIED KNOWING

5926
03:42:31,400 --> 03:42:35,720
THAT ITCR IS GOING TO -- HAS

5927
03:42:35,720 --> 03:42:36,680
CONCERTED EFFORT FOR MORE

5928
03:42:36,680 --> 03:42:38,320
FREQUENT SUSTAINED COMMUNICATION

5929
03:42:38,320 --> 03:42:40,160
WITH OTHER NCI PROGRAMS AROUND

5930
03:42:40,160 --> 03:42:43,040
DATA MANAGEMENT ANALYTICS.

5931
03:42:43,040 --> 03:42:45,840
HOWEVER, ALONG THIS THEME, THIS

5932
03:42:45,840 --> 03:42:47,960
BROAD THEME OF NCI PROGRAM

5933
03:42:47,960 --> 03:42:50,160
INTEGRATION AROUND DATA AND

5934
03:42:50,160 --> 03:42:52,160
ANALYTICS, WE RECOMMEND THE NCI

5935
03:42:52,160 --> 03:42:56,320
CREATE A MORE SIGNIFICANT

5936
03:42:56,320 --> 03:42:59,320
MANDATE IN INFORMATICS DATA

5937
03:42:59,320 --> 03:43:02,800
SCIENCE PARTICULARLY IN CCSG,

5938
03:43:02,800 --> 03:43:04,960
SPORE, CLINICAL TRIAL NETWORK U

5939
03:43:04,960 --> 03:43:07,320
54, AKIN TO THE INFORMATICS

5940
03:43:07,320 --> 03:43:10,160
MANDATE IN CTSA.

5941
03:43:10,160 --> 03:43:12,480
WE WOULD LIKE TO ADVISE THE NCI

5942
03:43:12,480 --> 03:43:15,320
CREATE A COMMITTEE TO PROVIDE

5943
03:43:15,320 --> 03:43:18,480
SUCH GUIDANCE WITH I THE,CR NCI

5944
03:43:18,480 --> 03:43:19,480
CREATED FANTASTIC PROGRAM THAT

5945
03:43:19,480 --> 03:43:21,480
CAN BE USED TO ELEVATE

5946
03:43:21,480 --> 03:43:22,800
INFORMATICS AND DATA SCIENCE

5947
03:43:22,800 --> 03:43:26,160
RESOURCE COMMITMENTS IN CRITICAL

5948
03:43:26,160 --> 03:43:27,280
NCI PROGRAMS.

5949
03:43:27,280 --> 03:43:30,280
THESE PROGRAMS NEED MORE

5950
03:43:30,280 --> 03:43:31,800
GUIDANCE TO MOVE FORWARD IN

5951
03:43:31,800 --> 03:43:34,560
NEEDED WAYS, SO WE RECOMMEND THE

5952
03:43:34,560 --> 03:43:37,120
NCI CREATE A COMMITTEE TO

5953
03:43:37,120 --> 03:43:39,440
CONSIDER MORE CLEAR INFORMATICS

5954
03:43:39,440 --> 03:43:41,080
MANDATES IN LARGE NCI PROGRAMS

5955
03:43:41,080 --> 03:43:43,440
SUCH AS SPORES CCG, CLINICAL

5956
03:43:43,440 --> 03:43:46,200
TRIALS NETWORKS, U 54, THROUGH

5957
03:43:46,200 --> 03:43:47,720
GREATER INTEGRATION WITH THE

5958
03:43:47,720 --> 03:43:51,960
ITCR.

5959
03:43:51,960 --> 03:43:55,280
>> COMMENTS?

5960
03:43:55,280 --> 03:43:57,600
>> LET ME SEE IF DINA HAS

5961
03:43:57,600 --> 03:44:02,640
ANYTHING TO SAY.

5962
03:44:02,640 --> 03:44:04,960
>> SYLVIA, THANK YOU FOR THOSE

5963
03:44:04,960 --> 03:44:05,960
COMMENTS, CLEARLY WE HAVE

5964
03:44:05,960 --> 03:44:08,440
INVESTED A HUGE AMOUNT IN IF

5965
03:44:08,440 --> 03:44:10,920
ITCR AND THERE ARE MANY VALUABLE

5966
03:44:10,920 --> 03:44:13,040
PROGRAMS THAN AS JULIE SHOWED

5967
03:44:13,040 --> 03:44:16,040
REALLY HAVE ALREADY BEEN TAKEN

5968
03:44:16,040 --> 03:44:18,360
UP BY THIS COMMUNITY.

5969
03:44:18,360 --> 03:44:19,760
I THINK THE SUGGESTION AND I

5970
03:44:19,760 --> 03:44:22,160
THINK MICHAEL'S ALSO IS ONE HA

5971
03:44:22,160 --> 03:44:25,720
WE SHOULD REALLY LOOK AT TO SEE

5972
03:44:25,720 --> 03:44:32,560
HOW WE CAN REALLY PROMOTE A MORE

5973
03:44:32,560 --> 03:44:34,800
EFFECTIVE UPTAKE OF TOOLS AND

5974
03:44:34,800 --> 03:44:36,840
STANDARDIZATION ACROSS ALL THE

5975
03:44:36,840 --> 03:44:38,400
CENTERS THOUGH I SAY THAT WITH

5976
03:44:38,400 --> 03:44:42,200
SOME HESITATION.

5977
03:44:42,200 --> 03:44:43,760
BUT I THINK IT IS CERTAINLY

5978
03:44:43,760 --> 03:44:44,560
SOMETHING WE SHOULD LOOK AT AND

5979
03:44:44,560 --> 03:44:45,000
PURSUE.

5980
03:44:45,000 --> 03:44:45,960
THANK YOU.

5981
03:44:45,960 --> 03:44:50,320
>> I AGREE WITH DINA.

5982
03:44:50,320 --> 03:44:51,840
LET US THINK IT OVER.

5983
03:44:51,840 --> 03:44:53,080
I HAVE TO CONFESS I DON'T KNOW

5984
03:44:53,080 --> 03:44:57,400
ENOUGH ABOUT THE CTSA MANDATE TO

5985
03:44:57,400 --> 03:44:58,160
HAVE A OPINION.

5986
03:44:58,160 --> 03:44:59,640
I NEED TO BE EDUCATED ON THIS

5987
03:44:59,640 --> 03:45:02,320
TOPIC.

5988
03:45:02,320 --> 03:45:05,720
TO BE CLEAR YOU WOULD RECOMMEND

5989
03:45:05,720 --> 03:45:08,320
A SORT OF -- GIVE ADVICE TO THE

5990
03:45:08,320 --> 03:45:10,440
NCI WHICH IS ACTUALLY PROBABLY

5991
03:45:10,440 --> 03:45:12,600
WORKING GROUP TO PRESUMABLY BSA

5992
03:45:12,600 --> 03:45:15,360
I WOULD THINK.

5993
03:45:15,360 --> 03:45:17,800
ON BIOINFORMATICS STRATEGY

5994
03:45:17,800 --> 03:45:20,160
ACROSS MAJOR PROGRAMS LIKE CCSG

5995
03:45:20,160 --> 03:45:21,760
AND SPORES PROGRAM THAT MIGHT

5996
03:45:21,760 --> 03:45:24,760
LEVERAGE ITCR, MIGHT NOT

5997
03:45:24,760 --> 03:45:26,160
NECESSARILY BE ITCR.

5998
03:45:26,160 --> 03:45:27,000
>> THAT'S RIGHT.

5999
03:45:27,000 --> 03:45:28,160
WE THOUGHT IT WAS BIGGER SO WE

6000
03:45:28,160 --> 03:45:31,000
DIDN'T WANT TO BRING IT UP IN

6001
03:45:31,000 --> 03:45:31,480
DISCUSSION.

6002
03:45:31,480 --> 03:45:33,240
AND SO PAULETTE RECOMMENDED THAT

6003
03:45:33,240 --> 03:45:37,760
WE BRING IT UP HERE.

6004
03:45:37,760 --> 03:45:42,280
>> IS THE ISSUE TRAINING OR

6005
03:45:42,280 --> 03:45:44,360
SUSTAINING TOOLS, OR DATA

6006
03:45:44,360 --> 03:45:47,360
SHARING AND POLICIES ACROSS NCI

6007
03:45:47,360 --> 03:45:48,880
INFRASTRUCTURE OR ALL THAT?

6008
03:45:48,880 --> 03:45:51,040
>> IT IS ALL OF THAT BUT IT IS

6009
03:45:51,040 --> 03:45:53,320
INTEGRATION, IT IS REALLY MORE

6010
03:45:53,320 --> 03:45:57,040
STREAMLINING BECAUSE THERE'S ALL

6011
03:45:57,040 --> 03:45:59,560
THESE SEPARATE EFFORTS THAT ARE

6012
03:45:59,560 --> 03:46:02,720
GOING TO THWART ANY ABILITY TO

6013
03:46:02,720 --> 03:46:03,760
REALLY LEVERAGE TYPE OF DATA THE

6014
03:46:03,760 --> 03:46:04,960
NCI IS CREATING IN THESE

6015
03:46:04,960 --> 03:46:08,600
MULTIPLE PROGRAMS.

6016
03:46:08,600 --> 03:46:12,480
SO IT IS REALLY A GREAT TIME TO

6017
03:46:12,480 --> 03:46:13,960
BRING ALL THESE FOLKS TO THE

6018
03:46:13,960 --> 03:46:15,320
TABLE AND HAVE THESE DISCUSSIONS

6019
03:46:15,320 --> 03:46:16,640
BECAUSE THERE'S BEEN A LOT OF

6020
03:46:16,640 --> 03:46:17,720
PROGRESS IN A NUMBER OF

6021
03:46:17,720 --> 03:46:21,440
INITIATIVES.

6022
03:46:21,440 --> 03:46:24,320
AND SO YEAH, IT IS REALLY ABOUT

6023
03:46:24,320 --> 03:46:27,280
STREAMLINING, INTEGRATING, FOR

6024
03:46:27,280 --> 03:46:28,760
EXAMPLE EVEN WITH ONE PROGRAM

6025
03:46:28,760 --> 03:46:29,640
THAT I HAVE BEEN WORKING WITH

6026
03:46:29,640 --> 03:46:31,720
CLOSELY WHICH IS A CANCER

6027
03:46:31,720 --> 03:46:35,560
SYSTEMS BIOLOGY CONSORTIUM, BOTH

6028
03:46:35,560 --> 03:46:39,400
FOLKS IN THOSE PROGRAMS DEVELOP

6029
03:46:39,400 --> 03:46:40,080
COMPUTATIONAL MODELS AND THERE

6030
03:46:40,080 --> 03:46:43,800
ISN'T AN INTEGRATION WITH ITCR

6031
03:46:43,800 --> 03:46:44,680
PLATFORMS.

6032
03:46:44,680 --> 03:46:46,000
SO JUST ONE EXAMPLE.

6033
03:46:46,000 --> 03:46:47,200
BUT IN THE CONTEXT OF TALKING

6034
03:46:47,200 --> 03:46:50,400
ABOUT THAT, WE RECOGNIZE IN MANY

6035
03:46:50,400 --> 03:46:52,520
-- EVEN WITH OUR CANCER CENTERS,

6036
03:46:52,520 --> 03:46:54,400
THE MANDATE AROUND INFORMATICS

6037
03:46:54,400 --> 03:46:56,720
IS BIGGER THAN IT IS AROUND

6038
03:46:56,720 --> 03:46:59,480
RIGHT NOW, IT IS NOT JUST

6039
03:46:59,480 --> 03:47:02,360
BIOSTATISTICS, IT IS A LARGER

6040
03:47:02,360 --> 03:47:03,800
MANDATE AND IT KIND OF GETS

6041
03:47:03,800 --> 03:47:06,240
CAUGHT UP IN DISCUSSION OF

6042
03:47:06,240 --> 03:47:08,040
BIOSTATISTICS WHICH IS FINE BUT

6043
03:47:08,040 --> 03:47:09,160
IT IS DIFFERENT.

6044
03:47:09,160 --> 03:47:12,040
I THINK NEEDS TO BE MORE CLEARLY

6045
03:47:12,040 --> 03:47:14,600
SPECIFIED, I THINK THE CCSGs

6046
03:47:14,600 --> 03:47:15,760
NEED TO UNDERSTAND THAT BETTER

6047
03:47:15,760 --> 03:47:16,160
AS WELL.

6048
03:47:16,160 --> 03:47:21,480
AND I THINK THE ITCR CAN HELP IN

6049
03:47:21,480 --> 03:47:26,160
THOSE REALLY CLEAR FIND THOSE

6050
03:47:26,160 --> 03:47:27,480
ISSUES.

6051
03:47:27,480 --> 03:47:28,720
>> MICHAEL.

6052
03:47:28,720 --> 03:47:31,600
>> SO THINK OF IT NED AS YOU GOT

6053
03:47:31,600 --> 03:47:32,960
A LOT OF RICH DATA SOURCES.

6054
03:47:32,960 --> 03:47:35,080
WE SAW AT LEAST A HALF DOZEN

6055
03:47:35,080 --> 03:47:37,640
SPECTACULAR DATA SOURCES THAT

6056
03:47:37,640 --> 03:47:42,560
YOU PRESENTED TODAY IN THESE NEW

6057
03:47:42,560 --> 03:47:44,320
COLLABORATIVE PROGRAMS.

6058
03:47:44,320 --> 03:47:46,880
THEY ARE ISLANDS UNTO THEMSELVES

6059
03:47:46,880 --> 03:47:49,160
WITHOUT THE PIPE AND ANALYTICS

6060
03:47:49,160 --> 03:47:53,120
THAT GLUE BIGGER DATA SOURCES

6061
03:47:53,120 --> 03:47:53,640
TOGETHER.

6062
03:47:53,640 --> 03:47:56,160
DATA COMMONS IS A GREAT RESOURCE

6063
03:47:56,160 --> 03:48:00,160
BUT POST ECGA, THE IMPACT USE OF

6064
03:48:00,160 --> 03:48:02,520
LARGE DATA SETS ACROSS NCI IS

6065
03:48:02,520 --> 03:48:04,520
NOT NEARLY ASPECT TACK LAR AS IT

6066
03:48:04,520 --> 03:48:05,600
COULD BE IN MY OPINION.

6067
03:48:05,600 --> 03:48:08,960
THE WAY TO DO THAT, IS TO CREATE

6068
03:48:08,960 --> 03:48:11,040
THE PIPE AND THE ANALYTIC FRAMES

6069
03:48:11,040 --> 03:48:14,360
THESE MODELS PROVIDE AND START

6070
03:48:14,360 --> 03:48:15,080
TO PULL THEM TOGETHER.

6071
03:48:15,080 --> 03:48:16,880
THIS IS WHERE -- IT IS ALWAYS

6072
03:48:16,880 --> 03:48:19,000
HARD FROM LEADERSHIP PERSPECTIVE

6073
03:48:19,000 --> 03:48:21,120
TO SAY YOU SHALL DO THIS OR YOU

6074
03:48:21,120 --> 03:48:24,480
SHALL CONSIDER THAT.

6075
03:48:24,480 --> 03:48:27,160
BUT ITCR IS MASSIVELY

6076
03:48:27,160 --> 03:48:28,280
UNDERMARKETTED TO YOUTH PROGRAMS

6077
03:48:28,280 --> 03:48:30,320
AS STARTING POINT THERE'S GREAT

6078
03:48:30,320 --> 03:48:32,400
SOFTWARE AND TOOLS THAT ARE

6079
03:48:32,400 --> 03:48:33,440
THERE THESE PROGRAMS COULD BE

6080
03:48:33,440 --> 03:48:35,560
POINTED TO, AS FIRST ORDER

6081
03:48:35,560 --> 03:48:37,320
CONSIDERATIONS INSTEAD OF

6082
03:48:37,320 --> 03:48:40,560
SETTING UP NEW HOME BREW FOR

6083
03:48:40,560 --> 03:48:42,080
EACH COORDINATING CENTERS AND

6084
03:48:42,080 --> 03:48:45,520
EACH ANALYTIC FRAMES ACROSS

6085
03:48:45,520 --> 03:48:45,920
PROGRAMS.

6086
03:48:45,920 --> 03:48:48,760
THIS IS JUST A REALLY MISSED

6087
03:48:48,760 --> 03:48:49,400
OPPORTUNITY.

6088
03:48:49,400 --> 03:48:51,280
I TALKED TO YOU ABOUT THIS AND

6089
03:48:51,280 --> 03:48:54,480
YOU HEARD THIS WITH MANY OF MY

6090
03:48:54,480 --> 03:48:56,480
COMMENTS ON THESE PROGRAMS USING

6091
03:48:56,480 --> 03:48:58,920
THE PIPE, USING SOLID PIPE THAT

6092
03:48:58,920 --> 03:49:01,560
IS WELL SUPPORTED ACROSS

6093
03:49:01,560 --> 03:49:02,880
MULTIPLE PROGRAMS GETS THINGS

6094
03:49:02,880 --> 03:49:04,960
DONE, LET ME EXPLAIN THE CTSA

6095
03:49:04,960 --> 03:49:07,880
PIECE BECAUSE I RUN THE

6096
03:49:07,880 --> 03:49:10,400
BIOMEDICAL INFORMATICS SCORE FOR

6097
03:49:10,400 --> 03:49:10,800
CTSA.

6098
03:49:10,800 --> 03:49:14,880
YOU CAN THINK OF RCSG PROGRAM

6099
03:49:14,880 --> 03:49:16,880
MAJORITY SUPPORTS SPORES, THEY

6100
03:49:16,880 --> 03:49:19,760
MADE INFORMATICS MANDATE, WHEN

6101
03:49:19,760 --> 03:49:22,480
COVID HIT YOU WERE ABLE TO SHARE

6102
03:49:22,480 --> 03:49:23,440
180 MILLION PATIENT DATA THROUGH

6103
03:49:23,440 --> 03:49:27,320
COMMON SET OF THREE DATA MARKS

6104
03:49:27,320 --> 03:49:33,240
NCI -- NCATS SUPPORTED TO THEN

6105
03:49:33,240 --> 03:49:34,760
BLEW WHAT I THIS I IS MAJOR

6106
03:49:34,760 --> 03:49:36,440
DISCOVERY PROGRAM FOR THAT

6107
03:49:36,440 --> 03:49:38,520
DISEASE.

6108
03:49:38,520 --> 03:49:40,520
NCI WOULD BE WELL SERVED TO

6109
03:49:40,520 --> 03:49:42,160
INTEGRATE ITS OWN IN THE SAME

6110
03:49:42,160 --> 03:49:43,640
FASHION FROM BIOSPECIMENS TO

6111
03:49:43,640 --> 03:49:46,760
GENOMIC DATA TO IMAGING, USING

6112
03:49:46,760 --> 03:49:48,960
STANDARD SOFTWARE MODELS AND PUT

6113
03:49:48,960 --> 03:49:52,320
THAT IN PLACE FOR CCSGS AND

6114
03:49:52,320 --> 03:49:55,920
SPORES.

6115
03:49:55,920 --> 03:49:59,840
>> MIKE.

6116
03:49:59,840 --> 03:50:03,160
THAT IS A GREAT IDEA TO TRY TO

6117
03:50:03,160 --> 03:50:05,400
SEE WHAT CAN LEVERAGE FROM CTSA.

6118
03:50:05,400 --> 03:50:07,760
I HAVE TWO QUICK THOUGHTS TO

6119
03:50:07,760 --> 03:50:10,840
OFFER FOR CONCENTRATION OF THE

6120
03:50:10,840 --> 03:50:13,080
-- YOUR BOARD N CAT AS YOU

6121
03:50:13,080 --> 03:50:17,840
DELIBERATE, ONE, HOW DO WE SCALE

6122
03:50:17,840 --> 03:50:20,520
OR GET MORE ENGAGEMENT WITHIN

6123
03:50:20,520 --> 03:50:24,080
COMMUNITY ENGAGEMENT IN NCI

6124
03:50:24,080 --> 03:50:26,480
PROGRAM PROGRAMS BEYOND CCSG,

6125
03:50:26,480 --> 03:50:28,920
SILOED BOB TALKED THIS QUITE A

6126
03:50:28,920 --> 03:50:31,960
BIT, WORTH CONSIDERING NIH WIDE

6127
03:50:31,960 --> 03:50:33,160
PROGRAM FOR COVID AND IT IS

6128
03:50:33,160 --> 03:50:35,320
IMPORTANT FOR NCI TO THINK ABOUT

6129
03:50:35,320 --> 03:50:40,240
HOW THIS IS DONE, UNDER CCSG.

6130
03:50:40,240 --> 03:50:41,880
THIS IS A QUESTION WE TALKED

6131
03:50:41,880 --> 03:50:43,800
ABOUT THE RFA AND WHAT IS THE

6132
03:50:43,800 --> 03:50:46,640
COST OF THE RPGs.

6133
03:50:46,640 --> 03:50:50,320
THERE IS A GOOD DISCUSSION

6134
03:50:50,320 --> 03:50:54,640
AROUND THE -- UNDERSTAND MORE

6135
03:50:54,640 --> 03:50:56,960
WHAT IS THE OFFSET OF COSTS,

6136
03:50:56,960 --> 03:50:59,640
OPPORTUNITY COSTS FOR RPG WHEN

6137
03:50:59,640 --> 03:51:03,040
THE RFA PROPOSED AND APPROVED.

6138
03:51:03,040 --> 03:51:06,400
SO THAT IS A QUICK I WANTED TO

6139
03:51:06,400 --> 03:51:07,360
SHARE.

6140
03:51:07,360 --> 03:51:12,920
>> I THINK ANNA BARKER.

6141
03:51:12,920 --> 03:51:17,960
>> COUPLE OF THOUGHTS ON THIS

6142
03:51:17,960 --> 03:51:21,080
DATA, DATA WAS THE RIGHT POINT.

6143
03:51:21,080 --> 03:51:23,280
WE SET UP TCGA THAT WAS THE

6144
03:51:23,280 --> 03:51:25,080
FIRST TIME WE REALLY ACTUALLY

6145
03:51:25,080 --> 03:51:27,000
HAD TO COLLABORATE ACROSS THAT

6146
03:51:27,000 --> 03:51:29,560
MANY INSTITUTIONS.

6147
03:51:29,560 --> 03:51:32,120
BELIEVE ME THAT WAS PULLING OUT

6148
03:51:32,120 --> 03:51:34,160
NAILS, NOT A SIMPLE THING TO DO.

6149
03:51:34,160 --> 03:51:36,080
WE DON'T -- I REMEMBER WHEN

6150
03:51:36,080 --> 03:51:38,040
PRESIDENT BIDEN WORKING WITH HIM

6151
03:51:38,040 --> 03:51:40,400
AND HIS FOUNDATION SETTING UP

6152
03:51:40,400 --> 03:51:42,000
THE FIRST MOON SHOT, HE WAS

6153
03:51:42,000 --> 03:51:44,640
TOTALLY STUNNED THAT WE COULDN'T

6154
03:51:44,640 --> 03:51:47,000
-- DATA, THAT WAS A MANTRA OF

6155
03:51:47,000 --> 03:51:48,040
EVERYTHING HE TALKED ABOUT AND

6156
03:51:48,040 --> 03:51:50,200
TODAY THAT'S STILL A MAN A TRAY

6157
03:51:50,200 --> 03:51:51,640
OF EVERYTHING TALKED ABOUT.

6158
03:51:51,640 --> 03:51:54,720
THE FACT IS WE HAVE THIS HUGE

6159
03:51:54,720 --> 03:51:55,840
ENTERPRISE IN CANCER WE HAVE

6160
03:51:55,840 --> 03:51:58,400
GROWN IT OVER THESE 50 YEARS AND

6161
03:51:58,400 --> 03:51:59,520
EVERYBODY HAS THEIR OWN WAY OF

6162
03:51:59,520 --> 03:52:01,440
DOING THINGS, THEY HAVE THEIR

6163
03:52:01,440 --> 03:52:03,720
OWN DATA MODEL, THEIR OWN DATA

6164
03:52:03,720 --> 03:52:05,440
SHARING, TOOLS, THEY HAVE

6165
03:52:05,440 --> 03:52:08,000
STANDARDS OR NO STANDARDS, GREAT

6166
03:52:08,000 --> 03:52:10,280
THING THAT CAME OUT OF THAT

6167
03:52:10,280 --> 03:52:11,960
PRESIDENT BIDEN INITIATIVE NOT

6168
03:52:11,960 --> 03:52:14,000
THAT WE DON'T HAVE STANDARDS WE

6169
03:52:14,000 --> 03:52:16,160
CAN HAVE BASKET FULL OF

6170
03:52:16,160 --> 03:52:19,440
STANDARDS, EVERYBODY HAS

6171
03:52:19,440 --> 03:52:22,560
STANDARDS, FOR NCI INSPIRATION

6172
03:52:22,560 --> 03:52:24,720
OF EVERYTHING, WHAT WE ARE TO

6173
03:52:24,720 --> 03:52:26,440
PROPOSING HERE, COME BACK TO THE

6174
03:52:26,440 --> 03:52:27,840
ORIGINAL PROPOSAL, IT IS THE

6175
03:52:27,840 --> 03:52:28,440
BEST IDEA EVER.

6176
03:52:28,440 --> 03:52:30,400
HOW DO WE DO IT AND HOW MUCH CAN

6177
03:52:30,400 --> 03:52:33,160
WE DO AND THE LAST THING I WILL

6178
03:52:33,160 --> 03:52:36,760
SAY IS DATA JUST PUTTING DATA IN

6179
03:52:36,760 --> 03:52:39,800
THE DATA MINING ACTIVITY OR DATA

6180
03:52:39,800 --> 03:52:42,000
SET IF WE PAY THROUGH NCI SHOULD

6181
03:52:42,000 --> 03:52:45,120
BE YES YOU HAVE TO DO THAT.

6182
03:52:45,120 --> 03:52:46,920
PRESIDENT BIDEN WAS SURPRISED TO

6183
03:52:46,920 --> 03:52:52,240
LEARN THAT WE HAVE NO -- HUNDRED

6184
03:52:52,240 --> 03:52:53,400
-- WHO DOESN'T WANT TO SHARE THE

6185
03:52:53,400 --> 03:52:53,600
DATA.

6186
03:52:53,600 --> 03:52:55,000
WE HAVE LOTS OF INSTANCES OF

6187
03:52:55,000 --> 03:52:58,120
PAYING PEOPLE, I KNOW IN TCGA WE

6188
03:52:58,120 --> 03:53:00,560
HAD LITERALLY PULL THE DATA OUT

6189
03:53:00,560 --> 03:53:02,360
AND MANY TIMES WE CAN'T GET IT.

6190
03:53:02,360 --> 03:53:03,280
WE HAVE NO -- THERE IS NO

6191
03:53:03,280 --> 03:53:07,880
RECOURSE.

6192
03:53:07,880 --> 03:53:11,840
SO -- (OVERLAPPING SPEAKERS).

6193
03:53:11,840 --> 03:53:14,560
>> HOWARD THEN FRANCIS.

6194
03:53:14,560 --> 03:53:18,000
>> IN CONTRAST TO MY COLLEAGUES

6195
03:53:18,000 --> 03:53:20,240
WHO TALKED ABOUT BASICALLY

6196
03:53:20,240 --> 03:53:24,720
EXPANDING EXISTING RESOURCES OR

6197
03:53:24,720 --> 03:53:26,080
YOU SHIPMENT MANDATES OR

6198
03:53:26,080 --> 03:53:30,320
PENALTIES I'M INSPIRED BY MY

6199
03:53:30,320 --> 03:53:32,520
RECENT READING OF OF BOOK I

6200
03:53:32,520 --> 03:53:35,040
SUGGEST FOR PEOPLE ESPECIALLY

6201
03:53:35,040 --> 03:53:36,720
PAGE 60, ANALYZING INNOVATIVE

6202
03:53:36,720 --> 03:53:38,320
WORKING PRACTICES THAT SUCCEEDED

6203
03:53:38,320 --> 03:53:41,640
BY PRIVATE PUBLIC ORGANIZATIONS,

6204
03:53:41,640 --> 03:53:43,200
TO DRIVE CHANGE AND QUALITY OF

6205
03:53:43,200 --> 03:53:44,520
DIVERSE BEHAVIORS WITH MINIMAL

6206
03:53:44,520 --> 03:53:47,040
OR NO EXPANDED RESOURCES,

6207
03:53:47,040 --> 03:53:49,960
SOMETIMES LESS RESOURCES THAN

6208
03:53:49,960 --> 03:53:53,840
THOSE EMPLOYED FOR YOU SHALL

6209
03:53:53,840 --> 03:53:55,280
MANDATES, SO THE BOTTOM LINE IS

6210
03:53:55,280 --> 03:53:57,280
IN CONTRAST TO THE CURRENT

6211
03:53:57,280 --> 03:53:59,200
LANGUAGE, ATTRIBUTED TO ME, IN

6212
03:53:59,200 --> 03:54:02,600
THE EXPERIMENTAL THERAPEUTIC

6213
03:54:02,600 --> 03:54:05,840
MINUTES, IT IS NOT A BIG DEAL

6214
03:54:05,840 --> 03:54:08,160
BUT I DIDN'T SAY EVER TO EXPAND

6215
03:54:08,160 --> 03:54:10,200
EXISTING RESOURCES AND MY

6216
03:54:10,200 --> 03:54:12,160
THOUGHTS ABOUT THIS UPCOMING

6217
03:54:12,160 --> 03:54:17,000
PROPOSAL THAT NED HAD AND OTHERS

6218
03:54:17,000 --> 03:54:19,720
ABOUT HAVING NCI EVALUATE DATA

6219
03:54:19,720 --> 03:54:23,880
SHARING PRACTICES BOTH

6220
03:54:23,880 --> 03:54:26,040
PRE-CLINICAL AND CLINICALS, I

6221
03:54:26,040 --> 03:54:26,840
WOULD RATHER HAVE NCI EVALUATE

6222
03:54:26,840 --> 03:54:30,360
PLAN AND UPCOMING DISCUSSION

6223
03:54:30,360 --> 03:54:31,600
ABOUT MULTI-REGIONAL WORK

6224
03:54:31,600 --> 03:54:32,440
STREAMS AND METRICS.

6225
03:54:32,440 --> 03:54:34,080
WE ARE NOT THE ONLY ONES I'M

6226
03:54:34,080 --> 03:54:35,760
FAMILIAR WHAT IS GOING ON IN THE

6227
03:54:35,760 --> 03:54:37,640
EUROPE AND THE UK, ESPECIALLY

6228
03:54:37,640 --> 03:54:39,240
ALONG WITH OPTIONS TO SUPPORT

6229
03:54:39,240 --> 03:54:40,520
TRAINING RESEARCH AND COST

6230
03:54:40,520 --> 03:54:43,520
EFFECTIVE BEST PRACTICES, ABOUT

6231
03:54:43,520 --> 03:54:46,440
SUSTAIN QUALITY AND VALUE OF

6232
03:54:46,440 --> 03:54:47,640
SHARED DATA DATABASES AND

6233
03:54:47,640 --> 03:54:50,920
ANALYTICS.

6234
03:54:50,920 --> 03:54:54,160
I EMPHASIZE COST EFFECTIVE.

6235
03:54:54,160 --> 03:54:55,480
BECAUSE I BELIEVE THERE ARE

6236
03:54:55,480 --> 03:54:57,680
INNOVATIVE APPROACHES THAT DON'T

6237
03:54:57,680 --> 03:54:59,280
REQUIRE WHAT WAS JUST STATED

6238
03:54:59,280 --> 03:55:05,160
ABOUT THE PENALTIES AND PANEL

6239
03:55:05,160 --> 03:55:06,080
DATES AND EXPANDING COST

6240
03:55:06,080 --> 03:55:07,440
RESOURCES.

6241
03:55:07,440 --> 03:55:08,720
>> GREAT.

6242
03:55:08,720 --> 03:55:12,640
FRANCIS, I THINK THIS WILL STOP

6243
03:55:12,640 --> 03:55:15,960
HERE AND MAYBE START OHIO WE

6244
03:55:15,960 --> 03:55:18,040
WANT TO VOTE ON THE

6245
03:55:18,040 --> 03:55:18,440
RECOMMENDATION.

6246
03:55:18,440 --> 03:55:21,160
>> WE DON'T VOTE ON THE

6247
03:55:21,160 --> 03:55:22,120
RECOMMENDATIONS.

6248
03:55:22,120 --> 03:55:26,840
JUST THAT RECOMMENDATIONS.

6249
03:55:26,840 --> 03:55:28,240
NCI WILL GIVE RECOMMENDATIONS

6250
03:55:28,240 --> 03:55:35,400
AND SUGGESTIONS, SOME VOTES.

6251
03:55:35,400 --> 03:55:39,320
IF IT DECIDES TO MOVE FORWARD

6252
03:55:39,320 --> 03:55:43,440
THE INSTITUTE WILL COME BACK

6253
03:55:43,440 --> 03:55:45,440
WITH SOMETHING YOU CAN VOTE ON.

6254
03:55:45,440 --> 03:55:45,920
>> OKAY?

6255
03:55:45,920 --> 03:55:49,400
>> FRANCIS.

6256
03:55:49,400 --> 03:55:53,080
>> I'LL BE QUICK.

6257
03:55:53,080 --> 03:55:55,360
FOLLOW-UP ON THE COMMENTS.

6258
03:55:55,360 --> 03:55:56,840
THIS COMES FROM MY EXPERIENCE

6259
03:55:56,840 --> 03:55:59,800
THROUGH CTSA OF MY INSTITUTION

6260
03:55:59,800 --> 03:56:04,640
AND AS PI OF OUR SPORE, THIS IS

6261
03:56:04,640 --> 03:56:05,720
CHALLENGING BECAUSE THERE ARE

6262
03:56:05,720 --> 03:56:09,240
MAJOR ISSUES, HIPAA ISSUES WITH

6263
03:56:09,240 --> 03:56:13,760
PATIENT DATA AND MOST DATA HAVE

6264
03:56:13,760 --> 03:56:15,880
BEEN MOST OF THESE SPORES ARE

6265
03:56:15,880 --> 03:56:19,840
LEVERAGED AND BUILD UPON THE

6266
03:56:19,840 --> 03:56:21,600
INSTITUTIONAL INFRASTRUCTURE AND

6267
03:56:21,600 --> 03:56:23,200
REGULATIONS THAT EXIST.

6268
03:56:23,200 --> 03:56:26,800
SO I THINK THE RECOMMENDATION BY

6269
03:56:26,800 --> 03:56:28,880
NED AND DINA TO SET UP A GROUP

6270
03:56:28,880 --> 03:56:32,880
LOOKING TO THIS IS CRITICAL.

6271
03:56:32,880 --> 03:56:35,240
BECAUSE MANDATE VERY DIFFICULT

6272
03:56:35,240 --> 03:56:39,600
GIVEN UNIQUENESS OF THIS MAYBE

6273
03:56:39,600 --> 03:56:41,120
GERMINATE DOWN TO SET OF SOME

6274
03:56:41,120 --> 03:56:43,240
PARAMETERS THAT WOULD MAKE

6275
03:56:43,240 --> 03:56:43,720
SENSE.

6276
03:56:43,720 --> 03:56:44,520
MIGHT BE THE WAY TO GO.

6277
03:56:44,520 --> 03:56:46,680
SO WE DO A LOT OF DATA HANDLING

6278
03:56:46,680 --> 03:56:48,800
AND MANAGING BUT BUILT ON

6279
03:56:48,800 --> 03:56:49,680
INFRASTRUCTURE OF THE

6280
03:56:49,680 --> 03:56:51,840
INSTITUTION AND THE SUPPORT THAT

6281
03:56:51,840 --> 03:56:52,840
INSTITUTION GIVES TO DO THIS.

6282
03:56:52,840 --> 03:56:56,960
WE CAN BE EXTREMELY EXPENSIVE

6283
03:56:56,960 --> 03:56:57,560
AND QUITE COMPLEX.

6284
03:56:57,560 --> 03:57:00,240
SO I THINK THAT WORKING GROUP IS

6285
03:57:00,240 --> 03:57:02,240
A GOOD IDEA TO JUST TEASE IT OUT

6286
03:57:02,240 --> 03:57:05,680
TO SEE HOW WE DEAL WITH IT.

6287
03:57:05,680 --> 03:57:08,160
>> SO THE WORKING GROUP YOU ARE

6288
03:57:08,160 --> 03:57:08,960
TALKING ABOUT FOR INSTANCE I

6289
03:57:08,960 --> 03:57:12,840
THINK YOU ARE ALLUDING TO WHAT

6290
03:57:12,840 --> 03:57:17,280
SYLVIA WAS PLACED ON THE TABLE.

6291
03:57:17,280 --> 03:57:18,280
>> I THINK SO.

6292
03:57:18,280 --> 03:57:20,240
NED REFERRED TO --

6293
03:57:20,240 --> 03:57:22,000
>> LIKE TO BE CLEAR, I DON'T

6294
03:57:22,000 --> 03:57:23,360
THINK I'M PROPOSING THAT YET.

6295
03:57:23,360 --> 03:57:24,680
I THINK WE HAVE PHOTO THINK

6296
03:57:24,680 --> 03:57:25,320
ABOUT IT.

6297
03:57:25,320 --> 03:57:27,000
THE IMPORTANT PART IS WHAT WOULD

6298
03:57:27,000 --> 03:57:27,760
THE CHARGE BE.

6299
03:57:27,760 --> 03:57:30,240
IF IT'S MERELY HOW WE DO DATA

6300
03:57:30,240 --> 03:57:32,160
SHARING BETTER, I DON'T THINK WE

6301
03:57:32,160 --> 03:57:33,440
NEED THAT WORKING GROUP, WE HAVE

6302
03:57:33,440 --> 03:57:35,320
TALKED ABOUT THAT ISSUE AND

6303
03:57:35,320 --> 03:57:36,920
CHALLENGES THAT ARE WELL KNOWN.

6304
03:57:36,920 --> 03:57:39,880
BUT WHAT FEELS NEW IS THIS SORT

6305
03:57:39,880 --> 03:57:44,600
OF BIOINFORMATICS HOMOJOE NAYTY

6306
03:57:44,600 --> 03:57:47,880
WE HAVE NOT TALKED MUCH --

6307
03:57:47,880 --> 03:57:48,920
HOMOGENEITY WE HAVE NOT TALKED

6308
03:57:48,920 --> 03:57:49,960
ABOUT AND IMPORTANT TOPIC SO WE

6309
03:57:49,960 --> 03:57:51,800
NEED TO THINK ABOUT WHO -- WHAT

6310
03:57:51,800 --> 03:57:55,680
ADVICE CAN WE GET AND I'M VERY

6311
03:57:55,680 --> 03:57:57,120
WORRIED AT FRANCIS AS YOU

6312
03:57:57,120 --> 03:57:59,680
ALLUDED TO CREATING AN UNFUNDED

6313
03:57:59,680 --> 03:58:02,320
MONEY DATE FOR SPORE PROGRAM

6314
03:58:02,320 --> 03:58:04,680
THOSE PROGRAMS ARE BOTH SOMEWHAT

6315
03:58:04,680 --> 03:58:06,600
TAXED BUT I THINK THAT THAT

6316
03:58:06,600 --> 03:58:08,080
MIGHT NOT BE WHAT IS ASKED FOR

6317
03:58:08,080 --> 03:58:11,160
HERE.

6318
03:58:11,160 --> 03:58:13,200
SO WE -- AS PAULETTE SAID I

6319
03:58:13,200 --> 03:58:15,520
THINK WE SHOULD TAKE THIS

6320
03:58:15,520 --> 03:58:16,760
RECOMMENDATION BACK AND WE WILL

6321
03:58:16,760 --> 03:58:18,760
GIVE AN ANSWER, LET US RESEARCH

6322
03:58:18,760 --> 03:58:20,960
AND MAYBE EVEN ASK MORE

6323
03:58:20,960 --> 03:58:22,280
QUESTIONS ABOUT THIS AND GET

6324
03:58:22,280 --> 03:58:26,680
BACK TO YOU AT A FUTURE MEETING

6325
03:58:26,680 --> 03:58:26,880
IF --

6326
03:58:26,880 --> 03:58:31,840
>> GREAT APPROACH.

6327
03:58:31,840 --> 03:58:33,120
>> THANK YOU, EVERYONE FOR THAT.

6328
03:58:33,120 --> 03:58:38,160
THAT WAS A GREAT DISCUSSION.

6329
03:58:38,160 --> 03:58:40,440
ANY OTHER THOUGHTS ISSUES

6330
03:58:40,440 --> 03:58:41,040
CONCERNS RECOMMENDATIONS?

6331
03:58:41,040 --> 03:58:42,560
THAT YOU THINK EITHER OF THE

6332
03:58:42,560 --> 03:58:46,720
BOARD OR BOTH THE BOARDS OR NCI

6333
03:58:46,720 --> 03:58:47,360
SHOULD CONSIDER?

6334
03:58:47,360 --> 03:58:51,040
>> ONE POINT I FAILED TO SAY WE

6335
03:58:51,040 --> 03:58:53,120
COMMITTED TO A PRESENTATION ON

6336
03:58:53,120 --> 03:58:56,360
THE CANCER RESEARCH DATA COMMONS

6337
03:58:56,360 --> 03:58:58,480
AND THAT'S IMPORTANT TOO IN THIS

6338
03:58:58,480 --> 03:58:59,400
DISCUSSION I THINK.

6339
03:58:59,400 --> 03:59:01,480
>> YES IT INTEGRATES HA

6340
03:59:01,480 --> 03:59:05,000
DISCUSSION.

6341
03:59:05,000 --> 03:59:06,360
ESPECIALLY THINKING IT'S

6342
03:59:06,360 --> 03:59:07,440
ASSOCIATED WITH SUGGESTIONS FOR

6343
03:59:07,440 --> 03:59:08,840
FUTURE AGENDA ITEMS.

6344
03:59:08,840 --> 03:59:12,240
I HEARD EARLIER SOMEONE TALK

6345
03:59:12,240 --> 03:59:16,880
OBESITY BUT ARE THERE OTHER KEY

6346
03:59:16,880 --> 03:59:22,840
AREAS ANYONE WOULD LIKE TO

6347
03:59:22,840 --> 03:59:23,160
NOMINATE --

6348
03:59:23,160 --> 03:59:28,440
>> PRESENTATION ON -- TRAINING

6349
03:59:28,440 --> 03:59:29,080
OPPORTUNITIES.

6350
03:59:29,080 --> 03:59:31,240
>> EDUCATIONAL TRAINING

6351
03:59:31,240 --> 03:59:33,880
ACTIVITIES?

6352
03:59:33,880 --> 03:59:36,440
>> SOME POINT WE TALKED ABOUT

6353
03:59:36,440 --> 03:59:39,400
DR. GOKDARD COMING TO GET HER

6354
03:59:39,400 --> 03:59:39,880
VISION.

6355
03:59:39,880 --> 03:59:42,560
SO WHENEVER THAT IS APPROPRIATE

6356
03:59:42,560 --> 03:59:43,920
SHE SETTLES IN I WOULD LOVE TO

6357
03:59:43,920 --> 03:59:45,760
HAVE THAT AS WELL.

6358
03:59:45,760 --> 03:59:50,760
>> YOU CAN SEE PHIL TOOK ABOUT A

6359
03:59:50,760 --> 03:59:53,560
YEAR, I ENCOURAGE THAT THESE

6360
03:59:53,560 --> 03:59:57,240
DIVISIONS ARE LARGE AND

6361
03:59:57,240 --> 04:00:00,080
PORTFOLIOS ARE COMPLEX ALLOW DR.

6362
04:00:00,080 --> 04:00:02,200
GODDARD TO TELL US WHEN SHE

6363
04:00:02,200 --> 04:00:04,440
FEELS COMFORTABLE BUT MIGHT TAKE

6364
04:00:04,440 --> 04:00:07,160
A WHILE GIVEN COMPLEXITY OF --

6365
04:00:07,160 --> 04:00:09,760
>> ONE THING LOOKING AT -- WITH

6366
04:00:09,760 --> 04:00:11,480
THIS INITIATIVE TODAY ACTUALLY

6367
04:00:11,480 --> 04:00:15,040
GOING OUT OF COUNTRY TO SET UP

6368
04:00:15,040 --> 04:00:18,840
CAPABILITIES, CAPACITY BUILDING.

6369
04:00:18,840 --> 04:00:20,280
MAYBE HAVE SOMEBODY FROM THE

6370
04:00:20,280 --> 04:00:23,360
FOGARTY INTENTER, IF YOU ARE

6371
04:00:23,360 --> 04:00:25,800
AWARE IT IS QUITE RESOURCE IN

6372
04:00:25,800 --> 04:00:26,680
TERMS OF NCI INTERNATIONAL

6373
04:00:26,680 --> 04:00:27,080
ACTIVITIES.

6374
04:00:27,080 --> 04:00:30,600
MAYBE HAVING A PRESENTATION

6375
04:00:30,600 --> 04:00:32,240
SOMETIMES FOR -- FROM THE

6376
04:00:32,240 --> 04:00:33,640
FOGARTY CENTER WOULD BE VERY

6377
04:00:33,640 --> 04:00:37,000
HELPFUL.

6378
04:00:37,000 --> 04:00:40,080
>> ASHI PUT A COMMENT IN THE

6379
04:00:40,080 --> 04:00:44,240
CHAT ABOUT AGING CANCER.

6380
04:00:44,240 --> 04:00:45,320
I KNOW THERE WERE SOME --

6381
04:00:45,320 --> 04:00:47,200
>> ALLOWED TO COMMENT YET SINCE

6382
04:00:47,200 --> 04:00:48,480
I WASN'T BEEN OFFICIALLY

6383
04:00:48,480 --> 04:00:49,000
APPROVED.

6384
04:00:49,000 --> 04:00:51,960
>> I WILL JUST SAY IT, THERE

6385
04:00:51,960 --> 04:00:55,880
HAVE BEEN SOME INTERACTIONS

6386
04:00:55,880 --> 04:00:58,240
BETWEEN NCI AND AGING AND SO I

6387
04:00:58,240 --> 04:00:59,600
THINK IT WOULD BE INTERESTED TO

6388
04:00:59,600 --> 04:01:01,720
HEAR ABOUT WHAT IS GOING ON

6389
04:01:01,720 --> 04:01:04,160
THERE, WHAT IS GOING ON

6390
04:01:04,160 --> 04:01:07,920
CURRENTLY AND IF THERE ARE

6391
04:01:07,920 --> 04:01:10,000
ANYTHING FOR FUTURE INTERACTION

6392
04:01:10,000 --> 04:01:16,000
BETWEEN THE TWO ICs.

6393
04:01:16,000 --> 04:01:19,680
>> YOU CAN PROVIDE COMMENT, JUST

6394
04:01:19,680 --> 04:01:22,160
CAN'T VOTE.

6395
04:01:22,160 --> 04:01:25,640
>> I HAVE WRITTEN THESE DOWN, I

6396
04:01:25,640 --> 04:01:27,720
THINK THESE -- FEW OTHERS AS

6397
04:01:27,720 --> 04:01:29,440
WELL -- GREAT RECOMMENDATIONS, A

6398
04:01:29,440 --> 04:01:34,880
FEW OTHERS AS WELL TOO.

6399
04:01:34,880 --> 04:01:36,000
>> OKAY.

6400
04:01:36,000 --> 04:01:39,200
IF YOU HAVE ANY ADDITIONAL

6401
04:01:39,200 --> 04:01:41,720
THOUGHTS THEN BRING IT UP LATER,

6402
04:01:41,720 --> 04:01:47,200
JUST SEND THEM TO ME, KEITH AND

6403
04:01:47,200 --> 04:01:48,480
PAULETTE.

6404
04:01:48,480 --> 04:01:50,320
WE WILL COLLATE THOSE AND ENSURE

6405
04:01:50,320 --> 04:01:53,640
THEY MAKE THEIR WAY ON TO FUTURE

6406
04:01:53,640 --> 04:01:54,800
AGENDAS.

6407
04:01:54,800 --> 04:01:58,440
INDIVIDUAL BOARD AGENDA

6408
04:01:58,440 --> 04:01:59,840
SUGGESTIONS SHOULD BE SENT TO

6409
04:01:59,840 --> 04:02:01,200
REPRESENTATIVE BOARD CHAIR AND

6410
04:02:01,200 --> 04:02:01,840
PAULETTE.

6411
04:02:01,840 --> 04:02:04,480
IF NCAB MEMBER SEND TO ME AND

6412
04:02:04,480 --> 04:02:07,480
PAULETTE, IF BSA MAKE SURE YOU

6413
04:02:07,480 --> 04:02:10,840
ADD KEITH AND PAULETTE.

6414
04:02:10,840 --> 04:02:17,640
ANY OTHER BUSINESS?

6415
04:02:17,640 --> 04:02:21,440
IF NOT WE CAN MOVE TO ADJOURN

6416
04:02:21,440 --> 04:02:23,360
THIS MEETING.

6417
04:02:23,360 --> 04:02:24,600
THANKS EVERYONE I THOUGHT IT WAS

6418
04:02:24,600 --> 04:02:27,240
A FANTASTIC MEETING, MY FIRST

6419
04:02:27,240 --> 04:02:29,840
EXPERIENCE AND THANK YOU

6420
04:02:29,840 --> 04:02:38,080
PAULETTE.

6421
04:02:38,080 --> 04:02:40,680
>> GREAT JOB CHAIRS AND GREAT

6422
04:02:40,680 --> 04:02:41,720
JOB COMMUNITY MEMBERS.

6423
04:02:41,720 --> 04:02:44,000
>> EVERYONE HAVE A GREAT HOLIDAY

6424
04:02:44,000 --> 04:02:44,720
SEASON.

6425
04:02:44,720 --> 04:02:46,000
NCAB MEMBERS WE WILL SEE YOU IN

6426
04:02:46,000 --> 04:02:48,800
FEBRUARY.

6427
04:02:48,800 --> 04:02:51,240
>> SAD HOW GOOD WE ARE GETTING

6428
04:02:51,240 --> 04:02:53,280
IN ZOOM MEETINGS.

6429
04:02:53,280 --> 04:02:55,640
WE WANT TO RETURN TO FACE TO

6430
04:02:55,640 --> 04:02:56,560
FACE AS SOON AS POSSIBLE.

6431
04:02:56,560 --> 04:02:57,600
>> ABSOLUTELY.

6432
04:02:57,600 --> 04:02:59,960
>> ALL RIGHT.

6433
04:02:59,960 --> 04:22:28,240
>> BYE-BYE.